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The ultimate aim of this six study research programme was to develop and evaluate an 
intervention to promote medication adherence for osteoporosis patients. Mixed 
methods were used, with a combination of qualitative, quantitative and interventional 
approaches. Each study involved the investigation of the psychological factors which 
contributed to adherence to osteoporosis medication. In addition to data collection 
through interviews and questionnaires, participants were asked to draw how they 
visualized their osteoporosis. 
This research drew on Leventhal’s Self-Regulation Model (Leventhal et al, 1984) and 
Witte’s Extended Parallel Process Model (Witte, 1992). The first three studies explored 
the role of psychological factors in osteoporosis medication adherence. The following 
factors were found to be related to adherence: concerns about medication (studies 1 
and 3), motivation (study 3) and self-efficacy (study 3). Further, study 2 suggested that 
misconceptions about osteoporosis may also contribute to treatment non-adherence. 
Study 4 tested the psychological impact of the intervention materials. The drawing 
element of the research indicated that drawing the condition enabled patients to 
express their emotional response it (study 2). 
Findings from the first four studies led to the design of a theory-based psychological 
intervention. The intervention comprised: psycho-education, motivational interviewing 
and plan-setting and was tailored to the needs of each individual. Medication 
adherence increased for seven of the eight study participants. Post-intervention, 
patients reported increased understanding of osteoporosis, a greater perceived need 
for medication and a stronger belief that osteoporosis medication could reduce the 
risk of osteoporotic fractures. Further, the evaluation suggested that the tailored 
element of the intervention was largely responsible for the increases in adherence 
(study 6).  
The key findings were that i) osteoporosis patients have misconceptions about their 
bone health and their medication ii) psychological factors are related to osteoporosis 
medication adherence iii) creating a drawing of osteoporosis may elicit an emotional 
response to the condition and iv) a psychological intervention has the potential to 
increase adherence to osteoporosis medication. Further research with a larger sample 
is required to assess the intervention’s effectiveness.  
 
 
                                                     
1
 The copyright of this thesis rests with the author and no quotation from it or information derived from 
it may be published without proper acknowledgement.  
The psychological factors in adherence to osteoporosis medication: an exploration and 





*Dr Janet Anderson and Professor John Weinman who have been excellent academic 
supervisors 
*Dr Beth Grunfeld and Professor Christian Heath for reviewing this work for the 
upgrade process 
*The expert patients and service users who assisted with the research design. With 
particular thanks to Dee Folkard and Pari Sabet 
*The patients who took part in the research 
*Local Collaborators at the study sites: Dr Halina FitzClarence, Professor Stephen 
Jackson, Dr Amelia Moore, Dr Daniel Bailey, Dr Ignas Fogelman & Dr Katie Moss 
*Phil Baker for assistance with authorship skills 
*Dr Chris Woodrow and Professor Toby Prevost for statistical support 
*Dr Alastair Ross for providing advice on various aspects of the data analysis 
*Paul Williams for working as an independent assessor on various aspects of the 
research  
*Dr Angus Ramsay, Dr Kellie Thompson, Dr Nao Kadote for assistance with visual data 
analysis 
*Martha Besser, David Besser, Dr Joseph Besser and Delia Williams for proof reading 
*The friends and family who supported me throughout my PhD, with special thanks to 
Kelly Collins and Emily Lee-Tyrassek 








The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
4 
 
ABSTRACT ................................................................................................................................. 2 
ACKNOWLEDGEMENTS ......................................................................................................... 3 
INTRODUCTION.................................................................................................................... 19 
1 OSTEOPOROSIS; A CLINICAL BACKGROUND ..................................................... 22 
1.1 Osteoporosis clinical background ................................................................................................22 
1.1.1 Definition................................................................................................................................. 22 
1.1.2 Prevalence ............................................................................................................................... 24 
1.1.3 Diagnosis and monitoring ....................................................................................................... 25 
1.1.4 Consequences of the condition ............................................................................................... 27 
Hip fracture ....................................................................................................................................... 27 
Forearm Fracture .............................................................................................................................. 28 
Vertebral Fracture ............................................................................................................................ 28 
1.2 Risk Factors .................................................................................................................................28 
1.3 Treatment for Osteoporosis ........................................................................................................31 
1.3.1 Pharmacological Treatments .................................................................................................. 31 
1.3.2 Non-pharmacological treatments ........................................................................................... 34 
1.4 Summary ....................................................................................................................................37 
2 ADHERENCE TO MEDICATION ................................................................................ 38 
2.1 Background .................................................................................................................................38 
2.2 Terminology ................................................................................................................................39 
2.3 The prevalence of non-adherence to medication ........................................................................40 
2.4 Measurement .............................................................................................................................41 
2.5 The determinants of non-adherence to medication ....................................................................44 
2.6 Adherence to osteoporosis medication .......................................................................................48 
2.6.1 Determinants of non-adherence to osteoporosis medication ................................................ 49 
Non-modifiable determinants .......................................................................................................... 50 
Modifiable determinants .................................................................................................................. 52 
2.7 Summary ....................................................................................................................................54 
3 INTERVENTIONS TO PROMOTE OSTEOPOROSIS MEDICATION 
ADHERENCE: THE ROLE OF HEALTH PSYCHOLOGY THEORIES .......................... 55 
3.1 Previous interventions to promote osteoporosis medication .....................................................55 
3.1.1 Limitations of former adherence interventions ...................................................................... 58 
3.2 Health psychology theories and their utilisation for improving adherence .................................60 
3.2.1 Risk perception: a central theme in health psychology theories ............................................ 61 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
5 
 
3.2.2 Perceptions of risk for osteoporosis and fractures ................................................................. 64 
3.2.3 Social Cognition Models .......................................................................................................... 65 
The Health Belief Model ................................................................................................................... 66 
Protection Motivation Theory .......................................................................................................... 67 
The Theory of Planned Behaviour .................................................................................................... 67 
3.2.4 Leventhal’s self-regulation model ........................................................................................... 68 
Cognitive Representations ................................................................................................................ 70 
Emotional Representations .............................................................................................................. 71 
An extension of the SRM .................................................................................................................. 71 
3.2.5 Empirical support for the SRM ................................................................................................ 72 
3.2.6 Application of SRM to adherence research............................................................................. 72 
3.2.7 Witte’s Extended Parallel Process Model ............................................................................... 74 
3.2.8 Application of EPPM to adherence research .......................................................................... 76 
The limitations of the social cognition models ................................................................................. 78 
3.2.9 Selection of behaviour change techniques ............................................................................. 79 
3.3 Current Gaps in the literature .....................................................................................................80 
3.4 Summary ....................................................................................................................................81 
4 THE RATIONALE FOR THE PRESENT RESEARCH ............................................. 83 
4.1 Rationale for innovative adherence interventions ......................................................................83 
4.2 Medical Research Council guidelines for complex interventions .................................................84 
4.3 Theory Selection; Extended SRM and EPPM ................................................................................87 
4.4 Research outline .........................................................................................................................89 
4.4.1 Study 1 (Critical Review; Preclinical) ....................................................................................... 90 
4.4.2 Study 2 (Qualitative Study; Preclinical) ................................................................................... 91 
4.4.3 Study 3 (Quantitative Study; Phase I) ..................................................................................... 91 
4.4.4 Study 4 (Quantitative Study: Phase I) ..................................................................................... 92 
4.4.5 Study 5 (Intervention Study; Phase II) ..................................................................................... 92 
4.4.6 Study 6 (Process evaluation study; Phase II) ........................................................................... 93 
4.5 Summary ....................................................................................................................................96 
5 STUDY 1: THE PSYCHOLOGICAL FACTORS IN NON-ADHERENCE AND NON-
PERSISTENCE WITH OSTEOPOROSIS MEDICATION; A CRITICAL REVIEW ...... 97 
5.1 Introduction ................................................................................................................................97 
5.2 Method ..................................................................................................................................... 100 
Search Strategy ............................................................................................................................... 100 
Inclusion Criteria ............................................................................................................................. 101 
Exclusion Criteria ............................................................................................................................ 101 
Procedure ....................................................................................................................................... 102 
5.3 Results ...................................................................................................................................... 103 
5.3.1 Data synthesis ....................................................................................................................... 114 
5.4 Discussion ................................................................................................................................. 118 
5.4.1 Gaps in the literature ............................................................................................................ 120 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
6 
 
5.4.2 Limitations ............................................................................................................................. 122 
5.5 Summary and next steps ........................................................................................................... 123 
6 STUDY 2: HOW DO OSTEOPOROSIS PATIENTS PERCEIVE THEIR 
CONDITION AND MEDICATION? ................................................................................... 124 
6.1 Background ............................................................................................................................... 124 
6.2 Introduction .............................................................................................................................. 125 
Rationale for study ......................................................................................................................... 128 
6.3 Aims .......................................................................................................................................... 128 
6.4 Method ..................................................................................................................................... 129 
6.4.1 Study Design .......................................................................................................................... 129 
Interview schedule development ................................................................................................... 129 
6.4.2 Participants ........................................................................................................................... 130 
6.4.3 Procedure .............................................................................................................................. 132 
Ethics............................................................................................................................................... 132 
Recruitment .................................................................................................................................... 132 
6.5 Analysis ..................................................................................................................................... 133 
6.5.1 Interview analysis .................................................................................................................. 133 
Familiarisation ................................................................................................................................ 134 
Thematic Analysis ........................................................................................................................... 134 
Indexing .......................................................................................................................................... 134 
Charting .......................................................................................................................................... 134 
Mapping and Interpretation ........................................................................................................... 135 
6.5.2 Patient drawing analysis ....................................................................................................... 135 
6.6 Results ...................................................................................................................................... 136 
6.6.1 Interviews .............................................................................................................................. 139 
Identity ........................................................................................................................................... 139 
6.6.2 Patient drawings ................................................................................................................... 140 
Length ............................................................................................................................................. 140 
Shape .............................................................................................................................................. 142 
Bone structure/deformity............................................................................................................... 142 
Drawings of people with and without osteoporosis ....................................................................... 142 
6.6.3 Interviews Continued ............................................................................................................ 144 
Cause .............................................................................................................................................. 144 
Timeline .......................................................................................................................................... 145 
Controllability/Cure ........................................................................................................................ 146 
Consequences ................................................................................................................................. 148 
Emotions ......................................................................................................................................... 150 
Risk perceptions.............................................................................................................................. 150 
Medication beliefs .......................................................................................................................... 152 
Adherence ...................................................................................................................................... 155 
Relationships .................................................................................................................................. 156 
Comparison between attenders and DNA’s ................................................................................... 157 
Recommendations for helping future patients to take their medication ...................................... 158 
6.7 Discussion ................................................................................................................................. 160 
6.7.1 Key findings ........................................................................................................................... 160 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
7 
 
6.7.2 Methodological contribution of drawings ............................................................................ 166 
6.7.3 Implications for interventions to improve adherence to osteoporosis medication ............. 168 
Limitations ........................................................................................................................................... 169 
Conclusions ........................................................................................................................................ 170 
7 STUDY 3: THE PSYCHOLOGICAL FACTORS RELATED TO OSTEOPOROSIS 
MEDICATION ADHERENCE ............................................................................................. 172 
7.1 Introduction .............................................................................................................................. 172 
7.2 Aims .......................................................................................................................................... 174 
Research Questions ........................................................................................................................ 175 
7.3 Hypotheses ............................................................................................................................... 175 
7.4 Method ..................................................................................................................................... 176 
7.4.1 Participants ........................................................................................................................... 176 
7.4.2 Measures ............................................................................................................................... 178 
The Illness Perceptions Questionnaire Revised (IPQ-R) (Moss-Morris et al, 2002) (shown in 
APPENDIX 11) ................................................................................................................................. 179 
The Beliefs about Medication Questionnaire (BMQ) (Horne et al, 1999) (Shown in APPENDIX 13)
 ........................................................................................................................................................ 179 
The Risk Perception Questionnaire (RPQ) (shown in APPENDIX 15) .............................................. 180 
Three self-report measures of adherence ...................................................................................... 181 
The Mediation Adherence Report Scale (MARS) (Horne, 1997b) (See APPENDIX 14) ................... 181 
Percentage non-adherence (APPENDIX 14) .................................................................................... 182 
The Difficulties Of Taking Osteoporosis Medication Questionnaire (DOTMQ) (APPENDIX 16) ...... 182 
7.4.3 Procedure .............................................................................................................................. 183 
Ethics............................................................................................................................................... 183 
Setting ............................................................................................................................................. 183 
Recruitment .................................................................................................................................... 184 
7.5 Analysis ..................................................................................................................................... 186 
7.6 Results ...................................................................................................................................... 188 
7.6.1 What is the extent of non-adherence in this population of osteoporosis patients? ............ 188 
7.6.2 Descriptive statistics and reliability analysis ......................................................................... 189 
7.6.3 Socio-demographic and clinical Factors ................................................................................ 195 
7.6.4 Correlation analysis ............................................................................................................... 196 
7.6.5 To what extent can adherence be predicted by the extended SRM? ................................... 200 
7.6.6 Can adherence be predicted by the EPPM? .......................................................................... 201 
7.6.7 To what extent does a combination of the extended SRM and the EPPM explain adherence?
 202 
7.6.8 A possible model of adherence ............................................................................................. 204 
7.6.9 Multiple linear regression ..................................................................................................... 206 
7.7 Discussion ................................................................................................................................. 207 
7.7.1 Key findings ........................................................................................................................... 207 
7.7.2 Limitations ............................................................................................................................. 210 
7.7.3 Implications for the design of interventions to improve adherence to osteoporosis 
medication ........................................................................................................................................... 212 
7.8 Conclusions and next steps ....................................................................................................... 213 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
8 
 
8 STUDY 4: OSTEOPOROSIS PATIENTS’ RATINGS OF FIVE VISUAL IMAGES 
OF OSTEOPOROSIS ............................................................................................................ 214 
8.1 Introduction .............................................................................................................................. 214 
8.2 Pictures in health communication ............................................................................................. 216 
8.2.1 Using visual images to change health behaviour .................................................................. 217 
8.2.2 Research using body scans in osteoporosis .......................................................................... 219 
8.3 Summary of the use of visual images in behaviour change interventions ................................. 220 
Research Questions ........................................................................................................................ 221 
8.4 Method ..................................................................................................................................... 221 
8.4.1 Measure ................................................................................................................................ 221 
The Osteoporosis Images Questionnaire (OIQ) (see APPENDIX 21) ............................................... 221 
8.4.2 Procedure .............................................................................................................................. 223 
8.4.3 Analysis ................................................................................................................................. 224 
8.5 Results ...................................................................................................................................... 224 
8.5.1 How do osteoporosis patients respond to visual images of osteoporosis? .......................... 225 
8.5.2 Were there different responses to the various images of osteoporosis? ............................. 227 
Frightened ...................................................................................................................................... 227 
Informed ......................................................................................................................................... 227 
Angered .......................................................................................................................................... 228 
Motivated ....................................................................................................................................... 228 
Depressed ....................................................................................................................................... 228 
Confident ........................................................................................................................................ 228 
Worried ........................................................................................................................................... 228 
Confident that medication can help ............................................................................................... 228 
Helpless ........................................................................................................................................... 229 
8.5.3 Were there any correlations between participants’ image rating scores and their illness 
perceptions, medication beliefs, emotions, risk perceptions and adherence?................................... 229 
8.6 Discussion ................................................................................................................................. 229 
Limitations ...................................................................................................................................... 231 
8.7 Conclusion ................................................................................................................................ 231 
9 STUDY 5: A MULTIFACETED INTERVENTION TO INCREASE ADHERENCE 
TO OSTEOPOROSIS MEDICATION: A CASE-SERIES APPROACH, ......................... 232 
9.1 Introduction .............................................................................................................................. 232 
9.1.1 N-of-1 Design ........................................................................................................................ 234 
9.1.2 Rationale for the selected behaviour change techniques ..................................................... 235 
Psycho-education: A tailored information booklet ........................................................................ 236 
Motivational interviewing (MI) ....................................................................................................... 237 
Implementation intentions (referred to as plan-setting) ............................................................... 237 
Telephone follow-ups ..................................................................................................................... 237 
9.2 Aims .......................................................................................................................................... 238 
Research Questions ........................................................................................................................ 238 
9.3 Method ..................................................................................................................................... 238 
9.3.1 Research Design .................................................................................................................... 238 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
9 
 
9.3.2 Participants ........................................................................................................................... 240 
Inclusion/exclusion criteria ............................................................................................................. 240 
Recruitment .................................................................................................................................... 240 
9.3.3 Measures and Materials........................................................................................................ 241 
9.4 Procedure ................................................................................................................................. 242 
9.4.1 Intervention summary .......................................................................................................... 243 
9.4.2 Setting and delivery .............................................................................................................. 245 
9.5 Analysis ..................................................................................................................................... 247 
9.6 Results ...................................................................................................................................... 248 
9.6.1 What is the impact of a (pilot) theory-based intervention on adherence to medication? ... 249 
9.6.2 What is the impact of a theory-based intervention to improve adherence on illness 
perceptions, medication beliefs, emotional responses and risk perceptions? ................................... 252 
Group 1: Participants who were not taking their prescribed strontium ranelate at baseline ....... 253 
Participant 3.................................................................................................................................... 253 
Participant 5.................................................................................................................................... 257 
Participant 7.................................................................................................................................... 260 
Participant 8.................................................................................................................................... 263 
Group 2: Participants who were taking their prescribed strontium ranelate at baseline .............. 265 
Participant 1.................................................................................................................................... 265 
Participant 2.................................................................................................................................... 268 
Participant 4.................................................................................................................................... 270 
Participant 6.................................................................................................................................... 272 
9.6.3 Were there changes in patient’s depictions of osteoporosis after the intervention? .......... 275 
Length ............................................................................................................................................. 276 
Shape .............................................................................................................................................. 276 
Bone deformity ............................................................................................................................... 276 
Drawings of people with and without osteoporosis ....................................................................... 277 
Length ............................................................................................................................................. 277 
9.6.4 Were there common trends between participants? ............................................................ 278 
9.7 Discussion ................................................................................................................................. 279 
Key findings ..................................................................................................................................... 279 
Limitations ...................................................................................................................................... 282 
9.8 Conclusions ............................................................................................................................... 282 
10 STUDY 6: PROCESS EVALUATION OF A COMPLEX BEHAVIOUR CHANGE 
INTERVENTION TO INCREASE ADHERENCE TO OSTEOPOROSIS MEDICATION
 284 
10.1 Introduction ......................................................................................................................... 284 
Research questions ......................................................................................................................... 285 
10.2 Method ................................................................................................................................ 285 
10.2.1 Research design ................................................................................................................ 285 
10.2.2 Measure ........................................................................................................................... 286 
10.2.3 Procedure ......................................................................................................................... 288 
10.3 Analysis ................................................................................................................................ 288 
10.4 Results .................................................................................................................................. 288 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
10 
 
10.4.1 Evaluation of the information booklet ............................................................................. 289 
10.4.2 What were the perceived mechanisms of the changes observed in adherence and/or 
psychological factors? ......................................................................................................................... 290 
Pre-intervention thoughts and behaviours .................................................................................... 291 
Post-intervention changes .............................................................................................................. 293 
10.4.3 What was each participant’s subjective experience of taking part in the intervention? . 296 
Research interpretations ................................................................................................................ 297 
Recommendations for future adherence interventions ................................................................. 303 
10.4.4 Were participants satisfied with the intervention? ......................................................... 303 
10.5 Discussion ............................................................................................................................ 304 
10.5.1 Summary of key findings .................................................................................................. 304 
10.5.2 Suggested improvements for future adherence intervention design .............................. 306 
10.5.3 Limitations ........................................................................................................................ 307 
10.6 Conclusions .......................................................................................................................... 308 
11 GENERAL DISCUSSION ........................................................................................ 309 
11.1 Summary of studies .............................................................................................................. 309 
11.2 Contributions to knowledge about the psychology of osteoporosis medication adherence . 310 
11.3 Theoretical contributions ..................................................................................................... 313 
11.4 Methodological contributions .............................................................................................. 315 
11.5 The contribution of drawings and images of osteoporosis ................................................... 317 
11.6 Patient and public involvement ............................................................................................ 318 
11.7 Limitations ........................................................................................................................... 319 
11.8 Overall conclusions............................................................................................................... 321 
11.9 Future work .......................................................................................................................... 324 
Study features recommended for the next stage of intervention development ........................... 327 
11.10 Concluding remarks .............................................................................................................. 328 
REFERENCES ........................................................................................................................ 329 
APPENDICES ........................................................................................................................ 354 
APPENDIX 1. Search Strategy (study 1) ...................................................................................... 355 
APPENDIX 2. Checklist for study inclusion (study 1) .................................................................. 356 
APPENDIX 3. First page of favourable opinion letter from research ethics committee for Study 2
 ................................................................................................................................................... 358 
APPENDIX 4. Paper published in peer reviewed medical journal (study 2) ............................... 359 
APPENDIX 5. Topic guide (study 2) ............................................................................................ 360 
APPENDIX 6. Reliability of the coding framework ..................................................................... 365 
APPENDIX 7. Patient drawings of bones with and without osteoporosis (study 2) ................... 368 
APPENDIX 8. Participant drawings of people with and without osteoporosis ........................... 374 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
11 
 
APPENDIX 9. First page of favourable opinion letter from research ethics committee for Study 2
 ................................................................................................................................................... 378 
APPENDIX 10. Contextual data collection questionnaire (study 3) ........................................... 379 
APPENDIX 11. Demographic data collection sheet (study 3) ..................................................... 380 
APPENDIX 12. Illness Perceptions Questionnaire Revised (IPQ-R) adapted for osteoporosis 
(study 3): .................................................................................................................................... 382 
APPENDIX 13. The beliefs about medication questionnaire, adapted for osteoporosis (study 3)
 ................................................................................................................................................... 393 
APPENDIX 14. The Medication Adherence Report Scale (MARS) (studies 3 and 5) ................... 394 
APPENDIX 15. The Risk Perceptions Questionnaire (RPQ) (studies 3 and 5) ............................. 395 
APPENDIX 16. Difficulties Of Taking Osteoporosis Medication Questionnaire (DOTMQ) (studies 
3 and 5) ...................................................................................................................................... 398 
APPENDIX 17. Scoring the Illness Perceptions Questionnaire Revised – for osteoporosis (3) .. 399 
APPENDIX 18. Distribution of extended SRM scores (study 3) .................................................. 400 
APPENDIX 19. Distribution of RPQ scores (study 3) ................................................................... 409 
APPENDIX 20. All study scale correlations (study 3) .................................................................. 413 
APPENDIX 21. Osteoporosis Images Questionnaire (OIQ) (study 4) .......................................... 415 
APPENDIX 22. Scoring the image questionnaire (study 4) ......................................................... 427 
APPENDIX 23. Distributions of image rating scales (study 4)..................................................... 428 
APPENDIX 24. First page of favourable opinion letter from research ethics committee for Study 
5 ................................................................................................................................................. 437 
APPENDIX 25. Participant drawings of bone pre- and post- intervention (Study 5) .................. 438 
APPENDIX 26. Evaluation topic guide (Study 6) ......................................................................... 450 
APPENDIX 27. Example of framework analysis of interview data for the theme ‘pre-intervention 
adherence and beliefs’ (study 6)................................................................................................ 453 
 
List of figures 
FIGURE 1. ELECTRON MICROSCOPE IMAGES OF NORMAL AND OSTEOPOROTIC BONES .................................................... 23 
FIGURE 2. SELF-REGULATION MODEL OF ILLNESS COGNITIONS AND EMOTIONS (LEVENTHAL ET AL, 1984) ......................... 70 
FIGURE 3. THE EXTENDED PARALLEL PROCESS MODEL (WITTE, 1992) ....................................................................... 76 
FIGURE 4. INFORMATION, MOTIVATION AND BEHAVIOURAL SKILLS MODEL (FISHER & FISHER, 1992) ............................ 79 
FIGURE 5. MRC’S FRAMEWORK FOR THE DESIGN AND EVALUATION OF COMPLEX INTERVENTIONS (CAMPBELL ET AL, 2000) 86 
FIGURE 6. EXTENDED SELF-REGULATION MODEL ANNOTATED FOR UTILISATION IN THE PRESENT RESEARCH ....................... 94 
FIGURE 7. EXTENDED PARALLEL PROCESS MODEL, ANNOTATED FOR UTILISATION IN THE PRESENT RESEARCH ...................... 95 
FIGURE 8. FLOWCHART OF STUDY INCLUSION/EXCLUSION...................................................................................... 104 
FIGURE 9. THE EXTENDED SELF-REGULATION MODEL (SRM) (ADAPTED FROM LEVENTHAL ET AL, 1984). ....................... 128 
FIGURE 10. PARTICIPANTS’ DRAWINGS OF BONES WITH AND WITHOUT OSTEOPOROSIS ............................................... 142 
FIGURE 11. PATIENTS’ DRAWINGS OF PEOPLE WITH OSTEOPOROSIS ........................................................................ 143 
FIGURE 12. DISTRIBUTION OF ADHERENCE TO MEDICATION IN OSTEOPOROSIS PATIENTS (MARS SCORES) ...................... 189 
FIGURE 13. SCREE PLOT INDICATING A FOUR FACTOR SOLUTION ............................................................................. 203 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
12 
 
FIGURE 14. REASONS FOR INTERVENTION DECLINE OR STUDY EXCLUSION ................................................................. 241 
FIGURE 15. MARS SCORES FOR ALL PARTICIPANTS PRE-, DURING AND POST-INTERVENTION ........................................ 250 
FIGURE 16. PERCENTAGE NON-ADHERENCE; PRE-, DURING AND POST-INTERVENTION ................................................. 251 
FIGURE 17. CHANGES IN TOTAL BARRIERS SCORE PRE-, DURING AND POST-INTERVENTION ........................................... 252 
FIGURE 18. PARTICIPANT 3: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 254 
FIGURE 19. PARTICIPANT 3: BMQ SCALES SCORES PRE-, DURING AND POST-INTERVENTION ........................................ 255 
FIGURE 20. PARTICIPANT 3: RPQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................... 256 
FIGURE 21. PARTICIPANT 5: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 258 
FIGURE 22. PARTICIPANT 5: BMQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION .......................................... 259 
FIGURE 23. PARTICIPANT 5: RPQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................... 259 
FIGURE 24. PARTICIPANT 7: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 261 
FIGURE 25. PARTICIPANT 7: BMQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION .......................................... 262 
FIGURE 26. PARTICIPANT 7: RPQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................... 262 
FIGURE 27. PARTICIPANT 8:  IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................ 264 
FIGURE 28. PARTICIPANT 8: BMQ SCALE SCORES PRE-,DURING AND POST-INTERVENTION .......................................... 264 
FIGURE 29. PARTICIPANT 8. RPQ SCORES PRE-, DURING AND POST-INTERVENTION .................................................... 265 
FIGURE 30. PARTICIPANT 1: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 267 
FIGURE 31. PARTICIPANT 1: BMQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION .......................................... 267 
FIGURE 32. PARTICIPANT 1: RPQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................... 267 
FIGURE 33. PARTICIPANT 2: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 269 
FIGURE 34.PARTICIPANT 2: BMQ SCALES, PRE-, DURING AND POST-INTERVENTION ................................................... 269 
FIGURE 35. PARTICIPANT 4: IPQ-R SCALES, PRE-, DURING AND POST-INTERVENTION ................................................. 271 
FIGURE 36. PARTICIPANT 4: BMQ SCALE SCORES, PRE-, DURING AND POST-INTERVENTION ......................................... 271 
FIGURE 37. PARTICIPANT 4: RPQ SCALE SCORES, PRE-, DURING AND POST-INTERVENTION .......................................... 272 
FIGURE 38. PARTICIPANT 6: IPQ-R SCALE SCORES PRE-, DURING AND POST-INTERVENTION ......................................... 274 
FIGURE 39. PARTICIPANT 6: BMQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION .......................................... 274 
FIGURE 40. PARTICIPANT 6: RPQ SCALE SCORES PRE-, DURING AND POST-INTERVENTION ........................................... 275 
FIGURE 41. DISTRIBUTION OF IPQ TIMELINE SCORES ............................................................................................ 400 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
13 
 
FIGURE 42. DISTRIBUTION OF IPQ CONSEQUENCES SCORE .................................................................................... 401 
FIGURE 43. DISTRIBUTION OF IPQ PERSONAL CONTROL SCORES ............................................................................. 402 
FIGURE 44. DISTRIBUTION OF IPQ TREATMENT CONTROL SCORES ........................................................................... 403 
FIGURE 45. DISTRIBUTION OF IPQ CYCLICAL TIMELINE SCORES ............................................................................... 404 
FIGURE 46. DISTRIBUTION OF IPQ EMOTIONS SCORES .......................................................................................... 405 
FIGURE 47. DISTRIBUTION OF IPQ COHERENCE SCORES ........................................................................................ 406 
FIGURE 48. DISTRIBUTION OF BMQ NECESSITY SCORES ........................................................................................ 407 
FIGURE 49. DISTRIBUTION OF BMQ CONCERNS SCORES ....................................................................................... 408 
FIGURE 50. DISTRIBUTION OF RPQ SUSCEPTIBILITY SCORES ................................................................................... 409 
FIGURE 51. DISTRIBUTION OF RPQ MEDICATION EFFICACY SCORES ......................................................................... 410 
FIGURE 52. DISTRIBUTION OF SELF-EFFICACY SCORES ........................................................................................... 411 
FIGURE 53. DISTRIBUTION OF RPQ EMOTION SCORES .......................................................................................... 412 
FIGURE 54. DISTRIBUTION OF FRIGHTENED RATING SCORES ................................................................................... 428 
FIGURE 55. DISTRIBUTION OF INFORMED IMAGE RATING SCORES ............................................................................ 429 
FIGURE 56. DISTRIBUTION OF ANGRY RATING SCORES........................................................................................... 430 
FIGURE 57. DISTRIBUTION OF MOTIVATED RATING SCORES .................................................................................... 431 
FIGURE 58. DISTRIBUTION OF DEPRESSED RATING SCORES ..................................................................................... 432 
FIGURE 59. DISTRIBUTION OF CONFIDENCE RATING SCORES ................................................................................... 433 
FIGURE 60. DISTRIBUTION OF WORRIED RATING SCORES ....................................................................................... 434 
FIGURE 61. DISTRIBUTION OF CONFIDENCE THAT MEDICATION CAN HELP RATING SCORES ............................................ 435 
FIGURE 62. DISTRIBUTION OF HELPLESS RATING SCORES ....................................................................................... 436 
List of tables 
TABLE 1. CHANGE IN SPINAL BMD AND FRACTURE RISK IN MAJOR* TRIALS OF OSTEOPOROSIS THERAPY FOR 
POSTMENOPAUSAL OSTEOPOROSIS (CEFALU, 2004) .................................................................................... 32 
TABLE 2. OVERVIEW OF THESIS RESEARCH IN RELATION TO MRC FRAMEWORK STAGES ................................................. 90 
TABLE 3. COMPARISON OF QUALITY ASSESSMENT SCORES WHEN RATED BY TWO RESEARCHERS ..................................... 103 
TABLE 4. SUMMARY OF STUDIES INVESTIGATING THE PSYCHOLOGICAL FACTORS RELATED TO ADHERENCE ........................ 105 
TABLE 5. TABLE OF THE DETERMINANTS OF NON-ADHERENCE TO OSTEOPOROSIS MEDICATION ...................................... 114 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
14 
 
TABLE 6. TABLE OF THE PSYCHOLOGICAL FACTORS RELATED TO NON-PERSISTENCE WITH OSTEOPOROSIS MEDICATION ....... 116 
TABLE 7. THE RELATIONSHIP BETWEEN LIFESTYLE FACTORS AND ADHERENCE AND PERSISTENCE ..................................... 118 
TABLE 8. STUDY 2 PARTICIPANT'S DEMOGRAPHIC AND CLINICAL INFORMATION ......................................................... 130 
TABLE 9. MAIN THEMES AND SUB THEMES ......................................................................................................... 137 
TABLE 10. LONGEST LINE MEASUREMENT FOR DRAWINGS OF BONES WITH AND WITHOUT OSTEOPOROSIS ...................... 141 
TABLE 11. STUDY 3 AND 4 PARTICIPANTS’ DEMOGRAPHIC AND CLINICAL DESCRIPTIVE DATA ......................................... 178 
TABLE 12. EXAMPLE QUESTIONS/STATEMENTS FOR EACH QUESTIONNAIRE AND SCALE ................................................ 180 
TABLE 13. PRACTICAL BARRIERS OF TAKING OSTEOPOROSIS MEDICATION ................................................................. 183 
TABLE 14. PERCENTAGE OF NON-ADHERENT PATIENTS FOR EACH MARS ITEM .......................................................... 188 
TABLE 15. DESCRIPTIVE STATISTICS AND RELIABILITY ANALYSIS FOR ADHERENCE MEASURES (PROPERTIES OF MULTI-ITEM 
SCALES) ............................................................................................................................................. 189 
TABLE 16. CORRELATION ANALYSIS BETWEEN THE THREE MEASURES OF ADHERENCE .................................................. 190 
TABLE 17. DESCRIPTIVE STATISTICS AND RELIABILITY ANALYSIS OF IPQ-R AND BMQ SCALES........................................ 191 
TABLE 18. RPQ DESCRIPTIVE STATISTICS AND RELIABILITY ANALYSIS OF RPQ SCALES .................................................. 194 
TABLE 19. CORRELATIONS BETWEEN IPQ-R VARIABLES ........................................................................................ 196 
TABLE 20. CORRELATIONS BETWEEN ALL SCALES AND MEASURES OF ADHERENCE ....................................................... 199 
TABLE 21. SUMMARY OF THE VARIANCE IN ADHERENCE EXPLAINED BY THE EXTENDED SRM......................................... 201 
TABLE 22. SUMMARY OF THE VARIANCE IN ADHERENCE EXPLAINED BY EPPM ........................................................... 202 
TABLE 23. FACTOR LOADINGS AND COMMUNALITIES BASED ON A PRINCIPLE COMPONENTS ANALYSIS WITH OBLIQUE ROTATION 
FOR 15 SCALES FROM THE EXTENDED SELF-REGULATION MODEL AND THE EXTENDED PARALLEL PROCESS MODEL ..... 204 
TABLE 24. SUMMARY OF THE VARIANCE IN ADHERENCE EXPLAINED BY A COMBINATION OF THE EXTENDED SRM AND THE 
EPPM ............................................................................................................................................... 206 
TABLE 25. THE IMAGES TESTED AS POTENTIAL INTERVENTION MATERIALS ................................................................. 222 
TABLE 26. STUDY 4 DESCRIPTIVE STATISTICS ....................................................................................................... 225 
TABLE 27. PARTICIPANT’S COMMENTS OF 5 IMAGES/PICTURES OF OSTEOPOROSIS (A-E) ............................................ 226 
TABLE 28. DEFINITIONS OF BEHAVIOUR CHANGE TECHNIQUES ................................................................................ 236 
TABLE 29. SUMMARY OF INTERVENTION ASSESSMENT TIME POINTS ........................................................................ 239 
TABLE 30. DEMOGRAPHIC AND CLINICAL FACTORS INFORMATION OF STUDIES 5 AND 6 PARTICIPANTS ............................ 240 
TABLE 31. INTERVENTION SCHEDULE OF ASSESSMENT AND INTERVENTION DELIVERY ................................................... 244 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
15 
 
TABLE 32. IMPLEMENTATION OF EACH INTERVENTION COMPONENT ........................................................................ 247 
TABLE 33. MARS SCORES OVER TIME FOR THE WHOLE SAMPLE.............................................................................. 249 
TABLE 34. CHANGES IN AVERAGE PERCENTAGE NON-ADHERENCE SCORES OVER TIME ................................................. 251 
TABLE 35. CHANGES IN AVERAGE TOTAL BARRIERS TO ADHERENCE SCORES OVER TIME ................................................ 252 
TABLE 36. EXAMPLE OF PARTICIPANT DRAWINGS PRE- AND POST-INTERVENTION ....................................................... 275 
TABLE 37. DRAWINGS OF BONES WITH AND WITHOUT OSTEOPOROSIS; MEASUREMENTS THROUGH THEIR LONGEST LINE, PRE- 
AND POST-INTERVENTION ...................................................................................................................... 276 
TABLE 38. DRAWINGS OF PEOPLE WITH AND WITHOUT OSTEOPOROSIS; MEASUREMENTS THROUGH THEIR LONGEST LINE, PRE-
AND POST-INTERVENTION ...................................................................................................................... 277 
TABLE 39. EVALUATION OF TAILORED INFORMATION BOOKLET ............................................................................... 289 
TABLE 40. STUDY 6 THEMATIC ANALYSIS ............................................................................................................ 290 
TABLE 41 PRE-INTERVENTION THOUGHTS AND BEHAVIOURS .................................................................................. 291 
TABLE 42. POST INTERVENTION CHANGES .......................................................................................................... 294 
TABLE 43. SUBJECTIVE EXPERIENCE OF THE INTERVENTION .................................................................................... 298 
TABLE 44. PARTICIPANT SATISFACTION WITH THE INTERVENTION ............................................................................ 303 
TABLE 45. SUMMARY OF THE INTERVENTION DEVELOPMENT STUDIES PRESENTED IN THIS THESIS ................................... 309 
TABLE 46. SUCCESSFUL MECHANISMS FOR INCREASING ADHERENCE ........................................................................ 312 
TABLE 47. PATIENT AND PUBLIC INVOLVEMENT IN RESEARCH ................................................................................ 318 
TABLE 48. KEY FOR APPENDIX 20. ALL STUDY SCALE CORRELATIONS .................................................................... 414 
TABLE 49. PARTICIPANT 1. BONE DRAWINGS ..................................................................................................... 438 
TABLE 50. PARTICIPANT 1. PEOPLE DRAWINGS ................................................................................................... 439 
TABLE 51. PARTICIPANT 2. BONE DRAWINGS ..................................................................................................... 440 
TABLE 52. PARTICIPANT 2. PEOPLE DRAWINGS ................................................................................................... 441 
TABLE 53. PARTICIPANT 4. BONE DRAWINGS ..................................................................................................... 442 
TABLE 54. PARTICIPANT 4. PEOPLE DRAWINGS ................................................................................................... 442 
TABLE 55. PARTICIPANT 5. BONE DRAWINGS ..................................................................................................... 443 
TABLE 56. PARTICIPANT 5. PEOPLE DRAWINGS ................................................................................................... 444 
TABLE 57. PARTICIPANT 6. BONE DRAWINGS ..................................................................................................... 444 
TABLE 58. PARTICIPANT 6. PEOPLE DRAWINGS ................................................................................................... 445 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
16 
 
TABLE 59. PARTICIPANT 7. BONE DRAWINGS ..................................................................................................... 446 
TABLE 60. PARTICIPANT 7. PEOPLE DRAWINGS ................................................................................................... 447 



















The psychological factors in adherence to osteoporosis medication: an exploration and 




AIDS – Acquired Immune Deficiency Syndrome 
BMA - British Medical Association 
BMD - Bone Mineral Density 
BMQ – Beliefs about Medication Questionnaire 
BPS – British Psychological Society 
CSM – Common Sense Model 
DEXA – Dual Energy X-ray Absorptiometry  
DHP – Division of Health Psychology 
DNA – Did Not Attend 
DoH- Department of Health 
DOTMQ – Difficulties Of Taking Osteoporosis Medication Questionnaire 
EPPM - Extended Parallel Process Model  
HBM – Health Belief Model 
HIV – Human Immunodeficiency Virus 
HRT – Hormone Replacement Therapy 
IBM SPSS – International Business Machines Statistical Packages for the Social Sciences 
IPQ – Illness Perceptions Questionnaire 
HCP – Health Care Professional 
HRT – Hormone Replacement Therapy 
MHRA – Medicines and Healthcare Products Regulation Agency 
MI – Motivational Interviewing 
MPR – Mean Possession Ratio or Medication Possession Ratio 
MRI – Magnetic Resonance Imaging 
MRC- Medical Research Council 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
18 
 
NOF – National Osteoporosis Foundation 
NOS – National Osteoporosis Society 
NICE – National Institute for Health and Clinical Excellence 
NHS – National Health Service 
NMC – Nursing and Midwifery Council 
PMT – Protection Motivation Theory 
PIS – Participant Information Sheet 
PPI – Patient and Public Involvement 
SCM – Social Cognition Models 
SD-Standard Deviation 
SRM – Self-regulation model 
TPB – Theory of Planned Behaviour 
WHO – World Health Organisation 
The psychological factors in adherence to osteoporosis medication: an exploration and 




This thesis will provide a contribution to the body of knowledge of the reasons for low 
adherence to oral medication prescribed for osteoporosis. Osteoporosis is a condition 
of bone deterioration, which commonly affects older people, though it can also occur 
in younger people to a lesser extent. The number of people worldwide aged 65 and 
over is expected to increase by approximately 850,000 each month (Kinsella & Velkoff, 
2001). Increasing life expectancy in many parts of the world means that osteoporosis 
and the fractures caused by osteoporosis will result in an increasing burden to the 
population worldwide. Considering the severity of hip fractures, it is of high 
importance that innovative methods are designed to help osteoporosis sufferers to 
manage their bone health and prevent these debilitating fractures.  
The main objective of the present research was to design and evaluate a theory-based 
behaviour change intervention to promote osteoporosis medication adherence, for 
patients with problems with medication adherence. At the heart of the intervention 
lies the premise that psychological factors underpin behaviour, therefore attempts to 
change these psychological factors may have an impact on the behaviour. Given the 
theorised link between psychological factors and behaviour, it is expected that some 
psychological factors (e.g. beliefs and emotions) may act as barriers to adherence. A 
series of studies guided by the Medical Research Councils (MRC’s) framework for the 
design and evaluation of complex interventions (Campbell et al, 2000) led to the design 
of an innovative adherence intervention. 
Four intervention development studies (both qualitative and quantitative) were 
undertaken to inform the design of a pilot multi-faceted behaviour change 
intervention. The objective of these studies was to find out as much as possible about 
osteoporosis medication adherence before designing an intervention. An outline of the 
stages of adherence intervention development is provided below. 
The opening chapter will provide a review of the clinical background and definition of 
osteoporosis, given that extensive knowledge of the medical condition under 
investigation is required for the delivery of a behaviour change intervention with this 
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population of patients. Both the aetiology and the risk factors for osteoporosis will be 
discussed, as well as the relevant pharmacological and non-pharmacological 
treatments. In addition, the ways in which health psychologists can help to improve 
health outcomes for osteoporosis patients will be outlined. 
Chapter two is a discussion of the problem of low adherence to medication, firstly as a 
general problem across medical conditions, progressing to focus specifically on this 
problem in relation to osteoporosis medication. The estimated prevalence of non-
adherence will be documented, as well as the known reasons for low adherence.  
The next chapter provides a discussion of the literature focussing on the potential 
solutions to the problem of low medication adherence. Behaviour change 
interventions previously carried out to improve adherence to osteoporosis medication 
are discussed. A key section of this chapter is a review of the relevant literature and 
theories which could be applied to the problem of low adherence to medication. 
Examples of previous applications of these theories to the problem of low medication 
adherence are included.  
Chapter four provides a summary of the previously presented literature and 
progresses to explain a novel method which was used to design an intervention to 
improve adherence to osteoporosis medication. This chapter discusses the MRC’s 
framework for the design and evaluation of complex interventions, which was used to 
guide the stages of intervention development. This chapter outlines the two health 
psychology theories that were selected to inform the design of the present research, 
with diagrams to show how the theories were operationalised. The two theories used 
were an extended self-regulation model (Leventhal et al, 1984; Horne, 1997) and the 
extended parallel process model (Witte, 1992). 
The fifth chapter presents study 1; which is a critical review of the psychological 
determinants of adherence to osteoporosis medication. All previously published 
studies which aimed to quantify the relationship between psychological factors and 
adherence were included. The studies were assessed for quality before the data were 
synthesised in order to produce a list of the psychological factors related to non-
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adherence to osteoporosis medication. This enabled the identification of gaps in the 
literature, which brought a focus to the research presented in the remainder of the 
thesis. 
The sixth chapter describes study 2, which is a qualitative study titled: ‘how do 
osteoporosis patients perceive their condition and medication.’ To gather information 
about how patients perceived their condition, they were interviewed and asked to 
draw how they visualised it. The interview schedule was based upon two theories of 
behaviour change, to explore whether these theories would be appropriate to 
underpin an adherence intervention for osteoporosis patients. 
Chapter seven presents study 3, a cross-sectional questionnaire study drawing on two 
theoretical models to investigate the relationship between illness perceptions, 
emotional responses, risk perceptions, medication beliefs and adherence to 
osteoporosis medication. Patients’ difficulties with taking osteoporosis medication 
were also assessed. The aims were to identify the psychological predictors of 
adherence and to evaluate the explanatory value of a range of potential predictors.  
The eighth chapter describes study 4, which is a questionnaire study to assess how 
patients respond to some potential intervention materials. The study was set to 
explore how patients respond to visual images/pictures of osteoporosis and to 
investigate which images might be effective to use in an intervention to promote 
medication adherence. A review of the use of visual images to communicate about 
health in other clinical settings is included.  
Based upon the results of the studies described above, an adherence intervention was 
designed and the research aim was to assess participants’ response to the 
intervention. Chapter 9 presents the Adherence To Osteoporosis Medication (ATOM) 
intervention (study 5). A process evaluation of the ATOM intervention is presented in 
chapter 10 (study 6). The final chapter provides a general discussion, with the 
implications for the design of a future intervention to promote adherence to 
osteoporosis medication. 
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1 Osteoporosis; a clinical background 
Chapter overview 
Osteoporosis is a common chronic, asymptomatic skeletal disease which primarily 
affects older people. The prevalence of chronic illness is rising due to increasing life 
expectancy and our lives are becoming progressively more sedentary (in the developed 
world). It is predicted that by the year 2050, there will be over 250,000 people living in 
the UK over the age of 100, in comparison to 10,000 in 2008 (NMC, 2009). Moreover, 
in the UK ‘by 2018 nearly three million (mainly older) people, will have three or more 
conditions all at once’ (DoH 2012, p9). Hence it is vital that health researchers strive to 
find methods to facilitate patients’ self-management of chronic conditions.  
The opening section will provide the clinical background and definition of osteoporosis. 
The prevalence of osteoporosis will be described, as well as future predictions of 
worldwide case numbers. Potential causes and the consequences of this condition will 
be discussed. The second section will describe the risk factors for osteoporosis, under 
the broad headings of controllable and uncontrollable, which will highlight the illness 
self-management required from individuals with osteoporosis. The third section will 
discuss the treatment options available for osteoporosis patients. Finally, areas in 
which health psychologists may be able to help patients suffering with osteoporosis to 
improve their bone health will be identified. 
1.1 Osteoporosis clinical background 
1.1.1 Definition 
Osteoporosis is a condition of the skeletal system for which there is no known cure. It 
has been defined as ‘a disease characterised by low bone mass and micro-architectural 
deterioration of bone tissue, leading to enhanced bone fragility and consequent 
increase in fracture risk’ (WHO, 1994). In other words, bones affected by osteoporosis 
become thin and weak and break easily (Eastell, 2005).  Hence it is a condition which 
puts a patient at high risk of suffering a fracture. While there is no cure for 
osteoporosis, the weakening of bones can be decelerated using medication and non-
pharmacological treatments described later in this chapter. 
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Osteoporosis has been called ‘the silent thief of bone’ because it is asymptomatic in 
the majority of cases (O’Connor, 1997). The definition of osteoporosis has developed 
and progressed, mirroring increasing medical knowledge of the features of the 
condition (Cummings et al, 2002). A French pathologist called Jean Georges Chretien 
Frederic Martin Lobstein 'the Younger' first discovered osteoporosis in 1820 and gave 
the disease its name (Schapira & Schapira, 1992). The term ‘osteoporosis’ is derived 
from the Greek words ‘osteon’ and ‘poros’ which when combined mean ‘porous bone.’  
 
Non-osteoporotic bone     Osteoporotic bone 
Figure 1. Electron microscope images of normal and osteoporotic bones 
A clinical definition of osteoporosis includes a description of the quality of the bone, 
which is given in terms of bone mineral density (BMD). BMD refers to the amount of 
minerals (such as calcium) in the bone and is now accepted as a key measure in 
determining a diagnosis of osteoporosis. In clinical practice, osteoporosis is diagnosed 
when the BMD in the lumbar spine, the femoral neck or the total hip is less than 2.5 
standard deviations (sds) below the normal BMD for a healthy 30 year old (Kanis et al, 
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1994). Osteopaenia is the term used to describe a bone condition in which BMD is in 
the range between 1.5 and 2.5 sds below that of a normal healthy 30 year old and is a 
precursor to osteoporosis (Kanis et al, 1994). The clinical definition allows osteoporosis 
to be labelled as a disease rather than merely a risk factor for fracture (Schapira & 
Schapira, 1992). BMD measurements form part of the basis for decisions about 
treatment options, along with other risk factors described below. 
The progression towards a clinical definition reflects advancement in both knowledge 
and medical technology, which now allows BMD to be measured and quantified using 
a Dual Energy X-ray Absorptiometry (DEXA) scan. However, the problem with such 
clinical definitions is the implication that there is a ‘normal’ bone mass to which 
everyone can be compared. It is argued that it would be more worthwhile to make a 
comparison of an individual’s peak BMD i.e. the point at which bones are strongest 
across the life span (usually between the ages of 20 and 30), with their BMD in later 
life (Fogelman, 1989). BMD measurements could then be used to monitor bone 
deterioration by comparison with peak bone mass.  
Bone is a living bodily tissue. From birth until death, bone is continuously being built 
up (formation), by osteoblast cells and broken down (resorption), by osteoclast cells 
through a process called bone turnover, also known as bone remodelling (Cummings et 
al, 2002). With increasing age comes an increase in the rate at which bone is broken 
down. This means that in older age the process of bone turnover results in an overall 
net loss of bone. The functional problem in osteoporosis is related to the speed of 
bone turnover, in which osteoclasts break down the bone faster than osteoblasts can 
replace it. Recently, it has emerged that bone turnover can be monitored using 
chemical bone markers, though they cannot be used to diagnose osteoporosis (Biver, 
2012). 
1.1.2 Prevalence 
Osteoporosis is a very common condition and although osteoporosis can affect men, 
most sufferers are women, usually post-menopause. In postmenopausal women, bone 
loss is exacerbated by a lack of oestrogen (Nordin et al, 1966). It is estimated that 
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osteoporosis affects 50% of women and 30% of men over 65 years of age (Wolf et al, 
2000). For women aged 80 years of age and over, the prevalence of osteoporosis is 
estimated at 70%; for women aged 60 and under, it is 15% (Melton et al, 2005). 
Osteoporosis afflicts people worldwide; it was estimated that 673 million people 
worldwide had osteoporosis in 2005 and if current trends in the ageing population of 
the world continue, this figure is predicted to at least double by 2050 (Reginster & 
Burlet, 2006). In the UK it is estimated that three million people suffer with 
osteoporosis (Burge et al, 2001). Its prevalence for people over 50 years of age is 50% 
for women and 20% for men (Van Staa et al, 2001). 
The areas of the body most commonly affected by osteoporotic fractures are the wrist, 
hips and spine (Blouin et al, 2008). In the year 2000 it was estimated that the 
worldwide number of new osteoporotic fractures was nine million; 1.6 million of these 
were hip fractures; 1.7 million were forearm fractures and 1.4 million were vertebral 
fractures (Blouin et al, 2008). With increasing life expectancy, the number of people 
living with one or more chronic conditions is rapidly growing (Stephens & Flick, 2010). 
This means that patients live for longer with a potentially reduced quality of life and 
increased reliance on the healthcare system. If healthcare services do not improve the 
way in which osteoporosis is managed and prevented, these figures will continue to 
rise dramatically. 
1.1.3 Diagnosis and monitoring 
The asymptomatic nature of osteoporosis in its early stages means there are no bodily 
indications of a problem and no discernible symptoms. Therefore it is very difficult to 
diagnose the disease until a fracture occurs (Kanis et al, 2004). This means that people 
are often unaware of having osteoporosis and do not realise how easily they can break 
a bone. This can result in people having pain from undiagnosed fractures for long 
periods of time. Although DEXA scans (discussed above) can detect osteoporosis and 
osteopaenia, it is common for a patient to first learn of the condition when they suffer 
from one or more fractures.  
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The order of events is usually that a fracture signals to healthcare professionals that 
the patient may have low bone mass; hence a fracture is suffered before a diagnosis of 
osteoporosis is given in the majority of cases. This is unfortunate because if a patient 
could be made aware of their poor bone health early on, they could take action to 
prevent the situation from deteriorating to the point where they suffer a fracture. A 
patient will be diagnosed with osteoporosis based upon how the fracture was 
sustained and by taking a host of other factors into account (which will be discussed 
below in the risk factors section). It is not routine practice within the NHS for older 
people to be screened for osteoporosis. The national osteoporosis society argues that 
routine screening/scanning would be of great benefit to patients (Nelson et al, 2002), 
as this would enable patients who are a high risk of fracture to take preventative steps. 
However, evidence for doing so is difficult to obtain, particularly in light of the debate 
as to whether BMD predicts fracture risk (discussed below). 
There is a debate as to whether BMD should be used to assess fracture risk. The use of 
BMD as a measure of osteoporosis and an indicator for medical intervention is 
contested by many researchers (see for example McGrother et al, 1999; Ruhl, 2008; 
Napoli, 2009). These authors believe that bone mineral density cannot predict fracture 
risk, because there are a host of other factors to take into account (these factors are 
described in the following section). On the contrary, others believe BMD should be 
used to predict fracture risk because ‘the relationship between bone mineral density 
and fractures is analogous to that between blood pressure and stroke and it is just as 
strong’ (Eastell, 1999).  
It is now common in clinical practice for BMD and other risk factors to be taken into 
account before deciding whether osteoporosis/osteopaenia requires treatment using 
the FRAX®™ tool. FRAX®™ is a web based tool which has been developed by the World 
Health Organisation (WHO). It calculates an individual’s risk for suffering a fracture 
(with or without a bone mineral density reading) and results in a score which is said to 
be able to determine a patient’s 10 year fracture risk (Kanis et al, 2008). FRAX®™ uses 
the following risk factors to determine fracture risk: age, gender, weight, height, 
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current smoking, BMD, prior fracture history, parental history of hip fracture, smoking 
status, alcohol consumption, rheumatoid arthritis and steroid use. 
Markers of bone turnover can be used to investigate and measure the process of bone 
remodelling. Markers include the cells involved in the formation and resorption of 
bone, osteoblasts and osteoclasts. Resorption markers can be measured in urine and 
serum, whereas formation markers can be measured in serum or plasma (Cummings et 
al, 2002). Biochemical markers can also be used as a factor to determine a FRAX®™ 
score. Biochemical markers are helpful in the assessment and monitoring of an 
individual with osteoporosis for two reasons: a) they can highlight underlying causes of 
bone loss, providing the basis for a more detailed evaluation of the patient and b) they 
can also be used to assess response to treatment (providing a baseline measurement 
has been taken before medication is begun). However, some changes found can be 
due to natural variability in the markers (Nishizawa et al, 2004).  
1.1.4 Consequences of the condition 
Osteoporosis can cause sufferers to experience painful fractures, hospitalisation and 
serious long term health consequences such as physical disability, reduced quality of 
life, loss of independence, decreased confidence and even mortality (Pasco et al, 
2005). Due to bone weakness, the major complication for people who have 
osteoporosis is an increased risk of a fragility fracture (also known as insufficiency 
fractures). A fragility fracture is a broken bone sustained on low impact (Giangregorio 
et al, 2009) e.g. by coughing, bending over or sneezing. Fractures are usually classified 
as vertebral (spinal) and non-vertebral and can vary greatly in terms of severity and 
recovery depending upon their bodily location. Osteoporosis patients often suffer 
many fractures, some undiagnosed for a long period of time. Fractures can lead to 
chronic pain. Patients’ fracture risk is manageable / preventable by patient adherence 
to treatment recommendations which will be discussed below. 
Hip fracture 
Hip fractures are the most debilitating type of osteoporosis related fracture, which in 
the vast majority of cases require hospital admission. As well as being associated with 
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a poor quality of life, hip fractures are associated with mortality. Once a patient suffers 
a hip fracture, they can become immobile for a long period of time and around one 
third of these patients does not recover (Cooper, 1997) and can require long-term 
medical care. Recently, a systematic review was conducted to explore hip fracture 
related mortality. It was found that hip fracture patients had between 8.4% and 34% 
increased relative risk of mortality when compared to age matched controls in the first 
year after hip fracture (Abrahamsen et al, 2009). The death rate within one year of a 
neck of femur (hip) fracture is typically reported as between 20% and 35% (Boereboom 
et al, 1991). The fact that fractures are related to mortality further highlights the 
importance of fracture prevention. 
Forearm Fracture 
Fractures of the distal forearm are usually caused by a fall on the outstretched hand, 
commonly among the middle aged and elderly (WHO, 1994). A fracture of the forearm 
can result in the need for surgical procedures and dependence on others to carry out 
daily activities (WHO, 2003). While fractures of the forearm do not cause as many 
problems as hip fractures, they can increase the risk of future fractures (Silman, 1995).  
Vertebral Fracture 
Many vertebral fractures are asymptomatic and remain undetected (Cooper et al, 
1992). One of the most dreaded consequences for osteoporosis patients (both 
aesthetically and as an increased risk factor for pneumonia) is kyphosis, which involves 
curvature of the upper spine (an anterior curvature). Kyphosis is also known as a 
hunchback or dowagers hump. This can result from fractures in the upper spine and 
can cause impaired mobility, discomfort, breathing difficulties, loss of appetite and loss 
of height (Black et al, 1994; Katzman et al, 2011). Kyphosis and loss of height are the 
only visible signs of osteoporosis.  
1.2 Risk Factors 
While the causes of osteoporosis are not yet fully understood, the risk factors are 
known and can be split into two categories; controllable and uncontrollable. The 
uncontrollable risk factors include: age, gender, heredity, race, hyperparathyroidism, 
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vertebral deformity, renal failure and amenorrhoea. As age increases the risk of 
osteoporosis also increases. The controllable life-style risk factors for osteoporosis are: 
diet, exercise (both lack of exercise or over exercise), falls, smoking, anorexia, 
alcoholism and osteoporosis medication adherence.  
Osteoporosis can be either a primary condition or secondary to another medical 
condition. When it is a primary condition in women, it is known as postmenopausal 
osteoporosis, due to the loss of oestrogen that takes place during the menopause. 
Oestrogen is known to protect against bone loss (Nordin et al, 1966). There are many 
diseases to which osteoporosis is secondary, for example: Cushing’s disease, kidney 
disease and metastatic cancer (Gallagher, 1990). There are iatrogenic causes of 
osteoporosis secondary to drug use, such as glucocorticoids (Cummings et al, 2002) 
and Armidex, which is a drug used to treat breast cancer. Further, co-morbidities 
which increase a person’s risk of falling may make them at increased risk of fracture, 
e.g. glaucoma (resulting in impaired vision) and alcoholism (resulting in ataxia). 
Diseases or medical conditions such as: rheumatoid arthritis, stroke, transient ischemic 
attack, muscular atrophy, motor neurone disease and Parkinson’s disease can cause 
people to become immobile can also result in osteoporosis (Cummings et al, 2002). In 
addition: anorexia, coeliac disease and food intolerances which cause malnutrition can 
also result in osteoporosis.  
As previously mentioned, osteoporosis is predominantly a female disease. There are 
three main reasons for this: 1) Oestrogen is protective against osteoporosis so when 
women produce less oestrogen post-menopause, they have an increased risk of 
developing the condition (Nordin et al, 1966). 2) As a general rule, women have a 
lower peak bones mass than men. In other words, women usually have a thinner body 
build and smaller bones. 3) Women of some cultures/religious beliefs are required to 
cover up some or all of their bodies, which can prevent them from absorbing vitamin 
D, which is obtained through sunlight. The role of vitamin D in bone health is explained 
in more detail below. 
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Other risk factors (which are difficult to determine as controllable or uncontrollable) 
include: steroid use, malabsorption (gut disorders), thyrotoxicosis, myeloma, primary 
biliary cirrhosis, hypogonadism, previous fragility fracture and mastocytosis (Harper & 
Webber, 1998; Cummings et al, 2002). More recently it has been found that major 
depression is a risk factor for low bone mineral density (Yirmiya & Bab, 2009) and a 
small relationship has been found to exist between stress and bone mineral density 
(Yilmaz & Eren, 2009).  
A balanced diet is important for healthy, strong bones. While it is well known that 
calcium is an essential dietary component for healthy bones, the benefits of 
magnesium and potassium are less well documented. A four year longitudinal study 
carried out by Tucker et al (1999) with a large sample of osteoporotic men and women 
found that higher intake levels of potassium, magnesium and fruit and vegetables 
were associated with greater bone mineral density scores (in both the hips and 
forearm). The evidence for a relationship between obesity and osteoporosis is 
conflicting. Whereas weight and load on the bones might be beneficial for bone health, 
childhood obesity has also recently been linked to a reduction in bone mineral density 
in later life (Slavkin, 2000). 
Research that has focused on education status and its possible links to osteoporosis 
has yielded mixed results. It would be reasonable to suggest that individuals who have 
higher levels of education would be better informed about health protective 
behaviours and therefore less likely to suffer from osteoporosis. However, one group 
of authors found the opposite to be true (Brennan et al, 2009). An explanation for this 
finding could be that people with higher levels of education are thinner (due to being 
well informed about the health risks of being overweight) and being thin leads to 
smaller bones which increases the chance of osteoporosis (Clark & Tobias, 2010). This 
is important because it shows that while socio economic status may influence bone 
health, the mechanisms behind how this occurs remain unclear. Previous research has 
shown that marital status was associated with fractures (Brennan et al, 2009). Those 
who are married or living with a partner were less likely to suffer a fracture than those 
living alone. This is likely to be due to increased social support.  
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1.3 Treatment for Osteoporosis 
While there is no cure for osteoporosis, there are various treatments which can 
improve bone mineral density and therefore reduce the risk of fracture. Osteoporosis 
is of interest to health psychologists as it is a chronic condition in which successful 
treatment requires self-management. Self-management is defined as ‘the individual’s 
ability to manage the symptoms, treatment, physical and psychosocial consequences 
and lifestyle changes inherent in living with a chronic condition’ (Barlow et al, 2002). 
Successful management of osteoporosis involves: medication-taking (when it is 
prescribed), a calcium-rich diet (or supplementation), vitamin D from sunlight (and 
from the diet to a lesser extent), weight-bearing exercise and following treatment 
recommendations. Chronic illness sufferers are not necessarily proficient at self-
managing their illness, therefore, there is scope for health psychologists to have a 
beneficial impact on improving the self-management of chronic conditions such as 
osteoporosis. 
Treatment for osteoporosis requires taking action in order to reduce the risk of an 
adverse health event in the future. The treatment options for osteoporosis can be 
separated into two categories; pharmacological and non-pharmacological. Both types 
of treatment require elements of self-management on the patient’s behalf to ensure 
that they follow their treatment regimes. Poor adherence to treatment is a major 
clinical problem which prevents treatments from being successful; this problem is the 
focus of the present research (discussed in chapter 2). The pharmacological and non-
pharmacological treatment regimes for osteoporosis patients are detailed below. 
1.3.1 Pharmacological Treatments 
There are a wide range of pharmaceuticals available for the treatment of osteoporosis. 
These treatments include two distinct types: antiresorptive and anabolic. 
Antiresorptive treatments such as bisphosphonates and denosumab inhibit osteoclast 
activity (or the breakdown of bone). Anabolic treatments such as strontium ranelate 
and parathyroid hormone can build new bone. Hormone Replacement Therapy (HRT) 
and calcium and vitamin D supplementation are also used in the treatment of 
osteoporosis. These will all be discussed in this section. Other treatments aside from 
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medication include surgical options, such as titanium plates, pins or vertebral plasty, 
which can help to support the spine and prevent fractures. 
Table 1. Change in Spinal BMD and Fracture Risk in Major* Trials of Osteoporosis 
Therapy for Postmenopausal Osteoporosis (Cefalu, 2004) 
 
There is strong evidence from many studies that osteoporosis can be effectively 
managed and osteoporotic fractures can be prevented with medication (Cranney et al, 
2002; Cefalu, 2004; Wells et al, 2008). However, the medication effectiveness relies on 
it being taken regularly in the fashion prescribed, which will be discussed in chapter 2. 
The following will discuss the most commonly used agents for treating osteoporosis. 
The treatments described in this section have all been found to significantly reduce the 
risk of fracture. Bisphosphonates are the first line treatment choice for osteoporosis 
(DeVilier, 2009). They work by slowing down the process of bone resorption, (i.e. 
reducing the speed of bone loss) and have been shown to reduce fracture risk and 
increased bone strength (Cranney et al, 2002; Wells et al, 2008). The majority of 
patients will respond well to the medication, provided the treatment is taken correctly 
and regularly. There are many different types of bisphosphonates available, with 
various dosing frequencies and methods of administration. Bisphosphonates can be 
taken in tablet form (for daily and weekly doses) and intravenously (once every three 
months and yearly doses). Daily bisphosphonates called alendronate (Fosamax) were 
previously the most common choice of treatment for osteoporosis. Scientific 
advancement has meant that lower dosing frequencies, such as the weekly 
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(alendronate or risedronate) and monthly (ibandronate) have been developed and are 
now more commonly prescribed than daily doses. There is also a three monthly 
infusion called pamidronate. Oral bisphosphonates are recommended for use for up to 
five years (Black et al, 2006). More recently an annual infusion called zoledronate has 
been approved for the treatment of postmenopausal osteoporosis (Black et al, 2007).  
When patients are prescribed any of the orally administered bisphosphonates, they 
are required to take them on an empty stomach, because food interferes with the 
absorption of these drugs. Patients are also required to take the medication with a 
large glass of plain water and to remain upright (sitting or standing, not lying) for half 
an hour after ingesting it. The instruction to remain upright is required to prevent 
severe side effects. One of the problems with daily/weekly oral bisphosphonates is 
that they are known to produce unpleasant side effects e.g. indigestion, reflux, 
diarrhoea, joint pain for some patients. In rare cases bisphosphonates have been 
linked to osteonecrosis of the jaw (DeVilliers, 2009).  Bisphosphonates have also been 
linked to oesophageal erosion and oesophageal cancer (Green et al, 2010). Before 
patients are prescribed bisphosphonates, they should be advised to have a dental 
check-up. This is because a tooth extraction in a patient taking bisphosphonates could 
lead to serious complications such as osteonecrosis of the jaw (Marx 2003).  
The introduction of a yearly infusion of zoledronate as the routine treatment for 
osteoporosis patients within the NHS has eliminated several of the problems 
associated with non-adherence to medication. This is because patients do not have to 
remember to take their medication regularly and also, there are no oesophageal side 
effects. Intravenous doses require the patient to make a short hospital visit, as the 
infusion is administered over at least fifteen minutes. Although zoledronate 
demonstrates perhaps the best overall efficacy data thus far for any osteoporosis 
treatment (Rizzoli, 2010), it is currently not available to all NHS patients, as it is 
awaiting clearance from the National Institute for Health and Clinical Excellence (NICE). 
In addition, some patients suffer acute flu like symptoms after the first infusion in 
particular and the drug is used with caution in those with renal impairment.  
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Strontium ranelate (Protelos) is an anabolic agent which is commonly prescribed for 
osteoporosis and has been found to reduce the risk of fracture (Stevenson et al, 2007). 
Strontium ranelate is a powder which is dissolved in water and is taken orally. The 
administration directions are not easy; patients are required to take the medication 
midway through a four hour fast. In other words they are required to take it two hours 
after eating and then fast for two further hours. The reason for fasting is that the 
medication is poorly absorbed. Patients are advised to take it two hours after dinner 
before they go to bed. There can be side effects with this medication which include: 
diarrhoea, nausea, loss of memory and rash. While strontium ranelate has been found 
to improve Quality Adjusted Life Years (QALYs), it was found that strontium ranelate is 
not as cost effective as bisphosphonates (Stevenson et al, 2007). It is therefore often 
given to patients who cannot tolerate the side effects of bisphosphonates.  
Another anabolic agent used to treat osteoporosis is teriparatide (Forsteo), which is a 
parathyroid hormone. Researchers have found this medication to be very effective in 
improving bone mineral density and it has been named the gold standard for treating 
osteoporosis (Neer et al, 2001). It can be either self-administered by daily injections, or 
administered by a team of nurses who visit patients at home every day. However, it 
does not improve bone density for all osteoporosis sufferers. It is a very expensive 
medication and is currently only recommended for patients over 65, or those with very 
severe osteoporosis who have suffered multiple fractures. 
HRT is considered as a second line treatment option for osteoporosis in older 
postmenopausal women. It produces effects similar to bisphosphonates (Cefalu, 2004). 
HRT has a role in the treatment of younger women at high risk of fracture, particularly 
if they have menopausal symptoms. However the British Medical Association (BMA) 
warns that HRT increases the risk of breast cancer (Mayor, 2003) and stroke.  
1.3.2 Non-pharmacological treatments 
There are also non-pharmacological treatments which can be used to prevent 
fractures. These involve diet, exercise, falls prevention and adherence, which are the 
major modifiable behaviours which can impact osteoporosis (aside from medication-
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use). Health psychologists can design behaviour change interventions for patients to 
promote engagement in these health related behaviours. Many of the health 
behaviours discussed below are also relevant to the self-management of other medical 
conditions.  
A balanced diet is needed to maintain the structure and function of the skeletal 
system. Various vitamins and minerals within the diet are important for maintaining 
bone health. Calcium is needed to keep bones and teeth rigid and is important for 
many of the body’s metabolic processes (Cummings et al, 2002). It is believed that 
calcium needs to be built up from when a person is young and into early adulthood 
(around 25-30), in which peak bone mass is reached. Calcium can be obtained from the 
diet from milk and other dairy products as well as through supplementation. Much of 
the calcium consumed by an individual is not absorbed by the body. Post-menopause, 
women excrete more calcium due to a decrease in the ability to absorb calcium. As for 
many other medical conditions, high sodium chloride (common salt) intake is not 
advised for patients with osteoporosis. This is because sodium competes with calcium 
for absorption into the kidneys (Saric et al, 2005) and it can cause more calcium to be 
excreted in urine (Caudarella et al, 2009).  Malnutrition such as anorexia nervosa may 
have a detrimental effect on bone health because it results in a failure to reach peak 
bone mass which is a result of a lack of vitamins and minerals (Seeman et al, 1992). 
Vitamin D is a hormone which is essential for healthy bones; it is absorbed into the 
body through exposure to sunlight (Holick, 2007). Vitamin D is integrally involved in 
bone metabolism through stimulation of calcium absorption from the intestine and 
resorption from the kidneys. Deficiency in vitamin D is common due to the weather 
conditions in countries such as the UK, where it is difficult for individuals to get the 
required level of sunlight exposure throughout the year. To a lesser extent vitamin D 
can be obtained from food such as oily fish. Vitamin D deficiency is known as 
osteomalecia and can result in osteoporosis, muscle weakness and reduced immune 
system function. However, there is mixed evidence as to whether vitamin D 
supplementation can reduce the risk of fracture (Sahota, 2010). 
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People who are physically active have higher bone mass; this is important when 
considered in conjunction with the increase in sedentary lifestyles typical of 
contemporary society. This sedentary lifestyle could be detrimental to bone health. To 
reduce the likelihood of fractures, it is important for people to engage in weight 
bearing exercises such as walking - which can strengthen the bone (Inoue, 1993). There 
is a curvilinear relationship between weight bearing exercise and bone mass.  
Increasing the weight loaded onto bones increases bone mass up to a certain point, 
whilst not enough weight bearing exercise can be detrimental to bone health. 
Extensive exercise (e.g. marathons) can also be detrimental to bone health as too 
much pressure can be placed on the skeleton (Torstveit, 2010).While weight bearing 
exercise is recommended for osteoporosis patients, this should be carried out with 
caution, due to an increased risk of falling. 
Falling over is a common cause of fracture for older people. Patients with osteoporosis 
need to do whatever they can to prevent themselves from falling over, due to their 
high fracture risk even with low impact falls/injury.  Falls prevention can involve: 
removing hazards from the environment, muscle strengthening and balance training 
exercises (Yardley et al, 2006). Once a person has suffered a fracture they are at 
increased risk for subsequent fractures (Gardsell, 1989). For example, a prior vertebral 
fracture significantly increases the risk of a subsequent vertebral fracture (Lindsay et 
al, 2001). Therefore falls prevention is a high priority in reducing the consequences of 
osteoporosis. In conjunction with other methods of falls prevention, individuals can 
wear hip protectors to protect themselves against hip fracture (Handoll, 2010). They 
can also be made aware of the importance of always holding on to a rail when they 
climb stairs.  
While moderate amounts of alcohol may be beneficial to bone health, excessive intake 
can result in an increased risk of falling. As well as making people ataxic and hence 
more likely to fall, a high intake of alcohol results in reduced bone formation. 
However, moderate alcohol intake has not been linked to an increased fracture risk 
and recently it has been indicated that barley which is found in beer could be 
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beneficial to bone health, because barley contains silicon which improves bone 
mineral density (Casey & Bamforth, 2010).  
1.4 Summary 
Osteoporosis is a very common condition (particularly in women) and the fractures 
caused by osteoporosis can result in severe disability and even mortality. There is a 
wide range of effective treatments available to lower the risk of fracture. Osteoporosis 
is a condition which requires self-management from the patients, due to the chronic 
nature of this condition. There is scope for health psychologists to develop self-
management interventions with an aim to improve bone health and prevent fractures. 
This can be achieved through the promotion of behaviour to reduce the risk of fracture 
such as: medication-taking, maintaining a diet rich in calcium, exposure to sunlight for 
vitamin D, weight bearing exercise and falls prevention. Adherence to the 
recommended health related behaviour is a key focus for health psychologists. The 
next chapter will discuss the problem of low adherence to medication for the 
treatment of chronic conditions, a worldwide clinical problem which can lead to poor 
health outcomes for patients. 
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2 Adherence to medication 
Chapter overview 
This chapter will introduce the problem of non-adherence to prescribed medication, in 
two main sections. The first will describe the problem of low adherence to medication 
across medical conditions, including the prevalence, determinants and implications of 
non-adherence. The terminology used to describe patients’ medication-taking 
behaviour will be described, namely compliance, adherence and persistence. In the 
second section, the same format will be used to discuss the adherence problem in 
relation to osteoporosis treatment.  
2.1 Background 
Health psychologists are interested in adherence to medication because of the 
behavioural influence it has on patients’ health outcomes. It is well established that 
non-adherence to osteoporosis medication is associated with an increased risk of 
fracture (Siris et al, 2006; Patrick et al, 2010; Ross et al, 2011). Low adherence to 
treatment is a major public health concern worldwide, particularly for chronic 
conditions, which can require the burden of a lifetime of medication. Osteoporosis is a 
condition with serious personal costs for patients, including: painful fractures, 
hospitalisation, reduced quality of life and disability, as well as financial consequences 
for healthcare services. The medical profession prescribes medication which has been 
shown to be effective to lower the risk of fracture. However, success of the treatment 
depends on patient adherence (Cranney et al, 2002; Wells et al, 2008). Low levels of 
treatment adherence can result in increased hospital admissions which are 
preventable and are a waste of health care resources. Across medical conditions, 
patients who take their prescribed medication have been found to have better health 
outcomes. Yet osteoporosis has two clinical features that mean designing 
interventions for adherence are challenging; it is chronic and asymptomatic.  
As well as being a potential cause of deterioration in a patient’s health, it is estimated 
that with low adherence to treatment, the outlay to the NHS is up to £150m per year 
in medication costs (McDowell and Barnett, 2012). It has become essential to find 
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ways to help patients manage long-term conditions and improve their quality of life 
(DoH, 2012). Given that medication is the most common medical intervention (Horne 
et al, 2005), it is worthwhile investigating various ways of optimising treatment 
delivery, to prevent adverse health outcomes, enhance patients’ quality of life and 
improve the quality of the healthcare service (Osterberg & Blasche, 2005; McDowell & 
Barnett, 2012). The NICE (2009) state that non-adherence to medication highlights a 
failure in health service delivery. Before designing behaviour change interventions to 
promote treatment adherence, it is vital to review the literature in order to select a 
behaviour change technique which is likely to be efficacious.  
It is now commonly accepted that psychological and social factors play an important 
role in a person’s illness experience, health choices and outcomes (Weinman & Petrie, 
1997). For this reason, health psychologists are interested in the relationship between 
beliefs and health related behaviour. It is theorised that a patient’s beliefs about their 
health and illness are important determinants of their illness self-management 
behaviour, such as medication-taking. Theories of this nature will be discussed in 
chapter three.  
2.2 Terminology 
The terminology used to describe patients’ medication-taking behaviour has changed 
over time (Cramer et al, 2008). In the research literature, the term compliance was 
previously used to signify the extent to which a patient follows treatment regimens 
prescribed by their doctor (Miller et al, 1997). Recently, as the healthcare system has 
aimed to shift from ‘doctor-centred care’ to ‘patient-centred care’, the terminology 
used has also shifted to reflect this change (Endelman, 2000). For this reason, 
researchers now more commonly use the term adherence in place of compliance. The 
rationale for this terminology shift was to move away from the idea of patients 
passively following their doctor’s orders, towards a doctor-patient agreement of 
treatment plans. Furthermore, the term adherence is intended to be less judgemental 
than compliance (McDonald et al, 2002) and would therefore facilitate a more 
collaborative doctor-patient relationship. 
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More recently, Haynes et al (2008) suggested that adherence consists of two elements 
of medication-taking, compliance and persistence. Compliance and persistence have 
been defined as “the extent to which a patient acts in accordance with the prescribed 
interval and dose of a dosing regimen” and “the extent to which a patient continues to 
follow the treatment advice without a break and without stopping” respectively 
(Cramer et al, 2008 p 46). For the purposes of this thesis, the term adherence will be 
used to signify medication-taking behaviour, because the term adherence incorporates 
all elements of patients’ medication-taking behaviour.  
There are various definitions of adherence; adherence has been defined as ‘the extent 
to which a patient’s behaviour…coincides with medical or health advice’ (p2868) 
(McDonald et al, 2002). NICE (2009) report that the term adherence ‘presumes an 
agreement between a doctor and patient’ (p3). DiMatteo et al (2002) describes non-
adherence as a missed chance for therapeutic benefit. The terms adherence, 
persistence and compliance are often used interchangeably even though they refer to 
different elements of medication-taking behaviour, which can cause problems with 
analysing and interpreting adherence to medication data. Without a universal 
language to describe medication-taking behaviour, it is likely that researchers will 
measure different elements of it. For example, in studies of persistence, the duration 
over which doses are taken is measured.   
2.3 The prevalence of non-adherence to medication 
Patients with chronic, long-term conditions such as osteoporosis are noted to have 
problems with medication regimens, with an estimated 30-50% of medications (across 
countries and medical conditions) failing to be taken as prescribed (World Health 
Organisation, 2003). This has implications for patients, the healthcare system and 
society (NICE 2009). If a medicine is correctly prescribed, improving adherence (across 
medical conditions) would have greater health benefits than improving the nature of 
the medication (Horne et al, 2005). Interventions designed to improve adherence 
should focus on conditions which now have efficacious medications to treat them 
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(Horne et al, 2005), however, medication-taking is a complex behaviour with no single 
factor predicting it.  
Despite the large and growing body of research indicating the effectiveness of 
medication for many medical conditions (and the poor health outcomes associated 
with non-adherence), healthcare professionals still have great difficulty in convincing 
patients to follow medication and treatment advice in all specialities of the health care 
setting (NICE, 2009). In the research literature, it is estimated that only 50% of 
prescribed medications are taken (Haynes, 1996). It is expected that in practice, the 
rate of adherence is lower than that detected in research studies, given that research 
includes an element of adherence monitoring (Papaioannou et al, 2007). 
When a doctor prescribes medication to an out-patient, self-management is required 
on the part of the patient to go and pick up their prescription and then to take the 
medication as directed. The problem of non-adherence is described as a hidden 
problem, difficult to detect by healthcare providers and concealed by patients (Horne 
et al, 2005). While non-adherence is often hidden, it has been stated that non-
adherence usually manifests three months after a medication is prescribed (Cummings 
et al, 2002). Therefore interventions to target adherence and improve self-
management are likely to beneficial within the first three months of treatment. 
2.4 Measurement  
Obtaining a valid and reliable measurement of adherence to medication is a significant 
problem for researchers and to date there is no commonly accepted accurate 
measurement. There are a wide range of measures in adherence research, each with 
its own merits and flaws. Measures of adherence can be categorised as direct or 
indirect (Osterberg & Blaschke, 2005). Direct measures include direct observation and 
measurement of biomarkers in blood and urine. Indirect measures include self-reports 
(questionnaires, interviews or diaries), clinical outcomes, pill counters and performing 
pill counts, medication possession ratio (the number of doses collected from the 
pharmacy) and healthcare providers’ opinion (estimation).  
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In-direct measures of adherence are most commonly adopted by researchers due to 
their practicality. The use of self-reports is the most convenient and commonly used 
method of measurement in psychology research, yet its validity is questionable 
(Baumeister, 2007). Presentational bias is a major problem with self-report scales, 
because it may mean that people are motivated to present themselves as adherent 
rather than accurately reporting their medication-taking behaviour. The medication 
adherence report scale (MARS) is a commonly used (validated) measure of adherence 
to medication (Cohen et al, 2009). The MARS attempts to overcome problems of the 
accuracy of self-report data by starting with the following statement: 
“Many people find a way of using their medicines which suits them. 
This may differ from the instructions on the label or from what their doctor has said. 
We would like to ask you a few questions about how you use your medicines.” 
However, a further problem in using self-report is not only about relying on a patient 
to be truthful, but also to be accurate in their recall of events.  
Pill counters are commonly used electronic devices which are fitted to a medication 
bottle and used to count the number of doses taken. Methods that involve taking an 
accurate measure of how much medication has been taken, such as pill counters, may 
influence adherence rates because patients know they are being monitored. Another 
way to monitor adherence to medication is to get a doctor’s estimate of how much 
medication their patient has taken. The accuracy of this measure is limited (Brody, 
1980). It is an opinion rather than a measure. 
Another way to measure medication adherence is through the use of biomarkers. 
Biomarkers are chemicals found in blood or urine which indicate an individual’s 
physiological state. While they may overcome the problem of errors in human 
judgement, they are not completely accurate as a measure of adherence because 
some patients may not be responding to the medication, even though they are taking 
it (Cummings et al, 2002). Further, they are not routine tests for osteoporosis patients. 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
43 
 
A measure to quantify adherence, which attempts to overcome many of the above 
mentioned biases, is to use electronic records of prescriptions that patients have 
collected from the pharmacy (although this is not feasible in the UK). This type of 
measurement is called the Mean Possession Ratio (MPR) (Andrade et al, 2006) which is 
estimated by the number of daily doses required, divided by 365; this provides the 
number of days of medication that is available to the patient during a one-year period. 
The problem with using the MPR is that it cannot accurately show a patient has 
actually used their medication - it only indicates that medication has been collected 
from the pharmacy. This poses a challenge for many reasons; aside from the problem 
of not knowing whether the patient has actually taken the medication, it will not then 
be accurate when a patient is required to change their medication. If a patient is asked 
to change their medication and they adhere to it, the MPR can make their adherence 
appear to be higher than 100% (Lekkerkerker et al, 2009). This measure could lead to 
an overestimation of adherence and over adherence is still classed as non-adherence. 
The data collected using MPR can be difficult to interpret.  
Further, the MPR cannot measure whether the medication was taken as prescribed, on 
time, etc. For example, if the instructions state the medication should be taken in the 
morning, or should be taken on an empty stomach. The reasonable assumption in 
using this measure is that patients would not continue to collect medication that they 
were not using. A further problem is that data collected using the MPR relies on the 
data recorded by the pharmacy to be correctly entered. It is important to keep these 
issues in mind when reviewing studies which have used the MPR measure.  
A previous suggestion to tackle the problem of selecting an adherence measure is to 
use two or more different measures together (Osterberg and Blaschke, 2005), but the 
usefulness of using various measures of adherence simultaneously is debateable. A 
recent study investigating adherence to Human Immunodeficiency Virus (HIV) 
medication found that using self- reports, MPR and biomarkers concurrently as 
measures of adherence made the results difficult to interpret, because each measure 
gave a different result which showed no relationship to the others (Holzemer et al, 
2006). It is difficult to determine which of these measures of adherence are valid and 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
44 
 
reliable. Collecting adherence data in many different ways to look for comparisons was 
counterproductive in this study.  
A further measurement issue to consider when designing adherence interventions is 
determining how long to measure medication-taking behaviour for i.e. the optimal 
amount of time to enable an accurate measurement of medication-taking, or the 
number of follow-up measurements required, e.g. 3 months or 6 months after 
beginning measurement (Haynes et al, 2008). 
Health outcome data should always be collected as an outcome measure in 
interventions to improve adherence to medication (Haynes et al, 2008), e.g. the 
number of fractures sustained in the case of osteoporosis (Gleeson et al, 2009). When 
interventions do not measure the relevant health outcome(s), they are omitting an 
important indication of adherence, because health is the overall goal of adherence to 
medication. A systematic review investigating adherence to osteoporosis medication 
interventions excluded those studies which did not include the number of fractures as 
an outcome measure, because they were viewed as having missed the most important 
result (Imaz et al, 2010). One of the disadvantages of not measuring the relevant 
health outcomes is that it could lead to research which is less clinically relevant.  
2.5 The determinants of non-adherence to medication 
In order to understand non-adherence, Schousboe et al (2013) stated that 
‘understanding the aetiology of the phenomenon is critical to craft practical 
management strategies that may mitigate the problem’ (p22). This means that before 
designing an adherence intervention, the determinants of non-adherence should be 
identified. The reasons for non-adherence to medication are multi-factorial; over 200 
reasons have been documented by researchers (Vermeire et al, 2001) at the patient, 
health-care provider and system levels (Miller et al, 1997). It has been suggested that 
the reasons for non-adherence will vary from person to person (Solomon et al, 2010). 
There are many variables which may influence adherence to medication and the 
reasons for non-adherence are still poorly understood by health researchers and 
healthcare professionals. Studies indicate that demographic factors such as gender, 
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race and socio-economic status are not consistently associated with adherence to 
medication (Horne et al, 2005).  
Non-adherence to medication is often conceptualised by researchers as intentional 
and unintentional (Horne, 1997) and there is a large body of evidence to support this 
distinction (Wroe et al, 2002). This is a useful distinction, as it highlights the 
importance of understanding whether non-adherence is a conscious process or not. 
The reasons for non-adherence can also be classified as patient centred or 
doctor/organisation centred. This distinction is useful because recognition that the 
problem is also at the system level removes the blame from the patient (Barber, 2002). 
Intentional non-adherence occurs when a patient makes an active deliberate choice to 
miss a dose of their medication (Horne, 1997). For example, deciding not to take 
medication to avoid unpleasant side effects would be classified as intentional non-
adherence. Another intentional reason for non-adherence is related to not being able 
to feel the benefit of medication e.g. not perceiving that the drugs are working, or not 
perceiving a need for medication. Intentional non-adherence highlights the fact that 
patients’ beliefs about their medication can play a big role in their decision about 
whether to take it, which will be discussed below.  
Unintentional non-adherence is a more passive process. Some unintentional reasons 
for non-adherence include: lack of manual dexterity (and therefore inability to 
administer medication), problems with understanding how to administer the 
treatment and cognitive deficits such as Alzheimer’s disease, confusion and 
forgetfulness (which could be key problems in older populations [Ryan, 1999]). The 
proportion of intentional and unintentional non-adherers is unknown (Barber, 2002).  
However, there are some factors which are difficult to classify as intentional or 
unintentional. For example, a patient may omit a dose of their medication because 
they feel too unwell to take it. This example could be classified as intentional or 
unintentional non-adherence. The financial cost of medication is a factor which may 
lead to poor adherence, though it is difficult to categorize this as intentional (when 
individuals choose to spend their money on something else) or unintentional (when 
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individuals do not have the required amount of money). Financial cost is not relevant 
to older patients in the UK because there are free prescriptions for all over the age of 
60. The inconvenience of a particular medication regime is also difficult to categorize 
as intentional or unintentional because the inconvenience may result in an intentional 
choice not to take the medication, or it may mean that a patient is unintentionally 
unable to follow instructions. This is similar to the problem of side effects, which may 
render the patient physically unable to take medication due to suffering its unpleasant 
effects (e.g. vomiting) even though the patient wants to take their medication. While it 
is important that both intentional and unintentional reasons are taken into account 
when trying to find ways to improve adherence, it is possible that this distinction is too 
simple and other reasons for non-adherence are therefore missed. 
Further investigation of the distinction between intentional and unintentional non-
adherence to medication for chronic conditions has produced some interesting 
findings. Gadkari & McHorney (2012) wrote a paper titled ‘unintentional non-
adherence to chronic prescription medications: How unintentional is it really?’ These 
authors studied adherence to medication in 24,017 adults with at least 1 of 6 chronic 
conditions. These were asthma, hypertension, diabetes, hyperlipidemia, osteoporosis 
and depression. Both types of non-adherence were measured (intentional and 
unintentional). Importantly, unintentional non-adherence was predicted by: 
 Patients’ beliefs about the necessity of medication  
 Their concerns about taking it 
 Their concerns about affordability.  
This demonstrates that seemingly careless/unconscious behaviours are related to 
beliefs. The findings from this paper suggest that unintentional non-adherence may 
reflect intentions.  
Numerous studies have demonstrated that communication and the doctor–patient 
relationship influences adherence to medication (Lau et al, 2008; Young & 
Oppenheimer, 2009). It is logical that the relationship between doctor and patient, 
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including the way they communicate, is of utmost importance when influencing 
adherence to medication, because it is vital that both parties understand each other. It 
is important that patients feel able to discuss any concerns about the medication they 
have been prescribed. The importance of this relationship was confirmed by a meta-
analysis whose authors concluded that good doctor-patient communication is 
correlated with patient adherence to treatment (Zolnierek & Dimatteo, 2009). These 
findings indicate that interventions to promote adherence should focus on improving 
communication between patients and health care professionals (HCPs). 
The number of medications a patient is currently prescribed is likely to have an 
influence on medication adherence. It is expected that an increased number of 
medications with varying administration instructions is a barrier to adherence because 
of the complexity of following multiple medication regimes. This is particularly relevant 
to older people, who are likely to have multiple co-morbidities. Roth & Ivey (2005) 
conducted a telephone interview study with 100 elderly patients and found the mean 
number of prescribed medications was 9.6. Adherence to these medications was low 
at 53%, but this percentage varied according to the type of medication prescribed.  
Previously researchers have investigated the rate of adherence to placebo 
medications, with some interesting findings. There is some evidence to suggest that 
adherers tend to have better health outcomes than non-adherers (Simpson et al, 
2006). Patients who adhered to a placebo medication tended to have better health 
outcomes (including mortality rates) than those who failed to take the placebo as 
prescribed. This is known as the healthy adherer effect. There are mixed findings of the 
healthy adherer effect in osteoporosis patients. In the fracture intervention trial, 
patients who were adherent with their placebo medication had a lower risk of hip 
fracture than those who took less of their medication (Curtis et al, 2011). Fracture risk 
was ascertained by t-scores and BMD. The authors concluded that adherence could be 
a proxy measure for other factors related to bone health, e.g. adherent patients may 
be more likely to engage in other behaviours to prevent fracture, such as physical 
activity. However, (Caderette et al, 2011) did not find any evidence for the healthy 
adherer effect in osteoporosis patients.  
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Another possible explanation for the placebo effect is perhaps the characteristics of 
people who adhere to medication may be different to those who are non-adherent, 
e.g. patients who follow their doctor’s advice are more competent and able to follow 
instructions. Perhaps adherent patients are more likely to follow doctors’ advice about 
healthy behaviours in general, not just regarding medication-taking. In other words, it 
is possible that adherers have better health outcomes due to their compliant nature, 
or their ability to control their own health behaviour, in addition to the 
pharmacological components of the medication. Another possible explanation is that 
those who have positive outcome expectancies are more likely to be adherent with 
treatment recommendations (Rudy et al, 2009). 
2.6 Adherence to osteoporosis medication 
The rate of non-adherence to osteoporosis medication is similar to the rates reported 
for other chronic medical conditions such as cancer, heart disease as well as for mental 
illness (Horne et al, 2005). Despite the ability of current medical preparations to 
reduce the risk of fracture, several systematic reviews conclude that adherence to 
osteoporosis treatment is lower than required for sufficient protection from fractures 
(Gleeson et al, 2009; Cramer et al, 2007; Imaz et al, 2010). A meta-analysis including 
more than 50,000 study participants has shown that adherence to osteoporosis 
medication is 48% (Kothawala et al, 2007), whereby medication was taken on 48% of 
the days it was required. It has been estimated that after the first year of treatment, 
only 45% of patients continue to take their medication as prescribed by their doctor 
(Solomon et al, 2005). A more recent systematic review estimates adherence to 
osteoporosis medication to be between 41% and 76% and persistence at one year was 
estimated to be between 39% and 67% (Gleeson et al, 2009). The adherence rates in 
these reviews are a cause for concern. Further, it is estimated that adherence rates are 
lower for conditions with no daily symptoms (Osterberg & Blaschke, 2005). Finally, 
research studies are likely to overestimate adherence (as discussed in the 
measurement section), therefore the actual adherence rates could be lower. 
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A serious direct consequence of failure to adhere to osteoporosis medication is a 
fracture. Many studies have demonstrated that lack of adherence leads to a greater 
chance of sustaining a fracture (Caro et al, 2004; Huybrechts et al, 2006; Blouin et al, 
2008). For example, in a large cohort study of over 21, 000 female participants with 
osteoporosis, 41% were found to be non-adherent to alendronate or risedronate 
(Blouin et al, 2008). These authors also reported that women over 80 years of age who 
did not take their medication were at a 48% greater risk of fracture when compared to 
those who were adherent. A study which included a systematic review and meta-
analysis demonstrated that fracture risk is increased by 46% (n=171,063) if a patient is 
not adherent to their medication regime (Imaz et al, 2010). This increased fracture risk 
is the justification to find a way to assist patients with medication adherence.  
A further cause for concern for osteoporosis patients is that one group of researchers 
found adherence to osteoporosis treatment to be worse than medication adherence in 
other chronic conditions, such as diabetes and hypertension (Briesacher et al, 2008). A 
possible reason for this low level of adherence is that patients’ do not perceive 
osteoporosis as a serious condition (Rimes et al, 1999). A study of 956 patients with 
osteoporosis indicated that after seven months, almost a quarter of them had 
terminated their medication-taking (Tosteson et al, 2003). Gadkari & McHorney (2012) 
compared adherence across six chronic diseases and found that osteoporosis had the 
highest level of unintentional non-adherence. Further research is needed to ascertain 
the reasons for this low level of medication adherence. Following on from this, 
interventions need to be designed to improve adherence, ultimately for patients to get 
the desired improved health outcomes from their medication, in order to prevent their 
health from deteriorating and consequently to stem the waste of NHS resources.  
2.6.1 Determinants of non-adherence to osteoporosis medication 
Many researchers have investigated the influence of demographic factors on 
adherence to osteoporosis medication. As shown in other medical conditions, there 
are no consistent links between demographic variables and adherence to osteoporosis 
medication (Solomon et al, 2005). Identifying the demographic predictors of non-
adherence might be useful in identifying patients who are likely to be non-adherent. 
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Possible demographic and clinical predictors of non-adherence to osteoporosis 
medication include: age, number of co-morbidities, dosing frequency, inconvenience 
of the medication regime, side effects. These factors will be examined below, as well 
as the influence of the doctor-patient relationship and the media. 
Non-modifiable determinants  
There are mixed findings as to whether age is related to osteoporosis medication 
adherence. In many studies, age was not associated with non-adherence (Lo et al, 
2000; Downey et al, 2006; Carr et al, 2006). Increasing age was associated with higher 
adherence in some studies (Recker et al, 2005) and lower adherence in others 
(Solomon et al, 2005). Older people often have multiple co-morbidities resulting in 
them having to take many different medications (Briesacher et al, 2008). This makes 
their medication regime more complicated and more difficult to adhere to. Lack of 
adherence in older people is likely to have worse outcomes (Myers & Midence, 1998) 
which highlights the importance of further research in this area.  
The number and type of illnesses an individual is prescribed medication for are 
believed to be predictors of adherence to osteoporosis medication. Briesacher et al, 
(2008) conducted a study to compare the literature on adherence for seven diseases: 
hypertension, diabetes, hypercholesterolemia, hyperparathyroidism, gout, seizure 
disorders and osteoporosis. Adherence to osteoporosis medication was 51% and it 
decreased as co-morbidity increased. Adherence to osteoporosis and gout medication 
was lower compared to the other medical conditions, possibly because these diseases 
are generally thought to be less serious than the others in the study. Similarly, 
Penning-van Beest et al, (2008) reported that as the number of co-medications 
prescribed increased, osteoporosis medication adherence decreased. 
There are many osteoporosis medication related factors which can influence 
adherence to medication. There are numerous studies demonstrating that dosing 
frequency of medication has been shown to influence adherence in osteoporosis 
patients (Rabenda & Reginster, 2005; Penning-van Beest et al, 2008). Medications 
which do not have to be taken daily could be one answer to the problem of poor 
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adherence to medication. However, there is mixed evidence as to whether reducing 
the dosing frequency from daily to weekly improves adherence. A number of studies 
show improved adherence to weekly rather than daily dosing regimens (Rabenda & 
Reginster, 2005; Carr et al, 2006; Cramer et al, 2007). However, although adherence 
was better, it was still sub-optimal with a weekly dosing frequency. A more recent 
study with a large sample has shown that dosing frequency was not a significant 
predictor of adherence when other variables were controlled (McHorney et al, 2008).   
Reducing the dosing frequency may improve low adherence, but it does not 
completely solve the problem, possibly because weekly doses are still fairly regular. 
Yearly doses of zolendronate are available to NHS patients, but only those with a 
special need for this medication e.g. severe osteoporosis or difficulty swallowing 
tablets. Patients who are prescribed zolendronate are required to attend a hospital 
appointment for a 15-20 minute intravenous infusion once a year, rather than having 
the burden of following a strict medication regime every day/week. However, yearly 
doses may also have adherence problems, as a patient still needs to remember to get 
their dose each year. In a study that assessed adherence to zolendronate, only 64% of 
patients who had received their first infusion returned for their second infusion a year 
later (Lee et al, 2012). This shows that dosing frequency is not the only issue of 
relevance to patient adherence.  
A further medication related factor is the complex administration procedure for 
osteoporosis medication. This has been shown to influence a patient’s medication-
taking (Lau et al, 2008). Some osteoporosis medications require the patient to modify 
their behaviour after taking the medication. For example, some prescriptions require 
the patient to fast for 2 hours before and after taking it, or to remain upright for one 
hour after taking the medication. This makes the medication inconvenient and requires 
organisation and planning.  
There is strong evidence to suggest that the side effects related to osteoporosis 
medication predict non-adherence (Carr et al, 2006; McHorney et al, 2007; Lau et al, 
2008). Bisphosphonates can result in gastrointestinal upset and joint pain and 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
52 
 
strontium ranelate can lead to diarrhoea and memory loss. Given that osteoporosis is 
asymptomatic, it is unsurprising that patients would choose to stop taking a 
medication that was giving them additional discomfort. This issue is discussed further 
detail in chapter 5. 
Modifiable determinants 
Whereas clinical and demographic determinants of adherence are mainly non-
modifiable, there are factors related to adherence which are amenable to 
intervention. For example, doctor-patient communication has been demonstrated to 
be a factor in adherence to osteoporosis medication. Lau et al (2008) carried out a 
qualitative study to investigate patients’ reasons for low adherence to osteoporosis 
medication regimes. Patients reported that a good relationship with their doctor was 
needed, this enabled them to contact their doctor to discuss problems with their 
medication regime.  
Patients’ perceptions of their disease and treatment are likely to be shaped by 
communication from healthcare workers. This shows how the problem of non-
adherence can be doctor/organisation centred as well as patient centred. ‘The patient 
must understand the problems presented by impending bone loss and appreciate his 
or her personal involvement in the solution’ (Gold et al, 2006, p26). In addition, 
communication about how medication impacts on fracture risk is also likely to be 
important. Interventions to improve adherence must find a way to communicate the 
important role of self-management in osteoporosis care. Osteoporosis is a condition 
which is chronic, asymptomatic and self-managed, therefore clear communication 
from health care professionals to patients of the fracture risks involved in the 
condition are essential.  Previous research suggests that interventions aiming to 
improve communication between HCPs and patients might increase the uptake of 
osteoporosis preventative behaviours such as adherence to medication.  
McBean et al (1994) reported that there is a need for the risks in osteoporosis to be 
communicated effectively to its sufferers. Recognising that conversations about 
medication are a type of risk communication is useful, because it highlights the 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
53 
 
complexity of the conversation and the difficulty of the communication. Following on 
from this, future interventions to improve adherence to medication could work on 
finding the best way to communicate the increased risk of fracture which exists when a 
patient does not take their medication as prescribed. 
A possible mechanism for the influence of doctor-patient communication on 
adherence has been suggested in a study of the predictors of the patients 
understanding the perceived need for osteoporosis medication (Schousboe et al, 
2011). It was found that patients’ trust in their physician was directly related to their 
perceived need for medication, whereas open communication and physician’s decision 
making style were indirectly associated with perceived need. Physicians’ decision-
making style and communication were directly related to patients’ trust in the 
physician. This demonstrates the need for effective doctor-patient communication and 
shows that if a patient trusts their physician they are more likely to perceive a need for 
their prescribed medication. 
A final noteworthy issue which may influence a patient’s decision to initiate or take 
osteoporosis medication is the publicity the medication receives, regarding the risks 
associated with medication. The media recently reported that osteoporosis medication 
doubles the risk of oesophageal cancer (Green et al, 2010), but a close look at the 
above study reveals that the authors admit that there is no certainty that the patients 
who developed oesophageal cancer actually took the medication, only that they were 
prescribed the medication. When studies report harmful effects of medication and the 
media publishes them without reporting the full story, it can cause patients to make 
bad decisions based upon misrepresented information. A more scientifically robust 
study reported no association between bisphosphonate use and oesophageal cancer 
(Cardwell et al, 2010). 
A further set of potentially modifiable determinants of adherence are patients’ beliefs, 
motivation and emotions. These are likely to be influenced by doctor-patient 
communication and the media, discussed in this section. The literature of the role of 
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psychological factors and adherence to medication will be the focus of a critical review 
in chapter 5.  
2.7 Summary 
Adherence to medication is viewed as a behaviour which needs to be improved. While 
osteoporosis is a serious disease, it is well documented that its sufferers do not take 
their medication as prescribed, therefore reducing its therapeutic benefit. This chapter 
has emphasised the severity of the problem of low adherence to osteoporosis 
medication, particularly the resultant lack of protection against fragility fractures. To 
reduce the problem of low adherence, interventions are required, particularly for 
conditions when an effective treatment is available (Horne et al, 2005). This is 
particularly true for silent conditions, where there are no physical signs of the 
condition, which may contribute to low adherence.  
This chapter provided a review of the determinants of non-adherence. There are 
numerous factors which influence adherence to medication; at the patient, HCP and 
system level (Miller et al, 1997). Studies of the relationship between demographic 
variables and adherence have not been able to identify the causes of the non-
adherence to date. As well as an understanding of patients’ beliefs about their illness 
and medication, there is a need to gain understanding of the psychological factors that 
underpin non-adherence to osteoporosis medication. This will be the focus of a critical 
review in chapter 5. 
It is clear that there is a need for interventions to improve the way the health risk 
associated with not taking medication is communicated. As well as a need for 
interventions to improve adherence, there is a need for qualitative work to gain a 
deeper understanding of osteoporosis patients’ illness and medication beliefs, as this 
will give insight into the specific beliefs which could be altered to improve adherence. 
The following chapter will introduce some of the psychological theories of health 
behaviour change which might be usefully applied to the problem of low adherence to 
medication.   
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3 Interventions to promote osteoporosis 
medication adherence: The role of health 
psychology theories  
Chapter overview  
Existing theories of how patients understand their medical condition and risk will be 
the topic for the current chapter, which presents the theoretical frameworks which 
could be usefully applied to the problem of low adherence to medication. This chapter 
is in 3 main sections. Previous psychological/behaviour change interventions which 
have been developed to reduce osteoporosis medication non-adherence will be 
discussed, before exploring the theories which could potentially be applied to this 
problem. Following this, the limitations of these interventions will be presented. The 
next main section is a review of the risk perceptions literature; given that risk 
perceptions are central to many health psychology theories. The final section will 
discuss the theories of behaviour change which have been applied to the problem of 
low adherence to medication. 
3.1 Previous interventions to promote osteoporosis 
medication 
Given that medication is the most common medical intervention (Horne et al, 2005), 
low adherence reveals a failure in the delivery of healthcare. While healthcare 
practitioners have no direct control over their patients’ health related behaviours, they 
have the ability to try to influence them to change and adopt more healthy behaviours 
(Rollnick et al, 1999). While many interventions have been tested to improve 
adherence across a variety of chronic illnesses, few have been effective (Haynes et al, 
2008). This ultimately means that patients cannot achieve the most therapeutic 
benefit possible from their medication. In the case of interventions that have been 
moderately successful, the reasons for success are difficult to identify (Campbell et al, 
2000; Redfern et al, 2011). Improving adherence in osteoporosis patients would 
significantly reduce fractures, resulting in better health and quality of life, reduced 
admissions to hospital and a decrease in healthcare costs.  
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There have been four recent systematic reviews of the effectiveness of interventions 
designed to improve adherence to osteoporosis medication (Crammer et al, 2007; 
Gleeson et al, 2009, Imaz et al, 2010; Hiligsmann et al, 2013). Some examples of the 
behaviour change techniques employed in these interventions include: nurse 
monitoring of adherence (Clowes et al, 2004), an osteoporosis education leaflet 
(Guilera et al, 2006) and a motivational interviewing and telephone reminder 
intervention (Cook et al, 2007). There have also been interventions to improve doctor-
patient communication during medical consultations (e.g. Shu et al, 2009). Authors 
who reported improved adherence appear to have used longer follow-up of adherence 
than those that did not (Gleeson et al, 2009), although the exact length of time 
patients should be followed-up is still unknown. This means that research designs 
could be improved by incorporating a longitudinal focus. The following will discuss 
some of the adherence interventions introduced in this paragraph. 
The use of an educational intervention to improve adherence to medication has been 
tested (Guilera et al, 2006). The experimenters gave osteoporosis patients an 
educational leaflet to promote medication adherence. It was found that while patients 
understood the educational leaflet and reported that it increased their health 
awareness, it did not improve their adherence. This study suggests that education 
alone is not enough to have an effect, because raising awareness of the importance of 
behaviour change did not improve adherence behaviour. It is indicated that a more 
complex adherence intervention is required. 
Monitoring is viewed as an effective method to improve adherence to medication 
(Cummings et al, 2002). A nurse monitoring intervention produced some positive 
results in a hospital inpatient population (Clowes et al, 2004). This intervention 
consisted of two experimental groups. In group A, patients medication-taking was 
monitored by nurses. Patients in group B received the same care as group A, with an 
additional component of feedback about whether their condition was improving. 
Adherence was measured using an electronic pill counter and it was found that patient 
adherence was 68% in group A and 63% in group B in comparison to 42% in the control 
group. The close level of monitoring used in this intervention was possible because the 
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patients were hospitalised. This would not be feasible for outpatients. More practical 
methods for improving adherence for outpatients are needed.  
More recently, motivational interviewing has been used to counsel patients about 
medication adherence. Motivational interviewing (MI) is a recommended behaviour 
change technique of guiding patients to draw on their own motivation for engaging in 
health related behaviour (Rollnick et al, 1999). MI has improved adherence to 
medication for patients with AIDS (Dilorio et al, 2008) and hypertension (Ogedegbe et 
al, 2008). MI interventions have also been employed for patients prescribed 
osteoporosis medication. These studies are described below. 
A telephone counselling intervention to improve adherence to osteoporosis 
medication was successful (Cook et al, 2007). This was a multi-factorial intervention in 
which nurses were trained to counsel osteoporosis patients about their goals for 
treatment, to assess thoughts and feelings which may act as barriers to adherence and 
to help patients to build and maintain motivation to engage in taking their medication 
as prescribed. Nurses also provided patients with education about osteoporosis. 
Patients received a written progress note after each telephone call from their nurse. 
The authors make the point that while the benefits of motivational counselling in 
behaviour change are well known, it is not widely used in adherence research, even 
though there is a strong need for behaviour change in this area. It should be noted that 
while this study was found to be beneficial in improving adherence, it did not have a 
control group. Effects were compared with non-participants, which makes it difficult to 
determine the impact of the study. Finally, this intervention appears to be very labour 
intensive and perhaps not possible in the context of the NHS. It would be beneficial to 
test a brief version of this intervention for effectiveness. 
A more recent trial of MI was conducted, called the osteoporosis telephonic 
intervention to improve medication adherence (OPTIMA) trial. While osteoporosis 
medication adherence increased in the intervention group, the results were not 
statistically significant (Solomon et al, 2012). The authors of the OPTIMA trial conclude 
that even though the results were not statistically significant, they were clinically 
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relevant because adherence was 8% higher in the intervention group than the control 
group, which would lower the risk of fracture for some patients. Before employing the 
method of MI as a behaviour change technique to promote adherence, it would be 
beneficial to ascertain the extent to which motivation is related to adherence. It is 
unclear whether a brief, less intensive version of the OPTIMA trial would be effective 
in increasing adherence. 
It is well known that interventions to enhance adherence need to be complex in order 
to be effective (Dunbar-Jacob et al, 1995; Haynes et al, 2008). Complex in this context 
means that the intervention should consist of multiple components. Interventions are 
also more likely to be effective if they are tailored to the needs of the individual 
(Haynes et al, 2008). A systematic review has shown a combination of the following 
behaviour change techniques to be successful in increasing adherence to medication: 
information (verbal or written), reminders, reinforcement, counselling, telephone 
follow-up and other forms of monitoring (McDonald et al, 2002). However, it is not 
clear which techniques should be included in an intervention to increase adherence to 
osteoporosis medication. 
3.1.1 Limitations of former adherence interventions  
While behaviour change techniques which are likely to increase adherence have been 
identified, the combination and intensity of these techniques required to improve and 
maintain adherence is still unknown (Haynes et al, 2008). Systematic reviews assessing 
interventions to promote medication adherence show that flawed research 
methodologies have been used in the majority of previous studies (Crammer et al 
2007, Gleeson et al, 2009, Imaz et al, 2010). The most recent Cochrane review of 
interventions to improve adherence concluded that, ‘current methods of improving 
adherence are mostly complex and not very effective, so that the full benefits of 
treatment cannot be realized’ (Haynes et al, 2008, p2). There is a need for improved 
research methods in adherence intervention design.  
Despite guidelines stating the importance of tailoring interventions to meet patients 
individual needs (WHO, 2003), it seems that few authors of intervention studies to 
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improve adherence to osteoporosis medication used tailoring. There is a need for the 
authors of psychological interventions to select behaviour change techniques which 
focus on the needs of individual patients, in order to be effective (Haynes et al, 2008). 
For example, tailored education which is designed based upon the needs of the 
individual may be an example of this.  
Gleeson et al (2009) identified some problems with previous research methods used in 
the design of osteoporosis medication adherence interventions in their systematic 
review of interventions: lack of tailoring, poor selection of outcome measures, lack of 
double blinding, lack of theory-based interventions and lack of evaluation. Only one of 
the seven studies included in the review used double blinding, which is a requirement 
of randomised controlled trials, to reduce potential bias. Further, only one study in 
Gleeson’s review contains data for the total number of fractures participants had 
sustained. Similarly, another systematic review showed that many interventions did 
not include the number of fractures as an outcome measure (Imaz et al, 2010). 
However, this would require an intervention with a long term follow-up period, which 
is a challenge for researchers. However, these oversights in research methodology 
could mean these studies were not able to yield robust results and consequently our 
knowledge of what is effective is sparse. 
To date there have been no studies which have explicitly used health psychology 
theory to underpin interventions to improve adherence to osteoporosis medication. 
The benefit of using a theory to inform the design of behaviour change interventions is 
the provision of clear guidance for how to do so, as well as a theoretical rationale for 
selecting the intervention components. It is difficult to measure the effective 
ingredients of an intervention to promote adherence if the intervention components 
are not clearly defined from the outset of the study. Previous interventions to improve 
adherence to osteoporosis medication have not been sufficiently evaluated, so it is 
difficult to determine the effective components of these interventions, as well as the 
elements which were not relevant/needed (Gleeson et al, 2009). No previous 
interventions used the MRC’s framework for the design and evaluation of complex 
interventions (Campbell et al, 2000); which emphasises the importance of 
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interventions with evaluation built into their design. This is important because there is 
no benefit in repeatedly running complex behaviour change interventions when some 
components are ineffective.  
In summary, while some previous interventions to promote osteoporosis medication 
adherence have had limited success, the reasons for any improvements in adherence 
are poorly understood. It would be beneficial to design an adherence intervention for 
osteoporosis patients based upon the MRC’s framework for the design and evaluation 
of complex interventions. The active ingredients of effective interventions need to be 
identified so that these interventions can be rolled out across the healthcare service, 
to improve health outcomes for osteoporosis patients. The following sections will 
introduce a number of health psychology models, which may be beneficial for 
informing the design of adherence interventions.  
3.2 Health psychology theories and their utilisation for 
improving adherence 
Many health psychologists view the current bio-medical model dominant in healthcare 
as reductionist (Engel, 1977). While the biomedical model includes the role of 
biological processes and their impact on health, there is no accounting for the role of 
psychological or social factors. Health psychologists argue for the adoption of a 
biopsychosocial model in healthcare, which accounts for the influence of factors other 
than purely biological processes on health. This section will focus on the psychosocial 
factors which can influence health behaviours.  
Using psychological models of health behaviour to investigate non-adherence to 
medication may reveal innovative solutions to the problem of low adherence. It has 
recently been said that ‘understanding the mental models of osteoporosis, fractures 
and the medications recommended to reduce their risks of fractures that patients 
employ when weighing the risks and benefits of treatment is critical if we are to make 
better progress in reducing non-adherence with fracture prevention 
medication’(Schousboe, 2013, p26). This section will also describe a selection of the 
health psychology theories which have been used to describe and explain health 
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related behaviour and inform interventions for behaviour change processes. It is well 
documented throughout the health psychology literature that health related 
behaviour change is difficult to achieve. Using theory to investigate behaviour change 
might be beneficial because it can enable a systematic investigation of the particular 
psychological constructs relevant to the target behaviour. These health psychology 
theories will be discussed, because they could be used in the design of an intervention 
study to improve adherence to medication.  
Psychological models of behaviour are used to explain and predict how individuals will 
react to risk information. They are used within the field of health psychology to 
investigate how individuals will respond to being diagnosed with a physical illness, or 
whether individuals will engage in health protective behaviours such as medication 
adherence. There are two types of behaviour change theories; cognitive science and 
socio-cultural (Berry, 2004). The cognitive science approach investigates behaviour at 
the level of the individual and suggests that individual’s risk perceptions (which are 
seen to be formed individually rather than as members of a group) will determine how 
they respond to risk information. In contrast the socio-cultural approach views risk 
probabilities as socially and/or culturally constructed and so takes into account the 
broader social context in which they exist (Lupton, 1999).  
3.2.1 Risk perception: a central theme in health psychology theories 
The perception of risk is central to many health psychology theories. There are many 
definitions of risk perceptions, such as ‘the subjective judgement that people make 
about the characteristics and severity of a risk’ (HSE, 2009, p2). Generally definitions of 
risk perception include a combination of both the likelihood and the severity of the risk 
as factors relevant to the perception of risk. Risk perceptions are believed to be the 
psychological determinants and primary motivators for health related behaviours in 
many health psychology behaviour change theories (Brewer et al, 2004; Floyd et al, 
2000).  
Health psychology theories are based upon the underlying assumption that decisions 
about health are made through systematic cognitive processing of the relevant health 
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information (Brewer et al, 2007). In other words, people assess whether to engage in a 
given health behaviour (such as a vaccination) by assessing their level of risk. Therefore 
a perception of high risk is expected to be an important motivator for health protective 
behaviour. 
The measurement of risk perception is difficult. Slovic (1987) used psychometric tests 
to measure risk perceptions and produced cognitive maps of risk attitudes and 
perceptions. He identified the factors involved in the recognition of risk as the 
following; familiarity, control, catastrophic potential, equity and level of knowledge. He 
used factor analysis to identify three levels of subjective risk perception which were 1) 
dread risks (where consequences were fatal), 2) unknown risks and 3) the number of 
people exposed to the risk. It has been suggested that individuals’ risk perceptions and 
judgements about risky behaviours are influenced by their emotional response to the 
risk (Loewenstein et al, 2001). It is now generally accepted that although we can try to 
measure risk perception, it is a subjective experience (Slovic, 2010). Affect may explain 
why people engage in unhealthy behaviours despite knowing they are harmful, e.g. 
smoking. 
An interesting point about risk perception is the common finding that people often 
estimate their own level of risk as lower than that of other peoples. They take the view 
that they are less likely to have negative experiences and more likely to have positive 
experiences in comparison to others. This phenomenon has been termed “optimistic 
bias,” “comparative bias” or “unrealistic optimism” (Weinstein & Klein, 1996). While 
optimism is beneficial in so far as it can mean people do not worry unnecessarily, it 
could make people more likely to engage in risky behaviour because they believe they 
have less chance of it resulting in hazardous outcomes. In other words people tend to 
underestimate their level of risk in comparison to others, which could mean they do 
not believe there is a need to take precautions to protect themselves against poor 
health outcomes. This has been shown to be true for beliefs about the risk of 
contracting many diseases including cancer (Fontaine and Smith, 1995). Optimistic bias 
has been noted as a barrier to effective risk communication (Weinstein, 1989; Berry, 
2004).  
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The first studies conducted to investigate optimistic bias were carried out on samples 
of young college students and younger adults. However, recent studies have suggested 
that optimistic bias is present throughout an individual’s lifespan (Renner et al, 2000). 
This is useful knowledge and it shows that public health campaigns could work on 
reducing optimistic bias in order to make risk perceptions more accurate, with the aim 
of promoting health related behaviour or reducing risky behaviour. The implications of 
the phenomenon of optimistic bias is that risks should be communicated in a way that 
highlights personal risk and makes the risk information less general and more specific 
to the person. 
The relationship between risk perceptions and behaviour is bidirectional, therefore the 
cause and effect is difficult to evaluate. “Risk perceptions can affect protective 
behaviour and protective behaviour can affect risk perceptions” (Brewer et al, 2004, 
p125). The relationship between these variables is intricate and reciprocal and is best 
examined using longitudinal study designs rather than cross-sectional (Brewer et al, 
2004).  
Some key questions are; how do risk perceptions influence health behaviour and is 
aiming to change risk perceptions likely to be a successful strategy for changing 
behaviour? (Wright, 2010). Wright’s review of the literature indicates that there is a 
small yet significant relationship between risk perceptions and behaviour. Wright also 
notes that the strength of this relationship may be stronger than has been found in 
research to date because of the methodological challenges of measuring risk 
perceptions. Similarly, a recent meta-analysis of behaviour change interventions 
concluded that increasing risk perceptions does change intentions and behaviour 
(Sheeran et al, (2013), particularly when the intervention targeted both a) an 
individual’s perceived level of threat and b) their perceived ability to deal with the 
threat. An important question which arises from Sheeran’s meta-analysis is; how can 
perceptions of risk be increased in order to aim to change behaviour?  
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3.2.2 Perceptions of risk for osteoporosis and fractures 
The risk of fracture in osteoporosis is particularly difficult to communicate and 
comprehend, because everyone carries a certain level of risk for sustaining a fracture. 
For example if an individual was in a serious accident, e.g. road traffic accident, they 
may sustain a fracture regardless of whether they have osteoporosis. This is perhaps 
why it is difficult for osteoporosis patients to understand their level of risk of fracture 
in comparison to others who do not have osteoporosis. 
Hvas et al (2005) studied healthy women’s awareness of the risk of osteoporosis in a 
qualitative study and found that patients who felt worried about their risks were more 
likely to engage in osteoporosis preventative behaviours. This study used fear appeals, 
by providing information to raise patients’ awareness of the health threat. The authors 
suggest that fear appeals can be beneficial in producing behaviour change, although 
there are ethical concerns about using fear appeals. On the contrary, it seems just as 
unethical to fail to give patients the full information available about their health and 
how to maintain it in the clearest way possible. Future work is required to determine 
how patients respond to risk information about their condition.  
Qualitative studies have been conducted to assess patients’ thoughts and beliefs about 
their fractures (Meadows & Mrkonjic, 2003; Meadows et al, 2004). It was found that 
fracture patients believed that once a patient other than themselves had sustained a 
fracture, they were more likely to have another fracture. However, these fracture 
patients believed that they themselves were at less risk of sustaining a subsequent 
fracture in comparison to other patients. This provides evidence for patients with 
osteoporosis displaying optimistic bias, or having difficulty understanding their levels 
of risk in osteoporosis. 
Similar studies have been conducted to investigate patients’ perceptions of their 
fracture and future fracture risk (Giangregorio et al, 2008; Giangregorio et al, 2009). It 
was found that half of the osteoporosis patients in the study who had sustained a 
fragility fracture did not know or understand that they were at an increased risk for a 
future fracture; they also did not perceive the need to take their prescribed medication 
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for osteoporosis. These findings are important and perhaps indicate a failure in the 
communication of risk, in so far as either healthcare professionals are not 
communicating these patients’ risks to them effectively, or the patients have great 
difficulty in comprehending these risks. It is expected that lowered risk perceptions in 
osteoporosis could contribute to medication non-adherence. If patients do not 
understand their risks then they cannot behave in the appropriate manner to minimize 
these risks. More research is required to investigate this further, to determine the 
relationship between risk perceptions and adherence. 
3.2.3 Social Cognition Models  
Social Cognition Models (SCMs) were developed by social psychologists and can be 
seen as psychometric risk models which can be used to explain and predict behaviour 
and behaviour change (Conner & Norman, 2001). The SCMs are models of how 
cognitions influence behaviour and were devised in recognition of the need to 
understand behaviour in a social context (Rutter & Quinne, 2002). SCMs are also 
known as expectancy-value models, they suggest that individuals select their 
behaviours based upon the expectancy of the outcome and the value they place on it 
(Conner & Norman, 2001). The SCMs are a set of models which consist of theorised 
psychological determinants of behaviour and can be used to predict behaviour at a 
given time point (Armitage & Conner, 2000). Though developed within the field of 
social psychology, SCMs can also be used in health psychology to investigate how 
people respond to a health threat. Some examples of SCMs are provided below. 
Despite differences between these models in basic factors, the social cognition models 
are similar in so far as they theorise that risk perceptions are the key determinants of 
health behaviours, in other words ‘feelings of threat motivate behaviour change’ 
(Sheeran et al, 2013, p1). Many of these theories suggest that perceived susceptibility 
to and perceived severity of an illness are the key cognitions involved in an individual’s 
threat appraisal, which will predict their subsequent health behaviour (Rosenstock, 
1974; Rogers, 1975). Many social cognition models have been widely applied to 
adherence research. The most influential and widely used social cognitive theories will 
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now be discussed, including how they have been applied to the problem of low 
adherence to prescribed medication. 
The Health Belief Model 
The Health Belief Model (HBM) is an example of a social cognition model. The HBM 
was developed to predict health behaviour using: an individual’s ‘perceived severity’ 
and ‘perceived susceptibility’ of a given risk, as well as the ‘perceived benefits’ and 
‘perceived barriers’ to a given health behaviour (Rosenstock, 1974). Rosenstock 
proposed that if an individual perceives themselves to be at risk and they perceive the 
risk to be severe, they will act to reduce this risk, after analysing the perceived benefits 
and barriers of the risk reducing behaviour.  
The HBM has been used to investigate individuals’ beliefs about osteoporosis (Wallace 
et al, 2002; Cline et al, 2005). A cross-sectional questionnaire study (with osteoporotic 
and non-osteoporotic patients) investigated the relationship of components of the 
HBM with adherence to medication and HRT (Cline et al, 2005). They found that 
perceived susceptibility to osteoporosis and the perceived benefits of medication were 
related to adherence to medication. However, this paper also shows that the HBM 
constructs were not predictive of the use of HRT which used to be commonly 
prescribed to treat osteoporosis.  
A meta-analysis has shown that the four constructs of the health belief model were 
positively correlated with adherence to medical regimens in a variety of medical 
conditions (Harrison et al, 1992), with the HBM predicting 10% of the variance in 
adherence behaviour. The positive correlations indicate that the HBM would be a 
useful model to use in an intervention to improve adherence to medication. However, 
it is difficult to conclude on this because many of the included studies had 
methodological flaws. However, a difficulty with applying the HBM to the problem of 
adherence is that the HBM implies a one-off decision or cost-benefit analysis of 
whether to engage in a particular health related behaviour (Horne et al, 1999). 
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Protection Motivation Theory   
Protection Motivation Theory (PMT) is an extension of the health belief model. PMT 
was developed in order to explain how individuals make sense of fear appeals (Rogers, 
1975). The PMT is made up of 3 psychological predictors of preventative behaviours: 
(a) the perceived severity, (b) the perceived probability of occurrence and (c) the 
efficacy of the recommended health behaviour (belief that the protective behaviour 
will reduce the risk). This model can also be used to gain understanding of how people 
respond when they are diagnosed with an illness. This model predicts that if an 
individual feels highly susceptible and that the illness is of high severity, the individual 
is more likely to have the behavioural intentions to engage in health protective 
behaviour; if they feel that the protective behaviour will reduce their level of risk. 
Protection motivation is defined as danger control (Rogers, 1975), or feeling motivated 
to engage in a health protective behaviour. It is also theorised that fear resulting from 
health risk information will impact upon behavioural intentions, though indirectly.  
A meta-analysis of the PMT and health behaviours such as adherence to medication 
has shown that there are moderate effects on behaviour when an intervention is 
based upon this model (Floyd et al, 2000). It explains some of the variance in 
adherence behaviour, so therefore this model is likely to be useful to inform an 
intervention to improve adherence to medication. A problem with the PMT is that it 
does not explain why some health information messages are not attended to (message 
rejection) by individuals (Witte, 1992). A similar model to PMT is the Extended Parallel 
Process Model, which is described later in this chapter. 
The Theory of Planned Behaviour  
The theory of planned behaviour (TPB) (Ajzen, 1985) is another widely used theory of 
behaviour change, developed in the field of social psychology. The TPB is as an 
extension of the theory of reasoned action (Fishbein and Ajzen, 1975). The authors of 
the TPB suggest that intentions are the single most important determinant of 
behaviour, with behavioural intentions formed by attitudes (towards behaviour), 
subjective norms and perceived behavioural control (self-efficacy). However, there is a 
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gap between intentions and behaviour known as the intention behaviour gap. The 
TPB’s authors acknowledge that the intention behaviour gap is difficult to account for.   
The TPB has been widely used to investigate the problem of low adherence to 
medication. Abraham et al (1999) found that the TPB constructs predicted 50% of the 
variance in self-reported adherence to malaria medication. Reviews of adherence 
interventions based upon the TPB have shown mixed findings. In a meta-analysis, 
Hardemann et al, (2002) reviewed the use of the TPB to inform behaviour change 
interventions and found the results inconclusive due to methodological flaws. It is 
likely that the TPB has utility for adherence interventions, though more empirical work 
is needed to investigate this. 
3.2.4 Leventhal’s self-regulation model  
The Self-Regulation Model (SRM) is a social cognition model which explains how an 
individual copes with an illness as well as the cognitive and emotional responses to an 
illness diagnosis or a health threat (Leventhal et al, 1984). It is theorised that 
cognitions and emotions are used to guide behaviour. The SRM (Figure 2) has been 
identified as the most logically appropriate model for investigating the problem of low 
adherence to medication (Munro et al, 2007). The SRM is also known as the Common 
Sense Model (CSM), because it is an example of a common sense theoretical model 
created by a patient, based upon their perceptions and understanding of their illness. 
Further, it is theorised that patients will engage in a particular health protective 
behaviour if it makes common sense and fits with their illness perception.  
A major feature of the SRM is illness perceptions, defined as cognitive representations 
(beliefs) patients have about their illness (Weinman et al, 1996). This theory states that 
patients make sense of their illness by forming both cognitive and emotional 
representations of the illness, together called illness representations and emotional 
representations respectively. These representations describe how people view and 
make sense of their illness and exist as a parallel pair. In literature focusing on the 
SRM, illness representations are sometimes signified using the terms illness 
perceptions, illness cognitions or illness schemata, with synonymous definitions. 
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Patients may hold illness representations which act as barriers to them behaving in a 
way to prevent/manage their illness.  
Leventhal et al, (1984) proposed that patients’ illness and emotional representations 
form a model and are used to guide their illness management/coping, so that once a 
person forms these perceptions of their illness, they use them to regulate their 
behavioural response to the illness. Self-regulation is defined as “mental and 
behavioural processes by which people enact their self-conceptions, revise their 
behaviour, or alter the environment so as to bring about outcomes in line with their 
self-perceptions and personal goals” (Fiske & Taylor, 1991, p.181).  
According to the SRM the following distinct processes occur when a person is 
diagnosed with an illness or informed of a health threat; (1) interpretation (both 
cognitive and emotional), which leads to (2) coping, problem-focused or emotion-
focused which is followed by (3) appraisal, checking if the method of coping was 
effective (Leventhal et al, 2010). For a summary diagram of the model, see Figure 2. In 
contrast to other social cognition models, the SRM is a dynamic model, meaning that 
an individual’s appraisal of their ability to cope with a health threat/illness is 
continuously changing as they gain more knowledge and understanding of their illness 
and how to cope with it. Adherence is considered as a coping mechanism, because it is 
a way of managing the illness. 
The SRM is a suitable model to apply to the problem of low medication adherence 
because it describes the psychological processes through which people cope with an 
illness. It is called the self-regulation model because it suggests that people go through 
a continual process of self-regulation (appraisal of their resources for coping and 
action plans) in order to manage their illness. There are two theorised processes of 
coping; emotion-focused coping and problem-focused coping which can occur 
simultaneously (Leventhal et al, 1984). These coping mechanisms have also been called 
‘abstract conceptual’ or the ‘concrete experiential’ respectively. The coping 
mechanism is selected by a person based upon the information given about the health 
threat/illness and how that information is understood. Problem-focused coping 
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consists of finding instrumental solutions, whereas emotion-focused coping is about 
managing the emotions aroused by the health threat. Problem-focused coping is 
suggested to be more beneficial as this is associated with finding a way to deal with 
the problem. Adherence to medication is an example of problem-focused coping, 









Figure 2. Self-regulation model of illness cognitions and emotions (Leventhal et al, 1984) 
Cognitive Representations 
Cognitive representations are influenced by cultural factors (Landrine & Klonoff, 1992) 
past experience and the opinions of significant others (Leventhal et al, 1992). The 
authors of the SRM propose that patients make sense of their illness by developing 
their own understanding of five features typical of any medical condition: identity 
(what is it?), causes (what caused it?), consequences (how will this affect me?), 
timeline (what is the duration of the illness?) and control/cure (what do I need to do to 
treat it?) (Leventhal et al, 1992a).  It is proposed that these 5 features form a cognitive 
representation of the illness. A key element of this theory is that patients are more 
likely to be adherent with treatment recommendations if they have a coherent model 
of their illness – in which the illness makes sense to them. An extension of the SRM 
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predictor of coping when the SRM is being used to explore medication adherence 
(Horne et al, 1999).  
Emotional Representations 
In addition to this cognitive process, it was proposed that patients have an emotional 
representation of their condition (Leventhal et al, 1984). It was theorised that the 
emotional response to a medical condition could influence the selection of a coping 
method. It was suggested that the emotional response to having a medical condition, 
although independent, ‘can interact with and/or be part of the cognitive’ 
representation (Leventhal et al, 1992, p158). Cameron & Jago (2008) expanded the 
SRM to include strategies for emotional self-regulation. They reviewed two 
interventions focusing on promoting adjustment and well-being when individuals were 
diagnosed with a medical condition. They suggest that in order for patients to 
effectively cope with an illness diagnosis, both cognitive and emotional 
representations of the condition would be involved in self-regulation.  
An extension of the SRM 
An extension of the SRM was proposed by Horne (1997) and presented in a study by 
Horne & Weinman (2002), in relation to adherence to medication in asthma patients. 
The SRM was extended to include medication beliefs as an additional cognitive 
predictor of adherence (Horne et al, 1999). They found two groups of beliefs to be 
associated with adherence to medication; beliefs about the necessity of taking 
medication and concerns about the medication. There is a type of cost benefit analysis 
which takes place when a patient is consciously deciding whether or not to take 
medication (Donovan & Blake, 1992). The strength of the belief in the necessity of the 
medication is weighed against the concerns about the medication (Horne, 1997). This 
group of beliefs is known as the necessity-concerns framework (NCF). This proposed 
extension SRM states that patients will assess the appropriateness of the treatment by 
trying to understand their own personal need for the medication and weighing this 
against their concerns about the medication (e.g. side effects, being dependent on the 
medication, overuse of medication prescriptions, harmful chemicals etc.).  
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Horne et al (1999) developed the beliefs about medications questionnaire (BMQ), for 
the purpose of investigating the role of medication beliefs in medication adherence. 
This is a brief questionnaire which assesses patients’ beliefs about their medication, 
particularly the NCF as discussed above. The BMQ has been validated as a measure of 
beliefs about medication and used widely in adherence research in many medical 
conditions. 
3.2.5 Empirical support for the SRM 
Questionnaires to measure the psychological constructs included in the SRM have 
been developed and validated and can be adapted for use in many medical conditions 
(Weinman et al, 1996; Moss-Morris et al, 2002). Detailed descriptions of these 
questionnaires are provided in chapter 7. These questionnaires make it possible to 
quantify the relationship between illness perceptions and various health related 
behaviours, such as adherence to medication. Many studies have shown empirical 
support for the SRM, with associations between illness perceptions and adherence. 
Some of these studies will be described in this section. 
Overall the SRM has been used in many studies of illness behaviour, particularly in 
relation to how cognition is related to illness coping behaviours, such as adherence. 
Hagger & Orbell (2003) carried out a meta-analytic review of 45 studies to investigate 
the relationship between illness representations and a range of health behaviours. 
They detected a small yet significant relationship between coping behaviours and 
illness representations. Beliefs of a strong illness identity and serious consequences 
were associated with emotion-focused coping, whereas a strong belief in the 
controllability beliefs of the condition was associated with problem-focused coping. 
Hagger & Orbell’s (2003) meta-analytic review provides evidence that illness 
representations are related to adherence. This shows the importance of identifying 
individual’s illness representations before designing interventions to promote 
adherence to medication.  
3.2.6 Application of SRM to adherence research 
The most common use of the SRM to date has been to explore the illness 
perceptions/illness representations of patients with a given medical condition. The 
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SRM has been usefully applied to the problem of poor adherence to medication in 
many medical conditions, in various types of studies. For example, Chen et al (2010) 
have used this model to gain an understanding of illness perceptions in patients with 
hypertension. It was found that hypertensive patients did not understand that their 
condition was controllable, implying that adherence may be improved by helping 
patients to understand that cardiovascular disease is controllable/manageable. In 
other words, the SRM was used to identify erroneous illness perceptions, e.g. ‘there is 
nothing I can do to improve my hypertension’, which might be amenable to change 
through psychological intervention. 
Other studies have shown that illness perceptions can influence adherence to 
medication. Halm et al (2006) studied patient adherence to asthma medication. They 
found that over half their study participants believed that their asthma was only 
present at the time they experienced symptoms. Importantly, the group of patients 
who did not identify asthma as a chronic condition were less likely to adhere with 
recommendations for inhaler use. This study demonstrates how illness beliefs can 
influence adherence.  
As previously discussed, medication beliefs have been found to be related to 
adherence to osteoporosis medication (Horne & Weinman, 2002). Therefore it would 
be expected that a theory including medication beliefs would be suitable to use in the 
design of an intervention to improve adherence to medication. The extension of SRM 
to include medication beliefs (Horne, 1997) will from now on be referred to as the 
extended SRM. The extended SRM was used to inform the design of interventions for 
patients with end stage renal disease (Karamanidou et al, 2008) and patients who have 
suffered a stroke (O’Carroll et al, 2013a).   
Karamanidou et al (2008) carried out an innovative psycho-educational intervention, in 
which patients with end stage renal disease were shown a model of the kidney 
alongside an explanation of how the phosphate binding medication used to treat it has 
its effect. The intervention group demonstrated improved knowledge, increased 
understanding of the medication regime and increased belief in the response-efficacy 
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of the medication. This demonstrates the benefits of using theory to design an 
intervention. 
The extended SRM was used to inform the design of an RCT to improve adherence to 
anti-hypertensive medication for stroke patients, with good results (O’Carroll et al, 
2013a). The intervention was designed based upon the MRC’s framework for the 
design and evaluation of complex interventions. The intervention aimed to target both 
intentional and unintentional non-adherence, using two key intervention components. 
Intentional non-adherence was addressed by ‘eliciting and modifying any emergent 
erroneous beliefs regarding the patient’s medication and their stroke’ (O’Carroll et al, 
2010, p3). Implementation intentions, also known as if-then plans were selected to 
target unintentional non-adherence. Former studies by this research group found 
stroke patients’ beliefs about medication (e.g. too many medicines are prescribed) can 
prevent them from adhering to their prescribed medication (O’Carroll et al, 2008). 
However, the authors reported that the use of electronic pill counters to measure 
adherence may have influenced adherence rates, because electronic pill counters 
make the pill bottle physically different and are a constant reminder to the patient that 
they are being assessed. (O’Carroll et al, 2013b).  
3.2.7 Witte’s Extended Parallel Process Model 
Another model which could be used to explore adherence to medication is the 
extended parallel process model (EPPM). Similar to PMT, the EPPM states that when a 
person is faced with a health threat, they appraise two components of it: the level of 
threat and their ability to deal with it (Witte, 1992). The EPPM is based upon 
Leventhal’s parallel process model (Leventhal, 1970). The EPPM (see Figure 3) provides 
a theory for situations when increasing risk perceptions will and will not result in risk 
reducing behaviour (Witte, 1992). Witte suggests that when people receive health risk 
information which implies a low risk, the message is not further processed, because it 
is viewed as trivial or irrelevant. However, if people feel there is a high probability of 
experiencing a health problem (high vulnerability/susceptibility) and that the health 
problem is serious (high severity) then the person will experience high fear arousal. If a 
The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
75 
 
person experiences high fear arousal, this fear could act as a motivator for the person 
to assess their ability to deal with the health threat.  
According to the EPPM there are three possible responses to fear arousal; danger 
control (risk reducing behaviour, e.g. taking medication as prescribed) or fear control 
(denial and avoidance of the health threat), see Figure 3. Efficacy messages are 
theorised to predict whether an individual will engage in danger control or fear 
control. When perceived efficacy is greater than perceived threat, the danger control 
response will be initiated. To the contrary, when perceived threat outweighs perceived 
efficacy, the resultant response will be fear control (Witte, 1992). While PMT and the 
EPPM are similar, the difference is that fear arousal was assigned a more important 
role in the prediction of behaviour in the EPPM than in PMT. The author of the EPPM 
states that fear arousal alone will result in a maladaptive coping response; therefore it 
is important that messages of health risk do not just evoke fear. The inclusion of the 
role of self-efficacy in the EPPM is important and there is evidence that self-efficacy 
has a strong influence on behaviour (Bandura, 2004).  
A meta-analysis of studies investigating the effectiveness of fear appeals concluded ‘it 
appears that strong fear appeals and high-efficacy messages produce the greatest 
behaviour change, whereas strong fear appeals with low-efficacy messages produce 
the greatest levels of defensive responses’ (Witte & Allen, 2000, p591). This means 
that a fear appeal attached with a motivational message (or a message with emphasis 
that action should be taken) is likely to produce improved health related behaviour. To 
summarise the implications of this theory; if a fear appeal is coupled with a message 
which increases self-efficacy to deal with the threat, this message would be theorised 
by the EPPM to result in an adaptive coping response – e.g. an attempt to minimise the 
risk by adherence to medication.  
While the EPPM ‘owes its roots’ to the social cognition models, it differs from them 
because it theorises three potential responses to a health threat message (Witte, 1998 
p573). The prediction of when a message will be attended to might be beneficial for an 
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asymptomatic condition, in which risk communication of the severity of the condition 
is challenging. The three potential responses to a health threat message are:  
“(a) the traditional response of attitude/intention/behaviour change (danger control 
responses) 
(b) No response to the campaign due to low perceived threat 
(c) Fear control responses to the campaign such as denial, defensive avoidance, or 
reactance. It is important to note that campaigns can fail because they are ignored, as 
in b, or because they produce strong effects, such as denial or reactance which 












Figure 3. The extended parallel process model (Witte, 1992) 
3.2.8 Application of EPPM to adherence research 
Although there are many studies using the EPPM to promote health behaviours, to the 
author’s knowledge there is only one previous investigation of the influence of the 
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medication adherence, the following will describe studies which investigated the role 
of health threat messages for: motivating testicular examination, promoting safe sex 
and encouraging responsible consumption of alcohol. These studies have been chosen 
for this chapter because, although they are not exactly about adherence, there is some 
similarity given that they are investigating the uptake of a new health related 
behaviour. 
A study of adherence with a multivitamin tablet in patients with cardiovascular disease 
demonstrated the EPPM as a useful model for shaping health communication, in the 
form of an information leaflet (Mckay et al, 2004). The leaflet portrayed the severity of 
the disease (high threat) with a message about how to manage the threat (high self-
efficacy) and was found to make non-adherent patients more confident in their ability 
to take their medication. The authors comment that the EPPM was useful because it 
focuses on how to make a message persuasive, whereas interventions based on other 
models focus mainly on the content of the message. However, the study did not look 
at the relationship between the EPPM variables and adherence. There is a gap in the 
literature of studies investigating the relationship between the psychological 
constructs of the EPPM and adherence.  
The EPPM was used to design health risk information for 80 male students regarding 
the risk of developing testicular cancer (Morman, 2000). A health risk message was 
needed to inform men of the risks and motivate them to perform the testicular self-
exam (TSE). Four types of health risk messages were tested in the study, two with high 
threat/high efficacy and two with high threat/low efficacy. Information about 
testicular cancer was either fact based or a narrative from a patient. It was found that 
messages of high threat/high efficacy increased the participants’ intentions to 
regularly engage in TSE. When comparing the information that was fact or narrative 
based, there was no difference in reported intentions for TSE. This study showed the 
utility of the EPPM in the design of informational material to increase perceptions of 
risk. 
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The author of the EPPM designed a fear appeal campaign to promote safe sex (Witte, 
1998). The data collected from this study supported the EPPM and the author 
described the situations in which health campaigns are likely to fail. The study 
highlighted the importance of emphasising personal susceptibility to a health threat, 
which is a challenge for a health campaign intended for a large group of people, e.g. a 
national campaign. It is also commented that campaigns often fail because they fail to 
address the issue of response- efficacy. 
A larger study (n=224) investigated the relationship between EPPM variables and 
college students alcohol consumption (Moscato, 2001). In this study, students were 
invited to a meeting where they were informed by a panel consisting of law 
enforcement officers and the school principal about the problem of high alcohol 
consumption. During the meeting students were advised to attend alcohol free events. 
The message was delivered in the high threat/high efficacy format recommended by 
the author of the EPPM. This survey found that both perceived efficacy and perceived 
threat were significantly associated with drinking alcohol. Further, it was found that 
students were more likely to attend alcohol free events if they had heard the health 
threat message than if they had heard about it through a secondary source. This 
provides evidence for designing health promotion interventions based upon the EPPM. 
The low quantity of research focusing on the EPPM and medication adherence is 
surprising. The EPPM is particularly suited to the problem of promoting health 
behaviours such as adherence because it focuses on how health threat messages can 
be persuasive. A possible reason for this lack of research could be the ethical 
considerations involved in giving people information which might be frightening. This 
issue is discussed in further detail in study 4. 
The limitations of the social cognition models 
A criticism of many of the SCMs is they are based upon the assumption that people 
make conscious, rational choices about every health decision (Gebhardt & Maes, 2001) 
when in reality this is not always the case. Another problem common to the majority 
of SCMs is they do not take into account the role of emotions, such as fear – which are 
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likely to influence behaviour (Norman and Connor, 2001). Furthermore, they do not 
represent change as a process that occurs over time and can be criticised for being too 
simplistic, or relating to ‘single point decisions about recommendations for 
maintaining health (e.g. to attend for screening)’ (Weinman & Horne, 1998 p40). While 
many of the SCMs have overlapping constructs e.g. perceived susceptibility to an 
illness, the models have not been combined to form a more comprehensive model, 
(Armitage & Conner, 2000) which makes theory selection difficult.  
3.2.9 Selection of behaviour change techniques 
In the process of designing a psychological behaviour change intervention, as well as 
identifying the psychological constructs which require change, it is essential to select 
behaviour change techniques which are expected to influence the target behaviour 
(Michie et al, 2008). The following is the information, motivation and behavioural skills 
(IMB) model, a theory of the basic requirements of behaviour change (Fisher & Fisher, 
1992). The model focuses on the factors that need to change in order to attempt to 
















The psychological factors in adherence to osteoporosis medication: an exploration and 
intervention development  
80 
 
While this model is useful for a simple description, it has little detail about the specific 
cognitions which may require intervention in order to attempt to influence health 
related behaviour. While this model provides some clues for the types of behaviour 
change techniques to employ, more detail is needed. This shows that more complex 
social cognition models are needed to inform the design of behaviour change 
interventions. However, this model is a useful overall guide for the selection of 
behaviour change techniques for an adherence (or other behaviour change) 
intervention. 
3.3 Current Gaps in the literature 
As described above, many theoretical models can and have been applied to the 
problem of low medication adherence, but interventions to improve adherence to 
medication in osteoporosis patients have not drawn on them. There is a need for 
research to test health psychology theories to find out which would be effective in 
interventions to improve adherence to osteoporosis medication. There is a clear need 
for theory-based interventions, because interventions with osteoporosis patients to 
date have been difficult to systematically evaluate, due to this lack of a theory-base 
(Gleeson et al, 2009). 
It has been noted that the extended SRM could be used to explain patients’ self-
management behaviour such as their treatment choices (Hobro et al, 2006). The 
application of this theory to the problem of low adherence may give rise to a more 
detailed understanding of how people with osteoporosis make sense of their illness 
and medication. It is important for research to focus on understanding patients’ 
thoughts and beliefs about their illness because they may hold beliefs about their risk 
of illness which act as barriers to health behaviour improvements.  
There have been studies of osteoporosis patients’ medication beliefs. For example, 
Schousboe et al, (2010) explored patients’ medication necessity and concern beliefs, 
using the necessity-concerns framework. To the author’s knowledge, there is no 
published research to date which explicitly used the extended SRM with osteoporosis 
patients to explore illness perceptions and medication beliefs. Use of the extended 
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SRM allows researchers to gain insight into how patients understand their condition, 
which can then be used to inform interventions to improve their self-management 
behaviours (e.g. taking their medication, diet, exercise etc.).  
It is likely to be beneficial to use theory in the design of an intervention to improve 
adherence, because it can allow for a systematic investigation of the reasons for non-
adherence. It is logical to gain an understanding of patients’ illness beliefs before 
providing a behaviour change intervention, because the intervention might need to 
include information targeted at specific knowledge deficits, e.g. lack of understanding 
the condition is chronic and asymptomatic. Or if a patient incorrectly believes that a 
disease is not treatable, this belief (which could be a barrier to behaviour change), 
could be modified through intervention e.g. education, motivational interviewing etc. 
The self-regulation framework could be useful for guiding research in this field and 
could provide information which will be able to guide intervention design. 
There is a lack of research investigating the risk perceptions of osteoporosis patients, 
particularly empirical research to look at the relationship between risk perceptions and 
adherence to medication. To the author’s knowledge there are have been no studies 
using the EPPM in the design of an adherence intervention. Further, there are few 
studies which attempt to modify osteoporosis patients’ illness perceptions/risk 
perceptions. Patients’ perceptions of illness and risk need to be understood to identify 
inaccuracies that may be linked to behaviour. There is a gap in the literature for new 
methods of risk communication in osteoporosis. These could be investigated using the 
both the extended SRM and the EPPM as a framework on which to base the research.   
3.4 Summary 
This chapter highlights that even though there have been nearly four decades of 
research investigating the problem of low adherence to medication, there is still a 
need for innovative methods and more effective adherence interventions for 
osteoporosis patients. In summary, finding a way to persuade individuals to adopt 
health protective behaviours is difficult and this is likely to be due to variations in their 
perceptions of risk and optimistic bias. There is a need for a balance between 
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interventions which will not only increase adherence to medication, but are also 
feasible and practical within the current climate of the NHS. The ultimate aim of this 
intervention would be to reduce the incidence of osteoporotic fractures.  
This section has discussed the relevant theories which have the potential to inform the 
design of an intervention to increase osteoporosis medication adherence. These 
theories are about how people respond to health risk information. Two theories stand 
out as particularly relevant as possible elements of the solution of the problem of low 
adherence to medication, the extended SRM and the EPPM. It is very important that 
theory is used in the design of interventions to change health behaviour, because they 
can be clearly defined (in terms of what the intervention includes) and evaluated (in 
terms of the level of success of each component). The following chapter will discuss 
how these theories will be used to guide the present research, with a proposal for an 
innovative intervention to promote adherence to prescribed medication for 
osteoporosis.  
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4 The rationale for the present research 
Chapter overview 
This chapter will draw together and summarise the literature reviewed in the previous 
chapters in order to set the agenda for the research. It will summarise the limitations 
of previous interventions to promote osteoporosis medication adherence, proceeding 
to a suggestion for a new approach to investigate the problem of low adherence to 
osteoporosis medication. The theories which were used to investigate this problem 
will be summarised, with a description of how the theories were used. This chapter will 
justify the use of two particular theories for this thesis; the extended self-regulation 
model and the extended parallel process model. Diagrams are used to highlight how 
theory was used to inform the design of the present research. This chapter will 
describe how the Medical Research Council’s framework for the design and evaluation 
of complex interventions (Campbell et al, 2000) was applied to the intervention 
development. This chapter will also address the proposed method to design and test 
the adherence intervention, particularly to justify the choice of using an N-of-1 case-
series design. 
4.1 Rationale for innovative adherence interventions 
The documented low level of osteoporosis medication, coupled with strong evidence 
to indicate that adherence to medication can significantly reduce fracture risk, 
provides the scientific justification for further research to focus on promoting 
osteoporosis medication adherence. Moreover, many of the methods used to measure 
medication adherence provide overestimations of adherence, which suggests that in 
practice adherence may be lower than the research literature suggests (Haynes et al, 
2008). The issue is of particular importance when considered in the context of the 
rapidly aging population.  
Previously, many behaviour change interventions were not fully defined or developed 
(Campbell et al, 2000). Without clear definition or evidence-based development, it is 
difficult to provide evidence of the effectiveness of the intervention in order to 
implement it on a larger scale. Before designing interventions to improve adherence, 
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there is a need to gain understanding of the determinants of adherence through 
empirical research. In particular, it is likely to be beneficial to gain understanding of the 
strength of the relationship between these determinants and adherence.   
While many interventions have previously been developed to improve adherence, they 
have been limited in their success because they are not theory-based, well developed 
or sufficiently evaluated. There is a clear need for studies to evaluate the intervention 
components and mechanisms of change. Better quality interventions, which use the 
best measures of adherence possible, including the number of fractures as an outcome 
measure are required (Gleeson et al, 2009). Interventions which are found to improve 
adherence to osteoporosis medication could then be adapted for use with patients 
with other medical conditions. 
Given the lack of multi-dimensional evaluation of previous interventions, the design of 
future behaviour change intervention studies should include plans for evaluation 
(Campbell, 2007). The majority of interventions previously carried out with an aim to 
improve adherence have been randomised controlled trials. An innovative approach to 
investigate low adherence to medication is to use a different research method such as 
an N-of-1 design that would allow for in-depth investigation of non-adherence with a 
small sample of patients. Further, this design would allow each component of the 
intervention to be evaluated in detail. While the findings from this type of study could 
not be generalised to the population, a case study has the potential to determine 
which components of an intervention are effective. The use of an N-of-1 case-series 
approach to study adherence to medication is a novel method to investigate this 
problem and would be an original contribution to the health psychology literature.  
4.2 Medical Research Council guidelines for complex 
interventions 
The Medical Research Council (MRC) has published guidelines for the design and 
evaluation of complex interventions in order to ensure an evidence-base for 
interventions of high quality and effectiveness (Campbell et al, 2000; Campbell et al, 
2007), see Figure 5. These guidelines state the importance of building an evidence 
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base for non-pharmacological interventions, so that these interventions are developed 
with the same scientific rigour used to develop pharmacological interventions. The 
guidelines provide a framework for the stages of intervention development, with two 
important precursors to intervention design: to select a theory on which to base the 
intervention and to plan an evaluation at the design stage (Campbell et al, 2000; Craig 
et al, 2008). The guidelines for evaluation are that each separate component of the 
intervention should be evaluated independently to determine its own individual 
effectiveness and whether it is practical and feasible to implement. This section will 
give a detailed description of the MRC’s guidelines and discuss how they were used in 
this research.  
An intervention that is composed of several interacting components would be 
considered a complex intervention (Campbell, 2007). According to the MRC’s 
guidelines, complex interventions are required when there are many different factors 
which influence the target behaviour (e.g. adherence to medication) and large 
variability in outcomes (Campbell et al, 2000; 2007). Adherence interventions can also 
be considered to be complex because the target behaviour (adherence to medication) 
is difficult to change and to sustain. Further a behaviour change intervention focussing 
on altering psychological constructs (e.g. beliefs and emotions) is complex because of 
the large number of different variables involved. The measurement of these 
psychological constructs provides a study with many outcome variables to be 
measured. It has been suggested that there are ‘specific difficulties in defining, 
developing, documenting and reproducing complex interventions that are subject to 
more variation than a drug’ (Campbell, 2000, p694). 
The MRC’s framework explains that trials for interventions should include various 
phases in their development from preclinical to implementation of an intervention 
across the NHS. The aim of carrying out the preclinical phase is to identify theory and 
potential intervention components through literature reviews and exploratory studies. 
Phase I involves modelling the potential components, by looking at their relationship 
with the target behaviour. Phase II is informed by the former phases and is an 
exploratory trial of a behaviour change intervention. Phase III is a randomised 
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controlled trial (RCT) and Phase IV is large scale implementation of the intervention 










Continuum of increasing evidence 
Figure 5. MRC’s framework for the design and evaluation of complex interventions 
(Campbell et al, 2000) 
Before large scale RCTs are developed to change behaviour, there needs to be 
preliminary work to ensure that the intervention has a high likelihood of success in 
changing the target behaviour. While randomised controlled trials (RCTs) are often 
noted as the gold standard to evaluate an intervention, this does not imply that they 
should be used for all research projects (Campbell et al, 2000). RCTs are expensive and 
labour intensive and should not be embarked upon unless there is good evidence to 
suggest that they will be a success and worthwhile. The continuum of increasing 
evidence (see Figure 5) is recommended because it allows interventions to be designed 
with background work and reasonable expectation that they will be effective. An RCT is 
therefore one of the final phases in the development of an intervention. When little is 
known about the theory underpinning a given intervention, it is important to carry out 
research in the early phases of the MRC’s guidelines, e.g. theory, modelling and 
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early phases of intervention development, see Table 2 for the research undertaken at 
each stage. 
4.3 Theory Selection; Extended SRM and EPPM 
In summary of the theories selected, this research has drawn on two complementary 
theories of behaviour; the extended self-regulation model (SRM) and the extended 
parallel process model (EPPM). Both models have been previously used to inform the 
design of behaviour change interventions (as discussed in the former chapter). Yet 
each model describes a different mechanism through which to influence behaviour, 
the extended SRM addresses a patient’s view of their illness and medication and the 
EPPM addresses perceptions of risk and motivation. The selection of these theories 
will be justified below.  
The SRM focuses on representations of the illness as a whole, rather than simply 
focusing on the health related behaviour that needs to change or be adopted. The 
extended self-regulation model (extended SRM) is of close relevance to the problem of 
low adherence to medication, given that it explains how an individual copes with an 
illness. It describes the psychological (cognitive and emotional) processes which occur 
when an individual is diagnosed with an illness. The extended model includes the role 
of medication beliefs as a factor influencing adherence and suggests that if a person 
has high concern beliefs and a belief that the medication is not necessary, they are less 
likely to take their medication (Horne, 1997). The authors of the original SRM 
recognise that responses to an illness are not static and are likely to change over time 
with increasing knowledge and experience, which is relevant to a condition such as 
osteoporosis (Leventhal et al, 1984). When an individual has an illness for a long time, 
it is possible that they gradually gain a deeper understanding of it, which may influence 
how they manage it. The application of this theory to the problem of low adherence 
may give rise to a more detailed understanding of how people with osteoporosis make 
sense of their condition and medication. 
The EPPM is similar to the extended SRM in so far as it describes how an individual 
responds to a health threat. There are two theorised methods of coping with the 
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threat; danger control and fear control. In addition, the author of the EPPM provides a 
theory to explain when a health message (fear appeal) is likely to be successful in 
motivating individuals to change their behaviour (Witte, 1992). The theory provides 
advice for how to make a health communication message persuasive by altering risk 
perception. The model shows that to increase protection motivation, a health message 
which increases threat (perceived susceptibility, perceived severity) and coping 
(perceived self-efficacy and response-efficacy) should be used.  
The two similar models stand out from other social cognition models. As well as 
explaining the role of cognitions, they offer an explanation of how an individual’s 
emotional responses to an illness may impact how they choose to manage their 
medical condition. Both models focus on how a patient will respond to health risk 
information or an illness diagnosis. The authors of these models theorise that when 
fear control or emotion focused coping take place, an individual is likely to avoid taking 
the necessary steps to manage their illness, because their energy is expended on 
managing/avoiding the emotional response to the information/diagnosis.  
The EPPM can make some important additions to the extended SRM, by providing a 
model for how risk communication should be framed in order to be persuasive. 
Further, the EPPM highlights the role of efficacy messages to increase the likelihood of 
behaviour change. The EPPM includes information about how motivation can promote 
health related behaviours. Similarly, the extended SRM can make some useful 
additions to the EPPM, by providing an explanation of how patients view and cope 
with their illness, including specific illness and medication beliefs and emotions which 
may influence adherence. A further reason the extended SRM is suited to investigate 
the problem of low adherence is the recognition of behaviour as dynamic in nature, 
with the inclusion of a feedback loop. This is relevant to a long-term condition such as 
osteoporosis, because the feedback loop allows for long-term processing of 
information related to the condition. 
The use of two models will ensure many of the variables which have previously been 
demonstrated to contribute to adherence to medication can be systematically tested, 
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as well as some variables which have not been previously investigated. This should 
increase the likelihood of developing effective behaviour change interventions. Using 
these two models together might produce a strong, comprehensive theoretical 
framework of adherence to medication. Using one without the other could omit 
important factors related to adherence. Using these theoretical frameworks would 
mean that patients’ illness perceptions, medication beliefs, risk perceptions and 
emotional responses could be assessed to determine their problematic beliefs and 
hence the type of behaviour change intervention that is required. Using these theories 
allows the identification of specific beliefs which require intervention. Hence this use 
of theory could add an element of tailoring to the interventions, which has been 
demonstrated as a successful component in previous interventions (Haynes et al, 
2008).  
4.4 Research outline 
The overall objective of the present research was to design and evaluate a theory-
based behaviour change intervention to increase osteoporosis medication adherence, 
for patients who had difficulties with taking their prescribed medication. To meet this 
objective, it was decided to find out as much as possible in relation to osteoporosis 
patients medication adherence, through a series of intervention development studies. 
The overall purpose of the studies carried out prior to the intervention was to guide 
the design of the intervention. Each intervention development study has its own 
objectives, which are briefly outlined below.  
This section will also provide the details of how the MRC’s guidelines for the design 
and evaluation of complex interventions have been applied to the research presented 
in this thesis. A summary of the research undertaken at each stage of intervention 
development is provided in Table 2. As well as the MRC’s guidelines, each of the 
intervention development studies used the extended SRM and the EPPM to inform 
their design (see Figure 6 and Figure 7). 
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Table 2. Overview of thesis research in relation to MRC framework stages 
Intervention development 
stage (from MRC 
framework) 
Type of study Title of study 
Preclinical  Critical review Study 1: The psychological 
factors in non-adherence 
and non-persistence with 
osteoporosis medication; a 
critical review 
Preclinical Qualitative interview 
study 
Study 2: How do 
osteoporosis patients 
perceive their condition and 
medication? 
Phase I Cross-sectional, 
questionnaire study 
Study 3: The psychological 
factors related to 
osteoporosis medication 
adherence 
Phase I Cross-sectional, 
questionnaire study 
Study 4: Osteoporosis 
patients’ ratings of five visual 
images of osteoporosis 
Phase II Intervention, a series of 
case studies 
Study 5: A multifaceted 
intervention to increase 
adherence to osteoporosis 
medication: a case-series 
approach 
Phase II Qualitative interview 
study 
Study 6: Process evaluation 
of a complex behaviour 
change intervention to 
increase adherence to 
osteoporosis medication 
 
4.4.1 Study 1 (Critical Review; Preclinical) 
To gain a detailed understanding of what we already know, a critical review of research 
investigating the relationship between psychological factors (e.g. beliefs & emotions) 
and adherence to osteoporosis medication was carried out. The included studies were 
synthesised to produce a list of the known psychological factors that are related to 
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osteoporosis medication adherence and persistence. As well as the identification of 
psychological factors related to adherence, a further objective of this review was to 
identify gaps in the literature.  
4.4.2 Study 2 (Qualitative Study; Preclinical) 
The next stage of preparation for the intervention development was a qualitative study 
to explore in-depth the relevance of the two theories identified in the literature review 
in chapter 3; the extended SRM and the EPPM. The study investigated how patients 
think and feel about their condition, medication and the associated fracture risk. A 
further aim of the study was to explore the content of patients’ drawn images of 
osteoporosis; a method which was used to gain further insight into how patients 
viewed their condition. The extended SRM and the EPPM were used to guide the 
interview schedule design. The study objectives were to identify patients’; 
1. Perceptions of osteoporosis 
2. Beliefs about their medication 
3. Judgements about their fracture risk 
4. Emotional responses to their condition 
5. Visual representations of osteoporosis 
4.4.3 Study 3 (Quantitative Study; Phase I) 
The overall objective of study 3 was to quantify the relationship between psychological 
factors and adherence, for a theoretical underpinning of the adherence intervention. 
The psychological factors which were selected for investigation were those of the 
extended SRM and EPPM, with questionnaires to collect data. Quantitative methods 
were used to investigate the same factors in study 2. Following this, analysis of 
relationships between each of these variables was carried out. The objectives were to 
investigate: 
 The extent of self-reported non-adherence to medication in patients with 
osteoporosis/osteopaenia 
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 The range of illness perceptions, medication beliefs, emotional responses and 
risk perceptions 
 The barriers to taking osteoporosis medication 
 The factors that are associated with adherence to osteoporosis medication 
The psychological factors identified as related to medication adherence were the focus 
of an intervention to increase adherence to osteoporosis medication. The aims for the 
intervention are outlined in the study 5 section. 
4.4.4 Study 4 (Quantitative Study: Phase I) 
The aim of study 4 was to test some potential intervention materials. There is a lack of 
research of how osteoporosis patients respond to visual images of their condition. 
Osteoporosis patients were given some images/pictures of osteoporosis to observe 
and comment on in a questionnaire study, to assess the visual impact. Based upon the 
premise of the EPPM that threat messages should also include an efficacy message in 
order to change behaviour (Witte, 1992), each image included an attached caption 
with an aim to promote self-efficacy. Participants were asked to rate these images and 
captions in terms of whether they made them feel frightened, informed, angry, 
motivated, depressed, confident, worried or that there was no point in taking action to 
improve osteoporosis. The objectives were to explore the following: 
 How do osteoporosis patients respond to visual images of osteoporosis? 
 Are there a range of responses to various images of osteoporosis? 
4.4.5 Study 5 (Intervention Study; Phase II) 
The main aim was to pilot a novel multi-faceted adherence intervention to increase 
adherence to prescribed medication for osteoporosis. This was carried out with eight 
women with osteoporosis with an N-of-1 case-series design. The adherence 
intervention was based upon the findings of the previously described intervention 
development studies and two behaviour change theories; the extended SRM and the 
EPPM. The intervention comprised: psychoeducation, motivational interviewing 
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components and implementation intentions (or plan-setting). An objective of this 
study was to develop a method for diagnosing patients informational needs in order to 
develop a tailored intervention. Further aims were to investigate:  
 The effect of the intervention on adherence 
 The effect of the intervention components on illness perceptions, emotional 
responses, medication beliefs and risk perceptions 
 How patients depict their condition before and after the intervention 
 The effective intervention components 
4.4.6 Study 6 (Process evaluation study; Phase II) 
The purpose of study 6 was to provide a detailed process evaluation of the 
effectiveness and acceptability of the intervention in study 5. This is a vital step in 
order to determine whether the intervention could be beneficial if rolled out on a 
larger scale. Based upon the findings of this detailed evaluation, the intervention could 
be refined and tested in future research. The follow questions were explored: 
 What were the perceived mechanisms of the changes observed in adherence 
and/or psychological factors? 
 What was each participant’s subjective experience of taking part in the 
adherence intervention research? 
 Were participants satisfied with the intervention? 

















Figure 6. Extended Self-regulation Model annotated for utilisation in the present research
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The need for interventions to promote medication adherence is clear, to improve 
health outcomes for patients and to reduce the healthcare costs involved. However, 
the most effective method of doing this has not yet been determined. This chapter 
summarised the theory selection for the present research, in which two theories were 
combined to investigate the problem of low adherence to medication; the extended 
SRM and the EPPM. While both theories are similar, a combination allows the 
exploration of more variables which might be related to adherence. 
Two theories have been selected because they can both add something beneficial. The 
EPPM adds information about the role of motivation, self-efficacy and how to 
shape/deliver a health risk message. The extended SRM determines the specific beliefs 
about illness and medication which may require intervention, as well as showing the 
dynamic nature of an individual’s lay model of their illness and how this model 
continuously adapts to new information. 
A psychological intervention which improves adherence to osteoporosis medication 
could be used in future practice within the NHS to improve the quality of osteoporosis 
care by helping patients to get the most health benefit possible from their medication, 
or adapted for use with patients with other medical conditions. This could have 
implications for future policy making. This thesis will proceed to present a series of 
intervention development studies. The first stage of intervention development was a 
systematic search of the literature and synthesis of studies which focused on the 
psychological factors associated with adherence and persistence with osteoporosis 
medication.   
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5 Study 1: The psychological factors in non-
adherence and non-persistence with 
osteoporosis medication; a critical review 
Chapter overview 
Before designing an intervention to promote medication adherence, it is essential to 
identify the psychological factors and theories which are related to the target 
behaviour. Literature focusing on the psychological factors related to adherence and 
persistence with osteoporosis medication was critically reviewed. Online databases 
were searched and 13 articles met the inclusion criteria for the systematic review. The 
papers were assessed for quality. Data from studies which were rated as being of ‘high 
quality’ were synthesized to provide a list of the psychological factors associated with 
adherence and persistence with oral medication for osteoporosis.   
5.1 Introduction 
Until recently, the psychological factors/drivers of non-adherence to osteoporosis 
medication had not been investigated. In recent years there has been a new focus on 
behaviour change interventions that seek to alter psychological factors, based on the 
premise that behaviour is commonly associated with underlying psychological factors, 
such as beliefs. Before interventions are designed to promote medication adherence, 
there is a need to gain an understanding of the psychological factors that underpin 
adherence to medication (Horne et al, 2005). There is a need to draw comparisons and 
look for patterns that may exist in the research previously carried out, to identify the 
psychological factors related to medication adherence. 
Much previous work in this area focused on the socio-demographic or clinical factors 
which are related to medication adherence. While this is fruitful in enabling the 
identification of patients who may be at high risk of non-adherence, there is no scope 
for altering socio-demographic or clinical factors. Numerous studies show that various 
psychological factors are associated with treatment adherence across a range of 
medical conditions (Horne, 1999; Weinman & Petrie, 2003). In order to carry out a 
review of the psychological factors related to adherence, it is important to define 
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psychological factors. For the purpose of this review, psychological factors are defined 
as any psychological construct (e.g. belief, emotion or state) which can influence 
behaviour.  
Beliefs about illness and medication have been found to predict treatment adherence 
in a variety of chronic conditions (Weinman & Petrie 1997; Schousboe, 2013). There is 
some evidence that this is true for osteoporosis patients. For example, researchers 
have found the following beliefs to be significantly correlated with adherence to 
osteoporosis medication: the perceived need for and the efficacy of medication; 
concerns about medication and side effects (McHorney et al, 2007; Carr et al, 2006; 
Blouin et al, 2008; Schousboe et al, 2010). In other words, it has been established that 
an individual’s beliefs correspond with their behaviour. This association is important 
because beliefs about illness and medication are amenable to psychological 
intervention (Horne et al, 2005). Therefore psychological interventions aimed at 
changing beliefs may have the potential to impact upon behaviour.  
McHorney et al (2007) carried out a study to investigate the drivers of non-adherence 
to bisphosphonates in osteoporosis patients. It was found that patients who doubted 
the efficacy and safety of the medication had the poorest adherence (though this was 
measured by self-report). McHorney et al (2008) have suggested that this shows the 
need to address patients’ medication beliefs and side effects when designing 
psychological interventions. This is known as the necessity/concerns framework 
(Horne, 1997). There are many studies across medical conditions to suggest that 
patients’ concerns about their prescribed medication are factors in determining 
whether they will take their medication (e.g. Horne et al, 1999). For example, in 
osteoporosis the following concerns about medication have been documented: direct 
harm, artificiality of medication, lack of understanding in relation to how they work 
and physician over-prescription of medication (Unson et al, 2003). Further, Schousboe 
et al (2010) investigated how necessity and concern beliefs influence adherence to 
medication. They found that doubts about the necessity of medication-taking and 
concerns about the medication were significantly associated with persistence but not 
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adherence to medication. They conclude that there is a different set of drivers of both 
adherence and persistence. 
There is also evidence that the underlying model of osteoporosis and its associated 
risks that many patients hold is faulty. Giangregorio et al (2008; 2009) investigated 
fracture patients’ causal attributions for fractures. It was found that over half of the 
study participants believed the cause of their fracture was due to events like a fall 
rather than to osteoporosis. Not recognising the cause of their fracture to be an 
underlying bone disease highlights a lack of understanding of the nature of the disease 
and the cause of osteoporotic fractures. This clearly shows that patients do not 
understand the risks of their underlying bone condition. These findings are valuable for 
healthcare professionals and they demonstrate that patients need a clearer 
understanding of their medical condition if they are going to be able to self-manage it 
effectively. This is suggestive of the need for a more in-depth investigation of the 
illness beliefs of osteoporosis patients.  
Many studies have explored whether adherence improves when the dosing frequency 
of osteoporosis medication is reduced. A critical review of these studies indicates a 
significant improvement in adherence with weekly rather than daily doses of 
bisphosphonates (Lee et al, 2011). While there is evidence to suggest that less 
frequent dosing regimens are associated with increased adherence,  the authors 
suggest that psychological factors such as perceived medication efficacy and side 
effects were as important, if not more so, than dosing frequency when predicting 
osteoporosis medication adherence.  
Much of the previous research surrounding illness and medication beliefs of 
osteoporosis patients has taken place in the United States and has investigated 
patients’ beliefs about using HRT as a treatment for osteoporosis (e.g. Ballard, 2002). 
However, given that HRT is no longer a commonly used therapy for the treatment of 
osteoporosis, papers investigating treatment adherence to hormone replacement 
therapy were excluded from the present review.  
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To give this review a narrow focus, papers reviewing adherence to the following were 
also excluded; calcium or vitamin D only, infusions to treat osteoporosis, comparisons 
of daily and weekly doses. The following study types were also excluded: studies of 
non-psychological factors (e.g. demographic and clinical factors), qualitative studies 
and studies that used an interventional approach. 
Side effects are commonly demonstrated to influence adherence to osteoporosis 
medication (Carr et el, 2006; McHorney et al, 2007; Penning-van Beest et al, 2008). It is 
debatable as to whether side effects should be included in a review of the 
psychological factors contributing to adherence to medication, however, it was 
decided that side effects would be included on the basis that the interpretation of the 
experience of side effects is a psychological process (Rief et al, 2011). 
The objective of this review was to systematically identify and synthesize existing 
knowledge about the relationship between psychological factors and medication 
adherence. The identification of the psychological factors associated with adherence 
to medication in osteoporosis is beneficial because these factors could be the focus of 
a future intervention to promote adherence.  
5.2 Method 
Search Strategy 
Variations of the following terms were used to systematically search the databases: 
osteoporosis, adherence, determinants and medication. A detailed list of the search 
terms and there variations is included in APPENDIX 1. Endnote was used to discard 
duplicates (papers which were retrieved on two or more databases). It was decided to 
search no further databases when saturation point was reached; this was when the 
final database searched (Medline®) yielded no new papers. 
 A range of databases were searched, including: 
 EMBASE (1974-2013) 
 Medline® (1946-2013) 
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 PsychInfo (1806-2013) 
 Scopus (1945-2013) 
 Web of Knowledge (1900-2013) 
In addition, the references of all the relevant papers were searched to ascertain 
whether any papers were not retrieved during the electronic search. 
Inclusion Criteria 
 Adherence to medication in patients with osteoporosis or osteopaenia 
 Oral medications (bisphosphonates, strontium ranelate or raloxifene)  
 Measure of adherence to medication and psychological factors 
 Quantitative studies assessing the level of significance of any relationships 
 All papers published until July 2013 were included 
Exclusion Criteria 
 Adherence in medical conditions other than osteoporosis/osteopaenia  
 Intravenous medications for osteoporosis (e.g. pamidronate, zolendronate or 
teriparatide) 
 Hormone replacement therapy 
 Qualitative studies 
 Interventional studies to promote adherence 
 Studies of the relationship between adherence and demographic/clinical 
factors 
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 Papers were excluded when they investigated adherence to medication for 
various chronic medical conditions and they did not provide separate analyses 
for osteoporosis patients’ data. 
Procedure 
The electronic databases listed above were searched using the search terms shown in 
APPENDIX 1. The titles and abstracts of all the electronic search results were screened 
for inclusion in the review. Papers that appeared to meet the inclusion criteria were 
screened in full. When papers were screened in full, many were excluded (see Figure 8  
for the reasons for exclusion).  
The author assessed the quality of all the included papers, by calculating a total score 
out of 20; a high score indicated high quality. This was carried out using the 
assessment tool shown in APPENDIX 2 (Kmet et al, 2004). This tool was adapted for use 
with non-randomised studies, by excluding irrelevant criteria for quality, e.g. 
randomisation, allocation concealment etc. The sample size was deemed to be 
adequate if there were more than 10 participants for each variable being investigated.  
To assess the validity of the quality checking procedure an independent assessor also 
assessed over 50% of the papers (n=8) for quality. Both the author and the 
independent assessor compared scores to check the level of agreement. It was decided 
to rate papers that scored >17/20, as high quality. Given that this was a critical review, 
papers that were not rated as high quality were excluded from the data synthesis. This 
led to the exclusion of three papers from the review. There was a high level of 
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Table 3. Comparison of quality assessment scores when rated by two researchers 
Authors Quality Score (author) Quality score (independent 
assessor) 
Berecki-Gisolf et al (2008) 20 20 
Carr et al (2006) 20 20 
Fitt et al (2001) 20 20 
Huas et al (2010) 19 20 
Kamatari et al (2007) 16 16 
McHorney et al (2007) 20 20 
Rossini et al (2006) 14 13 




The relationship between a large number of different psychological factors and 
adherence was investigated. In order to synthesise the data, a table including a list of 
each psychological factor and its reported relationship with adherence is presented in 
Table 5. A separate table of the psychological factors in osteoporosis medication 
persistence is also included in Table 6.   
5.3 Results 
The search strategy revealed 2975 potential papers for inclusion in the review (see 
Figure 8 on the next page). When duplicates and irrelevant papers that did not meet 
the inclusion criteria were excluded, 74 papers remained and were accessed in full text 
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Figure 8. Flowchart of study inclusion/exclusion 
Irrelevant papers were excluded, 
studies of: non-psychological 
factors associated with 
adherence, adherence only, 
preference for a particular 
medication (n=2340) 
Exclusion of studies: adherence 




Papers for quality assessment 
n=15 










Searches of EMBASE, Medline®, 
PsychINFO, Scopus and WOK 
(n=2975) 
Duplicates were excluded 
(n=560) 
 
Review of full text articles of 
potentially relevant studies 
(n=75) 
Exclusion of non-psychological 
factors associated with 
adherence e.g. clinical or socio-
demographic factors 
n=27 
Excluded based on quality score 
n=3 
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Raloxifene High tolerability and 
motivation were 
related to high 
adherence 
16 
*Papers including the role of side effects as determinants of non-adherence; †Terms used to denote adherence match those adopted by the papers 
authors. 
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5.3.1 Data synthesis 
Table 5. Table of the determinants of non-adherence to osteoporosis medication 
The psychological factors related to non-
adherence to osteoporosis medication 
The number of studies that 
investigated this factor 
The number of studies 
reporting a significant 
relationship between this 
factor and adherence 
Side effects 3 3 
Use of additional medication for gastro-
intestinal side effects (proxy measure of side 
effects) 
1 1 
Beliefs about osteoporosis 2 1 
Perceptions of illness severity 3 2 
Illness severity  1 1 
Knowledge 4 3 
Self-rated knowledge 1 1 
Medication beliefs (Necessity) 1  0 
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The psychological factors related to non-
adherence to osteoporosis medication 
The number of studies that 
investigated this factor 
The number of studies 
reporting a significant 
relationship between this 
factor and adherence 
Medication beliefs (Concerns) 5 4 
Perceived drug effectiveness 2 2 
Satisfaction with medication 1 1 
Medication self-efficacy 1 1 
Mental quality of life 1 1 
Satisfaction with doctor-patient 
communication 
2 1 
Trust in the doctor 1 0 
Recall of BMD scan result 1 1 
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Table 6. Table of the psychological factors related to non-persistence with osteoporosis medication 
The determinants of non-adherence to 
osteoporosis medication investigated 
The studies that investigated 
this factor 
The studies reporting a 
significant relationship 
between this factor and 
adherence 
Side effects 3 3 
Use of additional medication for gastro-
intestinal side effects (proxy measure of side 
effects) 
2 2 
Illness severity 1 1 
Knowledge 1 1 
Willingness to take prescribed medication 1 1 
Medication beliefs (Necessity) 1 1 
Medication beliefs (Concerns) 3 3 
Perceived drug effectiveness 1 1 
Satisfaction with medication 2 1 
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The determinants of non-adherence to 
osteoporosis medication investigated 
The studies that investigated 
this factor 
The studies reporting a 
significant relationship 
between this factor and 
adherence 
Medication self-efficacy 1 1 
Quality of life 2 1 
Mental health 1 0 
Motivation 1 1 




Table 7. The relationship between lifestyle factors and adherence and persistence 















between this factor 
and adherence 
Alcohol intake 2 1 
Exercise 3 3 
Smoking 1 1 
Body Mass Index 1 0 
5.4 Discussion 
For successful osteoporosis medication adherence in order to reduce the risk of 
fracture, this critical review emphasises the importance of the following factors; the 
experience of side effects, concerns about medication, knowledge and perceived 
severity. Much of the previous research in this field focused on the determinants of 
non-adherence, with fewer focused on the determinants of non-persistence with 
osteoporosis medication. It is noteworthy that the studies included good sample sizes 
and overall had a high level of quality. Only papers with a very high quality score 
(>17/20) were included in the synthesis of information for the present review. The 
majority of papers conducted only univariate analysis of the predictors of adherence. 
Side effects were the most commonly researched determinants of non-adherence, 
with agreement between all studies that the experience of side effects is related to 
osteoporosis medication adherence (Tosteson et al, 2003; McHorney et al, 2007; 
Solomon et al, 2011;) and persistence (Tosteson et al, 2003; McHorney et al, 2007). In 
other studies, side effects were measured by mean possession ratio (MPR) for 
medications to reduce acid related side effects or gasto-protective medications 
(Penning-van Beest et al, 2006; Berecki-Gisolf et al, 2008; Penning-van Beest et al, 




2008;), because these medications are often used to counteract the side effects of 
osteoporosis medication. However, it is possible that this proxy measure is not valid 
for the measurement of side effects.   
Concerns about medication have been frequently investigated in relation to both 
adherence and persistence to osteoporosis treatment, with consistent evidence of a 
strong relationship. Four out of five studies reported a strong association between 
adherence and concerns about medication (Carr et al, 2006; Yood et al, 2008; Solomon 
et al, 2011; McHorney et al, 2007). However, Schousboe et al (2010) did not find an 
association between concerns about osteoporosis medication and adherence, but did 
find an association between concerns about osteoporosis medication and persistence. 
The authors of all the studies investigating the relationship between concerns about 
osteoporosis medication and persistence found a significant association (Carr et al, 
2006; McHorney et al, 2007; Schousboe et al, 2010). Hence there is strong evidence 
that concerns about medication are related to treatment non-adherence/persistence.   
Perceived necessity for osteoporosis medication was only assessed in one study 
included in this review. While it might be expected that it predicts both adherence and 
persistence, perceived necessity was strongly related to non-persistence, but not non-
adherence (Schousboe et al, 2010). The author’s explanation for these mixed findings 
is that there are different explanatory factors for both adherence and persistence. 
Four studies assessed patients’ knowledge of osteoporosis and investigated whether 
such knowledge predicted adherence. While three of the studies found that as 
knowledge increased, adherence increased (Ringe et al, 2007; Yood et al, 2008; 
Solomon et al, 2011), the other study did not find any association (Vytrisalova et al, 
2008). It should be noted that knowledge was measured differently in each study and 
this could account for the discrepancy between findings. However, overall the majority 
of evidence suggests that knowledge of osteoporosis is an important determinant of 
adherence. Further, recall of the bone mineral density scan results was associated with 
better adherence (Fitt et al, 2001). Perceived knowledge was also related to adherence 
in the only study it was investigated (Huas et al, 2010). This finding is in agreement 




with Leventhal’s SRM, in which it is theorised that when a patient feels that they have 
a coherent model or understanding of their illness, they are more likely to adopt a 
problem-focussed coping mechanism, such as adherence. 
Patients’ perceptions of the severity of the condition have been the focus of three 
studies, two of which showed an association with adherence (Yood et al, 2008; Huas et 
al, 2010). One group of researchers found a link between the actual severity of 
osteoporosis with both adherence and persistence (McHorney et al, 2007). Overall 
there is evidence to suggest that when patients perceive themselves to be at risk of a 
fracture, they take their medication as prescribed. 
As well as investigating the psychological determinants of adherence, many of the 
studies included in this review have drawn out a relationship between lifestyle factors 
(e.g. diet, smoking, exercise) and adherence. In three studies, engagement in physical 
exercise was associated with increased adherence, however, it is unlikely that lifestyle 
factors and non-adherence are causally related. A possible explanation for the 
relationships detected between lifestyle factors and adherence is that a person who is 
non-adherent also engages in other behaviours which may cause a risk to their health. 
Perhaps this relationship is due to smokers and non-adherers placing little value on 
their health. 
5.4.1 Gaps in the literature 
There has been little exploration of the emotional response to having osteoporosis as a 
predictor of non-adherence to osteoporosis medication. While two studies 
investigated a relationship between mental health/ mental quality of life and 
adherence, there were mixed findings. One study found an association between high 
adherence and good mental quality of life (Huas et al, 2010), another study found no 
association between mental health and medication persistence (Berecki-Gisolf et al, 
2008). This review has identified a gap in the literature, with the need for more 
investigation of the role of emotional response to osteoporosis in adherence and 
persistence with osteoporosis medication. It is theorised that emotional response to a 
medical condition is likely to influence and be influenced by the behavioural 




response/coping mechanisms (Leventhal et al, 1997): effects may be bi-directional and 
can only be understood when investigated in prospective or intervention studies. 
A further gap in the literature is only two of the included studies investigated the 
relationship between adherence and motivation (Tosteson et al, 2003; Ziller et al, 
2011). Further, medication self-efficacy was only investigated in one study, with a 
reported relationship between this factor and both adherence and persistence. Overall 
this is a gap in the literature worthy of more research, because motivation is a factor 
for which psychological interventions are available.   
Apart from the necessity/concerns framework (Horne et al, 1997), no researchers 
explicitly used other health psychology theories to guide their exploration of the 
psychological determinants of adherence and persistence with osteoporosis 
medication. This sheds light on a problem with the research in this area to date, 
because lack of theory-base means that important determinants of behaviour may be 
omitted from the investigation. A lack of theory-base also means that mediating 
processes/mechanisms cannot be explored. Future research could provide more 
insight to the problem of low adherence if the determinants are explored using a 
theoretical focus. 
This review indicates that there are very a small number of studies which investigated 
the relationship between beliefs about osteoporosis and adherence to osteoporosis 
medication, with two sets of authors reporting studies of the relationship between 
beliefs about osteoporosis and adherence. One group of authors reported a 
relationship between adherence and beliefs about osteoporosis, whereas another 
group of authors did not (Solomon et al, 2011). There was a tendency for previous 
researchers to investigate perceptions of osteoporosis using healthy participants, 
rather than a clinical population of osteoporosis sufferers (Hsieh, 2001; Ballard, 2002; 
Williams et al, 2002; Gerend, 2006). However, there is a need for more studies to 
assess the relationship between beliefs about osteoporosis and adherence in a clinical 
population. 





A major limitation of the studies investigated is the common use of cross-sectional 
designs to examine the relationship between psychological factors and adherence. 
Therefore it is difficult to know if factors such as beliefs are causal for adherence or 
whether they are an effect. This is particularly true for factors such as emotions and 
quality of life, which may be the end result of a worsening medical condition which is 
due to low adherence. Also, some of the possible psychological predictors of 
adherence may be related to each other, such as side effects and concerns about 
medication. Multivariate statistics are needed to evaluate the contribution of each of 
the variables to the prediction of adherence. 
The present critical review included only published manuscripts, which means it is 
likely to be influenced by publication bias. It is noteworthy that many studies do not 
report factors which were not associated with adherence. A review of unpublished 
work would be beneficial and could enable the discovery of factors unrelated to 
adherence. Further, a review of qualitative studies investigating the determinants of 
adherence would also be beneficial and may be able to fill some the gaps in the 
literature. 
Research for each psychological factor was synthesised in Table 5 and Table 6. The 
problem with synthesizing data of this nature is that often the 
questionnaires/measures for each psychological construct are not the same. For 
example, in one study, knowledge was assessed using a 4 item questionnaire (Ringe et 
al, 2003), whereas in another, knowledge was assessed using a 20 item questionnaire 
(Vytrisalova et al, 2008). Further the 4 item questionnaire included items of knowledge 
about medication, whereas the 20 item questionnaire focused on knowledge of 
osteoporosis only. 
A further difficulty was that the various authors used different terms to signify 
adherence, compliance and persistence. It would be beneficial if the scientific 
community who study adherence to medication could use the same definitions of 
adherence, which would allow ease of comparison across the literature. 




5.5 Summary and next steps 
There is strong evidence from this critical review that if behaviour change 
interventions are targeted at the following psychological constructs, adherence to 
osteoporosis could be improved: the experience of side effects, concerns about 
medication, knowledge and perceived severity of osteoporosis. Other psychological 
factors require more research to determine their relationship with adherence, such as 
beliefs about osteoporosis, emotional responses and motivation for adherence. There 
is a need for theory-based research to investigate the determinants of non-adherence. 
Before adherence interventions are designed, it is vital to do preliminary research to 
investigate the psychological determinants of the target behaviour for the particular 
patient group/medical condition being investigated. In particular, it would be 
worthwhile for such studies to be theory-based and to further investigate the 
relationship between illness beliefs, emotions and risk perceptions and adherence to 
osteoporosis medication. There are few studies assessing the relationship between the 
following psychological factors and adherence: medication self-efficacy, perceived 
necessity for medication, emotional responses and mental health/mental quality of 
life, which shows the need for further research to determine these relationships.  
The next two studies will focus on the gaps in the literature identified in this review. A 
theory-based investigation of the relationship between psychological factors and 
adherence will be the focus of a questionnaire study (study 3) presented in chapter 7. 
However, prior to this, a qualitative study was carried out to explore how osteoporosis 
patients perceive their condition and medication for it. This qualitative study is 
presented in the following chapter, with an overall aim to ascertain whether two 
theories of health behaviour have the potential to be beneficial as a basis for an 
intervention to improve osteoporosis medication adherence.  
 




6 Study 2: How do osteoporosis patients 
perceive their condition and medication?2 
Chapter overview 
The work presented in this chapter constitutes a qualitative research project 
investigating the illness and treatment perceptions of osteoporosis patients. This study 
had two key aims: (1) to explore osteoporosis patients’ perceptions about their 
condition and medication; (2) to identify potential cognitive and emotional factors that 
may be related to osteoporosis medication adherence. In the present study, illness 
perceptions, medication beliefs, emotional responses and risk perceptions were 
explored using semi-structured interviews. To gather more data about how patients 
perceive their condition, they were asked to create a visual representation of 
osteoporosis through the use of drawing.  
6.1 Background 
The goal of anti-osteoporosis medication is to reduce fracture risk, improve quality of 
life and reduce hip fracture associated mortality (Bock & Felsenberg, 2008). Numerous 
researchers have concluded that osteoporosis medication can reduce the risk of 
fracture (Cranney et al, 2002; Wells et al, 2008). However, as discussed in chapter 2, 
osteoporosis patients commonly do not take their medication as prescribed by their 
doctor. Overall non-adherence renders medication an ineffective intervention. Non-
adherence to osteoporosis medication can result in increased risk of fractures and 
associated hospital admissions (Rabenda et al, 2009). There is a clear need for 
researchers to develop novel interventions to promote medication adherence, in order 
to help patients manage their condition effectively. 
Illness perceptions and medication beliefs have been found to be related to 
medication adherence for a variety of chronic conditions (Weinman & Petrie, 1997). 
Further, risk perceptions have been shown to be important motivators of health 
                                                     
2
 This paper was published online and was selected for publication in a special issue of the Archives of 
Osteoporosis (Besser et al, 2012). It was also presented at the British Psychological Society (BPS) Division 
of Health Psychology (DHP) annual conference (Besser et al, 2011).   




protective behaviours and this is also true for osteoporosis medication adherence 
(Giangregorio 2008; 2009). There have been many qualitative studies to explore 
patients’ perceptions of adherence in other medical conditions (e.g. Dean et al, 2005), 
as well as qualitative studies of osteoporosis patients medication adherence (e.g. 
Unson et al, 2003). However, to the author’s knowledge there have been no 
qualitative studies in relation to osteoporosis patients medication adherence based 
upon a theoretical framework. Given that these psychological factors are likely to 
underpin adherence behaviour, it was decided that a theory-based qualitative study 
would be carried out with osteoporosis patients to explore these factors in further 
detail. 
In addition to exploring the cognitions associated with illness through interviews, it 
may be useful to study how osteoporosis patients visualise their illness, as an 
alternative way of understanding their perception of their condition. Drawing is 
becoming a widely used method for exploring how patients view illness (Guillemin, 
2004) and can be used in addition to interviews/questionnaires to assess cognitive and 
emotional representations of illness (Kaptein, 2010). A patients’ visual representation 
of their illness is important and it may hold information which they use to determine 
how they will manage their illness. To date there has been no published exploration of 
the visual representations of osteoporosis patients. 
6.2 Introduction 
A qualitative study, based upon the components of the extended Self-Regulation 
Model (SRM), could expand current knowledge of how patients with osteoporosis 
make sense of their illness. A study of this nature could reveal detailed information of 
how people with osteoporosis view their illness. It is clear that interventions are 
needed to help patients with osteoporosis adhere to medication regimes. However, 
prior to intervention design it is important to carry out an exploratory study in order to 
gain a greater perspective and understanding of the potential theories and 
surrounding issues influencing an intervention of this nature (Campbell et al, 2007). In 




this case, the exploratory study needs to investigate patients’ cognitions and emotions 
which are likely to be related to medication adherence.  
Visual representations (imagery) of illness have been explored in coronary heart 
disease (Broadbent, 2006a), cancer (Harrow et al, 2008) and headaches (Broadbent, 
2009). Exploring visual imagery provides a platform to challenge patient’s mental 
images which may be negative or incorrect (Harrow et al, 2008). There is evidence to 
suggest that patients do hold mental images/representations of their illness. For 
example, Broadbent et al (2006a) found images to be useful in demonstrating how 
patients made sense of myocardial infarction (MI). Patients were asked to draw a 
picture of their heart after suffering an MI. They found that the size of a patient’s 
drawing of their heart was related to recovery, as measured by the speed at which 
participants returned to work. Patients who drew bigger hearts were slower to return 
to work. This shows how patients’ visual representations can be related to health 
outcomes.  
Furthermore, there are studies which indicate that using images could be powerful 
motivators for changing intentions and health behaviours (Shahab et al, 2007, Harrow 
et al, 2008). These studies are discussed in detail in study 4. If visual images can 
motivate behaviour change, then it is very important to investigate the way in which 
patients mentally visualise their illness/potential illness. Therefore the possibility 
exists, for patients who hold mental images with erroneous concepts of their illness, to 
modify their behaviour through intervention e.g. education about the illness. It would 
be beneficial if health care professionals understood the way in which patients view 
their illness in order to be able to help them to manage it.  
There has been a study of breast cancer patients’ visual representations of their 
condition (Harrow et al, 2008). This paper focused on the way in which patients’ 
mental images develop and how these are related to their illness beliefs about cancer. 
It was found that the participants (women with breast cancer) had very detailed 
mental images about their cancer and that these were strongly related to their illness 
beliefs. One of the participants in this study provided an example of how using an 




image can alleviate fears, e.g. her image of cancer changed from that of a snake 
moving around the body to a cloud which was in one place. This change in her mental 
representation of the disease made her feel less worried about the condition. The 
study reports ‘analysis suggested that the images offered by health professionals had 
the potential to remove or ameliorate anxiety or fear’ (Harrow et al, 2008, p 343). This 
shows how the use of images can be used to improve communication between health 
care professionals and patients. Furthermore, these authors found that clinicians’ use 
of visual representations of cancer, e.g. showing mammograms during their 
consultations was influential for altering the patients’ mental representation for their 
illness. This supports the idea that visual stimuli are understood by patients and can be 
used to alter mental representations.  
Cameron (2009) did a study which assessed the association between illness risk 
representations and risk appraisal, worry, self-protection intentions and self-
protection behaviours in patients with skin cancer. Illness risk representations are risk 
perceptions which are studied in relation to the self-regulation framework. 
Importantly, concrete visual images were predicted to be more influential than 
abstract information about the illness when aiming to change behaviour (Cameron, 
2009). It was found that the vividness of the patients’ symptom imagery independently 
predicted intentions and skin cancer risk reduction behaviours.  
An extension of the SRM was used to guide the design of the interview schedule. This 
was carried out in conjunction with previous research which suggests that 
cognitions/emotions about illness and medication may influence adherence to 
medication in other medical conditions, as well as in osteoporosis (e.g. Carr et al, 2006; 
McHorney et al, 2007). A study which investigates the way in which patients make 
sense of their illness using cognitive, emotional and visual representations could 
provide beneficial information to HCPs. Further, it could offer insight into the patients’ 
perspective of the illness. In turn the provision of such information could allow HCPs to 
address any common illness misconceptions held by patients.  




Rationale for study 
While there has been research investigating the role of medication beliefs and risk 
perceptions in osteoporosis medication adherence, there have been no previous 
studies investigating the role of illness perceptions from the extended SRM. This study 
could inform future interventions by helping to define the components required for an 
intervention of this nature, for example; which erroneous patient cognitive/visual 
representations require intervention? The psychological factors focused on in this 
study can be found in Figure 9. The literature indicates that patient’s medication 
beliefs and risk perceptions may also influence their adherence to osteoporosis 
medication, so these beliefs are being further investigated in this study. Much of the 
previous research of individual’s illness beliefs about osteoporosis has been carried out 
with healthy participants as opposed to osteoporosis patients. This indicates the need 







Figure 9. The extended self-regulation model (SRM) (adapted from Leventhal et al, 1984). 
6.3 Aims 
The overall aim of this study was to explore how osteoporosis patients think and feel 
about their condition and its treatment. The study explored how patients make sense 
of their illness and the associated fracture risk. The content of patients’ visual 
representation of osteoporosis was also explored. The objectives were to identify 
patients’; perceptions of their illness, beliefs about their medication, emotional 
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representations of osteoporosis. A further aim was to explore the psychological factors 
which might be related to adherence to medication, which might inform the design of 
an intervention to improve adherence. 
6.4 Method 
6.4.1 Study Design 
Semi-structured face-to-face interviews were used to gather information from hospital 
outpatients with osteoporosis. A qualitative methodology was chosen for this study 
because there is little previous work exploring the illness perceptions of osteoporosis 
patients (none of which utilised the SRM). Qualitative research enables the in-depth 
investigation of participants’ views and experience. This is the preferred research 
methodology for studies aiming to explore peoples’ attitudes and motivations (Keats, 
2000).  
The interview schedule covered the following topics: illness perceptions (identity, 
timeline, causes, controllability and consequences); emotions about the condition, 
medication beliefs (perceived need for medication and concerns about medication); 
risk perceptions (perceived severity and susceptibility) and adherence to medication. 
In addition to the interviews, patients were asked to draw a pair of bones, one with 
osteoporosis and one without. Half of the participants were also asked to draw a pair 
of people, one with and one without osteoporosis. Participants were asked to draw at 
the beginning of the interview, at the point when they were asked questions about the 
nature of the osteoporosis.  
Interview schedule development 
Patients and service users were involved in the design of the study. A focus group was 
conducted by the researcher in which service users were asked “what questions could 
osteoporosis patients be asked to gain a more in-depth understanding of how they see 
their illness.” This question was written on a large piece of paper and the service users 
were given post-it notes, on which they were asked to make a note of potential 
questions. The author also took part in this activity. Once the questions were 
formulated, the author and service users put them into categories and placed them in 




a logical order for interview. The service users generated some useful questions, such 
as ‘how does having osteoporosis influence your daily life? The interview schedule can 
be found in APPENDIX 5. 
The extended SRM model was used as a guide to generate additional questions to 
capture key theoretical constructs. This helped to formulate additional questions 
focussing on osteoporosis patients: illness perceptions, medication beliefs, emotional 
responses and risk perceptions, as well as adherence to medication. Finally, an expert 
patient reviewed the complete interview schedule and piloted the drawing task. She 
was asked to comment on the questions in terms of how easy they were to understand 
and whether the wording was appropriate. The expert patient was able to provide 
advice on questions which were not clear. She also drew a bone of an individual with 
and without osteoporosis. While she was apprehensive about the task, she reported 
that it posed no major difficulty.  
6.4.2 Participants 
Fourteen female outpatients with osteoporosis (n=10) and osteopaenia (n=4) took part 
in the study (mean age 69; range 58-82; SD 10.1). All participants had been prescribed 
medication for osteoporosis in the past or present, though one was in the process of 
deciding whether or not to start taking it. The number of fractures suffered ranged 
from zero and eight throughout their lifespan. They had suffered with osteoporosis for 
between two and 30 years prior to the interview. The majority were retired from work 
(n=9/14). Participant demographic and clinical information is summarised in Table 8. 
_______________________________________________________________________ 
Table 8. Study 2 participant's demographic and clinical Information 
_______________________________________________________________________ 






1 62 Osteoporosis Nurse 0 2 
2 82 Osteoporosis Retired 3 6 
3 60 Osteoporosis Lecturer 6 5 










4 76 Osteopaenia Teacher (retired) 5 3 
5 72 Osteoporosis Office Worker 
(retired) 
3 15 
6 82 Osteoporosis Lab Technician 
(Retired) 
Unknown Unknown 
7 56 Osteopaenia Government 
Officer 
1 3 
8 64 Osteoporosis Manager 
(Retired) 
8 10 
9 80 Osteoporosis Artist 8 10 
10 80 Osteoporosis Office Worker 
(Retired) 
Unknown Unknown 
11 59 Osteoporosis Unemployed 0 3.5 
12 58 Osteopaenia Teacher 
(Retired) 
0 Unknown 
13 62 Osteopaenia Teacher 
(Retired) 
0 5 




The participants were recruited from two clinics: a) an osteoporosis clinic screening 
research unit and b) a rheumatology clinic at a London teaching hospital and included 
patients who attended all their hospital appointments and patients who did not attend 
(DNA) their last clinic appointment. DNA is defined as a patient who did not attend 
their last clinic appointment with their doctor and did not contact the clinic to inform 
staff of the cancelation. DNA patients were included on the premise that as they are 
non-adherent to appointments, then they may also be non-adherent to medication 
and thus could provide insights into factors related to non-adherence. Eight of the 
women attended their last clinic appointment and six did not. Participants who did not 
speak English had to be excluded because this is a student project, with no available 
funding for translators.  
The majority of study participants had previously taken part in a clinical trial to 
measure the effects of teriparatide (an anabolic anti-osteoporosis agent described in 
chapter 1) on bone mineral density. Hence this was a group of patients who were likely 




to have been quite well informed about osteoporosis and medication. The clinical trial 
involved taking regular measurements of bone mineral density; therefore participants 




Ethical approval was sought from the proportionate review sub-committee of the 
South West London Research Ethics Committee (REC) 3 who gave a favourable 
opinion. Once a favourable opinion letter was received from the REC, research and 
development (R & D) approval was also obtained from Guy’s and St. Thomas’ R & D 
department. Patients were required to give written consent to take part in the study 
and for it to be audio recorded. It was arranged that the clinic doctor was available at 
the time of the interviews in case there were any adverse events. 
Recruitment 
Using the inclusion/exclusion criteria, a member of the clinic administrative staff 
identified 45 suitable participants and provided the author with their names and 
addresses. The author contacted these potential participants by post, 29 of these were 
non-attenders. A letter of invitation to take part in the study, together with an 
information sheet and a consent form were sent to the potential participants. They 
were also given the author’s contact details and encouraged to get in contact if they 
had any questions about the study. Participants were asked to sign and return the 
consent form if they agreed to take part. It was made clear to the participants that 
participation is voluntary and their hospital care would not be affected in any way 
whether they chose to take part or not. Participants were offered £5 for taking part, to 
cover the cost of expenses. Due to participants being recruited by post for this study, it 
is not known why some patients decided to decline their invitation. The inclusion 
criteria were: a diagnosis of osteoporosis or osteopaenia, experience of taking oral 
medication for osteoporosis (e.g. alendronate or strontium ranelate), willing to take 
part in an interview and English speaking. 




Interviews took place between September and November 2010. Interviews were 
carried out in a private room on the osteoporosis unit at Guy’s Hospital, London. The 
choice to carry out the interviews in the hospital was so that clinic staff would be there 
to provide advice and support if an interviewee became upset or unwell. The duration 
of the interviews was between 30 and 90 minutes in total. The clinic doctor introduced 
each participant to the author, who proceeded to explain that the research was being 
carried out for educational purposes. Each participant was given an overview of the 
topics included in the interview, which were: a section about osteoporosis, a section 
focussing on medication and finally a drawing exercise. It was highlighted that the 
interview was not a test, there were no right or wrong answers and that the interview 
was concerned with people’s personal experience of having osteoporosis.  
Each participant was firstly asked questions from the demographic questionnaire. This 
was carried out at the beginning of the interview in order to put the participant at ease 
with some easy questions. Following this, the participant was asked questions using 
the prompts from the interview schedule (see APPENDIX 5). Throughout the interview 
the researcher checked that the participant’s meaning was understood by repeating 
back their responses in summary form. 
Participants were asked to complete 4 drawing tasks. They were first asked to draw a 
bone without osteoporosis. They were then asked to draw a bone with osteoporosis. 
They were then asked to draw a person with and without osteoporosis (using ‘stick 
people’ for ease). The drawings were then the focus for a discussion about what lay 
behind the drawings, how they experienced osteoporosis and the effects it had on 
them. The drawings thus provided a way to approach the emotional aspects of having 
osteoporosis.  
6.5 Analysis 
6.5.1 Interview analysis 
Interviews were transcribed verbatim by the author. Framework analysis was used to 
make sense of the data transcripts (Ritchie et al, 2003). Framework analysis focuses on 




keeping the data close to what the participants actually say: therefore it is a useful 
type of analysis for a study which will be used to inform a future intervention study. 
Framework analysis consists of 5 main practical steps. While these steps are described 
separately it should be noted that they are intertwined and can overlap and occur 
simultaneously (Ritchie et al, 2003). The main practical steps are familiarisation, 
thematic analysis, indexing, charting, mapping and interpretation, which are described 
in relation to this study below. 
Familiarisation 
The researcher immersed themselves in the data in order to gain an overall picture. 
This process of familiarisation was carried out by listening to the audio-recordings, 
transcribing the interviews, then reading and re-reading the transcripts.  
Thematic Analysis 
Thematic analysis is a method of identifying and recording the major themes that 
occur in the data (Howitt, 2010). The thematic analysis can be carried out during the 
familiarisation phase, where a list is made of both the themes introduced by the 
interviewer and the themes that the participants generate. Once a list of themes was 
generated it was refined, so that overlapping constructs were combined. This resulted 
in a list of main themes and sub-themes. 
Indexing 
Each theme and sub-theme identified during the thematic analysis was given a number 
and letter code, e.g. main theme were given numbers 1, 2, 3 etc. and sub themes were 
assigned a, b, c etc. The author read through all the data, recording the relevant 
theme/subtheme (codes) in the margins of the recorded data. This allowed for themes 
which were continuously mentioned together to become clear. 
Charting 
At this stage a chart was developed, consisting of columns of themes and sub-themes, 
with a row for each participant. Quotes from the transcripts for each theme were 
transferred to this chart. This allowed all data for each theme and sub-theme to be 




viewed together in one column, to make it easy to compare the responses of different 
participants about the same topic. 
Mapping and Interpretation 
This is the final stage in which the final thematic framework of the data was identified. 
In the mapping stage a new chart was made. For each theme, data were merged into 
broader categories. These categories were then refined to ensure that they did not 
overlap. From this new chart the data were ready to be interpreted. This involved 
examining the data in relation to the original research questions. The new chart map 
presented data for each theme in a new column. A further column was used for 
interpreting the data contained in each theme. Relationships between themes were 
examined, as well as similarities and differences between the two groups (attenders 
and non-attenders). 
Two independent researchers each coded two of the transcripts to check the reliability 
of the coding framework (see APPENDIX 6). This provided instructions for how to code 
each theme, which included a description of the themes and examples of quotes 
typical of such themes. In order to check the accuracy of coding, each transcript was 
discussed between the researchers in detail. Any discrepancies in coding were 
discussed until there was consensus in relation to how the coding could be refined and 
how codes should be interpreted and applied.   
6.5.2 Patient drawing analysis 
Fourteen participants completed two drawings; one of a bone with osteoporosis and 
one without. Seven of the 14 participants completed an additional pair of drawings of 
both a person with osteoporosis and a person without osteoporosis. To investigate 
what the drawings revealed about patients’ illness representations, they were 
analysed by looking for the major features, focusing on the length, shape and bone 
deformity depicted. Drawings of bones with and without osteoporosis were measured 
through their longest line and the results between each participant’s pair of drawings 
were compared. Drawings were categorised for their similarities and differences, both 




within and between participants. The descriptions that participants gave about their 
emotions associated with the drawings were re-examined alongside their drawings.  
In a validity exercise, three researchers were asked to describe their observations of 
the drawings of individuals with and without osteoporosis. The purpose of this was to 
investigate any additional features and themes which the author had missed, to 
compare and validate the researchers’ interpretations and to check whether any new 
themes emerged. There was agreement between researchers in the themes identified, 
though the researchers identified additional features to those identified in the 
preliminary analysis, which were old age and infirmity. 
The three researchers were also given all of the participants’ sketches of bones (a total 
of 28 drawings) and were asked to put them into pairs of sketches they believed to be 
drawn by the same participant. To analyse the differences between the pair of bones 
drawn by each participant, three researchers were asked to filter through a collection 
of all 14 participants bone sketches which had been separated in to two groups (one 
group of sketches of bones with osteoporosis and a second group of sketches of bones 
without osteoporosis). The sketches were anonymous and therefore the participants 
could not be identified by the researchers.  The researchers’ task was to go through 
the collection and match pairs of sketches of bones they believed to have been drawn 
by the same participant. As well as identifying pairs of bones which were drawn by the 
same individual, the researchers were asked to identify which sketches were of 
osteoporotic bones and which were not. The same process was carried out for the 
seven pairs of drawings of people with and without osteoporosis. 
6.6 Results 
For the attender group, 16 participants were invited to take part in the study and six 
did not respond. For the DNA group, 29 participants were invited to participate and 25 
did not respond. Thirteen global themes initially emerged from the interview, with 59 
themes and 129 sub themes. This was aggregated to 11 global themes, 32 themes and 
24 sub themes (see Table 9). To aggregate the themes, all themes were listed and 
where there were overlapping concepts, the themes were merged. For example; 




medication beliefs was formed from two similar themes: beliefs about medication in 
general and beliefs about osteoporosis medication. 
Table 9. Main themes and sub themes 
Global Theme Themes Sub-themes 
Identity Knowledge  
Visual representation  
Symptoms  
Causes Causes of osteoporosis Modifiable and un-
modifiable 
Causes of fracture  
Timeline Chronicity  
Timeline of medication  
Controllability/Cure Feeling in control  
Confusion about control  
Cure  
Consequences No direct consequences  
Limitations to physical 
activity 
 
Physical consequences  
Medication  
Emotions No impact  
Fear  
Other emotions  
Risk Perceptions Severity  
Susceptibility Fracture risk in the next year 




Global Theme Themes Sub-themes 
Fracture risk across lifespan 
Comparison to heart 
disease/cancer 
 
Medication Beliefs General medication Positive or negative 
medication beliefs 
Osteoporosis medication Bisphosphonates 
administration 
 Side effects 
 Worry about potential side 
effects 
 Concerns about medication 
components. 
 
 Concerns about the duration 
required to remain upright 
after administering 
bisphosphonates 
 Incorrect prescriptions 
 Limit on number of doses 
 Access to zolendronate 
Adherence Adherence Good adherence 
Feedback Facilitates 
Adherence 
 Psychological barriers Refusal to take medication 
Forgetting 
Non-psychological barriers Side effects 
Change of Routine 
Other factors Alters the time/day of dose if 




Global Theme Themes Sub-themes 
forgets 
Relationships Doctor-patient relationship Communication 
Social-support  
Recommendations for 
helping future patients take 
their medication 
Education Using pictures  
Medication Instructions Include more information 
about the long-term effects 
of medication 
Patient centred care  
Monitoring and planning Dosette box 
 Set Routine/Plan 
 
6.6.1 Interviews 
In this section, data from each of the ten global themes is presented. This includes 
quotes to represent each theme. Due to the large amount of data generated in this 
study, only themes which were discussed by two or more people are described (unless 
stated).  
Identity 
The global theme identity describes how people understand and make sense of the 
nature of their illness and their symptoms. During the interviews, the majority of 
participants showed good knowledge of the clinical features of osteoporosis, which is 
further demonstrated throughout the other themes. They showed an understanding 
that osteoporotic bones are thin, weak and easy to break and reduced in bone mineral 
density. Interpretation of symptoms is a key indicator of how a patient understands 
their condition. While a small proportion of participants were certain there are no 
symptoms in the early stages of osteoporosis, half of the study participants were 
unsure. Some reported pain in the early stages and said they disagree with medics 
when they suggest that there are no symptoms. For example, one participant said she 
associates osteoporosis with aching. 




“I know they say osteoporosis is painless, I can’t really believe that.” (Participant 14) 
As well as reports of pain, one participant reported flaky nails and rotting teeth as a 
result of having osteopaenia. Some participants were unsure about which of their 
illness conditions was the cause of their symptoms, e.g. one woman was unsure as to 
whether arthritis or osteoporosis was causing her back to ache. One participant 
suggested that she may be hyper-vigilant to symptoms because she had been labelled 
with a condition. 
“I think that because I’m conscious of it, I think any pain that’s going on with my back I 
think, is that it? I think I could be over imagining it.” (Participant 7) 
Participants also talked about symptoms in the later stages of osteoporosis: painful 
fractures, loss of height and stooping. Six out of 7 people showed a curved upper spine 
in their drawings of stick people with osteoporosis. Patients’ drawings of osteoporosis 
were also indicative of how they viewed their condition. Some examples of these 
drawings are presented below. 
6.6.2 Patient drawings 
All patient drawings are presented in APPENDIX 7 and APPENDIX 8. The author looked 
for potential new/additional information that the drawings may have revealed about 
the patients’ understanding of their illness. The drawings of bones with and without 
osteoporosis are described below with the following categories: length, shape and 
bone structure.  
Length 
The five largest drawings were from participants: 1, 6, 10, 11 and 13. It is important to 
note that four out of these 5 large drawings were from patients in the DNA group. 
More differences between attenders and non-attenders are described in the 
discussion section. Analysis and comparison of the participants’ drawings of bones, 
both with and without osteoporosis, indicate that osteoporosis patients do not view 
osteoporotic bones to be very different in size to normal bones. This is indicated by the 
similarity in the length of the longest line through each participant’s pair of bone 




sketches (see Table 10). Patients’ drawings of bones were measured at their longest 
point.  









Size difference (cm) 
1 10 9.9 0.1 
2 6.1 5.8 0.3 
3 8.1 8 0.1 
4 3.8 3.7 0.1 
5 5.6 5.9 0.3 
6 10 10 0 
7 5.8 5.1 0.7 
8 3.9 4 0.1 
9 4.4 4.5 0.1 
10 11 11 0 
11 11 11.1 0.1 
12 6.8 6.2 0.4 
13 10.55 10.1 0.45 
14 3.4 1.7 2.7 
 
In the validity exercise, the researchers were able to successfully match patients’ pairs 
of drawings in the majority of cases (only 2 sets of drawings were paired incorrectly). 
However, they were not as commonly able to identify which drawing was of 
osteoporosis and which was not. A total of 10 pairs of bones were not correctly 




identified as osteoporotic or not. This highlights that while the bone drawings were 
similar within participants there was large variability in depictions of osteoporosis.  
Shape 
Eleven out of 14 participants drew cartoon type bones (see examples in Figure 10). 










Figure 10. Participants’ drawings of bones with and without osteoporosis 
Bone structure/deformity 
Some participants drew a deformed internal bone structure 10/14, while others drew 
a deformed outer edge of the bone (4/14). Only one participant demonstrated damage 
to both the internal bone and the outer edge. It is noteworthy that the majority of 
bones drawn without osteoporosis showed an absence of pores. Further, none of the 
drawings showed fractures.  
Drawings of people with and without osteoporosis 
Overall, while there was a similarity about the way in which participants drew bones 
with and without osteoporosis, the pairs of people they drew were very distinctive. 
The themes highlighted in participants’ drawings of people with osteoporosis were old 
  




b). Osteoporotic bone 
showing damage to 
internal structure 
(Participant 3) 
c). Osteoporotic bone 








age, infirmity, pain, stooped posture and faint sketches. Similar to drawings of bones, 
none of the participants focused on fractures.  Six out of seven participants depicted 
curvature of the spine as the deformity in their drawings of people with osteoporosis. 
Two participants’ drawings emphasised the loss of height attributable to osteoporosis. 
Participants were more likely to express emotions about their condition when looking 
at their drawings of osteoporosis than during other parts of the interview. For 
example, when participant 9 was asked about how osteoporosis affects her 
emotionally, during the interview she said:  
“I don’t really think about it. Accept trying to be a bit careful. But no fortunately I mean 
I don’t get pain and I don’t get trouble with it.” 
However, the drawing exercise provoked other feelings about her condition: 
“I’m very cross that I’ve got this awful shape and my friend, my son’s partner says 
stand up straight, she’s a yoga teacher. Well I can stand up straight. I find myself 













Figure 11. Patients’ drawings of people with osteoporosis 
Spine Curvature 
 
Shakiness and curvature 
 








6.6.3 Interviews Continued 
Cause  
Exploration of causal attributions for osteoporosis and fractures are described in this 
theme. Participants were asked about the causes of osteoporosis in general, as well as 
the cause of their own osteoporosis. Though participants were able to list some causes 
of osteoporosis in general, they usually struggled to identify a cause for their own 
osteoporosis. The majority of the participants’ responses about causes of osteoporosis 
could be categorised as modifiable and un-modifiable causes.  
When asked about the causes of osteoporosis in the general population, the 
modifiable causes most commonly reported were a diet low in calcium and vitamin D. 
Participants also identified smoking, weight, exercise and the idea that society as a 
whole is less active in general, as contributing factors which may result in osteoporosis. 
The un-modifiable causal factors discussed included: heredity, aging, small (thin) 
bones, hormonal causes (post-menopause, early menopause and hysterectomy) and in 
one case post-partum osteoporosis. 
While participants demonstrated an understanding of the causes of osteoporosis in 
general, they were often unable to identify the cause of their own osteoporosis. Just 
over a third of participants reported that they did not know the cause and said they 
had not previously thought about it. Participants who answered the question about 
the cause of their own osteoporosis often said heredity. Other factors participants 
discussed as potential causes of osteoporosis, which were difficult to classify as 
modifiable or un-modifiable were; osteoporosis which is secondary to other medical 
conditions and stress. The following quotes demonstrate participants’ uncertainty 
about what caused their own osteoporosis. 
“Well I mean I honestly don’t know, I would have thought something to do with how 
you live, how you eat, how you drink. But quite frankly in my case I’ve always been very 
comfortable…So I would have thought that I had a very good diet. Always. So I don’t 
know what happens, or whether it’s heredity I truly don’t know.” (Participant 14) 
Participants were asked if they had suffered any fractures and those who had were 
asked to describe what they believed to have caused these fractures. Some 




participants attributed their fractures to factors other than osteoporosis; they believed 
their fractures were due to falls or other medical conditions e.g. glaucoma which 
meant their fracture was caused by low visual acuity. This is illustrated below:  
“I think anyone who would have fallen like that would have fractured. It was a hard 
fall. I am not able to see all that well so I think this is why I fell over.” (Participant 2) 
Many participants described confusion about the cause of their fractures. A common 
reason for this confusion was because not only do people without osteoporosis suffer 
from fractures, but conversely not all fractures are a result of osteoporosis. One 
participant described her uncertainty about the link between osteoporosis and being 
clumsy. 
“I’m quite a clumsy person, I’m always rushing here, rushing there and forget to move 
my feet sometimes, so you know I am prone to, I feel, I am the sort who is prone to 
having accidents. And that’s frightening and I really don’t know, I don’t know whether 
osteoporosis would be cause of that or not.” (Participant 8) 
Timeline 
This theme describes how long patients believed they would have their condition for 
and how long they will need to take medication for it. The vast majority of patients 
understood that they would have osteoporosis for the rest of their lives. 
“Until I die.” (Participant 14) 
“Forever. It’s never going to go away.” (Participant 3) 
“You don’t get rid of it, do you?” (Participant 12) 
However, some participants talked about confusion regarding how long they would 
have osteoporosis. This confusion was in relation to the fact that they are only 
required to take their medication for a relatively short period of time. 
“I think I will have it for the rest of my life. Actually, I am a bit confused by this because 
the doctor gave me medication last week and told me to take it for two years. I would 
have thought I would have to take it for the rest of my life.” (Participant 2) 





This theme describes the level of control patients feel they have over their condition. 
Controllability/Cure was divided into 3 themes: feeling in control, confusion about 
control and fracture prevention. 
Most participants were able to list many things that people could do to prevent 
fractures. The most common was falls prevention; taking extra care to prevent 
themselves from falling over. It was common for participants to say they would stay at 
home to avoid adverse weather conditions such as snow. Other methods of control 
included diet, vitamin supplements, sunlight and wearing a corset to support the spine. 
Participants also discussed exercise, where some but not all knew that specifically 
weight bearing exercise is needed. Some participants also talked about specific posture 
exercises and about using balance training to help them become steadier in order to 
prevent falls.  
“Well, when you go out and it’s wet and you’re always careful you know, people might 
think, oh doddery thing, walking along but you have to be careful, you know. In case 
you slip over if you’re going up steps, or and I try not to go out in the snow or anything 
like that.” (Participant 11) 
“I’m always conscious that I must be careful, that’s the thing I live with.” (Participant 9) 
However, when asked directly what they could do to control their own personal 
osteoporosis, many were unsure. One patient suggested that one can never be in 
complete control of falls prevention. 
“I’m not sure about that, em, so they say. But em. And my mum clearly was told it was 
preventable and get your children to take action and that’s why I have. I’m hoping it’s a 
controllable condition, but I don’t know. There seem to be an awful lot of people with 
it. And you know, you see these self-help things, like take some pills or take exercise but 
do they know that that prevents it? I’m not so sure about it.” (Participant 13) 
“Then you, you never can stop falling over, accidents are going to happen aren’t they, 
you know.” (Participant 9) 
It seems that participants found it difficult to understand how methods of control 
could be linked to improving the risk of fracture. One participant reported that she had 




never been given any dietary information, so she thought there was no link between 
osteoporosis and diet. 
“Nobody’s ever said to me, if you did this or did that, or ate this or ate that, nobody’s 
ever given me a diet sheet, connected with it, so presumably the powers that be don’t 
believe diet has anything to do with it because nobody’s ever given me anything to say 
do this.” (Participant 8) 
Similarly, one participant could not understand the link between exercise and 
osteoporosis. 
“I mean you can exercise, but if it’s leaching from your bones I don’t know how exercise 
could make it stronger. Nobody has explained that so far.” (Participant 10) 
An important issue expressed by many participants in this study was the difficulty in 
controlling osteoporosis, particularly in cases where some individuals are suffering 
from multiple co-morbidities. Participants reported difficulty in managing other health 
conditions whilst simultaneously managing osteoporosis. Participants discussed how 
they feel torn between multiple conditions when trying to control them.  
“It’s all about probabilities, it’s you know, do I take statins so I can eat cheese so that I 
can have calcium and not have osteoporosis...is a complicated thing.” (Participant 13) 
“I used to eat a lot of cheese, but then I’ve had to cut down on that because of my 
cholesterol, so er you’re between the devil and the deep blue sea sometimes.” 
(Participant 4) 
Uncertainty about how to control osteoporosis was further highlighted by some 
patients who reflected questions back to the author with a variety of questions related 
to how to control osteoporosis.  
“Have you come across anything about exercise making your bones stronger?” 
(Participant 10) 
“I don’t know, is weight a burden on the bones, or do they need a bit of weight to be 
good bones? I’m too ignorant about it.” (Participant 8) 
“Does walking help do you think, that’s what I think but is it true?” (Participant 11) 
It seems that in a condition with no cure, it is difficult for patients to understand that 
there are ways of managing the condition and stopping it from getting worse. All 




participants were aware that there is no cure for osteoporosis, though some said that 
they hoped for a cure in the future. 
“Oh yes, I am certain there will be a cure, I don’t know, my general feeling is that.” 
(Participant 8) 
“Not at the moment, but they are coming up with new medications all the time so 
there may be one day…I hope.” (Participant 2) 
“I don’t see how it can be cured; there are too many bones in the body.” (Participant 9) 
Participants were also asked about the role of medication in controlling fractures, in 
particular whether they thought medication could prevent fractures. Half of the study 
sample reported that they had not thought about the possibility of medication in 
reducing or preventing the risk of fractures, or that medication cannot prevent 
fractures. 
“No, it would be unfair to say I’d ever connected it really.” (Participant 8) 
“Er, I’m not sure. I don’t think it could stop a fracture. A medicine could not stop you 
from falling down.” (Participant 2) 
Half the participants believed that medication could control osteoporosis. However, 
only 2 participants could clearly state that medication reduces fracture risk. For other 
participants it seems that they had only made the connection between medication and 
fractures during the interview. 
“Er, I think it’s proven that some medications reduce the risk of fractures. And I guess 
there is also the effect of, if you’re taking medication for osteoporosis, it will 
automatically alert you to be a bit more careful than you otherwise would be.” 
(Participant 3) 
“Well I think I suppose it makes it less likely that if you fell over and hurt yourself that 
the result would be a fracture.” (Participant 12) 
Consequences 
The consequences of having osteoporosis most commonly described by participants 
were:  limitations to their physical activity, medication and physical consequences. 
Generally participants reported that having osteoporosis did not have much impact on 




them and that they did not think about the condition every day, though some said that 
it limited their physical activity. As well as mentioning that being more careful is a 
method of controlling osteoporosis, participants noted that it limits their activity by 
causing them to be careful. Some participants reported that age would make them 
careful anyway, regardless of osteoporosis. 
“But physically, you know I still mow the lawn. But I wouldn’t do something like cycling. 
I used to ski, I wouldn’t dream of doing that, anything that involves you know, ice-
skate. So it limits my mobility to a certain degree and it limits what I can carry. Carrying 
stuff is less easy than it was that’s for sure.” (Participant 3) 
“Well I mean, if I’m getting up on a ladder, or if I do anything, I hang on like mad and 
so on. I suppose I might do that at my age anyway, thinking about it.” (Participant 5) 
Many participants reported that osteoporosis did not have much effect on their daily 
lives. Some participants said that the only consequence of the condition was the 
requirement to take medication.   
“It doesn’t affect me at all, I have no symptoms. The only way it affects me is that I 
have to take medication.” (Participant 1) 
“It doesn’t really; apart from it does mean that I have to take pain medication every 
day. I can’t go through a day without pain medication, you know I’ve been on the 
whole range.” (Participant 3) 
The physical corollaries participants discussed were: upper spine curvature, loss of 
height, hospitalization, brittle bones, disability and chronic pain from fractures. The 
majority of participants discussed curvature of the spine (kyphosis), especially when 
asked what osteoporosis is. Few participants noted mortality to be a possible or 
indirect consequence of osteoporosis. Participants’ drawings of osteoporosis further 
highlighted the perceived consequences of the condition. These are discussed in the 
drawing section below. 
“I think, people develop this what I think they call the dowagers hump, which is due to 
fractures, I think, of the spine and they sort of begin to shorten as it were and I think 
that has been my worst worry, is how it would affect my spine eventually, because I do 
tend to suffer with back ache.” (Participant 1) 





Over half the participants said they did not feel strong emotions about the condition, 
reporting that this was the case because osteoporosis was not a main feature in their 
daily lives. In answer to the question of how osteoporosis affected them emotionally, 
participants commonly reported that they didn’t think about osteoporosis much. Many 
participants reported feeling lucky that their osteoporosis was caught early and being 
managed.  
“I don’t really think about it. Accept trying to be a bit careful. But no fortunately I mean 
I don’t get pain and I don’t get trouble with it.” (Participant 9) 
“Actually I feel quite optimistic about my osteoporosis if you like because I know I’m 
being treated.” (Participant 12) 
However, these reports of a low emotional response and feeling lucky were contrasted 
during discussion with patients’ of their drawings of the condition. While at some 
points during the interview participants reported that they did not think about their 
osteoporosis, on occasion whilst talking about a different subject, some reported that 
having osteoporosis was very worrying. Many fears were discussed by this group, 
including fear of becoming wheelchair bound, fear of fracture, fear of falling and fear 
of kyposis. Other emotions discussed were shock, worry and anger.  
“So if I fractured my spine, I could end up in a wheelchair couldn’t I? Which is my 
biggest fear.” (Participant 4) 
“If you asked me what I thought about it, for me, curving that’s the thing that worries 
me most.” (Participant 9) 
Risk perceptions 
To explore patients’ perceptions of their risk of fracture in osteoporosis, patients were 
asked to think about both osteoporosis in general and their own osteoporosis. When 
asked about the seriousness of osteoporosis in general, all participants reported that 
osteoporosis is a serious condition. 
 “Well yes, it is a serious condition I think, mainly because of fractures and the disability 
it causes.” (Participant 1) 




 “I think it’s really serious because it just affects your quality of life so radically.” 
(Participant 13) 
However many also reported that their own osteoporosis was not severe. Some 
patients were unsure about how serious it was for them personally. 
Participants were also asked about their susceptibility to a) a fracture in the next year 
and b) a fracture in their life time, compared to other men and women of their age. 
There were a range of answers about susceptibility to fracture. It was most common 
for participants to report that their fracture risk was the same or lower than that of 
other men and women of their age. Interestingly, some believed that their fracture risk 
was lower because their osteoporosis had been identified, in comparison to others 
who have the condition but it remains undiagnosed.  
 ‘Well I mean you never know who is going to be hit by a bus, this would cause anyone 
to fracture, so I’m not at more risk.” (Participant 1) 
My fracture risk is less because “(a) I’m on zoledronic acid, (b) I take vitamin d and (c) 
I’m careful. So another 60 year old who was not aware that they might have 
osteoporosis bubbling around, in the background, probably stands a greater risk of 
fracturing something than me.” (Participant 3) 
Some participants reported that their fracture risk was higher than that of other 
people their age, because their active lifestyle could result in greater risk than for 
someone who was less active than them.  
“Well it’s probably more likely because I do a lot more. I’m not a stay at home and 
watch the telly all day sort of person. (Participant 9) 
However, there were other patients who were much less able to talk about their 
future fracture risk, including some who said that they did not like to think about their 
risk. 
“I suppose you’re making me think about things I don’t really want to think about.” 
(Participant 8) 
Participants were also asked about how serious they thought osteoporosis was in 
comparison to two other medical conditions; heart disease and cancer. While the 




majority thought osteoporosis was less serious than heart disease or cancer, some 
believed it to be equally or more serious. 
“And when I see people who are totally crippled, I can remember the doctor saying, 
there’s a lot of things as bad as cancer in this life. I totally believed him. I would put it 
on a par with any of those serious illnesses.” (Participant 14) 
“Well, if you’ve got cancer, you’re ill and that’s it, but you can have osteoporosis all 
your life can’t you.” I’d rather have cancer. It’s quicker. If you’re gonna do it you might 
as well do it properly.” (Participant 5) 
Medication beliefs 
There was variation in participants’ responses to the question, is medication in general 
positive or negative? Half of the study sample said medication was positive. 
“I’m not the least bit thoughtful about medication and I just think side effects, any side 
effects are probably not as bad as if you don’t take it and you miss out on some 
advantage of the medication.” (Participant 3) 
However, half of the participants listed various concerns about medication in general, 
particularly about: side effects, harmfulness, over-prescribing, addiction, suspicion of 
pharmaceutical companies, dislike of chemicals, drug interactions and overdosing. 
“You know even if you are taking Lemsip, I don’t think you should be taking one every 
hour, because it says that clearly. You should take it every 4 hours and paracetamol is 
really bad for you if you overdose on it so you know, I think you need to treat it with 
respect…they’re not sweeties.” (Participant 12) 
“Doctors are enthusiastic to give medicines because that’s what they do. I am keen to 
kind of make sure that it’s what I really need, so I’m kind of negative really.” 
(Participant 13) 
“If you can avoid medication I think you should. Because medication, whilst it might be 
good in some respects, it’s not natural, is it? You’re putting things into your body and I 
would avoid that if I could. But I do understand that there are occasions when you 
don’t have a choice really.” (Participant 5) 
“Because it must harm the insides somehow to keep taking pills. And if you’ve got a 
few things wrong with you and if you’ve got all these things mixed up inside, all these 
different problems, surely in the long run it don’t help.” (Participant 11) 
“But all medicines are poisons aren’t they?” (Participant 12) 




There was a range of responses about how easy osteoporosis medication is to 
administer. Most participants commented that it was easy to take. 
“The whole standing up thing is rubbish, because you know by the time you’ve taken 
your medication you clean your teeth, you make your bed, you fill the washing 
machine. So there’s no big deal about standing up, it’s not like I’m standing up thinking 
I can’t sit down. All you can’t do is take it and lie down. So, it’s not onerous because 
that’s what you do, you take your medication, you clean your teeth, you wash your 
face. Change your clothes, sort out the washing, make your bed.”(Participant 12) 
However, some participants commented that it is frightening to take, because of the 
fact it is dangerous if it gets stuck in the oesophagus. 
“And I did once get it stuck in my throat and I can remember thinking that was just, I 
was jumping up and down and panicking and my oesophagus got kind of, you know 
went into spasm because I was frightened and em, doing that every day was 
unpleasant.” (Participant 8) 
Two participants commented that while they found osteoporosis medication easy to 
take, their relatives who also had osteoporosis and were older found it much more 
difficult and misinterpret the medication administration instructions. 
“You do, you only take it once a week and it’s horrible. You have to sit upright and drink 
this stuff and it’s like an acidity sort of stuff. You then drink water to make it go down. 
She was very bent and crippled and it’s very hard to make stuff go down.” (Participant 
13) 
“Elderly people do not like doing that, they find it very difficult to comply, because they 
just can’t, you know they think from the instructions… one thing and another and she 
reads that as I have got to sit upright for half an hour in bed for one hour after taking it 
with water.” (Participant 3) 
The following will illustrate the specific concerns highlighted by participants in relation 
to osteoporosis medication. These included: concerns about side effects and dislike of 
using unnatural substances, the duration of remaining upright after taking medication, 
potential side effects, incorrect prescriptions and specific medication components. 
Many participants talked about the experience of side effects as a barrier to 
medication-taking. 




 “So I took Fosamax (bisphosphonates) for 9 months and in that time, it changed my 
digestion completely…so I was getting reflux.” (Participant 5) 
“The components of bisphosphonates are not a lot different to the chemicals they use 
to clean machine parts.” (Participant 7) 
“Er a friend of mine who has been on it for many many years before me, er she was told 
2 hours by her doctor, so I queried that with my doctor and she said well half an hour 
should be enough, an hour if you really want to, but I think 2 hours is excessive to stand 
or sit.” (Participant 8) 
“I’d read the leaflet about the oesophagus and er, a friend of my husbands, his wife 
had just died with having cancer on the oesophagus. And it was pretty awful evidently, 
so I thought, I don’t fancy that…Yeah, the thought of it. It probably doesn’t happen to 
many people, but once you start getting any sort of side effects, you think, oh maybe 
it’s doing it to me.” (Participant 5) 
One of the participants refused to take bisphosphonates because they contain 
aspartame, which she believes to be harmful.  
“When I researched it, it did say it contained aspartame and I understand aspartame to 
be quite a deleterious compound. And it strikes me quite absurd, because it’s not 
necessary in any way for osteoporosis, it’s just a sweetener, em and I’m fairly convinced 
I don’t know want to take aspartame on daily basis.” (Participant 7) 
One of the participants explained that this medication was incorrectly prescribed, 
because she had previous problems with indigestion. 
“I thought my indigestion wasn’t bad enough to make a difference and when I realised 
it did make a difference, I thought I’m gonna stop now, because it seems a bit 
stupid...because it says on this piece of paper, if you have indigestion don’t have it, so I 
probably shouldn’t have had it in the first place.” (Participant 5) 
While most of the patients did not doubt the efficacy of the medication and were keen 
to follow their doctors’ advice, one did doubt the efficacy of osteoporosis medication.  
“I don’t believe that they necessarily improve bone density, I think they give you higher 
bone density readings. I’m not convinced they give you higher bone density.” 
(Participant 7) 
One participant discussed how it was due to her upbringing that she was not keen on 
taking medication. 




“I don’t know. Erm, I suppose it is just inbred, I come from a generation, I mean, my 
mum’s generation-they have never taken a tablet in their life.” (Participant 5) 
One participant said there is a limit on the amount of doses of bisphosphonates that 
can be collected from a pharmacy at any one time, which makes collecting her 
prescription inconvenient. 
“I think they maybe have controlled how many they can provide, because although I’ve 
sometimes asked for 3, I’ve only been given 2 boxes…they do not marry up with the 
other prescriptions I take. Its nicer to get all my prescriptions in one go, but I can’t get 
those aligned.” (Participant 6) 
Adherence 
The majority of patients reported excellent adherence to their osteoporosis 
medication.  
“Let’s say I took it for 6 years, I might have missed it 3 times” (Participant 8) 
In contrast, a few patients reported some non-adherence. The reasons given for non-
adherence were classified as intentional and unintentional. The most common reason 
for which patients reported non-adherence was side effects. One patient was thinking 
about whether to initiate osteoporosis medication and one patient refused to take 
osteoporosis medication even though it was recommended by her doctor. 
“No, no, I will never take bisphosphonates” (Participant 7) 
The most common reasons given for omitting doses were unintentional, including: side 
effects, forgetting, altering the time/day of the dose and change of routine. 
“You know if you get up and do other things and you forget, that’s when you forget and 
then, you know maybe em, very rarely I forget. Very rarely. But I do forget, say once a 
month I might forget to take that days tablets.” (Participant 11). 
Some patients reported having to stop taking it due to fear of potential side effects. 
“And then I stopped taking them, I thought I’ll just get indigestion.” (Participant 14) 
Other patients discussed how a change of routine interfered with their medication-
taking regime. 




“I missed the dose because I was out, I wasn’t in my house and I was away. So a change 
in routine meant I couldn’t do it. Usually I have it with me, but I was unexpectedly 
delayed so I missed it, you know.” (Participant 12) 
Relationships 
The healthcare professional-patient relationship featured in all participants accounts of 
factors which influenced adherence to medication. Some participants reported that 
they had a good relationship with their doctor, which made it more likely for them to 
follow their doctor’s recommendations. 
“I’ve got a very sympathetic doctor, he’ll talk to me and listen to me and if he says do 
something, I’ll do it you know” (Participant 9). 
Some participants talked about a negative relationship with their doctor, exacerbated 
by: lack of time during the medial consultation, poor communication, lack of continuity 
of care and lack of a particular doctor’s knowledge of osteoporosis. 
“I mean I had a 15 minute appointment, of which he spent 10 minutes talking to 
somebody else and he did apologise and I spent 5 minutes with him and that was it, 
goodbye. And I thought I’ve wasted my time coming up here.” (Participant 10) 
“I think you’re treated in quite a childlike way, you’ve got to stand up for an hour. 
Okay, I can do that, why?” (Participant 7) 
There was one particular patient who was very confused by some conflicting 
information she received from two healthcare professionals. She had surgery on her 
broken ankle and after the operation the surgeon told her that her bones had the 
consistency of cheese and to initiate anti-osteoporosis medication immediately. 
However, she subsequently had a BMD scan and it was revealed by another 
osteoporosis consultant that her BMD was not in the osteoporotic range. She wrote to 
the surgeon to ask what he had meant regarding the consistency of her bones and why 
she was prescribed osteoporosis medication, because it did not correlate with her 
BMD scan or her osteoporosis consultant’s advice. The surgeon did not reply to her 
request for information. This conflicting information resulted in difficulty for the 
participant to understand her bone health.   
“I don’t really understand in the scheme of things how strong or not strong my bones 
are, cos you’ve got the surgeons who have actually been in there, who have said, these 




are cheesy, em and em, Dr X saying from the x-ray you don’ t look like that” 
(Participant 8) 
Social support was also discussed as a factor which could influence adherence. Many 
participants reported being reminded to take their medication by their families and 
being prompted to go for osteoporosis screening.  
“I just remember on a Sunday morning I have to have it and my husband now he’s got 
into the habit – have you had your medicine? And then sometimes I say oh no!” 
(Participant 4) 
“She was very anxious that her daughters in particular should not suffer and she’s quite 
an assertive person you know who, really didn’t want us to go through what she had 
been through. And wanted prevention, so she was pushing us the whole time to do it” 
(Participant 13) 
There is another example of social support where a participant told her mother not to 
take osteoporosis medication. 
“They started to give her risedronate, but I mean needless to say, all the, you know 
you’ve got to sit up for half an hour and blah blah all that kind of stuff every Saturday 
morning and, she just didn’t, she couldn’t comply with it and so I just said forget it, you 
know and in fact you know both her ankles healed very quickly and very well.” 
(Participant 3) 
Comparison between attenders and DNA’s 
There were some important differences between attenders and non-attenders in 
relation to some themes. The most striking difference between groups was related to 
medication beliefs. In this study, four out of six patients in the DNA group had 
concerns about medication, in comparison to one out of nine in the attenders group. 
Only one out of six of DNAs reported that medication in general was positive. While 
the majority of participants reported that their chances of suffering a fracture were 
the same as other women of their age, patients in the DNA group were more likely to 
report that their risk of fracture was higher (four out of six). Following on from this, the 
non-attenders discussed more negative emotional reactions to osteoporosis than non-
attenders.  




Recommendations for helping future patients to take their medication 
Participants were asked to provide recommendations to help osteoporosis patients 
improve their medication-taking. Their recommendations were categorised into 4 
themes: Communication and education, monitoring, planning and other. May 
participants discussed the importance of patients being better informed about their 
condition: 
“I just was given last Christmas er a hand held Dyson by one of my sons and there’s no 
er explanation there, how to use it, it’s all pictures. Following the pictures is so easy… 
I’ll tell you what’s interesting about that, he doesn’t have to do it in all different 
languages. Because it’s all pictures and there should be you know, you’ve got me to 
draw a stick person here, somebody could draw a head and a, you know an 
oesophagus going down to the stomach and whatever, people would understand. It’s 
the not being able to understand that is frightening.” (Participant 8) 
“Well I think patients need to be as well informed as possible about their illness and the 
importance of taking medication. I think if patients understand their illness and that 
their bones could deteriorate without medication, they will take their medication.” 
(Participant 1) 
“I think explain to them the reasons for taking medication in a particular way, would be 
helpful, so the across the board medications like risendronate, alendronate and all the 
rest of it, that have to be taken at a certain time and you have to sit up and all this kind 
of stuff. The reasons for that are not necessarily explained to people, they are simply 
prescribed to them.” (Participant 3) 
“It’s the same with almost everything in life…you need two people in a room, one who 
understands how it works and one who doesn’t and they need to, it needs to be written 
by the person who doesn’t know any of the biological things. You look in the packet of 
the alendronic acid or whatever it’s called and try reading that. That’s written for 
somebody with a doctorate, or at least a good degree…and a degree in kind of medical 
terms.” (Participant 8) 
“I don’t know, I suppose er, I don’t suppose people always understand the 
consequences of osteoporosis, it’s not apparent. You don’t have little red spots. I can 
bend over; I can do every activity I intend to do. It’s a bit of an unseen disease; it hasn’t 
impacted on my lifestyle at present. But I am aware of what could happen, you know, 
so perhaps people need to be aware of what will happen if they don’t take their 
medication.” (Participant 12) 
“I don’t think people say, well if you take this in the long term, these are the 
consequences. And I would like more feedback, like that.” (Participant 12) 




Many participants mentioned monitoring by doctors and pharmacists would help them 
to take their medication more accurately - in the form of medication reviews, more 
scanning and feedback.  
“I think I would like more feedback, even from my G.P to say how are you getting on 
with the drugs, are they okay? I don’t think that I get that really, even though my 
doctor is quite good, you know. And even when I come here, I don’t think that they said 
everything’s okay? And it’s almost swept aside and they think let’s not worry.” 
(Participant 12) 
“Secondly I think em, they should get some feedback, in the way of DEXA scanning. So 
see whether or not taking risendronate on a daily or weekly basis or whatever it is and 
complying with the instructions - has that made any difference? And if it hasn’t, why 
take it?” (Participant 3) 
It was very commonly reported that feedback in the form of scans helped participants 
to know that the medication was worth taking because their condition had improved. 
“Well, I think it must have worked because when I had a scan last week they said I had 
improved. I don’t feel any improvement though.” (Participant 1) 
“And we did see the results, it was on paper. That helped.” (Participant 5) 
Planning was another common theme for participants, as this helped them to take 
their medication. It was common for participants to talk about the need for habit and 
that routine was essential in their medication-taking behaviour. They also suggested 
pill boxes marked with the day using a calendar to mark the days the medication is 
due. 
“Perhaps get a box like me and put pills in for every day. Or if you can’t do it, the 
chemist can do it, put the pills in the box for you.” (Participant 11) 
“No it must be done at the same time every day, so that it becomes a habit, like 
cleaning your teeth. If it was at different times you would forget.” (Participant 4) 
Another way suggested to help people improve adherence was for health care 
professionals to provide patient centred care – to let patients feel that they are 
involved in the decision to initiate medication. 
“Me personally, it would be me in the driving seat and saying, I’ve had a big part in 
deciding to take it. I don’t want to be treated like, I’m the specialist, this is what you 




must do, because I don’t necessarily. I do trust the specialists, I’m not saying that they 
are deceiving me, I’m just saying they have an agenda and it might be different from 
mine.” (Participant 13) 
6.7 Discussion 
6.7.1 Key findings 
This qualitative study used two psychological theories and a novel drawing method to 
systematically explore psychological factors in osteoporosis/osteopaenia. Cognitive 
and emotional representations of the condition were explored. The study has 
produced some novel findings about how osteoporosis patients visualise and make 
sense of their condition. Overall this study revealed a wide range of patients’ beliefs 
about their condition and medication, which included some misconceptions and 
concerns about the condition and how to manage it. These findings have implications 
for the design of adherence interventions.  
The most striking finding in this study was that many patients did not know or 
understand that the key function of osteoporosis medication is to reduce the risk of 
fracture. It was quite surprising that a number of patients did not see a link between 
medication and fracture risk, or they thought that medication could not reduce the risk 
of fracture. The implication of this lack of understanding is that it may reduce how 
much patients perceive the need for medication. A way to communicate and help 
patients understand the link between medication and fracture risk needs to be 
developed, as this may improve medication adherence. 
In summary of other misconceptions identified, the study confirms that 
osteoporosis/osteopaenia patients have unrealistically low perceptions of their 
fracture risk (Giangregorio et al, 2008) and they attribute fractures to causes other 
than osteoporosis (Giangregorio et al, 2009). Although there was knowledge about 
some aspects of osteoporosis, including the nature of osteoporosis, the chronic 
timeline and the consequences, they also demonstrated a low understanding of some 
important features of the condition. There was confusion about: whether or not there 
were symptoms in the early stages of osteoporosis, the causes of osteoporosis and 
fractures and finally the methods of managing osteoporosis.  




This study has produced findings similar to studies of other chronic medical conditions. 
For example, participants have unrealistically low risk perceptions. This has been 
explained as a type of optimistic bias (Weinstein, 1989); in which individuals feel less 
prone to negative consequences than others who are at similar risk to them. In a 
similar vein, all participants reported that osteoporosis was a serious condition in 
general, though only one participant reported their own osteoporosis to be serious. 
Optimistic bias may be psychologically protective, e.g. it would not be helpful to 
continuously worry about having a fracture. However, low perceptions of risk may be 
an avoidant coping mechanism, in which a patient avoids facing their high level of risk. 
Either way, it is important that osteoporosis patients have an accurate understanding 
of their risk of fracture, so that they can behave in a way to minimize such risks. It was 
interesting that some participants felt that osteoporosis was more serious than cancer 
or heart disease, because of the duration and disability they have observed or 
suffered. This shows that disease severity is not only about mortality, but also about 
the impact of an illness on the quality of life. 
It was interesting that few participants linked their osteoporosis to behavioural and 
modifiable causes, which could suggest a lack of knowledge, or lack of acceptance that 
lifestyle choices can impact health. Alternatively, it may be psychologically protective 
for participants to disavow responsibility for their own behaviour and attribute it to a 
genetic cause. This has important implications for medication adherence - if patients 
view the causes of osteoporosis to be genetic rather than environmental, they may 
believe there is little they can do to control the course of the condition. A further 
factor which appeared to cause confusion is the cause of fractures, when anyone, 
osteoporotic or not, can fall and suffer a fracture. The implication of this finding is that 
education about osteoporosis should include a definition of a fragility fracture, which 
can be sustained on low impact (e.g. walking, lifting) in contrast to a non-osteoporotic 
fracture.  
While some participants demonstrated a good understanding of the asymptomatic 
nature of osteoporosis, others reported illness related symptoms. The same has been 
found for other asymptomatic conditions (e.g. Chen 2010). The experience of 




osteoporosis related symptoms is important and it is likely that the perception of 
illness related symptoms act as a guide to the need for medication. This could be 
problematic because patients may wait for symptoms before initiating medication, or 
interpret a lack of symptoms to mean that they are not unwell. Previous research 
indicates that bodily symptoms both create and update patients’ representations of 
their illness (Cameron & Leventhal, 2003). Further, patients who experienced pain in 
the later stages of osteoporosis were confused by HCPs claim that osteoporosis is 
‘silent’ or ‘painless.’ This implies the need for clearer communication that while there 
are no warning symptoms in the early stages, there are physical signs of the condition 
in the later stages, e.g. pain, spine curvature and loss of height.  
The report of symptoms in the early stages of osteoporosis could be a sign of patients 
perceiving symptoms as a result of being diagnosed with a medical condition and they 
are looking for a bodily sign to fit this label. Therefore, they may experience symptoms 
as a result of being labelled with a medical condition. This phenomenon has been 
shown in hypertensive patients (Baumann & Leventhal, 1985). It is possible that people 
find it difficult to understand that they can have an illness with no symptoms, because 
the disease is invisible and does not appear to affect them. Further, it should be clearly 
explained to patients that they require medication in the early stages of osteoporosis, 
even if there are no visible symptoms or signs of the condition. It also needs to be clear 
to patients that medication is used for fracture prevention rather than symptom 
alleviation, in order for them to understand the benefit of taking it. 
It was interesting to explore participants’ causal attributions for their fractures. 
Corresponding with the findings of previous researchers many participants attributed 
the causes of their fractures to factors other than osteoporosis e.g. sight problems or 
falls. French et al (2002) investigated patients’ causal attributions for myocardial 
infarction and found that these patients perceived a range of possible causes of MI, 
which were categorised by the researchers as proximal and distal. For example, a 
proximal cause could be stress, while a distal cause could be diet. In this study it 
appears that patients view the proximal cause of a fracture (a fall) to have more 
bearing on the outcome than the distal cause (the underlying bone fragility). The fact 




that some participants who had suffered fractures hold a causal attribution of falling 
rather than osteoporosis is problematic, because it may influence how they choose to 
manage the condition, e.g. they may choose falls prevention over medication to 
manage it, when in fact both are needed. 
Participants varied in their perceptions of the duration of osteoporosis, with the 
majority reporting that they will always have osteoporosis. It is positive that the 
majority of participants understood that they will have osteoporosis for the rest of 
their lives, because this demonstrates a good understanding of the chronic nature of 
the condition. However, some participants asked whether there was a cure. The fact 
that many patients said they hoped for a cure in the future is positive in that they have 
hope, but problematic where this may have a bearing on how they manage their 
condition e.g. neglecting management until there is a cure. Some of the participants 
were also confused that they were not required to take medication for the rest of their 
lives, even though the condition is chronic. This implies that the reasons for taking 
medication in the short term need to be clearly communicated to patients- i.e. that 
bisphosphonates are recommended for 5 years because there are no known benefits 
of remaining on the medication for a longer duration (Black et al, 2006). It is important 
that this miss-match in perception of timeline is addressed.  
Promoting self-management for patients with chronic conditions is well known to be 
difficult (Glasgow et al, 2003). Aside from falls prevention, there was uncertainty about 
how to control osteoporosis among this sample. Previous researchers have found that 
participants from a non-clinical population were unaware of how to prevent 
osteoporosis (Williams et al, 2002). Some participants said they were unsure about 
whether advice they were given about controlling/managing osteoporosis is proven. 
This is further highlighted by the questions participants asked the author about the 
condition, specifically in relation to controllability. One participant said she was never 
given any dietary information, so she assumed there were no specific dietary 
requirements for osteoporosis. Perhaps this could be addressed by psycho-educational 
interventions, providing patients with information about how their osteoporosis can 
be controlled. The misconceptions patients hold about their condition and medication 




could lead to mismanagement of the condition. The implication is that unclear 
information could reduce the coherence of patient’s illness representations, which is 
theorised to have an adverse effect on adherence (Leventhal et al, 1997).  
While this group of patients reported some limited activity as a result of osteoporosis, 
e.g. difficulty with carrying shopping bags, they were still all fully independent. A few 
reported that it was age rather than osteoporosis that limited their activity. Perhaps 
they were reluctant to accept that their medical condition was the cause of them being 
more careful, creating the necessity to protect themselves from a fall. This could be 
due to participants trying to normalise what is happening to them, or a denial/lack of 
acceptance of the limitations of the condition. One participant reported that 
medication was her only reminder of having osteoporosis. This highlights one of the 
difficulties of promoting medication adherence in asymptomatic conditions, patients 
may perceive the medication to result in more problems than it solves. 
Previous studies have shown that medication beliefs can predict medication adherence 
(Carr et al, 2008; McHorney et al, 2007). In the present study, the most commonly 
discussed barriers to adherence were concerns about side effects, or worry about 
potential side effects - such as oesophageal damage. Oesophageal cancer is extremely 
rare and its link with osteoporosis medication was misinterpreted by the media 
(Cardwell et al, 2010).  There is a debate as to whether patients should receive detailed 
information about potential medication side effects (Wells & Kaptchuk, 2012). While 
patients have a right to receive all available information about their medication, it is 
possible that raising the issue of side effects with patients causes some of them to 
experience side effects. Patients who were administered a placebo and informed that 
they would experience fictional side effects, commonly reported experiencing these 
side effects (Benedetti et al, 2007). This shows how expectations about medication can 
lead to a perceived response. 
It was interesting that the patient who had chosen not to take medication indicated 
major concerns in relation to osteoporosis medication and its efficacy as her reason for 
her decision not to take it. The same patient reported that she believed that her doctor 




had referred her to this research project as her beliefs were problematic. As a result of 
her medication beliefs she felt she was being treated as if ‘deviant’. This feeds directly 
into the next paragraph about the doctor-patient relationship. 
While patients were not directly asked about this, the doctor patient relationship 
emerged as an important feature in a patient’s decision to initiate and continue with 
their osteoporosis medication. The importance of this relationship has been 
documented in various prior studies (Lau et al, 2008; Young & Oppenheimer 2009; 
Zolnierek & DiMatteo 2009). One participant received conflicting information from two 
doctors about the severity of her osteoporosis, this left the patient distrusting her 
doctor and unsure of her need for osteoporosis medication. Aspartame is a component 
of bisphosphonates. One participant reported that this ingredient aggravated another 
of her medical conditions. She contacted her doctor to request an explanation for the 
inclusion of aspartame in such medication, however, she did not receive a response to 
this query. This shows patients taking an interest in osteoporosis medication, yet 
receiving no feedback or support. 
Comparisons between attenders and non-attenders were interesting. Negative beliefs 
about medication were more common in the group of non-attending patients, with 
four out of five non-attenders in this study reporting that medication in general is 
negative. Considering that medication beliefs are predictors of adherence (Carr et al, 
2006; McHorney et al, 2007), this suggests that these patients may be more likely to 
miss doses of their medication. This finding is in agreement with previous research 
from a large study, which has shown that patients who did not respond to 
questionnaires were more non-adherent than those who did respond (Gadkari et al, 
2011). It is interesting that the majority of DNA patients reported that their fracture 
risk was higher than that of the general population, while the attenders were more 
likely to report that their risk was the same or lower. Perhaps DNA patients’ high risk 
perceptions indicate their high emotional response to the condition and thus an 
avoidant coping mechanism such as not attending their appointment with their doctor. 
This interpretation is backed up by non-attenders describing more negative emotional 
reactions to the condition than attenders. 




6.7.2 Methodological contribution of drawings 
The research provides a description of a novel method of investigating how 
osteoporosis sufferers visualise their condition through the use of participants’ 
drawings. In terms of the SRM, this has allowed detailed investigation of illness 
‘identity’ and emotions. It has been previously documented that drawings activate 
emotions and cognitions (Bradley & Lang, 1992). Drawing has proved to be useful both 
in gaining further insight into how osteoporosis patients understand their condition, as 
well as eliciting their emotional responses to the condition.  
Every illness produces a specific, unique set of emotional responses (Fife, 1994). When 
interviewed, participants were asked to describe how they felt about having 
osteoporosis, they often reported no emotions. In many cases, before or after the tape 
recorder was running, patients reported concerns that they would not be a good 
candidate for the research as they did not worry about osteoporosis at all. It was not 
surprising that patients reported a low emotional impact of osteoporosis, because of 
its asymptomatic nature. This highlights how invisible the disease can be to its 
sufferers. When looking at their drawings and discussing osteoporosis, patients were 
more likely to report negative emotions such as fear, worry and anger. The contrast in 
the reporting of emotions across the two mediums; interviews and drawings, could be 
because drawings make concrete the effects of osteoporosis.  The findings of the 
present study support those of Cameron (2009), who showed that image 
representations are an important component of an illness risk representation, which 
can be used to predict health protective behaviours. This highlights the benefits of 
assessing an emotional response to a medical condition using drawings, which appear 
to access emotions in a way that interviews alone cannot. The study indicates that 
drawings can be used to supplement a discussion about how patients feel about 
having osteoporosis. 
Kyphosis (spine curvature) is one of the biggest fears for osteoporosis sufferers 
(highlighted in participants’ drawings). Drawings of people with osteoporosis indicate 
that these participants are most conscious and frightened of the visible signs of 
osteoporosis, with the majority depicting kyphosis and no drawings of a fracture. This 




may be because fractures are difficult to draw. Kyphosis does not happen to everyone 
with osteoporosis and this should be clearly communicated. It is important that the 
fears raised in this study are addressed – to ensure that patients do not develop 
avoidant coping mechanisms. One way of alleviating this fear could be to clearly 
communicate that medication can reduce the chances of fracture and long term 
immobility, even in the event of a fall. Without the opportunity to depict and talk 
about the emotional effects of osteoporosis, it is possible that patients will continue to 
believe the condition to be abstract and asymptomatic.   The fact that osteoporosis 
patients hold visual representations of their illness means that using images to 
communicate risk may be effective. It proved useful to have a team of researchers to 
analyse the drawings produced in this study, because interpretation of their meaning is 
subjective.  
The participant drawings produced similar results to those of previous authors who 
studied visual representations in other medical conditions. Broadbent et al (2006a) 
reported that the larger the patients drawing of the heart, the higher the cardiac 
anxiety. In the present study, it was found that the group who produced the largest 
drawings of bones were also the group who reported high levels of concern about 
osteoporosis medication and medication in general. This was the DNA group. This has 
been explained as drawing size increases as the saliency of the object increases 
(Craddick, 1961; Thomas et al, 1989). This provides support for using images as a 
method to assess illness representations. 
Within participants comparisons of drawings were interesting. Each participant’s pair 
of drawings of bones with and without osteoporosis was drawn very similar in size, 
which suggests a lack of understanding that osteoporotic bones may be small/thin in 
comparison to bones without osteoporosis. It was interesting that participants 
selected stereotypical cartoon type drawings of bones to represent osteoporosis. This 
suggests that drawings of cartoon type bones could be beneficial materials to use to 
communicate information about the condition to patients.   




6.7.3 Implications for interventions to improve adherence to 
osteoporosis medication 
This section will draw on the findings from this study which can be used to design a 
psychological intervention to improve adherence to osteoporosis medication. A key 
component of a successful intervention is to tailor interventions to each individual’s 
needs (Horne et al, 2005).  It is important to note that, because patients reported a 
vast range of various beliefs, the use of tailored psychological interventions is 
supported. This section will describe the study implications for future adherence 
interventions. 
In relation to strategies for promoting adherence, participants in this study suggested 
many useful ideas (presented in Table 9). The ideas they generated were similar to 
those found in previous studies, for example providing more accurate medication 
instructions, practitioner feedback and support and educational material (Lau et al, 
2008). A tailored psycho-educational intervention would be beneficial for patients with 
osteoporosis, to address patients’ misconceptions about their condition and 
medication. Further, psycho-education is a useful technique to highlight the various 
methods of controlling osteoporosis and preventing fractures. This study identified 
many common knowledge deficits. For example, more knowledge is needed on the 
causes of osteoporotic fractures, which are both poor bone health as well as a 
precipitating event, e.g. a fall or poor eye sight. This study suggests that general 
education for patients could focus on the causes of osteoporosis and methods of 
managing fracture risk. As well as education for patients, HCPs could be educated 
about the importance of emphasizing adherence to medication. 
The most commonly discussed concern about osteoporosis medication was side 
effects, or potential side effects. It is important that these concerns are addressed–
particularly the extent to which patients should tolerate minor side effects. 
Additionally, medication instructions should be adjusted so that patients understand, 
for example, that when taking bisphosphonates, it is necessary to remain upright but 
not necessarily static. Potential interventions to address negative medication beliefs 




include the provision of information about the benefits and barriers of taking 
medication.  
Other findings with implications for interventions include those regarding social 
support and feedback. The present study has shown how social support has a 
potentially positive or negative impact on adherence. Improved doctor-patient 
communication can be incorporated into future interventions, including education for 
health-care professionals (and medical students) about the impact of the doctor-
patient relationship and adherence. The HCP-patient relationship should be supportive 
and address patients’ fears and concerns regarding their illness and medication. 
Feedback from BMD scans was a crucial motivator of adherence for this group, which 
was documented in previous research (Lau et al, 2008). Scans provide concrete 
information about disease progression, which is fundamentally important in a 
condition which is asymptomatic. Such information could be used as intervention 
materials in future studies. Another example of providing concrete information about 
osteoporosis is the use of visual images/pictures of the condition. Patients suggested 
that visual images of osteoporosis would be beneficial in helping them to have a 
clearer understanding of their condition.  
Non-attending patients in this study expressed more concerns about medication than 
attending patients. While caution must be applied to making generalisations from this 
data, it is striking that so many had concerns about medication and indicates a possible 
association between low adherence and non-attendance. This also has implications for 
adherence interventions. Non-attending patients could be invited to take part in 
intervention studies, as this is a way of engaging them and possibly promoting 
medication adherence.  
Limitations 
A major challenge in adherence research is recruiting non-adherent participants. This is 
difficult and it is expected that those who agree to participation in research studies are 
likely to be more adherent/follow their doctor’s treatment advice. In an attempt to 
overcome this we recruited patients who had not attended their last clinic 




appointment -based upon the assumption that patients who did not attend their clinic 
appointment were also non-adherent with treatment recommendations. The reason 
for working with this assumption was to aim to recruit patients who had difficulties 
with medication-taking, in the hope that these patients could provide some new 
insight into the problem of non-adherence. Nonetheless, the majority of study 
participants reported being adherent with their medication regimes. This means we 
should exercise caution when forming opinions of patients based on their history of 
clinic appointment attendance. Knowledge of the nature of osteoporosis was high in 
this participant group. Some of this group had previously taken part in osteoporosis 
drug trials and were therefore possibly better informed about their condition and the 
role of medication than the general population.  
Conclusions 
The extended SRM provided a useful framework to systematically explore the cognitive 
and emotional factors which may influence adherence to medication, as it has 
produced some novel findings. The findings relevant for the design of a future 
intervention to improve adherence are:  
 Patients have a range of beliefs about osteoporosis and varying informational 
needs  
 Some patients were unaware that osteoporosis medication could achieve 
fracture risk reduction 
 Drawings of osteoporotic bones and people with osteoporosis aroused 
emotions for some patients in this study, suggesting that visual images may be a 
useful method of communicating risk in osteoporosis 
 Some patients have limited knowledge/ideas about the causes of their 
condition 
 There was limited knowledge about how to control/manage osteoporosis 




  Patients who fail to attend their clinic appointments may also have concerns 
about medication – and difficulties with adhering to it.  
This study highlights that osteoporosis patient’s illness perceptions, medication beliefs, 
emotional responses and risk perceptions are all factors which may influence the way 
in which they manage their condition. This study suggests that psycho-education might 
improve adherence to osteoporosis medication. Before an adherence intervention is 
fully designed and carried out, there is a need for future studies to develop this with a 
larger sample size, in order to identify the strength of the relationships between 
psychological factors and medication adherence. A test of the relationship between 
various psychological factors and adherence is presented in the following chapter. 




7 Study 3: The psychological factors related to 
osteoporosis medication adherence3  
Chapter overview 
This was a cross-sectional questionnaire study with a correlational design, which tested 
the relationship between the psychological constructs of two health psychology 
theories and adherence to medication. The overall goal was to provide a theoretical 
underpinning for an intervention to improve adherence to osteoporosis medication. 
Three different self-report measurements of adherence were used. It was found that 
patients had a wide range of beliefs about their osteoporosis. The data presented in 
this study forms the baseline data for the adherence intervention in chapter 9. 
7.1 Introduction 
Given that psychological factors have been found to predict adherence to medication 
in a variety of chronic conditions (Weinman & Petrie, 1997), the study was carried out 
to determine the relationship between various illness and medication beliefs and 
adherence to osteoporosis medication. While there have been many studies to assess 
the contribution of psychological factors to non-adherence to osteoporosis medication 
(reviewed in study 1), there are psychological models of behaviour which have not 
been applied to this problem with this clinical population. 
It would be beneficial to investigate the strength of the relationship between illness 
representations and adherence to medication in osteoporosis patients before deciding 
on whether to include illness representations in a psychological intervention to 
promote adherence. Illness representations can be measured using validated 
questionnaires such as the Illness Perceptions Questionnaire (IPQ) (Weinman et al, 
1996); the Revised Illness Perceptions Questionnaire (IPQ-R) (Moss-Morris et al, 2002), 
which includes additional scales; emotional response to illness and perceptions of 
cyclical timeline, or the Brief Illness Perceptions Questionnaire (BIPQ), which uses only 
one item to measure each scale (Broadbent et al, 2006b).  
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The Self-Regulation Model (SRM) and the extended SRM have been frequently applied 
to investigate the problem of low adherence to medication in many chronic illnesses, 
such as: coronary heart disease (Byrne, 2005), asthma (Horne & Weinman, 2002), 
chronic pain (Nicklas, 2010) and hypertension (Ross et al, 2004). Variation across 
medical conditions has been found, in so far as the amount of variance in adherence 
predicted by illness perceptions and treatment beliefs. For example, the extended SRM 
did not predict much variance in adherence to medication in CHD (Byrne, 2005). To the 
author’s knowledge, there has to date been no study measuring the illness perceptions 
of osteoporosis patients using any of the illness perception questionnaires. 
In brief summary, two theoretical approaches have been selected to gain 
understanding of the psychological predictors of adherence. These are the extended 
self-regulation model (SRM) and the extended parallel process model (EPPM). The 
authors of the extended SRM propose that a patient’s method of coping with a 
medical condition might be best understood by their cognitive and emotional 
representations of the condition, whereas the author of the EPPM proposes that a 
patient’s selected method of coping with an illness might depend upon their 
perceptions of risk associated with the condition. 
There is no standardised questionnaire to measure risk perceptions and the measure 
used will vary depending on the model being used to investigate the problem. Turner 
et al, (2008) designed a measure to assess risk perceptions about contracting HIV. 
Turner’s questionnaire was adapted for use in the present study with osteoporosis 
patients. 
There is no gold standard method for measuring adherence to medication, because 
every adherence measure has advantages and disadvantages. While self-report 
measures have the problem of presentational bias, they are most commonly used due 
to convenience and with the consideration that no measure of adherence is perfect. 
The five item Medication Adherence Report Scale (MARS) was used in the present 
study. The validity of the MARS has been established when used to measure 




adherence in patients suffering from asthma (Cohen et al, 2009), though its validity as 
a measure of adherence in osteoporosis patients is unknown.  
To date there have been no published studies that investigate the illness perceptions 
of osteoporosis patients using the self-regulation model (SRM); a widely used model of 
illness representations and coping. Similarly there are no published studies which 
examined the relationship between EPPM variables and adherence. The application of 
health psychology theory to the problem of low adherence may give rise to a more 
detailed understanding of how people with osteoporosis make sense of their illness 
and medication. 
The objectives of the study were to examine the relationship between 
cognitive/emotional representations of illness and adherence to medication; to 
compare the predictive power of the extended SRM and the EPPM and to ascertain 
whether the models can be brought together to form a new theory of health 
behaviour. The aim of the study was to investigate the relationship between a) illness 
perceptions, b) beliefs about medication, c) emotional responses, d) risk perceptions 
and adherence to osteoporosis medication. In total this study investigated the 
relationship of 20 different psychological factors with self-reported adherence to 
osteoporosis medication. If any of these psychological factors are identified to have a 
strong relationship with adherence to osteoporosis medication, they can then be 
targeted in a future adherence intervention. There is also a need to understand the 
practical barriers to adherence to medication. An example of this is the inconvenience 
of the medication regime, considering that some osteoporosis medications are 
prescribed with stringent requirements, e.g. to fast for two hours both before and 
after administering it, or to remain upright for half an hour after taking it. If practical 
barriers to adherence with osteoporosis medication can be identified, they can be 
targeted in a future behaviour change intervention to improve adherence. 
7.2 Aims 
The overall objective of the study was to investigate the relationship between various 
psychological factors and adherence to osteoporosis medication. Using quantitative 




methods, the study investigated illness perceptions, medication beliefs, risk 
perceptions and self-reported adherence to medication, as well as barriers to 
adherence in patients with osteoporosis or osteopaenia. Other objectives were to 
identify psychological variables that could be addressed in an intervention to improve 
adherence and to test two theories by examining which of their variables were related 
to adherence. It was anticipated that through the identification of cognitive and 
emotional representations related to adherence to medication, it would be possible to 
inform an intervention to improve adherence to osteoporosis medication. 
Psychological factors from two health psychology theories were investigated, the 
extended self-regulation model (SRM) and the extended parallel process model 
(EPPM). 
Research Questions  
 What is the extent of self-reported non-adherence to medication in patients 
with osteoporosis/osteopaenia? 
 What is the range of illness perceptions, medication beliefs, risk perceptions 
and emotional responses in osteoporosis patients? 
 What are the barriers to taking osteoporosis medication? 
 To what extent is adherence predicted by the extended SRM variables? 
 Can adherence be predicted by the EPPM variables?  
 What are the relative strengths of each model in predicting adherence? 
 To what extent does a combination of the extended SRM and the EPPM explain 
adherence? 
7.3 Hypotheses 
This paragraph will justify the hypotheses for investigating illness representations, 
medication beliefs and risk perceptions in the present study. Hagger & Orbell (2003) 
found a small but significant relationship between illness perceptions and coping. 




Previous work indicates that specific illness representations are related to adherence 
to medication in other medical conditions, e.g. a chronic timeline (Byrne et al, 2005) 
and the consequences of the condition (Horne & Weinman, 2002). Leventhal’s self-
regulation model suggests that emotional responses will have an influence on coping 
(Leventhal et al, 1984). The critical review (study 1) identified that medication beliefs 
are strongly related to adherence.  
1. Illness representations will have a small but significant relationship with 
adherence. Greater adherence will be associated with high perceptions of 
timeline, consequences and emotions 
2. Medication beliefs will be associated with medication adherence. Greater 
adherence will be associated with lower concerns about medication. 
3. Risk perceptions will be related to medication adherence. Greater adherence 
will be associated with higher perceived severity and susceptibility.  
7.4 Method 
7.4.1 Participants 
The study population consisted of female hospital outpatients (n=112) from four 
London teaching hospitals (mean age 67; range 43-89; SD 10.7). All participants were 
diagnosed with osteoporosis or osteopaenia. Patients who were prescribed an oral 
osteoporosis medication (alendronate, risedronate, raloxifene or strontium ranelate) 
for at least one month were invited to take part in this study. This ensured that 
participants were able to answer the question ‘how many doses have you missed 
during the last month?’ Patients were excluded if they were male, had cognitive 
deficits which impaired their ability to fill in questionnaires, were not prescribed 
medication for osteoporosis, were unable to administer their own medication, or were 
unable to speak English (unless they had a translator with them). Some patients were 
prescribed daily doses (n=43), others weekly doses of their medication (n=69).  




Participants from two groups were invited to the study; those who attended their last 
clinic appointment (attenders) and those that did not (non-attenders). The clinical 
factors recorded for each patient were:  
 Total number of fractures 
 Number of years with osteoporosis  
 Number of medical conditions 
 Number of medications prescribed  
 Name of prescribed medication for osteoporosis  
Participants often did not know exactly how long ago they had been diagnosed with 
osteoporosis, therefore they were asked to give an approximate time. The socio-
demographic variables included were:  
 Age 
 Nationality 
 Occupation  
 Social support (determined by the number of people with whom they were 
cohabiting).  
Over half of the study participants were aged over 65 (55%). Thirty eight per cent of 
the sample was retired and just over a third of them lived alone (35%). The majority of 
the participants were British (72%) or European (9%). The majority of participants had 
sustained at least one fracture (57%) with the number of fractures ranging from 0-10. 
There was a wide range of time within which participants had suffered with 
osteoporosis which ranged from less than one to 31 years. The majority of participants 
(89%) had another medical condition as well as osteoporosis and 60% were prescribed 
two or more medications. Patients were prescribed the following oral treatments for 




osteoporosis: Bisphosphonates (n=69), strontium ranelate (n=41) or raloxifene (n=2). A 
summary of the study participants’ demographic and social context data is provided in 
Table 11. 
Table 11. Study 3 and 4 participants’ demographic and clinical descriptive data
4
 
 Age No. of 
fractures 









Mean 67 2 7 3 5 
Median 67 1 5 3 4 
Mode 65a 0 5 3 3 
Std. 
Deviation 
10.79 2.05 5.84 1.88 3.84 
Range 43-89 0-10 1-31 1-11 1-21 
a multiple modes exist. The smallest value is shown 
7.4.2 Measures 
Six questionnaires with a total of 20 scales were used to investigate psychological 
factors and adherence. These measures and their scales are outlined below, with 
example questions from each scale shown in Table 12. Likert scales were used to 
measure responses, ranging from 1-5, where 1 = strongly agree and 5 = strongly 
disagree (unless stated). Questionnaires were completed by participants in the order 
they appear below.  
                                                     
4
 All scores are rounded up or down to their nearest whole number, with the exception of SD which is 
rounded to two decimal places. 




The Illness Perceptions Questionnaire Revised (IPQ-R) (Moss-Morris et al, 
2002) (shown in APPENDIX 11)   
This is a widely used validated scale that measures cognitive and emotional 
representations of an illness using 9 scales. The IPQ-R is demonstrated to be both a 
reliable and valid measure of illness perceptions (Moss-Morris et al, 2002). This 
questionnaire was derived from the theoretical constructs described in the self-
regulation model (Leventhal and Nerenz, 1984) and is an extension of the illness 
perceptions questionnaire (Weinman et al, 1996). The questionnaire was adapted for 
use with osteoporosis patients by changing the word ‘illness’ to ‘osteoporosis’.  
The scales of the original IPQ (Weinman et al, 1996) were described in a previous 
chapter (see chapter 3). The IPQ-R is an amended version of the IPQ, to include three  
additional scales; emotions, coherence and cyclical timeline. Personal control was sub-
divided into personal control and treatment control (Moss-Morris et al, 2002). High 
scores indicated: a greater number of perceived symptoms, strong perception of 
cause, perceived chronic timeline, high consequences, high perceived personal and 
treatment control and high emotional response. In some instances, the phrasing of an 
item required that the scoring be reversed to maintain consistency in the meaning of 
the item e.g. where strongly agree denoted a negative score. For this reason, 11 items 
were reverse scored (for details of questionnaire scoring see APPENDIX 17).  
The Beliefs about Medication Questionnaire (BMQ) (Horne et al, 1999) 
(Shown in APPENDIX 13) 
There are two parts to the original BMQ; the general and the specific. The general 
refers to beliefs about medication in general and was excluded from the present study. 
The BMQ specific was adapted for use with patients prescribed osteoporosis 
medication. There are two scales in this questionnaire: Necessity (5items) and 
Concerns (5 items). A high score indicates high perceived necessity for medication and 
a high level of concern about using the medication (for details of scoring see APPENDIX 
17).  




The Risk Perception Questionnaire (RPQ) (shown in APPENDIX 15) 
The RPQ is based upon the extended parallel process model (EPPM) and was adapted 
from a previous study (Turner et al, 2008) for use with osteoporosis patients. This 
questionnaire has 5 scales which are measured by 12 items. The scales are severity (2 
items), susceptibility (2items), self-efficacy (2 items), response-efficacy (2 items) and 
motivation (1 item). High scores indicate: high perceived severity, high perceived 
susceptibility, high perceived self-efficacy, high perceived response-efficacy and high 
motivation. It includes questions such as ‘I believe that AIDS is a serious disease’ and ‘I 
feel frightened of AIDS.’ This measure has been adapted to use in this study to 
investigate risk perceptions in osteoporosis patients (see APPENDIX 15 ). 
Table 12. Example Questions/statements for each questionnaire and scale 
Questionnaire Scale Example question or statement 
IPQ-R IPQ Identity Have you experienced pain recently? 
Was this pain related to your osteoporosis? 




My mental attitude e.g. thinking about life 
negatively 
IPQ Risk Factor 
Attribution 
Diet or eating habits 
IPQ Immune 
Attribution 
Poor immune system 
IPQ Chance 
Attribution 
Chance or bad luck 
IPQ Timeline I expect to have this osteoporosis for the rest 
of my life 
IPQ Consequences My osteoporosis causes difficulties to those 
who are close to me 
IPQ Personal The course of my osteoporosis depends on 








The negative effects of my osteoporosis can 
be prevented (avoided) by my treatment 




My osteoporosis is very unpredictable 
IPQ Emotions Having this osteoporosis makes me feel 
anxious 
BMQ BMQ Necessity Without my osteoporosis medicine I would be 
very ill 
BMQ Concerns I sometimes worry about the long-term 
effects of my osteoporosis medicine 
RPQ RPQ Severity My osteoporosis is a serious disease 
RPQ Susceptibility I feel that I may get a fracture in the future 
RPQ medication-
efficacy 
I am protected against fractures if I use my 
medication 
RPQ Self-efficacy I can use osteoporosis medicine without 
difficulty 
RPQ Emotions I feel frightened of having a fracture in the 
future 
RPQ Motivation I intend to take my osteoporosis medicine as 
prescribed 
Three self-report measures of adherence 
The Mediation Adherence Report Scale (MARS) (Horne, 1997b) (See 
APPENDIX 14) 
The MARS is a validated scale (Horne et al, 1999) with 5 items. Likert scales were used 
to measure responses, ranging from 1=Always to 5=Never. A high MARS score 
indicates good adherence, therefore 25 denotes full adherence. Previous studies have 




used a very stringent cut-off of 23/25 to delineate full adherence from partial/non 
adherence. The rationale for this stringent cut-off is that non-adherence is very 
difficult to detect/measure. 
Percentage non-adherence (APPENDIX 14) 
The second measure of adherence was the following item, ‘how many doses of your 
osteoporosis medication did you miss in the last month?’ The author added this item 
to the end of the MARS questionnaire. The number of missed doses was then 
converted to a percentage of non-adherence score. To calculate percentage non-
adherence, the number of missed doses was divided by the number of doses required 
and multiplied by 100. A high score indicates low adherence.  
The Difficulties Of Taking Osteoporosis Medication Questionnaire 
(DOTMQ) (APPENDIX 16) 
The DOTMQ was designed for this study with 14 barriers to medication listed and 
space for free text to identify barriers to taking osteoporosis medication. Participants 
were asked to tick items which they felt stopped them from taking their medication. 
The 14 items were selected based upon the barriers reported in study 2, as well as 
those commonly documented in the literature. However, only seven items were used 
in the analysis (see Table 13) because the other seven items overlapped with those of 
the BMQ or RPQ, e.g. did not think necessary and do not want to take this medication. 
This questionnaire was designed to capture an individual’s specific barriers to their 
medication, so that they could be targeted in a future intervention study. The measure 
originally included items about beliefs, motivation, side effects and practical barriers. 
However, it was decided to remove the beliefs, motivation and side effect items and to 
use the total number of practical barriers as a proxy measure of non-adherence. 
Because the DOTMQ was used as a dependent variable, the items which overlapped 
with items in the former questionnaires (IPQ, BMQ, RPQ and MARS) were excluded. To 
calculate the ‘total barriers’ score, participants scored one for each barrier they 
reported. Therefore a high score indicates a high number of perceived barriers to 
medication adherence. 
 




Table 13. Practical barriers of taking osteoporosis medication 
Difficulties of taking osteoporosis medication questionnaire 
Interferes with daily activities Hard to swallow 
Do not like the taste Not feeling well 





Ethical approval was sought and obtained from the Social Science, Humanities and Law 
Research Ethics Subcommittee (SSHL RESC), which forms a section of King’s College 
London University ethics committee. Participants were informed that the author 
would be undertaking future research and were asked if they were willing to take part 
in a future study, if they met the inclusion criteria.  
Setting 
This study took place in four hospital outpatient clinics. The following information 
about the four clinics was collected using a contextual data collection sheet, which was 
distributed to a rheumatology consultant at each hospital (see APPENDIX 10). 
Clinic A was the location from which the majority of the study sample was recruited 
(n=81). This was due to it being both the largest clinic and one in which the 
rheumatology consultant was particularly interested in the research. Clinic 
appointments were available for patients on three afternoons per week. The 
rheumatology clinic team consists of three healthcare professionals (HCPs) – the 
consultant, a rheumatology specialist nurse and a registrar. Patients who were 
prescribed osteoporosis medication were followed-up after 3 months and were given a 
30 minute appointment with one of the HCPs.  




Clinic B was the first clinic which was enrolled to take part in this study. However, 
recruitment was slow at this clinic because many of the patients were prescribed 
zolendronate and were therefore not eligible. There were two consultants carrying out 
one clinic each per week, with up to eight patients being seen by each consultant. 
Patients were usually allocated 15 minutes appointments and were reviewed yearly. 
Twenty-five patients were recruited from this clinic. Since recruitment at this clinic was 
very slow, it was decided to advertise the study on the National Osteoporosis Society 
(NOS) website, so that clinicians could get in contact if the study was suitable for their 
clinic. 
Clinic C had a consultant and a registrar each running one clinic per week, with up to 
eight patient appointments per session (usually three new patients and five follow 
ups). The consultant contacted the author and asked for the opportunity to take part 
in the study (through the advertisement on the NOS website). Patients are usually seen 
twice before discharge and they receive one or two follow-ups where medication 
adherence is reviewed. New patients are allotted a 30 minute consultation; follow-up 
patients were allotted 20 minutes. Patients are given the NOS drug treatment leaflet 
and many are referred to an exercise session with a strong educational component. 
Two patients were recruited from this clinic. 
Clinic D had one consultant running one clinic per week; with up to 12 patients seen 
during each clinic (four new patients and eight follow-up). Patients’ first appointments 
are usually 45 minutes, with one or two follow-ups lasting approximately 10 minutes. 
Patients on oral medications are being discharged to primary care where possible, 
while patients prescribed infusions are followed up at this trust yearly. The National 
Osteoporosis Society website leaflets are used to educate patients about adherence. 
Five patients were recruited from this clinic.  
Recruitment 
Two groups of patients were recruited for this study; those that attended their clinic 
appointments and those that did not attend their last appointment. To recruit 




attenders, osteoporosis clinics were visited on 41 different afternoons. Different 
recruitment processes were used across the clinics as follows:  
1) In clinics A and D, the doctors invited their patients to take part in the study at 
the end of their consultation. 
2) In clinics B and C, the author approached patients in the waiting room and 
invited them to participate. To protect confidentiality in the waiting room, 
patients were asked to read the inclusion criteria and to indicate whether they 
were eligible. If patients agreed to consider taking part, they were given the 
participant information sheet and were given the opportunity to ask questions. 
If they agreed they were asked to sign the consent form.  If they wanted to talk 
further about the study I took them into a private room to protect 
confidentiality. 
For non-attenders, secretaries from clinics A and B provided the author with the 
contact details for patients who had failed to attend their clinic appointments over the 
preceding six months. These patients were sent invitation letters and consent forms in 
the post to sign and return if they wanted to take part. Reminders were sent at three 
and six weeks after the questionnaires were initially sent out in order to enhance 
recruitment.  
Each participant was given six questionnaires to complete (a demographic data 
collection sheet and the five questionnaire measures described above). The 
questionnaires took between 30 and 45 minutes to complete. If patients were unable 
to fill in the questionnaires themselves, e.g. due to problems with manual dexterity, 
yet still wanted to take part, the author administered the questionnaires as a 
structured interview and patients’ responses were recorded for them. This took 
between 45 and 90 minutes. Patients were given the choice of completing the 
questionnaires in the waiting room or to take them home to complete and post back. 
Questionnaires were administered in clinic waiting rooms, either before or after 
patients’ consultations. To increase the response rate, patients were also given the 




option of taking questionnaires home to complete if they were unable to spare the 
time at the clinic. A private room was available at each clinic in case patients wanted to 
discuss matters confidentially with the author. There were two recruitment periods for 
the study; between July and December 2011 and again between September 2012 and 
January 2013. 
Overall, 170 sets of questionnaires were distributed by the author; 121 were returned 
(response rate = 71%) by the attenders (n=108) and non-attenders (n=13). For the 
attenders group, 141 questionnaires were distributed, with a response rate of 77%. 
Twenty-nine questionnaires were distributed to non-attending patients, 12 returned 
them with a response rate of 41%. Of the final 121 completed questionnaires, a 
proportion had to be excluded. In the attenders group, seven were excluded, two of 
whom had not completed over half of their questionnaires. A further five were 
excluded because they were prescribed only calcium or vitamin D for osteoporosis and 
had therefore completed the questionnaires in error. Two participants in the non-
attenders group were excluded because they were prescribed calcium only. Exact 
details of the number of participants who declined to take part in the study are non-
existent, as the clinic staff members assisting with the study were not able to keep 
records of the number of participants they invited due to their time constraints. 
7.5 Analysis 
Statistical analysis was carried out using IBM SPSS statistics version 18. Three main 
stages of data checking were carried out to ensure the database was correctly 
prepared for analysis. 
1) The accuracy of the entered data was checked twice by the author.  In addition, 
10% of the data were checked for accuracy by an independent assessor.  
2) Some questionnaire items required reverse scoring before the data were 
analysed. The SPSS function ‘recode’ was used to reverse score these items. 
Recoded variables were then manually checked to ensure that scores were 
reversed to the figures intended.  




3) After calculating mean scale scores using an SPSS syntax file, the total scores of 
the scales were manually calculated for five participants and the total 
compared with the SPSS database. This was carried out to further check that 
the data were entered correctly and to check that the SPSS syntax was correct. 
In addition, the independent assessor manually calculated each scale score for 
five different participants.  
The distribution scores of each scale were assessed to check that they met the 
assumptions for parametric tests. All three adherence measures were substantially 
skewed; the MARS score was negatively skewed, while percentage non-adherence and 
total barriers were positively skewed. Logarithmic transformation (Log10) is 
recommended for data that are skewed (Ferketich & Verran, 1994). It is important to 
note that before performing log10 transformation, first the direction of the MARS data 
had to be reversed, to make it positively skewed so that it was suitable for log10 
transformation. This had the effect of artificially reversing the direction of the 
relationships between the MARS score and the other study variables. Therefore, in the 
reported results, the direction of the relationships with the MARS score was reversed 
to reflect the direction of the original relationships.  
To compare the predictive value of each theory, multiple linear regressions using the 
enter method were carried out to test both models (the extended SRM and the EPPM) 
separately in order to investigate the extent to which these models predicted self-
reported adherence to medication for all three measures of adherence. These 
regressions were carried out to assess whether these variables explained the variance 
in adherence to medication. 
Factor analysis was used to reduce the number of study variables, with the aim of 
building a more parsimonious model of osteoporosis medication adherence. A final 
multiple linear regression was carried out to investigate the relationship between the 
newly constructed factors and adherence to medication, as well as to investigate 
whether the new variables could explain the variance in adherence behaviour. 





7.6.1 What is the extent of non-adherence in this population of 
osteoporosis patients? 
Based upon the Medication Adherence Report Scale (MARS), 26% of patients reported 
full adherence to their osteoporosis medication (with a score of 25/25). Using a MARS 
score of < 23 to signify non-adherence, 36% of the study participants were classified as 
non-adherent. Forty-six per cent of this sample reported missing at least one dose of 
their medication in the last month and 71% reported at least one barrier to taking their 
medication. The percentage of non-adherent patients for each MARS item is shown in 
Table 14. In congruence with other studies of adherence to medication, adherence 
scores were skewed (see Table 15). 
Table 14. Percentage of non-adherent patients for each MARS item 
MARS Item Percentage of participants who reported 
sometimes, often or always for each item 
I forget to take my medicines 22.5% 
I alter the dose of my medicines 10.1% 
I stop taking my medicines for a while 
every now and again 
22% 
I decided to miss out a dose 18.9% 
I decided to take less than instructed 10.1% 
 
Despite efforts to recruit patients who did not attend their clinic appointments, only 
11 of the 112 participants included in the study were non-attenders. Considering the 
large difference in the numbers of participants in each group, it was decided to carry 
out a non-parametric test to compare scores for adherence between these two 
groups. The same was carried out to investigate differences for all the study scales 
between these two groups. The Mann Whitney U test showed that there was a 
significant difference in adherence between the groups for the MARS score (U= 
299.00; p=.011) and the percentage non-adherence score (U= 291.00; p=.027). There 




was lower adherence in the non-attenders group. No significant differences were 
found for the number of barriers to adherence reported in each group, or for any of 
the psychological factors investigated. 
7.6.2 Descriptive statistics and reliability analysis 
Table 15. Descriptive statistics and reliability analysis for adherence measures 
















13.8 0-100 27.543 NA 1 2.30 
Total 
barriers* 
1.12 n/a 1.264 .518 6 1.194 
*There was space for free text to record additional barriers on the total barriers 
questionnaire, so there was no limit to the number of barriers reported. 
 
Figure 12. Distribution of adherence to medication in osteoporosis patients (MARS 
scores) 




Correlations between each of the three measures of adherence are shown below 
(Table 16).  
Table 16. Correlation analysis between the three measures of adherence 




















In each following section, study data from each model is presented in turn (extended 
SRM and EPPM). Firstly reliability analysis for each scale is displayed, as well as 
descriptive statistics (the distribution of scores in each scale). Secondly, correlation 
data are presented, followed by multiple linear regression data. Three multiple linear 
regressions were carried out for both models, to test the models for each adherence 
measure. The final section is factor analysis, with a multiple linear regression of the 
new overarching factors and adherence, again with each adherence measure. 
Descriptive statistics and Cronbach’s alpha for all the extended SRM scales (IPQ-R and 
BMQ) are shown in Table 17. The internal reliability of each scale was acceptable, with 
the exception of the IPQ-R Chance Attribution scale (= 0.302). Hence this scale was 
excluded from the analysis. 
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Table 17. Descriptive statistics and reliability analysis of IPQ-R and BMQ Scales 















6.91 0-21 4.630 .855 “ .345 
IPQ-R Medication 
related symptoms 
.675 0-21 1.681 N/A* “ 5.509 
IPQ-R Psychological 
Attribution 
2.02 1-5 .748 .895 6 .427 
IPQ-R Risk Factor 
Attribution 
2.52 1-5 .634 .669 7 .140 
IPQ-R Immune 
Attributions 
2.17 1-5 .731 .689 3 .004 
IPQ-R Chance 
Attributions 
2.34 1-5 .834 .302 2 .071 
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3.73 1-5 .696 .797 4 -.319 
IPQ-R Consequences 2.49 1-5 .756 .787 6 .289 
IPQ-R Personal Control 3.53 1-5 .683 .836 6 -.269 
IPQ-R Treatment 
Control 
3.43 1-5 .585 .651 5 .150 
IPQ-R Cyclical Timeline 2.56 1-5 .771 .697 3 .154 
IPQ-R Emotions 2.61 1-5 .947 .902 6 .201 
IPQ-R Coherence 3.64 1-5 .788 .885 5 -.414 
BMQ Necessity 3.08 1-5 .638 .730 5 .176 
BMQ Concerns 2.52 1-5 .722 .712 5 .333 
 *These scores contained a large number of zeros, making it impossible to perform a test of internal consistency. 




Descriptive statistics and Cronbach’s alpha for all EPPM scales are shown in Table 18. 
The internal reliability of each scale was acceptable, with the exception of the RPQ 
severity scale ( = 0.387). Therefore the severity scale was excluded from the analysis. 
It is expected that the low alpha was due to a low understanding that osteoporosis is a 
fatal disease, because while on average people agreed that osteoporosis was a serious 
disease (mean=3.98, SD=.763), it appears that they did not agree that it can be a fatal 
disease (mean=2.67, SD=1.090). All RPQ Scales were normally distributed. 
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Table 18. RPQ Descriptive statistics and reliability analysis of RPQ scales 







Severity 3.32 1-5 .740 .387 2 0.63 
Susceptibility 3.88 1-5 .616 .658 2 -.469 
Medication Efficacy 3.33 1-5 .793 .743 2 -.694 
Self-efficacy 3.70 1-5 .904 .834 2 -.965 
Emotions 3.10 1-5 .928 .870 2 -.230 
Motivation 4.37 1-5 .619 NA 1 -.434 




7.6.3 Socio-demographic and clinical Factors 
Correlation analysis was carried out in order to determine if any of the socio-
demographic or clinical factors were associated with medication adherence. Of all the 
demographic and clinical factors investigated only one small significant relationship 
was found. Age was negatively correlated with total barriers (r=-.213; p<.05), thus as 
age increased, the number of barriers to adherence reported decreased. No other 
relationships were detected for clinical or socio-demographic factors and adherence. 
While there were no significant relationships between the two BMQ scales (necessity 
and concerns), there were many relationships between IPQ-R scales, which are shown 
in the table below. As shown in  
Table 19, the majority of correlations between IPQ-R variables were as expected. For 
example there were strong positive correlations between: personal control and 
treatment control; emotions and perceived consequences and identity with perceived 
consequences. There were strong negative correlations between coherence and 
consequences, which means that as coherence increases, perceived consequences 
decrease. There was a negative relationship between personal control and 
psychological attributions, so that as personal control increased, psychological 
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7.6.4 Correlation analysis 
Table 19. Correlations between IPQ-R variables 
Scales5 1 2 3 4 5 6 7 8 9 10 11 12 
 2 .414** 
           3 .684** .215 
          4 .386** .319** .247* 
         5 .152 .118 .015 .443** 
        6 .289** .340** .179 .660** .370** 
       7 -.036 .024 -.105 -.049 -.088 -.108 
      8 .408** .447** .116 .394** .156 .443** .129 
     
                                                     
5 Note; *<.05; **<.001; Key for scales; 1. Osteoporosis symptoms; 2. General symptoms; 3. Medication related symptoms; 4. Psychological 
attribution; 5. Risk factor attribution; 6. Immune attribution; 7. Timeline (acute); 8. Consequences; 9. Personal control; 10. Treatment control; 11. 
Coherence; 12. Timeline (cyclical); 13. Emotions 
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Scales5 1 2 3 4 5 6 7 8 9 10 11 12 
9 -.109 -.161 .034 -.217* .133 
-
.353** -.198* -.187* 
    





   
11 -.204 
-
.254** -.150 -.176 .081 
-
.270** .188 -.172 .376** .312** 
  
12 .317** .373** .037 .313** .037 .501** -.038 .508** -.106 -.021 
-
.277** 
 13 .350** .459** .233* .474** .264** .359** .084 .755** -.106 -.234* -.187 .413** 
 
Note; *<.05; **<.001; Key for scales; 1. Osteoporosis symptoms; 2. General symptoms; 3. Medication related symptoms; 4. Psychological attribution; 
5. Risk factor attribution; 6. Immune attribution; 7. Timeline (acute); 8. Consequences; 9. Personal control; 10. Treatment control; 11. Coherence; 12. 
Timeline (cyclical); 13. Emotions 
 




Few IPQ-R variables were significantly correlated with self-reported adherence (see 
Table 20). There was a positive relationship between perceived negative consequences 
and the total barriers reported, so that as the consequences of osteoporosis increased, 
more barriers to taking medication were reported. Similarly a positive relationship 
between personal control and percentage non-adherence was found, being that as 
belief in personal control increased, non-adherence increased. As the emotional 
responses to having osteoporosis increased, more barriers to adherence were 
reported. 
The relationship between the two BMQ scales (necessity and concerns) was not 
significant (see APPENDIX 20). A significant relationship was detected between 
concerns about medication and two of the adherence measures; MARS and total 
barriers. The necessity scale did not correlate with any measures of adherence, though 
it correlates with: IPQ emotions (r=.282; p<.001); susceptibility (r=.367; p<.001) and 
coherence (r=.222; p<.05). The concerns about medication scale was significantly 
associated with many other scales in the study, for example, as concerns about 
medication increased, the emotional response increased (r=.562; p<.05).  
Correlations between all the scales measured in the study and each adherence 
measure are shown in Table 20. Motivation, self-efficacy and concerns about 
medication had the strongest associations with osteoporosis medication adherence. 

















Identity (number of 
osteoporosis 
symptoms) 








NS NS NS 
Psychological 
Attribution 
NS NS NS 
Risk Factor 
Attribution 
-.199* NS .245* 
Timeline (Chronic) NS NS NS 
Timeline (Cyclical) NS NS NS 
Consequences NS NS NS 
Personal Control NS .233* NS 
Treatment Control NS NS NS 
Coherence NS NS NS 
Emotions (IPQ) NS NS NS 
Necessity NS NS NS 
Concerns -.336** NS .387** 
Perceived 
Susceptibility 
NS NS NS 
Self-efficacy .415** -.299** -.554** 
Medication-efficacy NS NS NS 











Emotions (RPQ) NS NS .196* 
Motivation .432** -.333** -.321** 
Note; *<.05; **<.001; NS=not significant 
Adherence was significantly associated with motivation (for all 3 measures of 
adherence). The direction of the relationship is that as motivation increases, 
adherence increases. The concerns about medication score was associated with both 
the MARS and the total barriers scores, but not with percentage non-adherence. The 
data indicates that as concerns about medication increase, non-adherence increases. 
7.6.5 To what extent can adherence be predicted by the extended SRM? 
Multiple regression analysis was used to test if the extended SRM scales (IPQ-R and 
BMQ) significantly predicted participants’ adherence as measured using their MARS 
scores. The results of the regression indicated the predictor variable explained 11% of 
the variance in adherence to medication (r2 =.116, F=2.291; p=.013). It was found that 
concerns about medication significantly predicted the MARS score (=.446; p=000). 
Women were less likely to adhere to their medication as their concerns about 
medication increased. 
Similarly, multiple regression analysis was used to test if the extended SRM scales (IPQ-
R and BMQ) significantly predicted participants’ adherence as measured using their 
‘percentage non-adherence’ scores. This did not produce a significant model (r2 = .036; 
NS).  
Finally, multiple regression analysis was used again to test if the extended SRM scales 
(IPQ-R and BMQ) significantly predicted the score on the total barriers questionnaire. 
The results of the regression indicated the predictor variable explained 15% of the 
variance in adherence to medication (r2 =.145, F=2.821; p=.006). It was found that 
concerns about medication significantly predicted the ‘total barriers’ to adherence 
(=.472; p=000), so that as concerns about medication increased, the number of 




barriers to medication also increased. See Table 21 for a summary of the variance in 
each measure of adherence explained by the extended SRM. 
Table 21. Summary of the variance in adherence explained by the extended SRM 
Adherence 
Measure 
R2 F P % Variance 
explained 
MARS .116 2.291 .013 11 
%non-
adherence 
- - NS - 
Total Barriers .145 2.821 .006 15 
 
7.6.6 Can adherence be predicted by the EPPM? 
Multiple regression analysis was used to test if the RPQ scales significantly predicted 
the MARS score. The results of the regression indicated that two predictors explained 
28% of the variance (r2=.276, F=9.127, p=.000). It was found that self-efficacy predicted 
MARS score (=-.312, p=.000as did motivation (=-.393, p=.000).  
Multiple regression analysis was used to test if the RPQ scales significantly predicted 
participants self-reported percentage non-adherence. The results of the regression 
indicated the two predictors explained 13% of the variance (r2=.134, F=4.069, p=.002). 
It was found that self-efficacy significantly predicted percentage non-adherence (=-
.237, p=.003) as did motivation (=-.307, p=.004).  
Multiple regression analysis was used to test if the RPQ scales significantly predicted 
participants’ total barriers scores. The results of the regression indicated that the RPQ 
scales significantly explained 34% of the variance in total barriers (r2=.343, F=11.751, 
p=.000). It was found that self-efficacy significantly predicted total barriers (=-.491, 
p=.000), as did motivation (=-.237, p=.009). See Table 22 for a summary of the 
variance in each measure of adherence explained by the EPPM. 




Table 22. Summary of the variance in adherence explained by EPPM 
Adherence 
Measure 
R2 F P % Variance 
explained 
MARS .276 9.127 .000 28 
%non-
adherence 
.134 4.069 .002 13 
Total Barriers .343 11.751 .000 34 
 
7.6.7 To what extent does a combination of the extended SRM and the 
EPPM explain adherence? 
Due to the large number of predictor variables investigated in the study and the strong 
correlations between many of the variables, an exploratory factor analysis was used to 
explore the possibility of reducing the number of variables, with an aim to formulate a 
more parsimonious model to explain the study data. ‘The primary purpose of 
exploratory factor analysis is to arrive at a more parsimonious conceptual 
understanding of a set of measured variables by determining the number and nature 
of common factors needed to account for the pattern of correlations among the 
measured variables’ (Fabrigar et al, 1999, p274). Factor analysis was used in the 
present study to explore whether two models could be combined to explain 
adherence.   
Since there were many correlations between the psychological factors investigated in 
the study (see APPENDIX 20), it was hypothesised that it was possible to identify a 
smaller number of higher order factors that could be tested for their ability to predict 
adherence. An examination of the Kaiser-Meyer Olkin measure of sampling suggested 
that the sample was factorable (KMO=.598). Barlett’s test of sphericity was significant 
(X2 (426) = 78, p= .000). These tests indicate that the data were factorable and the 
sample size was acceptable for exploratory factor analysis (De Winter et al, 2009). 
The ‘scree test’ was used to determine the number of higher order factors (Cattell, 
1966). The scree plot (Figure 13) demonstrates that there are four factors above 1 
Eigenvalue, which denotes a four factor solution. A four factor solution means there 




are four over-arching factors which can be identified as possible adherence predictor 
variables (Figure 13).  
 
Figure 13. Scree plot indicating a four factor solution 
A principal components analysis with a promax (oblique) rotation of 13 scales was 
conducted. Oblique rotation is required when there are many correlations among the 
scales being analysed (Hendrickson & White, 1964). The severity and chance 
attribution scales were excluded from the exploratory factor analysis due to low 
reliability. Further, identity and the other three causal attribution scales were also 
excluded because they were dichotomous scales and were therefore too dissimilar to 
all the others to be included in the factor analysis. 
After inspection of the variables loading on each of the factors, they were named: 
Emotional responses, controllability, understanding and motivation. Table 23 shows 
the factors which load on the four main factors. These factors explained 68% of the 
variance. Theoretically the factor loadings are logical. 




7.6.8 A possible model of adherence 
Four scales loaded onto factor one, named emotional responses. The Eigen value 
showed that the first factor explained 24% of the variance. These scales indicate an 
emotional response to having osteoporosis, e.g. concerns about the medication could 
lead to a strong emotional response.  
Perceived control was the name assigned to factor two, on which three scales loaded. 
This factor explained 17% of the variance. It is clear from Table 23 that these three 
scales all related to the extent to which patients feel osteoporosis can be controlled, 
by them or by medication. 
The four scales that load onto factor three relate to patients perceived understanding 
of their condition. For example, this factor includes their understanding of the 
condition, or their need for medication.  This factor explained 15% of the variance.  
Two scales loaded onto factor four, self-efficacy and motivation. Given that self-
efficacy is theorised to be required for motivation, factor four was labelled 
‘motivation.’ Motivation explained 8% of the variance. Although motivation loads 
slightly higher on factor three, theoretically it belongs on factor four with self-efficacy 
rather than on factor three, which is about understanding. 
Table 23. Factor loadings and communalities based on a principle components analysis 
with oblique rotation for 15 scales from the extended self-regulation model and the 
extended parallel process model 
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7.6.9 Multiple linear regression 
The four newly identified factors (which are referred to as the new combined model) 
were regressed with each of the three measures of adherence. Multiple regression 
analysis was used to test if the new model significantly predicted the MARS score. The 
results of the regression indicated the predictor variable explained 29% of the variance 
(r2=.290, F=11.128, p=.000). Motivation was the significant predictor of the MARS 
score (=-.570, p=.000).  
Multiple regression analysis was used to test if the new combined model significantly 
predicted percentage non-adherence. The results of the regression indicated the 
predictor variable explained 10% of the variance (r2=.104, F=3.645, p=.009). Motivation 
was the significant predictor of percentage non-adherence (=-.380, p=.000).  
Multiple regression analysis was used to test if the new combined model significantly 
predicted the total barriers score. The results of the regression indicated the predictor 
variable explained 35% of the variance (r2=.346, F=13.453, p=.000). Motivation was the 
significant predictor of the total barriers score (=-.606, p=.000). See Table 24 for a 
summary of the variance in each measure of adherence explained by the EPPM. 
Table 24. Summary of the variance in adherence explained by a combination of the 
extended SRM and the EPPM 
Adherence 
Measure 
R2 F P % Variance 
explained 
MARS .290 11.128 .000 29 
%non-
adherence 
.104 3.645 .009 10 
Total Barriers .346 13.453 .000 35 
 





7.7.1 Key findings 
Over three quarters of the study participants reported a degree of non-adherence with 
their osteoporosis medication recommendations. The study identified that patients 
have a range of beliefs about their condition, medication and risk (see Figure 41 to 
Figure 53). This study provides evidence that illness beliefs, treatment beliefs, 
emotional responses and risk perceptions are implicated in adherence behaviour. The 
study identified a possible new model of adherence to osteoporosis medication, 
consisting of four psychological factors; emotional responses, perceived control, 
perceived understanding and motivation. Motivation was the only significant predictor 
variable in the multivariate analysis (this consisted of a combination of the motivation 
and self-efficacy scales from the EPPM).  
One of the valuable prospects of identifying psychological factors which are related to 
osteoporosis medication is that these factors may be amenable to psychological 
intervention. The study findings show empirical support for both the extended SRM 
and the EPPM; both were capable of explaining significant variance in adherence to 
osteoporosis medication. Self-efficacy and motivation were the strongest predictors of 
adherence. Concerns about medication were also a strong predictor of adherence. 
There is also support for a new model of adherence, consisting of a combination of 
psychological factors from both the extended SRM and the EPPM.  
Consistent with extant findings, the low level of adherence detected in this population 
of patients was as predicted. For example, WHO estimate that up to 50% of patients 
do not take their medication as prescribed (WHO, 1994). It was not surprising that the 
majority of the clinical or social context factors measured were not related to 
osteoporosis medication adherence, as similar research for other medical conditions 
has produced congruent findings (Osterberg & Blaschke, 2005). The present study 
detected a small relationship between age and barriers to medication, so that as age 
increases, the number of barriers to taking osteoporosis medication decreased. An 
explanation for this relationship could be that adherence to medication becomes more 
important to individuals as they get older. This could be because with ageing, avoiding 




poor health outcomes becomes increasingly important (Myers & Midence, 1998). 
Another possible explanation is that many of the older people in the study were 
retired, perhaps giving them less competing demands on their time and organisation. 
 
This was not the first study to compare two models in their prediction of health 
behaviour (Orbell et al, 2006). However, this was the first investigation of adherence to 
medication using the EPPM known to the author. It was also the first study to compare 
the EPPM and SRM known to the author. Based upon the amount of variance in 
adherence explained, the EPPM was superior to the extended SRM, for the MARS 
score, percentage non-adherence and total barriers. When both models were 
combined using exploratory factor analysis, they predicted 1% more of the variance in 
the MARS score and total barriers than either model alone. This provides some 
support for combining theoretical models. However, considering that correlations 
were modest and these models did not explain all the variance in the outcome scores, 
there are other factors which are not accounted for. It is likely that factors other than 
beliefs have an influence on adherence, such as doctor/patient relationship and 
communication, which were common themes identified in study 2 and in other 
previous research (Lau et al, 2008). 
This was the first investigation of the relationship between the extended SRM 
variables and adherence to osteoporosis medication known to the author. As shown in 
research for other medical conditions (Hagger & Orbell, 2003; Hagger et al, 2006), the 
extended SRM was found to predict a small but significant amount of the variance in 
adherence, for both the MARS and the total barriers score. This shows that illness and 
emotional representations predict adherence, therefore changing these 
beliefs/emotions could result in some change in behaviour.  
Many of the study findings replicate those of previous research. A key finding from the 
study was that motivation is a strong predictor of adherence. A large Italian study 
(n=9851) identified motivation, as well as side effects as predictors of adherence 
(Rossini et al, 2006). Given the evidence for motivation as a strong predictor, it would 
be beneficial to design an adherence intervention focussing on strengthening the 




motivation of osteoporosis patients, using motivational interviewing to help patients 
generate self-motivating statements about behaviour change (Rollnick and Miller, 
1995). 
Concerns about medication are well established predictors of non-adherence (Carr et 
al, 2006; IOF, 2006) and non-persistence (Schousboe et al, 2010) with osteoporosis 
medication using various measures of concerns. In the multivariate analysis, concerns 
about medication was the significant predictor variable. In contrast to existing findings 
in other medical conditions, perceived necessity for medication was not significantly 
associated with adherence in the present study, though this is in agreement with 
previous research with osteoporosis patients (Schousboe et al, 2010). Previous 
research has demonstrated that perceived medication efficacy predicts medication 
adherence (McHorney et al, 2007). Perhaps patients in the present study’s population 
did not perceive a need for osteoporosis treatment because of its silent nature. It is 
expected that perceived necessity will be ‘more influential in acute conditions, or 
those where the relationship between medication taking and symptomatic benefit is 
not apparent to the patient’ (Horne, 1997; p173). It should be noted that in Schousboe 
et al’s (2010) study, perceived necessity for medication was related to non-persistence, 
but not non-compliance. 
The present study identified self-efficacy for using medication to be one of the 
strongest predictors of adherence. It is likely that the reason self-efficacy was highly 
correlated with adherence was because there are many difficulties/barriers associated 
with bisphosphonates/strontium ranelate which limit patient’s adherence, e.g. fasting. 
The present study supports the previous findings of Schousboe et al (2010) regarding 
self-efficacy. Schousboe et al (2010) measured the impact of medication self-efficacy 
(belief in one’s ability to use medication without difficulty) and found it to be 
associated with non-adherence. Therefore belief in one’s ability to use medication 
without difficulty could be the focus of an intervention to promote adherence. A useful 
intervention to increase self-efficacy could be plan-setting using implementation 
interventions. This could help patients to overcome problems associated with planning 
how to take their medication around a fasting period. 




The finding that perceived susceptibility to fracture predicts adherence (Cline et al, 
2005) was not supported in the present study. In the structured interview the author 
carried out with participants who were unable to complete the questionnaires by 
themselves, it became apparent that some patients knew that they had an increased 
risk of fractures. However, they did not want to agree to ‘I feel I may get a fracture in 
the future’ because they wanted to have positive perceptions of their health risks in 
the future and did not want to attract negativity. Perhaps the specific statement used 
to measure susceptibility should be reworded for future studies. However, it is difficult 
to word susceptibility in a way that does not imply a negative outcome. 
The wide range of patients’ beliefs about osteoporosis and the medication provides 
evidence for tailoring adherence interventions to meet osteoporosis patients’ needs. A 
method for capturing these individual needs is to assess patients’ barriers to 
adherence. In a recent systematic review, it was recommended that adherence studies 
should use an assessment of the barriers to adherence to collect information about 
medication taking (Nguyen et al, 2013). The present study involved the design of a 
questionnaire to assess these barriers; the DOTMQ. However, an issue to be 
considered is whether the DOTMQ is a measure of adherence or rather a predictor of 
adherence. 
7.7.2 Limitations 
An important point is that in many studies of adherence, the number of participants 
classified as non-adherent is often only a small percentage. This means that adherence 
is being investigated at one end of the scale, in which the majority of patients are 
adherent. With a larger sample, with more patients classified as non-adherent, we 
might observe different results with stronger relationships between psychological 
factors and adherence. Conclusions about the differences observed between attenders 
and non-attenders in adherence should be made with caution, considering the large 
difference in numbers between the two groups. Further, there were a large number of 
non-responders in the ‘did not attend’ group, so the data collected may not be 
representative of the entire group. 




There are other limitations relating to the sample size and the data collected. Various 
oral medications for the treatment of osteoporosis were investigated in the study, 
however, there were not sufficient numbers of patients prescribed each to test as to 
whether different psychological factors predicted adherence to each medication. 
There are various recommendations for the sample size required in order to carry out 
factor analysis. One author recommends that the sample size should have five 
participants for every factor investigated and that the minimum sample size should be 
100 (Gorsuch, 1983). The present study met this criteria with 112 patients and a ratio 
of over 5:1 for each independent variable investigated.  
The limitation of cross-sectional studies is that the direction of the relationship 
between variables cannot be determined, due to the use of only one data collection 
time point. Further, this was a retrospective study and patients were asked to recall 
how many doses they had missed in the last month, which means the data are likely to 
be influenced by memory bias and difficulties of recall. Using self-report as a measure 
of adherence could be considered a limitation. This is discussed in the general 
discussion chapter of this thesis (chapter 11). The ‘barriers to adherence’ 
questionnaire showed promise as a type of proxy measure of non-adherence, because 
it was significantly correlated with both the MARS and percentage non-adherence.  
There are limitations associated with using theories to guide research, primarily that 
theories ultimately lead to the exclusion of variables which may be important 
predictors of adherence. In the present study, an attempt to overcome this limitation 
was the use of two theories. However, important factors known to be related to 
adherence were not investigated such as doctor/patient communication (Shu et al, 
2009) or the role of habit (Philiphs et al, 2008). This could explain why the theories 
were not able to explain more of the variance in adherence behaviour. While this is a 
limitation, it is a very difficult to design a study to investigate all the possible 
psychological predictors of adherence. 
Some patients recorded their questionnaire responses before their medical 
consultation, whereas others completed the questionnaires after. Data were not 




collected as to whether the medical consultation was before or after participants 
completed their questionnaires, which may have impacted their questionnaire 
responses. For example, if a patient was told during their medical consultation that 
their bone mineral density had not improved, this new information could alter their 
perception of the medication, which may influence their beliefs of medication 
necessity. For future research, patients could be asked to record whether they had 
seen their consultant before or after completion of the questionnaire.  
Only one questionnaire item was used to measure motivation. Participants were asked 
whether they agreed with ‘I intend to take my osteoporosis medication as prescribed’. 
This is a limitation of the study and could be overcome perhaps by including a Likert 
scale to rate the following item; ‘I feel motivated to take my osteoporosis medication 
as prescribed.’ 
7.7.3 Implications for the design of interventions to improve adherence to 
osteoporosis medication 
The study provides evidence for using a combination of two theoretical models in the 
design of an intervention to promote adherence. Self-efficacy and motivation are 
important psychological factors significantly associated with adherence and could be 
targeted in a future intervention to promote adherence. It would be expected that 
increasing both motivation and self-efficacy would increase adherence to some extent. 
A motivational interviewing intervention would be ideal to draw on and this could 
strengthen patients’ motivation for taking their prescribed medication. Further, a 
method of increasing self-efficacy for using medication is required.  
Given that both the extended SRM and the EPPM were found to significantly predict 
adherence, it would be beneficial to develop and test an adherence intervention based 
on these models. An intervention based upon these models would not be expected to 
completely eradicate the problem of low adherence, because there are other non-
modifiable factors which also relate to adherence e.g. age. However, the study findings 
suggest behaviour change interventions based on these models are likely to produce 
some increase in adherence. 




7.8 Conclusions and next steps 
The present study enabled the identification of the theoretical predictors of 
adherence, thus providing an evidence-base for the design of an intervention to 
increase adherence to osteoporosis medication. Psychological factors from both the 
extended SRM and the EPPM significantly predicted adherence to osteoporosis 
medication. The significant predictors of adherence to osteoporosis medication from 
these models were:  
 Concerns about medication  
 Motivation  
 Self-efficacy 
When the scales for the extended SRM and the EPPM were factor analysed, a potential 
new model of adherence was formed. This new combined model significantly 
predicted adherence to medication; with four psychological factors: 
 Emotional responses 
 Perceived control 
 Perceived understanding 
 Motivation 
Motivation and self-efficacy were consistent predictors of adherence across various 
measures of adherence. This study provides strong evidence that interventions to 
increase osteoporosis medication adherence should focus on these two factors. While 
some psychological predictors of adherence have been identified in the present study, 
there is no evidence base for the selection of specific intervention materials. 
Psychological theories are not easy to operationalize. Before designing a psychological 
intervention to promote adherence, intervention materials should be selected and 
tested. The following study demonstrates how images of osteoporosis were selected 
for inclusion in an information booklet about osteoporosis and its treatment. 




8 Study 4: Osteoporosis patients’ ratings of five 
visual images of osteoporosis 
Chapter overview 
This chapter presents a study that assessed osteoporosis patients’ responses to visual 
images of osteoporosis. Firstly a brief background of risk communication is considered. 
Secondly, the role of visual images/pictures in health communication is provided. 
Thirdly, intervention studies that have used visual images in health communication will 
be reviewed, including a review of the use of visual images such as body scans to 
communicate health risks across various clinical settings. Finally the present study is 
described in which visual images were utilised to communicate risk to osteoporosis 
patients. Further the impact of these images on patients’ cognitions, emotional 
responses and motivation to take their medication as prescribed is also discussed.  
8.1 Introduction 
Study 2 indicated that pictures of osteoporosis may be emotionally activating, 
indicating that visual representations of osteoporosis may have utility in adherence 
interventions, to inform patients of the effects of the condition and to motivate 
adherence. Harrow et al (2008) suggest that there is increasing interest in the 
relationship between visual representations of illness and the way in which physical 
images are used in health communication. However, the use of emotionally salient 
images needs to be carefully considered; negative emotions can motivate behaviour 
changes, but can also lead to avoidant responses if they lead patients to feel helpless 
(Witte, 1992). It may be particularly beneficial to use images to communicate risk in an 
asymptomatic condition such as osteoporosis where the patient experiences no 
concrete signs to indicate their illness condition. 
As discussed previously, there is some evidence to suggest that osteoporosis patients 
do not understand their diagnoses or the risks associated with their condition 
(Giangregorio et al, 2009). Study 2 produced similar findings. This indicates a need for 
improved communication of risk in osteoporosis. Further there is evidence to suggest 
that osteoporosis patients experience difficulties in understanding risk information. 




Cadarette et al (2007) found that when osteoporosis patients were fed back the results 
of their Bone Mineral Density (BMD) scans, 61% of patients understood the numerical 
information presented in relation to their BMD, but 39% did not understand such 
information. Similarly Pickney & Arnason (2005) reported that 63% of people with a 
normal BMD reading correctly recalled the information. These findings are in accord 
with those of other risk communication researchers, who found that understanding of 
numerical risk information is low (Berry, 2004; Lipkus, 2007). Difficulties in 
understanding numerical risk information highlight a need for innovative methods of 
communicating the risk of fracture to osteoporosis patients. 
Research has also focused upon the psychological impact of having a BMD scan. Rimes 
et al (1999) investigated the psychological and behavioural effects of having a BMD 
scan; they were interested in whether feeding back the BMD results to patients had 
any impact on osteoporosis preventative behaviours. Patients who were told that their 
BMD was low (which indicates they are likely to have or possibly develop osteoporosis) 
reported no increase in feelings of vulnerability but instead an increase in osteoporosis 
preventative behaviours. These findings suggest the potential use of a scan for 
prompting behaviour changes.  
It is possible that BMD scans could be perceived as frightening by osteoporosis 
patients, as well as having other negative effects. The author of one study reported 
that BMD scans caused patients to feel more fragile and fearful about mobilising due 
to the risk of fracture (Hvas et al, 2006). The authors conclude that ‘technological 
information indicating increased risk for osteoporosis appears to leave most affected 
women more uncertain and restricted than they used to be’(p2730). Although Hvas et 
al (2006) found their scans were not effective for communicating risk to osteoporosis 
patients’, their study findings should be treated with caution for a number of reasons. 
Both the type of information which was given to patients in relation to their scan as 
well as the method for identifying their risk perceptions were not reported. The design 
was cross-sectional and so was not appropriate for identifying causal processes. 
Patients had received bone scans somewhere between one and three years prior to 
the study and were not shown the scans. The study therefore investigated the 




patients’ experience of having a bone scan rather interpreting their response to the 
information included on their scan. The challenge in any health communication is to 
inform individuals of their risk, but without causing them to be immobilised by the fear 
of such risks. Therefore it is important to be guided by theory when implementing 
health communication messages, so that any negative effects can be minimised. The 
author of the extended parallel process model (chapter 3) proposes that health threat 
messages (e.g. pictures of a medical condition) should only be presented to patients if 
they are combined with messages about what can be done to manage the risk (Witte, 
1992).  
8.2 Pictures in health communication 
Risk communication is difficult because the information being conveyed is inexact 
(Berry, 2004). However, the way in which risk is communicated for diseases which are 
preventable / manageable is of great importance because it may influence subsequent 
behaviour. The use of images/pictures could contribute to a clearer way of 
communicating risk because ‘non lexical visual information is often the first cue to 
signal a threat’ (Bradley & Lang, 1999, p2). These authors argue that pictures are 
beneficial, particularly in healthcare because they activate cognitions and emotions 
and provide information which is concrete as opposed to abstract. There is strong 
evidence from a literature review to suggest that the use of pictures can enhance 
health communication (Houts et al, 2006). This review shows evidence from empirical 
studies that using visual images in health communication can improve the following: 
attention, comprehension, recall and adherence. Details of the way in which pictures 
have been useful in health communication and behaviour change interventions, will be 
discussed below. 
The use of images may be effective in risk communication because images can target a 
wider audience than text, including those with literacy problems and non-English 
speakers (Houts et al, 2006). Further, images are predicted to be more influential than 
other types of risk communication because images can be processed unconsciously 
(Horowitz, 1970), which means they are less likely to be filtered out through conscious 




thought processes. This is the reason that visual images are so commonly used in 
advertising. It is suggested that images can have their effect through subliminal 
influences on; emotions, beliefs and cognitions (Harrow et al, 2008; Williams & 
Cameron, 2009). If pictures can have a subliminal influence on health behaviour 
through advertising, it is worth exploring their influence in risk communication to 
promote healthy behaviours. 
The vividness of visual images used in a message has been found to be an important 
predictor of the message persuasiveness. Vividness was only effective in changing 
health behaviour when it was coupled with a high efficacy message about what can be 
done to minimise the health threat (Block and Keller, 1997). Careful selection of a 
visual image for use in a health behaviour change intervention is therefore important 
because not all types of images will be effective. 
8.2.1 Using visual images to change health behaviour 
The use of visual images (pictures) to convey a health risk in osteoporosis is innovative 
and has the potential to improve adherence. Hollands et al (2010) conducted a 
Cochrane review of studies which investigated the use of visual images as a motivator 
for health behaviour change, studies utilised the method of showing patients their 
body scans and subsequently explaining them. The use of body scans is based upon the 
assumption that showing a patient a depiction of what their condition is doing to their 
body will motivate them to take action to improve it. There were mixed results as to 
whether using images can motivate health related behaviour. This highlights the need 
for future work to explore the utility of body scans in risk communication. It may be 
that body scans are difficult for patients to interpret.  
There are some studies that suggest the use of images can be effective in changing 
health behaviour. The majority of research investigating the use of images in risk 
communication has focused on smoking cessation, with positive findings, e.g. a pilot 
intervention carried out by Shahab et al (2007) aimed to increase participants’ 
intentions to quit smoking using images. Participants in the intervention group were 
presented with ultrasound images of their clogged up arteries. The intervention group 




perceived that they were more susceptible to smoking related diseases and were more 
likely to participate in smoking cessation behaviours post-intervention than the control 
group. This study demonstrated the effectiveness of images to help patients better 
understand their risk of disease which can subsequently lead to changes in health 
behaviour.  
It is possible that images can have a negative effect on individuals. There has been 
much debate about the usefulness of picture warnings on cigarette packets (Ruiter & 
Gok 2005; Hammond 2006). For example, Hammond suggested that the pictures on 
cigarette packs are frightening and when not accompanied by any information for how 
to deal with the risk, the target individual is likely to ignore such picture warnings 
(Hammond, 2006). It is difficult to establish whether the images on cigarette packets 
are effective in promoting behaviour change. 
Health messages using images often rely on eliciting fear and this has brought about a 
debate in the research literature regarding the benefits of fear appeals (Benet et al, 
1993). Although there is evidence that fear appeals can bring about behaviour change, 
their use raises ethical concerns. However, considering that behaviour change is very 
difficult to encourage, it is plausible that some degree of fear is needed. It is important 
that the fear elicited is coupled with a motivational message of what can be done to 
minimise the health threat (Witte, 1992). This implies that an intervention using 
images to change health behaviour should be designed so that visual images are 
coupled with information about how to address the problem and therefore how to 
alleviate fear.  
Aside from the potential to elicit fear, a further problem with the use of 
images/pictures in risk communication is that substituting verbal or written 
information with visual images could lead to some of the valuable information being 
lost. There are no guarantees that pictures will be interpreted in the manner required 
and that the risks will be consistently understood by all. It is important that pictures 
are accompanied by an explanation in order to tailor it to the needs of the individual. 




Based upon the finding that not all types of image are beneficial in changing health 
related behaviour, it is important that any pictures selected for use in health / risk 
communication are carefully chosen and theory-based, in order to achieve effective 
communication and avoid any harmful effects associated with inappropriate use of 
pictures (Williams & Cameron, 2009). With a lack of theory-based studies for the use of 
visual images in health communication, there is a clear need for further research to 
look at what elements of a visual image are effective in influencing health behaviour.  
8.2.2 Research using body scans in osteoporosis 
Medical images of the body such as magnetic resonance imaging (MRI) scans and BMD 
scans have been investigated for their effectiveness for the communication of risk in 
several studies. The use of body scans to communicate risk to osteoporosis patients 
has been investigated (Cram et al, 2006; Estok et al, 2007) and allows for a very 
personal method to communicate risk to a patient, as they are presented with an 
image of their own body.  
A randomised trial was carried out, in which osteoporosis patients in the intervention 
group were sent their BMD scans to inform them of the progression of their illness 
(Cram et al, 2006). The effect of this information on initiation of osteoporosis 
medication and satisfaction with osteoporosis care was assessed. Although more 
patients in the intervention group had initiated their medication for osteoporosis, the 
results were not significant. On a positive note, patients’ satisfaction with their care 
increased.  
Estok et al (2007) looked at whether showing patients their body scans would 
influence their calcium intake and physical activity regimes. In this randomised 
controlled trial, patients were assessed at baseline and at 2 time points post-
intervention. At baseline, knowledge about osteoporosis predicted calcium intake and 
exercise levels. The authors noted a significant increase in calcium intake, but not in 
physical activity. 
Neither study involved the use of a theoretical framework to decide how to present 
the body scans, making it difficult to understand the reasons for success/failure in 




motivating behaviour change. While studies have investigated the impact of body 
scans on osteoporosis patients, none have examined whether other images, such as 
drawings of bones or pictures of people with osteoporosis can influence health 
behaviour. 
8.3 Summary of the use of visual images in behaviour change 
interventions 
It may be argued by some clinicians that presenting a patient with a visual image of the 
diseased area of the body is frightening and the concern is that it might be more 
harmful than beneficial. A Cochrane review of literature which assessed the impact of 
showing patients medical images of their own bodies demonstrated that the negative 
effects of this type of intervention are rarely explicitly measured (Hollands et al, 2010). 
It is important to investigate how patients respond to visual images, before employing 
them as intervention materials. 
Overall, there is mixed evidence as to whether visual images of medical conditions can 
improve the communication of risk. While some studies support this idea (Shahab et 
al, 2007; Harrow et al, 2008; Hollands et al, 2010) others suggest that visual images do 
not significantly improve health behaviour (Cram et al, 2006). It is difficult to draw 
conclusions based on previous research and more controlled studies in this area are 
needed which employ theory to design and test interventions that use visual images in 
risk communication.  
In study 2 it was observed that when patients were asked directly about their 
emotional responses to having osteoporosis, they reported a low emotional impact. 
However, when the patients were asked about how their drawings of osteoporosis 
made them feel, they described emotions such as anger and fear. Osteoporosis 
patients could benefit from new ways of having their fracture risks communicated to 
them,  as this could help patients self-manage their condition, as well as facilitate 
understanding of information related to osteoporosis.   
The rationale for the present study was to investigate the potential of visual materials 
for an adherence intervention. A set of images were rated in terms of how they 




impacted on osteoporosis patients’: anger, worry, motivation, confidence, depression 
and fear. One aspect of the study was to investigate the potential benefit of visual 
images for future interventions which aim to help patients understand their illness and 
motivate behaviour change.  
Research Questions 
 How do osteoporosis patients respond to visual images of osteoporosis? 
 Are there different responses to various images of osteoporosis? 
8.4 Method 
8.4.1 Measure 
The Osteoporosis Images Questionnaire (OIQ) (see APPENDIX 21) 
The OIQ was designed by the author for this study, to examine the responses of 
osteoporosis patients, when viewing images of osteoporosis. There were five images, 
each with nine related questions and five point Likert-scales to record responses. The 
nine questions were repeated for each image, each question formed a scale: 
frightened, informed, angered, motivated, depressed, confident, worried, confident 
that medication can help and helpless. The higher the score, the more positive or 
negative the reported response. There was also a free text box following each image 
for patients to record any comments about the image. 
The images included in the questionnaire were selected by the author and then shown 
to two expert patients to explore whether they felt they would be suitable for 
inclusion in an intervention. The five images were selected to reflect slightly different 
elements of the damage which can occur to the body in osteoporosis. A range of 
different images was selected to assess whether their effects would be different and 
whether it would be possible to tailor the choice of image to each individual. Four of 
the five images were of bones both with and without osteoporosis and had varying 
levels of detail. Two of the images were of hip bones and three were cross-sections of 
bones. One image was a drawing of osteoporosis by a participant from study 2. One 
image was of a person who developed kyphosis. Examples of the images used are 




shown below in Table 25. The nine questions were designed by the author and 
supervisory team and were based upon two themes, positive and negative effects. 
Table 25. The images tested as potential intervention materials 























The participants were the same sample (n=112) as in study 3, (see the previous 
chapter for their demographic and clinical information). One hundred of these 
participants were included in the analysis of study 3. One participant did not complete 
the OIQ because she said she would find the images pessimistic.  
The OIQ was distributed with the batch of questionnaires in study 3. The procedure 
was detailed in the previous chapter. Participants were given a questionnaire 
containing five images (shown in Table 25), which they were then asked to rate. There 
were nine statements about the influence of the images. For each image patients were 
asked to rate the effect it had on them. For each image, patients were asked to rate 
them with the following: ‘when I look at this picture I feel...: frightened, informed, 
angered, motivated, depression, confident, worried, confident that medication can 




help and helpless. There was a free text box after each statement for patients to add 
any additional comments about the images. 
8.4.3 Analysis 
In cases where more than two questionnaire items were missing (for one of the 
images), the participant’s data was excluded from the analysis of that particular image 
(n=2). To determine whether participants’ scores changed significantly across the 
different images, the Friedman test was used. The Friedman test is suitable to analyse 
the differences in responses to questions about each image, because the same 
questions were repeated for each image. For the qualitative data, participants’ 
comments were coded as positive or negative, depending upon how they influenced 
participants. Correlation analysis was also carried out to investigate relationships 
between participants’ responses to the images and all the scales in study 3 (IPQ-R, 
BMQ, RPQ and the three measures of adherence). 
8.5 Results 
Data for each stage of data analysis are presented in this section, including 
participants’ qualitative and quantitative ratings of the images and the results of the 
correlation analysis. Ten participants did not complete the OIQ. The reasons for this 
are unknown, although questionnaires were distributed at the osteoporosis clinic, 
many participants took their questionnaires home to complete. Descriptive statistics 
are shown in Table 26. 
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8.5.1 How do osteoporosis patients respond to visual images of osteoporosis? 










Frightened 3.43 .853 .897 5 -.527 
Informed 3.74 .567 .804 5 -1.45 
Angered 2.65 .787 .915 5 -.354 
Motivated 3.99 .532 .868 5 -.640 
Depressed 2.72 .856 .921 5 .128 
Confident 3.70 .655 .944 5 -.687 
Worried 3.15 .898 .923 5 -.400 
Confident that medication can 
help 
3.65 .614 .950 5 -.355 
Helpless 1.83 .620 .899 5 .495 
*Score range is 1-5, a high score indicates a high response 




Table 26 shows that the mean scores for each scale were higher for positively worded 
scales (e.g. informed, motivated) than for the negatively worded scales (e.g. 
depressed, helpless). The vast majority of participants did not complete the free text 
section of the questionnaires after each image. For those that did, there were mixed 
comments as to the influence of pictures on patients. Examples of participants’ 
comments about the pictures are shown in Table 27. 
Table 27. Participant’s comments of 5 images/pictures of osteoporosis (A-E) 
Image Positive comments Negative comments 




“When I look at this image I 
am concerned.” (Participant 
38) 
B “Makes me realise that 
osteoporosis is a serious 
condition and that 
taking treatment is a 
must.” (Participant 38) 
“This image is more 
frightening than the first 
one.” (participant 99) 
 
C “I can appreciate the 
fragility of bones with 
osteoporosis, it is a very 
good example.” 
(Participant 67) 
“This image is more 
frightening than the first 
one.” (participant 99) 
D “My G.P told me taking 
risedronate would help 
to prevent dowagers 
hump - this is what 
motivated medication-
taking.” (Participant 20) 
“I feel less good and less 
informed, as I have two 
aunts who looked like that 
and I assumed they had 
something else, e.g. 
ankylosing spondylitis” 
(Participant 18) 
E “Want to take action 
and medication on 
time.” (Participant 69) 
 
“This image is not helpful in 
any way. It conveys nothing, 
it is a bad drawing and 
suggests that this condition 
is not being taken too 
seriously.” (Participant 80) 




Image Positive comments Negative comments 
 
General Comments 
“Images are helpful.” 
(Participant 32) 
 
“Anything I feel is 
completely removed from 
the pictures.  A picture 
cannot make you feel 
anything.” (Participant 19) 
 
8.5.2 Were there different responses to the various images of 
osteoporosis? 
This section presents the results of the Friedman tests, which were carried out to 
investigate whether participants responded differently to each image. In cases where 
the Friedman test was significant, a Wilcoxon test was carried out to ascertain which 
image produced the strongest response. 
Frightened 
A Friedman test was conducted to evaluate differences between the median image 
ratings of fright: image A (median = 4), image B (median = 4), image C (median = 4), 
image D (median=4) and image E (median=3). The test was significant 2 (2, N =95) 
=30.288, p=.000 and the Kendall’s coefficient of concordance is .080. 
Follow up pairwise comparisons were conducted using a Wilcoxon test. The median 
frightened rating was significantly greater for the following: image A was more 
frightening than image E (p=.07); image B was more frightening than image A (p=.036); 
image B was more frightening than image C (p=.047); and images B and D were both 
more frightening than image E (p=.000 for both). The median frightening ratings for all 
the other images did not differ significantly. 
Informed 
A Friedman test was conducted to evaluate differences between the median image 
ratings of feeling informed: image A (median=4), image B (median=4), image C 
(median=4), image D (median=4) and image E (median=4). No significant differences 
were found. 





A Friedman test was conducted to evaluate differences between the median image 
ratings of anger: image A (median=3), image B (median=3), image C (median=3), image 
D (median=3) and image E (median=3). No significant differences were found. 
Motivated 
A Friedman test was conducted to evaluate differences between the median image 
ratings of motivation: image A (median=4), image B (median=4), image C (median=4), 
image D (median=4) and image E (median=4). The test was significant 2 (2, N =95) 
=14.302, p=.006 and the Kendall’s coefficient of concordance is .039. 
Follow-up pairwise comparisons were conducted using a Wilcoxon test. The median 
motivation score was significantly greater for image D than image E, (p=.010), but the 
median motivation scores for images A, B and C did not differ significantly.  
Depressed 
A Friedman test was conducted to evaluate differences between the median image 
ratings of depression: image A (median=3), image B (median=3), image C (median=3), 
image D (median=3) and image E (median=3). No significant differences were found. 
Confident 
A Friedman test was conducted to evaluate differences between the median image 
ratings of confidence: image A (median=4), image B (median=4), image C (median=4), 
image D (median=4) and image E (median=4). No significant differences were found. 
Worried 
A Friedman test was conducted to evaluate differences between the median image 
ratings of worry: image A (median=3), for image B (median=4), image C (median=3), 
image D (median=4) and image E (median=3). No significant differences were found. 
Confident that medication can help 
A Friedman test was conducted to evaluate differences between the median image 
ratings of confidence that medication can help: image A (median=4), for image B 




(median=4), image C (median=4), image D (median=4) and image E (median=4). No 
significant differences were found. 
Helpless 
A Friedman test was conducted to evaluate differences between the median image 
ratings of helplessness: image A (median=2), for image B (median=2), image C 
(median=2), image D (median=2) and image E (median=2). No significant differences 
were found. 
8.5.3 Were there any correlations between participants’ image rating 
scores and their illness perceptions, medication beliefs, emotions, 
risk perceptions and adherence? 
Correlation analysis was carried out to assess whether there were any relationships 
between the image ratings and adherence (as measured in study 3). Similarly the 
relationship between each image rating and the psychological factors investigated in 
study 3. For the majority of image rating scores, there were no significant relationships 
with any of the adherence measures. There were three small but significant 
relationships between image ratings and adherence. When ratings of depression 
increased, adherence decreased, for both the MARS score (r=.198; p=.049) and the 
number of missed doses (r=.261; p=.012). Similarly, individuals who rated the images 
as worrying had lower adherence (r=.215; p=.038).  
There were very few correlations between the image rating scores and the 
psychological factors measured with the IPQ-R, BMQ and RPQ in study 3. As ratings of 
confidence increased, IPQ-R personal control increased (r=-.201; p=.045). As BMQ 
necessity beliefs increased, ratings of depression decreased (r=.213; p=.036). There 
were no other significant relationships between ratings of images and the 
psychological factors measured in study 3. 
8.6 Discussion 
The study demonstrated the mixed effects images of osteoporosis can have on 
individuals. There is some evidence that osteoporosis patients differed significantly in 
their responses to each image. Further, the qualitative information suggests that 




different images did have different effects. Overall this provides an argument for 
tailoring the choice of image to each patient's needs. This study was worthwhile and 
overall participants did not agree that the images made them feel depressed, angry or 
helpless.  
Participants had a wide range of responses to each image, demonstrated in the 
distribution of ratings for each image (see APPENDIX 23 for histograms of the 
distribution of ratings). When the mean ratings of each image were compared, a 
significant difference was noted for ratings of how frightening the images were. There 
was also a significant difference for motivation, where one image (a person with 
kyphosis) was rated as significantly more motivational than the others. This 
information of varying responses to images provides evidence for tailoring the choice 
of an educational image of osteoporosis for each individual participant.  
The qualitative data also suggests that the same image can affect various participants 
differently. While some participants found the image worrying but informative, others 
did not perceive any helpful benefits. The finding that participants were affected 
differently by the same image provides evidence for tailoring images to individual 
needs. It is difficult to determine whether an image that is frightening is positive or 
negative; on one hand it may be detrimental to coping with the condition adequately, 
on the other hand, being frightened might be a cue to action to protect health.  
It was hypothesised that drawings of stereotypical cartoon type bones patients created 
in their drawings of osteoporosis in study 2 might be beneficial intervention materials, 
aimed at helping patients to better understand their condition. The present study 
indicates that this was not the case. Qualitative analysis of free text indicated that a 
drawing of osteoporosis was viewed as a poor representation of the condition and did 
not help to improve knowledge. Further, the drawing was rated as less motivational 
than an image of kyphosis. 
The OIQ might have provided a covert measure of how osteoporosis patients felt 
about their condition. The correlation analysis produced some important findings. 
When patients agreed that images of osteoporosis were depressing and worrying, they 




were less likely to be adherent to their osteoporosis medication. This finding provides 
some support for Witte’s extended parallel process model (Witte, 1992). If patients 
have strong negative emotional responses to osteoporosis, perhaps their energy is 
used to manage these emotions rather than to manage the condition.   
Limitations 
Almost ten per cent of participants did not complete the osteoporosis images 
questionnaire which might be explained by the questionnaire being administered as 
the last of a batch of six. However, for future studies it may be beneficial to shorten 
the OIQ. It could also be beneficial to use a Latin square design to vary the order of 
questions for each image and reduce order effects to make it feel less repetitive for 
participants.  
8.7 Conclusion 
The use of visual images to convey the details of fracture risk in osteoporosis is 
innovative and has the potential to improve adherence. To inform future 
interventions, it is important for intervention development studies to assess the 
impact of the intervention materials prior to their implementation. This is of particular 
importance when the intervention materials include potential ethical issues for 
consideration. There is evidence from the present study to suggest that different visual 
images produce varying reactions in individuals, in terms of how frightening or 
motivational they are. The implication of this is that tailoring medical images to the 
needs of the individual patient might be more beneficial than simply producing 
educational materials with a one size fits all approach. The following chapter presents 
a pilot behaviour change intervention to promote adherence to osteoporosis 
medication, which was based on the findings from studies 1-4. 




9 Study 5: A multifaceted intervention to 
increase adherence to osteoporosis 
medication: a case-series approach6,7 
Study overview 
The use of an N-of-1 case-series design to study adherence to medication is a novel 
method to investigate low adherence with osteoporosis medication. It is predicted that 
this method will provide new information about non-adherence to osteoporosis 
medication, as well as provide the opportunity to test and evaluate the interventions 
behaviour change techniques and theoretical basis for improving adherence to 
medication. The intervention was given the title: The Adherence To Osteoporosis 
Medication (ATOM) study. The design was multiple cases with multiple units of 
analysis. An overall objective of the ATOM intervention was to inform patients about 
their condition and medication. The ATOM intervention consisted of the following 
behaviour change techniques: tailored education, motivational interviewing, 
telephone follow-up and implementation intentions, which were evaluated using 
mixed-methods. The aim was to investigate whether the intervention changed 
osteoporosis patients’ beliefs about their condition, medication and fracture risk and 
to promote adherence to medication. A further aim was to assess whether patients’ 
drawings of osteoporosis changed after the intervention. This chapter will focus on the 
outcome evaluation of each participant’s response to the intervention. 
9.1 Introduction  
It has been previously documented that improving adherence to medication may have 
a higher impact on population health than improvement in the chemical properties of 
medical treatments (Haynes et al, 2008). There have been many previous attempts to 
improve adherence to osteoporosis treatment, yet essentially they have lacked a 
theory-base and evaluation (Gleeson et al, 2009). The limitations of previous studies 
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 Please find the ATOM intervention manual on the CD included in the back pocket of this thesis. 
7
 This study was presented at The Florence Nightingale School of Nursing and Midwifery annual 
conference, King’s College London (Besser et al, 2013b) 




make it difficult to interpret and explain any changes in adherence behaviour. In an 
attempt to overcome the problems of previous research, an adherence intervention 
was designed based upon the MRC’s framework for the design and evaluation of 
complex interventions, which recommends theory selection, testing and built in 
evaluation (Campbell et al, 2000; Craig et al, 2008). 
In accordance with the MRC’s framework, four intervention development studies were 
carried out before the intervention was designed. These were a critical review (study 
1), a qualitative study (study 2) and two quantitative studies (studies 3 and 4). Overall 
these studies have shown that patients have many informational needs about their 
condition and medication which have not been met, as well as beliefs which are not in 
accord with current scientific evidence. Studies 2 and 3 indicated that the theories 
selected to design an adherence intervention were appropriate and they enabled the 
identification of erroneous beliefs held by patients about their osteoporosis and 
medication. Importantly, these studies indicate that psychological factors are likely to 
have some influence on adherence behaviour.  
The previous studies presented in this thesis provide a description of the evidence for 
using two theories to inform the design and information to be included in an 
intervention to promote adherence to osteoporosis medication. Two theories were 
used in this intervention; the extended Self-Regulation Model (SRM) (Leventhal et al, 
1997; Horne, 1997) and the Extended Parallel Process Model (EPPM) (Witte, 1992). 
These theories define both a) the psychological constructs which should be targeted in 
the intervention and b) how intervention messages should be framed. The potential of 
these models to inform effective interventions to improve adherence to osteoporosis 
medication has not previously been investigated. 
Two theories are being used because each of them can add something beneficial. The 
empirical support for using the two models together came from study 3. When the 
scales included in the models were combined using factor analysis, the new scales 
predicted slightly more of the variance in adherence than either model alone. The 
EPPM adds information about the role of self-efficacy and how to shape/deliver a 




health risk message. The extended SRM determines specific beliefs about the medical 
condition and medication which may require intervention, as well as showing the 
dynamic nature of an individual’s lay model of their illness and how this adapts to new 
information. 
9.1.1 N-of-1 Design 
An N-of-1 design is similar to a case study, such as that used in clinical practice. A case 
study is defined as an ‘intensive investigation of an individual client’ (Kazdin, 1981, 
p184). It has been documented that the case study approach has been neglected 
within the field of health psychology and is at the bottom of the ‘tool box’ of research 
methods, when it has the potential to reveal a great deal about health behaviours 
(Radley & Chamberlain, 2001). The case study approach has the ability to reveal new 
information about the way in which osteoporosis patients take their medication, 
because it involves in-depth work with a small group of patients. This approach allows 
the inclusion of multiple repeated measures before, during and after the delivery of a 
behaviour change intervention, which would be very difficult with a larger sample size.  
A case study design has been selected to test behavioural theory in an intervention to 
promote adherence. As well as being recommended in the MRC’s framework for the 
design and evaluation of complex interventions (Craig et al, 2008), a case study is the 
most suitable approach for the following experimental conditions: 1) investigation of 
‘how’ or ‘why’ research questions, 2) the investigator has limited control over the 
events, 3) the focus is on behaviour in a real life context (Yin, 2009). A further 
justification for adopting the case study approach to test behavioural theory is that the 
psychological theories being investigated propose relationships between an 
individual’s thoughts and behaviour (Westmeyer, 2003). Therefore these theories are 
well suited to the study of individuals.  
A case study or N-of-1 design can be used to assess the effectiveness of a behaviour 
change intervention. Sniehotta et al (2012) investigated the usefulness of the case 
study approach to determine the effectiveness of an intervention. The intervention 
was based on self-regulation theory, with an aim to promote walking in healthy and 




obese adults. Walking increased for some participants who received the intervention. 
It was concluded that this method was useful to test behavioural theory.  
As far as the author is aware, to date there is only a single example of a previous 
adherence intervention for physical illness with an N-of-1 design. The intervention was 
designed to promote adherence to anti-retroviral medication for adolescents with 
AIDS (Gray et al, 2011). It consisted of behavioural family systems therapy and was 
delivered to four participants with low adherence. The intervention was successful in 
increasing adherence, reducing barriers to adherence and reducing viral load. 
9.1.2 Rationale for the selected behaviour change techniques 
An adherence intervention is regarded as complex because the target behaviour is 
difficult to change and to sustain and there are many factors known to influence 
adherence. Therefore a multifaceted intervention to promote adherence was selected, 
with various behaviour change techniques or components. All elements of the 
intervention were tailored to the needs of each individual. 
The behaviour change techniques used to promote medication adherence in the 
present study were selected based upon the findings of the previous intervention 
development studies, as well as previously published research. The techniques which 
were selected were as follows: psycho-education, motivational interviewing, 
implementation intentions and telephone follow-up.  As well being guided by the 
Information, Motivation and Behavioural skills (IMB) model (Fisher & Fisher, 1992), the 
rationale for the selection of each behaviour change technique was as follows. 
Definitions of behaviour change techniques have been provided by Michie and 
colleagues, so that researchers can ensure to use a common language when designing 
and evaluating interventions to promote behaviour change (Michie et al, 2008). These 
are being used to define the behaviour change techniques utilised in the present study 
(please see Table 28). 
  




Table 28. Definitions of behaviour change techniques 
Behaviour change 
technique label for this 
intervention 
Technique Definition 
Psycho-education Provide information about 
behaviour-health link 
General information about 
behavioural risk, for 
example, susceptibility to 
poor health outcomes or 






Identify barriers to the 
behaviour and plans ways 
to overcome them 
Follow-up telephone calls Use Follow-up prompts Contacting the person 
again after the main part of 
the intervention is 
complete 
Motivational Interviewing Motivational Interviewing Prompting the person to 
provide self-motivating 
statements and evaluations 
of their own behaviour to 
minimize resistance to 
change 
 
Psycho-education: A tailored information booklet  
 Osteoporosis patients have been found to have some misconceptions about 
their condition and medication (study 2; study 3). These can be addressed 
through the provision of information 
 
 Images of osteoporosis were found to be informative and positive (study 4) and 
patients had a range of responses to images. Therefore the choice of image was 
tailored to each individual 
Included in the tailored educational component of the intervention, patients were 
given the opportunity to ask any questions they had about their condition or 




medication. Patients were told that any questions which could not be answered by the 
author would be referred to their consultant rheumatologist, when the questions 
reached the limit of the author’s knowledge of osteoporosis.  
Motivational interviewing (MI) 
 The assumption of MI is that behaviour change is more likely to happen if a 
patient is able to make their own decision as to whether to change their 
behaviour (Rollnick & Miller, 1995) 
 Motivation was strongly correlated with adherence to osteoporosis medication 
(study 3) 
 The use of MI produced a clinically relevant increase in osteoporosis patients’ 
medication adherence (Solomon et al, 2010). While this intervention used both 
MI and education, it did not use the following behaviour change technique; 
implementation intentions 
Implementation intentions (referred to as plan-setting) 
 Self-efficacy was strongly correlated with adherence to medication (study 3). A 
technique for increasing self-efficacy for using medication is to use an if-then 
plan. An if-then plan allows a patient to set a routine for taking their 
medication, e.g. if it is 7am and I am in the kitchen, I am just about to do my 
ironing, then I will take my medication  
 If-then plans were previously found to improve adherence to medication to 
prevent epileptic seizures (Brown et al, 2009) and stroke (O’Carroll et al, 2013)  
Telephone follow-ups 
 Telephone follow-ups are a well-established method of increasing adherence 
(McDonald et al, 2002)  
 Telephone follow-ups provide an element of tailoring the intervention to the 
needs of the individual, for example a telephone follow-up can be used to 
check whether a patient understands the educational materials they were sent 
in the post 





An overall aim for this study is to test theory on a small scale and evaluate its effects. 
The intervention is based on four theoretical and methodological principles; small 
scale development and testing based on the MRC framework for complex 
interventions (Craig et al, 2008), using theory to inform the development of 
interventions, tailoring interventions to fit the specific needs of patients and in-depth 
quantitative and qualitative evaluation. If there is evidence that the intervention is 
beneficial it can then be refined and implemented in future research.  
The objectives of this study are as follows: 1) to find out whether a theory-based 
intervention can influence adherence 2) to investigate whether the intervention has 
any influence on illness perceptions, medication beliefs, risk perceptions and 
emotional responses to osteoporosis; 3) to determine which elements of the 
intervention are successful and unsuccessful and 4) to explore any changes in patients 
drawings of osteoporosis through comparison of pre- and post-intervention drawings. 
Research Questions 
 How does a (pilot) theory-based intervention impact adherence to medication? 
 What is the impact of a theory-based intervention to improve adherence on 
illness perceptions, medication beliefs, risk perceptions and emotional 
responses to osteoporosis? 
 Were there common trends between participants? 
 How do osteoporosis patients draw a visual representation of their condition 
before and after the intervention? 
9.3 Method 
9.3.1 Research Design 
The present study design was an N-of-1 design, with multiple case studies and multiple 
units of analysis. There were two units of analysis in this study; the individual patients 
and the intervention. During the intervention period, changes in patients' 




psychological variables from the extended SRM and the EPPM and adherence were 
recorded over four months at monthly intervals. Two baseline assessments were 
carried out prior to the intervention, with one assessment during the intervention and 
two after the intervention was complete. The assessment time points were as follows: 
time point one varied between three months and two years pre-intervention, time 
point two was two weeks prior to intervention, time point three was during the 
intervention, time point four was one to two weeks post-intervention. Time point five 
was one month post-intervention. A summary of the design is shown in Table 29. In 
addition to the quantitative assessments, patients were asked to draw how they 
visualised; (a) a bone with and a bone without osteoporosis and (b) a person with and 
a person with osteoporosis. Drawings were collected at two time points, pre- and post-
intervention.  The following tables demonstrate the timescale and the implementation 
of each intervention component for each participant. 
Table 29. Summary of intervention assessment time points 
Summary of intervention assessments 
Assessment Time point 
1 Baseline 18 
2 Baseline 2 
3 After psycho-education 
4 After MI & plan-setting 
5 One month post-
intervention 
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The participants were a sub-set of the study 3 participants who were identified with 
low adherence to medication. Patients were classified with low adherence when their 
MARS score ≤ 22. Their demographic and clinical information is presented in Table 30. 
Table 30. Demographic and clinical factors information of studies 5 and 6 participants 
Participant Age No. of 
fractures 









1 59 0 5 1 2 
2 68 0 16 4 4 
3 67 0 20+ 7 1 
4 61 7 3 2 1 
5 78 1 14 1 2 
6 58 0 5 1 2 
7 57 0 2 2 2 
8 69 0 15 2 3 
 
Inclusion/exclusion criteria 
All study 3 participants who were still prescribed an oral medication (bisphosphonates, 
raloxifene and strontium ranelate) for osteoporosis were invited to participate. All the 
patients who agreed to take part were prescribed with the same medication; 
Strontium Ranelate (SR). Participants who were on a drug holiday were excluded. 
Recruitment 
All the participants in study 3 whose MARS scores indicated low adherence (n=27) 
were telephoned to check their eligibility for the intervention. Some participants had 




their prescription discontinued by their doctor between study 3 and the present study 
and were therefore no longer suitable for inclusion. If participants were still eligible for 
the intervention they were invited to participate. If they wished to consider whether to 
take part, they were sent a participant information sheet and a consent form to return 
if they agreed. Participants were telephoned a week after they received the study 
information to check whether they wished to participate. In anticipation of difficult 
recruitment for a study of such long duration, it was decided to offer an incentive of a 














Figure 14. Reasons for intervention decline or study exclusion 
9.3.3 Measures and Materials 
The study 3 questionnaires provided the first baseline measure, pre-intervention. The 
assessment was repeated at four additional monthly intervals. To reduce participant 
burden and minimize attrition, it was decided that the questionnaires should be 
 Did not reply after their 
invitation ‘phone call and 
excluded after 3 attempts 
and/or 1 voicemail n=2 
 
Did not have time to take 
part n=1 
Not contactable and 
excluded after 3 
contact attempts and 1 
voicemail message 
n=1 
Eligible participants at 
baseline 1 (study 3) 
n=27 
 





On a drug holiday or their 
medication prescription 
had been terminated 
n=12 
13 participants were 
invited to take part 
One participant 
responded very late and 
was excluded due to 
time constraints  
Patient was located over 
100 miles away and did 
not want to commute n=1 




shortened. Both the IPQ-R and the BMQ were shortened from four to seven items per 
scale to two items per scale. This was carried out by inspecting Cronbach’s alpha for 
each scale and item deletion statistics of the study 3 data. Those two items with the 
highest alphas were selected to form the measure for each scale. The individual items 
for each scale are shown in the intervention manual (please see the accompanying CD 
for the intervention manual). 
The following primary outcomes measures were assessed: 
 Illness perceptions and emotional representations9 
 Medication beliefs10 
 Risk perceptions11 
 Adherence to medication12 
 Difficulties of taking osteoporosis medication13 
9.4 Procedure 
Each intervention component is briefly summarised below. The schedule used for the 
intervention components, length of each activity and the materials used is provided in 
Table 31. This is followed by an in-depth description of each intervention component 
including: the aim, delivery and content. A detailed description of the intervention and 
the intervention materials can be found in the intervention manual. 
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 The 2 item per scale IPQ-R, adapted from the IPQ-R (Moss-Morris et al, 2002) shown in the 
interventional manual 
10
 The BMQ (Horne et al, 1999) shown in APPENDIX 13 
11
 The RPQ (Turner et al 2008) shown in APPENDIX 15 
12
 The MARS shown in APPENDIX 14 
13
 The DOTMQ shown in APPENDIX 16 




9.4.1 Intervention summary 
1. Psycho-education (delivered by post, telephone and face-to-face 
hospital session):  
 Based upon each patient’s questionnaire responses taken at baseline 2, 
a tailored information booklet was designed and posted to participants 
(details of how information was tailored is included in the intervention 
manual)  
 The booklet includes a list of the benefits and barriers of taking 
osteoporosis medication 
 In addition to the information booklet, patients were given the 
opportunity to ask any questions they had about their condition and/or 
medication during a follow-up ‘phone call. Any questions which could 
not be answered by the author were referred to a medical specialist 
2. Motivational interviewing(MI) (delivered during face-to-face hospital 
session): 
 MI was used during the hospital session to help patients become aware 
of their motivation for taking their prescribed medication 
 Some patients who were ambivalent to change were assisted to make a 
list to weigh up the benefits and barriers of taking osteoporosis 
medication. 
3. Implementation intentions (plan-setting) (delivered during face-to-
face hospital session): 
 The hospital session included a section about the practical skills 
required to take medication as prescribed. This involved solving 
problems related to non-adherence, such as forgetting and routine 
setting 
 After MI, patients who felt motivated to take their medication were 









Table 31. Intervention schedule of assessment and intervention delivery 
Timeline Activity/assessment Length of activity Measures/Materials 




months and 2 
years prior to 
the first week 
of the 
intervention 
Baseline assessment 1 30-60 minutes IPQ-R, BMQ, RPQ, DOTMQ 
2-3 weeks prior 
to the first 
week of the 
intervention 
Invitation ‘phone call 5-10 minutes - 
1-2 weeks prior 
to the first 
week of the 
intervention 
Follow-up invitation ‘phone 
call to address participants 
questions about the study 
10-20 minutes - 
Week 1 Baseline assessment 2 
 
30-45 minutes Two item per scale IPQ-R 






Week 2 Tailored information booklet 
was posted to participants 
 
n/a Information booklet tailored to the 
needs of the patient as assessed at 
baseline 
Week 3 Follow-up educational ‘phone 
call 
 
30-45 minutes Script provided in intervention 
manual 
Week 4 Assessment 3 
 
25-45 Two item per scale IPQ-R 
Two item per scale BMQ 
RPQ 
MARS 
Weeks 5-6 MI and plan-setting session at 
hospital 
 
1 hour in clinic Script provided in intervention 
manual 
Week 7 Follow-up motivational 
‘phone call 
 
15-45 minutes Script provided in intervention 
manual 
Week 8 Assessment 4 
 
 
25-45 minutes Two item per scale IPQ-R 
Two item per scale BMQ 
RPQ 




Timeline Activity/assessment Length of activity Measures/Materials 
MARS 
Week 12 Assessment 5 
 
15-45 minutes Two item per scale IPQ-R 





Topic guide for evaluation 
 
9.4.2 Setting and delivery 
The majority of the intervention assessments and delivery took place over the 
telephone or post, with one exception. The face-to-face session took place at the 
osteoporosis clinic. The intervention was delivered by the study author, who had been 
conducting research about adherence to osteoporosis medication for 3.5 years at the 
time of the ATOM intervention delivery. When required, the author was supervised by 
her academic supervisors and a medical specialist. The author had experience of 
teaching and motivational interviewing training at an introductory level. Assessments 
three, four and five were carried out by an independent assessor in order to blind the 
author to the outcome data and reduce the risk of social desirability bias. Participants 
were asked to agree the time and date for each intervention component, to ensure 
smooth delivery of the intervention. 
The assessment of contextual data is an essential part of research using a case study 
design (Yin, 2009), because in-depth work with each patient allows time to collect a 
wealth of contextual data. The following demographic and clinical variables were 
ascertained at each baseline assessment and reassessed at the end of the intervention. 
 Age of the patient 
 number of years with osteoporosis  
 number of fractures 
 number of people co-habiting with 




  number of medical conditions  
 number of prescribed medications 
In order to tailor information to participants needs, their baseline questionnaire scores 
were used to diagnose whether they required information about a given psychological 
construct.  For example, if they had a low perceived coherence score, they were given 
information targeted at improving coherence. A table of questionnaire scores which 
indicated the need for intervention was created, so that when patients’ questionnaire 
response indicated low understanding, they would receive the appropriate information 
to address the low understanding (or misunderstanding). Therefore each participant 
received a slightly different information booklet, which omitted elements of the 
condition or medication for which they demonstrated good understanding. Full details 
of how information was tailored can be accessed in the intervention manual.  
As well as tailoring the textual information about osteoporosis and medication, the 
images of osteoporosis selected for each booklet were also tailored. Information from 
participants’ osteoporosis images questionnaires from study 4 were used to select the 
best images for each participant. Where possible the qualitative data was used to 
select an image, e.g. when a participant indicated that a particular image was 
informative or motivational they were provided with this preferred image. In the 
absence of qualitative data, images with the highest positive rating score were 
selected for the information booklet. In instances where more than one image had the 
same high positive score, images with the lowest negative score were used. In 
instances where there were multiple images with the same high positive and low 
negative score, the image with the highest range between high and low score were 
selected. 
The intervention was delivered as intended to all but one participant, who did not 
receive two elements of the intervention due to factors beyond the control of the 
patient or researchers. Table 32 below shows the intervention components that each 
patient received. 




Table 32. Implementation of each intervention component 
Participant 1 
 




































 X      
Questions 
answered 
        
Note; N/A indicates that the element of the intervention was not intended for the 
participant 
9.5 Analysis 
The data were analysed using descriptive statistics. Differences were analysed within 
single cases, to look for changes in adherence to medication, beliefs, emotions, 
motivation and self-efficacy. Adherence was assessed in terms of mean level of 
change, trend (slope) and positive shift in terms of percentage adherence. This method 
is commonly used in single case designs (Kazdin, 2011). Qualitative thematic analysis of 
the intervention process evaluation interviews was also conducted and is discussed in 
the following chapter. 




The dependent variable was adherence to medication, which was assessed with three 
different self-report measures, the same as in study 3. The independent variables 
were: illness perceptions, medication beliefs, emotional responses, risk perceptions 
and patients’ drawings. As mentioned previously, the scales used to measure the 
independent variables were shortened. Accordingly, baseline scores were calculated 
by selecting the shortened scales from the study 3 data for each patient.  
Participants’ drawings of osteoporosis were also analysed. Six participants completed 
two drawings; one of a bone with and without osteoporosis and one of a person with 
and without osteoporosis. The drawings were completed pre-and post-intervention. 
One participant refused to produce drawings. Another reported not knowing how to 
depict osteoporosis pre-intervention, but was able to complete a drawing post-
intervention. To investigate what the drawings revealed about patients’ thoughts 
about their illness, a thematic analysis was carried out, using the themes identified in 
the previous study of drawings of osteoporosis (study 2). Drawings of bones with and 
without osteoporosis were measured through their longest line and the results 
between each participant’s pair of drawings were compared. Drawings were 
categorised for their similarities and differences, both within and between 
participants. In a validity exercise, a second researcher was asked to carry out a 
thematic analysis of the drawings. There was agreement between researchers in the 
themes identified.  
9.6 Results  
Firstly changes in adherence are presented. This is followed by a presentation of each 
case study, with scores for beliefs, emotions, risk perceptions, motivation and self-
efficacy for each case. The participants are divided into two groups; four patients who 
had not initiated their prescribed medication at the outset of the study (group 1) and 
four patients who were taking their medication but with some difficulties (group 2). In 
group 1, 75% of patients initiated their strontium ranelate during the study. In group 2, 
all patients showed a slight increase in their adherence.  




9.6.1 What is the impact of a (pilot) theory-based intervention on 
adherence to medication? 
Prior to the presentation of the narratives for each case study, the data collected for 
each of the three measures of adherence are described. Following this the outcome 
evaluation data are presented (the process evaluation is in the following chapter). 
Table 33 below provides a comparison of the average MARS scores for all patients 
from baseline 1 until the final assessment. There was an increase in mean and median 
adherence scores, though no increase for the most common score.   
Table 33. MARS scores over time for the whole sample 
Time point Mean Median 
1 3.17 3.50 
2 2.65 3.90 
3 2.90 3.70 
4 3.63 4.50 













Figure 15. MARS scores for all participants pre-, during and post-intervention
14
 
For the MARS score, all participants showed some increases in their adherence, with 
the exception of participant 5 (see Figure 15). Participant 8 started taking her 
medication after the education session. Improved adherence was also demonstrated 
by decreases in the percentage non-adherence score (see Figure 16). Where there is 
no score MARS score adherence, it indicates that patient was not taking their 
medication and was therefore exempt for answering questions about adherence. 
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 Note: There are missing MARS scores for participants 3, 5, 7 and 8. Missing scores indicate that the 
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Figure 16. Percentage non-adherence; pre-, during and post-intervention 
Figure 16 above demonstrates that between the pre- and post-intervention 
assessment percentage non-adherence decreased for all but one of the study 
participants (participant 5). Table 34 shows a decrease in the average percentage non-
adherence for all participants, when their scores were grouped together. 
Table 34. Changes in average percentage non-adherence scores over time 
Time point Mean Median 
1 47.08 31.7 
2 50.00 33.3 
3 46.46 23.3 
4 32.50 16.7 
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Figure 17. Changes in total barriers score pre-, during and post-intervention 
While the average number of total barriers reported decreased (see Table 35), the 
graph above shows that only one participant reported fewer barriers to adherence 
post-intervention (participant 7). Many participants reported a decrease in barriers at 
baseline 2, before the intervention had commenced (see Figure 17). One reported 
more barriers at one month post-intervention than they reported at baseline 1. 
Table 35. Changes in average total barriers to adherence scores over time 
Time point Mean Median 
1 4.13 5 
2 4.88 5 
5 3.17 3 
9.6.2 What is the impact of a theory-based intervention to improve 
adherence on illness perceptions, medication beliefs, emotional 
responses and risk perceptions? 
To examine changes within participants, data to demonstrate the changes in 
psychological factors for each individual case from baseline to one month post-
























Total barriers to adherence 
Baseline1
Baseline2
1 month post intervention




Group 1: Participants who were not taking their prescribed strontium 
ranelate at baseline   
Participant 3 
Participant three was a 67 year old woman who was diagnosed with osteoporosis over 
20 years ago and had suffered no fractures. She was not in employment during the 
intervention. She said it was likely that her mother also had osteoporosis, though it 
was not diagnosed. As well as osteoporosis, participant 3 suffered from: chronic 
fatigue syndrome, chronic pain, irritable bowel syndrome, insomnia, anxiety and 
depression. She was not prescribed any mediation other than SR. At baseline one she 
reported “I am someone who finds it very difficult to take any kind of allopathic 
medication” and listed five barriers to taking SR. There were two years between each 
baseline assessment.  
While at baseline one she reported missing half of her doses of SR, by baseline two she 
was not taking any of the medication, reportedly because her care had moved to a 
new General Practitioner (G.P.) who had not yet prescribed it, even though it was 
recommended by her osteoporosis consultant. During the intervention period she re-
initiated her SR.  
During her MI session she reported that the motivation for wanting to take the SR was 
that she was getting older and that improving her bones might also improve other 
areas of her life. For her medication plan, she opted to take her medication sometime 
between 2 am and 6 am, since she often did not sleep well at night and this routine 
would not interfere with her daily meal times.  
However, this participant had a markedly different experience during the intervention 
to the rest of the study participants. After saying she felt motivated to take her SR in 
her MI and plan-setting session, she was asked by her osteoporosis consultant to wait 
two weeks before re-initiating her medication, pending an announcement from the 
Medicines and Healthcare Products Regulatory Agency (MHRA) concerning the safety 
of SR. After the two week period, the osteoporosis consultant made an appointment 
to see participant 3 and recommended that the medication was safe for her to use. 




Due to this time lag it was decided that participant 3’s second follow-up ‘phone call 
would be omitted, given that it could not be delivered at the time it was planned for. 
Therefore it was not possible to review and amend her medication plan if necessary. 
Nonetheless, it appears that her adherence increased two weeks after her MI session 
(see Figure 15 and Figure 16). In the final assessment she reported that she was taking 
her SR, even though her G.P had advised against it. 
In terms of illness perceptions (see Figure 18), her timeline score increased slightly, but 
only to a three which indicates unsure, rather than disagree. Two scores fluctuated 
with an overall increase: cyclical timeline and consequences. Her belief in the ability of 
the medication to control osteoporosis and her emotional response to the condition 
increased. Her coherence score increased after the intervention but decreased at one 
month post-intervention. 
 
Figure 18. Participant 3: IPQ-R scale scores pre-, during and post-intervention 
For medication beliefs, the patient’s necessity beliefs increased after the MI session, 
though her concern beliefs fluctuated over the course of the intervention (see Figure 
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patient was warned by her osteoporosis consultant that the medication may be unsafe 
for her to use.  
 
Figure 19. Participant 3: BMQ scales scores pre-, during and post-intervention  
In contrast to the IPQ-R treatment control score, the patients RPQ medication efficacy 
score decreased slightly after the intervention. Her susceptibility score remained 
stable. Her self-efficacy and motivation showed a slight increase prior to the 
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Figure 20. Participant 3: RPQ scale scores pre-, during and post-intervention  
Participant 3 declined to complete the IOQ even though she completed the other 
questionnaires distributed in study 3. She said she would find the images of 
osteoporosis pessimistic and not in line with her way of thinking. Therefore it was not 
possible to provide this patient with a tailored image of osteoporosis in her 
information booklet. The patient was offered the opportunity to receive an untailored 
image and she also declined this offer.  
Participant 3 also refused to create drawings of osteoporosis at both baseline and the 
final assessment. She reported that she did not want to create a negative image of 
osteoporosis. Although she refused to do the drawing, she explained what she would 
draw at baseline. She said she had recently seen a BMD scan and she would produce a 
drawing of a hip similar to her scan. She said for the normal bone, she would draw a 
clear bone and for the bone with osteoporosis, she would draw the damaged bits 
shaded. She said that she would not want to draw too much damage to the bone, 
because it conflicts with her way of thinking positively, although she is aware of the 
damage. For the drawings of people with osteoporosis, she said two images come to 
mind. One drawing of an elderly lady with a curved spine and one of a younger person 
for whom the disease is invisible, so there would be no difference between depictions 
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Participant 5 was the oldest participant in the study, aged 78. She had no family history 
of osteoporosis and had suffered one fracture prior to the study. She had suffered with 
osteoporosis for 14 years. Other than osteoporosis, she had two other medical 
conditions and was prescribed three medications in total. These were hypothyroidism 
for which she was prescribed thyroxin and glaucoma for which she was prescribed eye 
drops. She was prescribed SR and calcichew for her osteoporosis. At her first baseline 
she reported five barriers to taking the medication. She reported that her main barrier 
was the fasting period required which disrupted her social life, particularly now that 
she was retired and did not want to fast for a four hour period during the day. 
However, she was taking other protective measures to prevent fractures, including: 
daily exposure to sunlight for vitamin D, a calcium rich diet and a hip protector for long 
days out or if the weather conditions were unsafe. There were two years between 
each baseline assessment.  
This participant’s MARS score at baseline 1 was 19/25. Between baseline 1 and 2 she 
informed her doctor she had decided she no longer wanted to take her prescribed SR 
and her prescription was therefore terminated. It was difficult to decide whether to 
invite this patient to participate in the intervention, but she was included because her 
osteoporosis consultant said she could benefit from the intervention. This was because 
she had decided to discontinue the medication against her doctor’s advice. Overall her 
decision to discontinue SR did not change during the study period. Between 
assessments three and five, the patient was told she had high cholesterol, which could 
mean that SR would no longer be appropriate for her.  
The participant was ambivalent to re-initiate her medication, therefore decisional 
balance was used during her MI session. For every benefit she could identify with 
taking the medication, she could also list a barrier. While she recognised the 
importance of taking the medication, she said ‘I know I should take it, but I can’t’. 
When asked if there was anything that could help her to take this medication as 
prescribed, she said there was not, though she would take something else for it if that 
was possible.  




This participant showed an increase in perceived coherence of osteoporosis and a 
decrease in cyclical timeline (see Figure 21). This indicates she had a better 
understanding of osteoporosis post-intervention. Her personal control score increased 
at the baseline 2 assessment. Her emotional response to the condition remained low 
throughout the study. Her beliefs about treatment control and chronic timeline 
fluctuated during the study period. 
 
Figure 21. Participant 5: IPQ-R scale scores pre-, during and post-intervention 
For medication beliefs, both necessity and concerns scores were low for this 
participant (see Figure 22). Concerns about medication slightly decreased between 
baseline 2 and the final assessment. BMQ scores were missing from this patient at the 
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Figure 22. Participant 5: BMQ scale scores pre-, during and post-intervention 
At baseline 2, participant 5 agreed that she was susceptible to fracture. However, post-
intervention she was unsure about her susceptibility (see Figure 23). Even though she 
agreed that the medication can protect her against fractures, she had low self-efficacy 
for taking the medication. After her first assessment at baseline 1 she decided to 
discontinue her SR and the graph below shows that from baseline 2 she had low 
motivation for taking SR. Similar to the IPQ score, her emotional responses to having 
osteoporosis fluctuated but remained low throughout the study. 
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Participant 7 was a 57 year old woman who was diagnosed with osteoporosis two 
years prior to the study and had suffered no fractures. She was in full time 
employment. Both her mother and father were also diagnosed with osteoporosis. 
There were three months between her two baseline assessments. Other than 
osteoporosis, she was diagnosed with coeliac disease. As well as SR, she was 
prescribed vitamin D for osteoporosis. During her first baseline assessment, she 
reported that she was not taking the medication. In the free text box she wrote ‘I can’t 
see that the benefits outweigh the drawbacks.’  
Participant 7 responded well to the intervention with an increase in MARS score 
(Figure 15) and a decrease in percentage non-adherence (Figure 16). At baseline 2 this 
patient reported that she had reinitiated her medication after she had received the 
‘phone call to be invited for the intervention. She said that over the two years she was 
prescribed with SR, she estimated having intermittently taken only three months of 
her doses in total.  
Her motivation for taking the medication was to prevent fragility fractures, to build 
bones and prevent low quality of life. During the hospital session, she said she had a 
healthy scepticism towards SR. The author found it difficult to tell whether she was 
ambivalent about whether she should take her medication, so it was decided to offer 
the patient the opportunity to explore the benefits and barriers of SR, which she 
accepted. She welcomed the opportunity to make a plan for taking her medication. 
Her plan involved ensuring that she would eat her evening meal earlier in the evening, 
so that she had enough time to fast for two hours and to take the medication before 
going to bed. In her follow-up ‘phone call she said she needed to make some 
amendments to her plan because it was difficult to implement on evenings when she 
attended seminars, when she would end up having to eat late. Therefore a different 
plan was made to enable her to take her medication on an evening when she would be 
going out to a seminar.  She said she would take her medication at 8.30 pm, during the 
seminar and that therefore she was free to eat up until 6.30pm before the seminar and 
again after 10.30 pm on these nights. 




Many of participant 7’s IPQ-R scores increased during the intervention and then 
reverted to the baseline 1 score by the final assessment (Figure 24). This was true for 
cyclical timeline, perceived negative consequences and the emotional response. 
Perceived coherence made a large increase, as did beliefs in treatment control and 
personal control.  
 
Figure 24. Participant 7: IPQ-R scale scores pre-, during and post-intervention  
For medication beliefs, participant 7’s necessity score increased after her MI session, 
but decreased by one month post-intervention (see Figure 25). Her concerns about 
medication scores fluctuated during the study, though after the hospital session her 
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Figure 25. Participant 7: BMQ scale scores pre-, during and post-intervention  
Medication efficacy gradually increased after baseline 2 for participant 7 (see Figure 
26). Susceptibility to fractures increased after the hospital session and increased 
slightly more post-intervention. Self-efficacy increased slightly after the MI and plan-
setting session.  
 
Figure 26. Participant 7: RPQ scale scores pre-, during and post-intervention  
In contrast to many of the other participants, participant 7’s drawings of osteoporosis 
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Participant 8 was a 69 year old woman who was diagnosed with osteoporosis for 15 
years at the time of the study and had suffered no fractures. She was in part-time 
employment (three days per week). She said it was likely that her mother also had 
osteoporosis, though it was not diagnosed. She was initially prescribed two different 
bisphosphonates for osteoporosis, but had to stop taking them both due to side 
effects. As well as osteoporosis, she had an overactive thyroid. She was prescribed 
three medications: thyroxin, vitamin D and SR. She reported that although she took 
her thyroxin and vitamin D with no problems, she had failed to initiate her SR 
prescription. At baseline 1 she said I ‘have some psychological block following the 
previous experiences with osteoporosis medications.’ There were three months 
between her two baseline assessments. 
During the intervention she initiated her SR and her adherence gradually increased. 
She initially planned to take her medication on her work days, so was able to take it for 
three days a week. In her follow-up ‘phone call we revised her plan so that she could 
find a way to take her medication on her days off work. She identified that on Sundays 
she could take the medication in the morning before church, giving her enough time to 
fast, because she always had her breakfast when she got home from church. On her 
other days off work she planned to take the medication in the afternoon between a 
four hour fast after lunch and before dinner. 
The majority of participant 8’s scores remained stable during the study period. She had 
high perceptions of: timeline, personal control and perceived coherence (see Figure 
27). She had low perceptions of cyclical timeline, consequences and a low emotional 
response to the condition. Her perception of treatment control increased after she 
received the information booklet and again after the MI and plan-setting session. 
Between assessments four and five, participant 8 had a high blood pressure reading, 
which meant that her prescribed for SR had to be temporarily suspended, due to the 
recently evident links between taking SR and cardiovascular events (MHRA, 2013).  





Figure 27. Participant 8:  IPQ-R scale scores pre-, during and post-intervention 
Her concerns about medication fluctuated slightly and she remained unsure of the 
necessity for the medication throughout the intervention period and at follow-up (see 
Figure 28). 
 
Figure 28. Participant 8: BMQ scale scores pre-,during and post-intervention 
Although participant 8’s motivation had dropped at baseline two, it increased after she 
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after the information booklet, but increased slightly after the MI and plan-setting 
session. As for IPQ emotions, RPQ emotions remained low during and post-
intervention. 
 
Figure 29. Participant 8. RPQ scores pre-, during and post-intervention 
Group 2: Participants who were taking their prescribed strontium ranelate 
at baseline  
Participant 1 
Participant 1 was a 59 year old woman who was diagnosed with osteoporosis five 
years prior to the study and had suffered no fractures. She was in full-time 
employment. She had no family history of osteoporosis. She said she was shocked with 
her diagnosis of osteoporosis due to her age (54) at the time of diagnosis. She said her 
age made it difficult to accept the diagnosis of osteoporosis, because she believed it to 
be a condition suffered by older people. Between the two baseline measures she went 
through many changes. At baseline 1 she was a smoker, diagnosed with depression 
and she was prescribed anti-depressants. However, by baseline 2 she had ceased 
smoking and was no longer prescribed with anti-depressants. At baseline 1 she was 
prescribed with alendronic acid for osteoporosis, but she had difficulty with taking it 
and eventually had to terminate it due to the side effects she experienced. By her 
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SR with vitamin D supplementation. She reported that the four hour daily fasting 
required was her major barrier to taking SR. There were 18 months between baseline 1 
and baseline 2. 
During the hospital session she identified her main motivation to take the medication 
was that she wanted to improve and be ‘as good as possible’. She welcomed the 
opportunity to make a plan for taking her medication. Her plan involved taking SR at 
night before she went to sleep and as a back-up to take it in the middle of the night 
when she woke up. She also set a reminder on her mobile phone during the hospital 
appointment. In her follow-up ‘phone call we did not need to make any amendments 
to her plan because she said her original plan worked very well. Throughout the 
intervention her medication-taking increased, though it appeared to have decreased at 
the end of the intervention on one of the adherence measures (see Figure 15). The 
participant attributed her missed doses of SR to being away on a holiday for the last 
month of the intervention. 
The majority of participant 1’s illness perceptions remained stable throughout the 
course of the intervention, with an increase in perceived coherence after she received 
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Figure 30. Participant 1: IPQ-R scale scores pre-, during and post-intervention  
Participant 1’s concerns about medication score decreased over the course of the 
intervention (see Figure 31). Her necessity beliefs increased after the MI and plan-
setting session.  
 
Figure 31. Participant 1: BMQ scale scores pre-, during and post-intervention  
Participant 1’s RPQ scores fluctuated throughout the course of the intervention, with 
motivation to take SR remaining high throughout the entire study (see Figure 32).  
 









   
   
   
   
   
   
   
   
   
   
   




















   
   
   
   










MI & plan setting
1 month post-
intervention




Figure 32 shows that self-efficacy was maintained one month post-intervention, but 
her belief in the medication efficacy decreased one month post-intervention, to 
indicate that she was unsure about the medication efficacy. 
Participant 2 
Participant 2 was a 68 year old woman who was diagnosed with osteoporosis 16 years 
prior to the study and had suffered no fractures. She was in full-time employment. 
There was no history of osteoporosis in her family. As well as osteoporosis, she 
suffered from high blood pressure, dry skin and dry eyes. She was prescribed with four 
medications for these conditions, this increased by one during the winter, during 
which time she was additionally prescribed vitamin D for osteoporosis, due to a lack of 
sunlight during the winter. Although her MARS score at baseline was 21/25, she 
reported no barriers to taking SR. During the course of the intervention her adherence 
scores were high and stable. She did not exhibit many problems with medication 
adherence.  
During her hospital session she said that to remind herself to take her medication 
before she goes to sleep, her medication is kept next to her bed. She reported that her 
motivation for taking the medication was that she wants to improve her bone health. 
The patient’s total barriers to adherence increased from zero to two during the 
intervention. While initially at baseline 1 she reported no barriers, she reported that 
when she felt unwell (e.g. with a cold) she would not take her SR.  
Although in terms of adherence it seemed that the patient perhaps did have any 
serious problems of missing doses, her highest MARS score was recorded at one 
month post-intervention. There were some positive changes in the direction of her 
beliefs, towards being more concordant with those of healthcare professionals. During 
and post-intervention the following scores increased: timeline scores, personal control, 
coherence, treatment control scores (see Figure 33), demonstrating a better 
understanding of the condition. 





Figure 33. Participant 2: IPQ-R scale scores pre-, during and post-intervention 
While there were also changes in her BMQ scale scores, there were no changes in her 
RPQ scores. Participant 2’s beliefs in the necessity of the medication increased 
particularly after the MI session (see Figure 34). Concerns about medication fluctuated 
pre-, during and post-intervention. Participant 7 asked some questions about the 
safety of SR. During her hospital session she reported that having the opportunity to 
ask about the long term safety of the medication had reduced her concerns about 
taking it.   
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At baseline 1 this participant did not produce any drawings of osteoporosis. She 
reported that she did not know what to draw. Even after being given some 
encouragement she said she did not know what to draw. However, in her final 
assessment (one month post-intervention), she was able to create some drawings of 
osteoporosis. 
Participant 4 
This participant was a 61 year old woman who had suffered with osteoporosis for 
three years and had sustained seven fractures in her lifetime. Her mother was also 
diagnosed with osteoporosis. As well as osteoporosis she suffered with chronic back 
pain, for which she was prescribed daily exercises. At baseline she reported two 
barriers to adherence, with the main one as ‘the timing, leaving two hours after eating 
is tricky when occasionally dinner is late.’ There were two years between the two 
baseline assessments. 
Her MARS score at baseline one was 22/25, therefore she was on the borderline cut-
off to indicate non-adherence. Over the course of the intervention it became apparent 
that she occasionally missed doses, but on the whole she took her medication as 
prescribed. Her MARS score had improved by baseline two. During her MI session she 
reported that her motivation for taking the medication was that she trusted her 
doctor’s expertise. She had already developed a routine for taking her medication, so 
during the plan-setting her plan was reaffirmed. She was congratulated for taking her 
medication as prescribed and her question was addressed by a medical specialist 
about whether she could take pain killers during the four hour fast. 
Some of participant 4’s illness perceptions increased in the desired direction; timeline 
and treatment control (see Figure 35). Her perceived coherence increased after 
receiving the information booklet and remained high at each following assessment. 
Her emotional response and perceived negative consequences scores fluctuated. Her 
rating of personal control increased at the assessment after the information booklet, 
but decreased by the following assessment.  





Figure 35. Participant 4: IPQ-R scales, pre-, during and post-intervention 
Participant 4 scored low on both of the medication beliefs measured; necessity and 
concerns (see Figure 36). Her necessity scores fluctuated slightly, whereas the 
concerns score remained stable. She disagreed that SR was a cause for concern. Even 
though she reported having faith in her doctor’s prescription of SR, she was still unsure 
of the need for it. 
 








   
   
   
   
   
   
   










MI & Plan setting









   
   
   
   
   
   
   
   
   
   
   
   
   










MI & Plan setting
1 month post intervention




Participants 5’s motivation and susceptibility to fracture remained high throughout the 
study period (see Figure 37). This high susceptibility score is likely to be related to her 
having experienced seven fractures prior to the study. Her medication efficacy follow a 
similar pattern to the IPQ-R treatment control score, it increased immediately after 
receiving the information booklet, but then decreased post-intervention. This 
participant’s self-efficacy score fluctuated but remained high post-intervention.  
 
Figure 37. Participant 4: RPQ scale scores, pre-, during and post-intervention 
Participant 6 
Participant 6 was a 58 year old woman who was diagnosed with osteopaenia 
approximately five years prior to the study and had suffered no fractures. The 
diagnosis was later upgraded to osteoporosis. She was in the process of changing jobs 
at the time of the study. Her mother was also previously diagnosed with osteoporosis. 
Apart from osteoporosis she had been previously diagnosed with pancreatitis. In the 
time between her two baseline measures (six months), she did not experience any 
changes in clinical or social context. Apart from her SR she was also prescribed vitamin 
D for osteoporosis. Her MARS score at the first baseline was 18/25, with three missed 
doses of SR for the month she was assessed. On the baseline total barriers 
questionnaire, she reported ‘would like to see a better explanation of my condition 
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During participant 6’s MI session she reported that her experience of being 
hospitalised with pancreatitis motivated her to take her medication as prescribed. She 
asked a large number of questions in the opportunity she was given during the 
educational telephone follow-up. These questions were referred to her osteoporosis 
consultant and addressed during her MI session. The osteoporosis consultant advised 
that the patient should make an additional appointment to see her consultant if she 
still had unanswered questions. During her MI session, her current plan for taking the 
medication, which she had initiated before her participation in the intervention was re-
affirmed. Her plan involved taking the medication at night before she went to sleep 
and as a back-up to take it in the middle of the night when she woke up. In her follow-
up ‘phone call we did not need to make any amendments to her medication plan 
because her original plan worked well. Throughout the intervention her medication-
taking increased at each time point and also increased post-intervention (see Figure 15 
and Figure 16).  
Perceived coherence increased for participant 6 after she received her information 
booklet (see Figure 38). This change was maintained one month post-intervention. Her 
perception of treatment control increased during the course of the intervention. Her 
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Figure 38. Participant 6: IPQ-R scale scores pre-, during and post-intervention 
Both sets of medication beliefs fluctuated during the intervention for participant 6 (see 
Figure 39). After the MI session she was unsure about whether she was concerned 
about her medication, whereas before this she disagreed that she had concerns about 
taking SR. 
 
Figure 39. Participant 6: BMQ scale scores pre-, during and post-intervention 
Participant 6 showed a reduction in emotional response to osteoporosis in the risk 
perceptions measure (see Figure 40), in contrast to the IPQ emotions score. Self-
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Figure 40. Participant 6: RPQ scale scores pre-, during and post-intervention 
9.6.3 Were there changes in patient’s depictions of osteoporosis after the 
intervention? 
Six of the eight participants created a pair of drawings of bones and people with and 
without osteoporosis both pre- and post-intervention. One participant completed the 
drawings at the post-intervention assessment only and one participant refused to 
create any drawings of osteoporosis. 
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Measurements were taken through the longest line of both the pre-and post-
intervention drawings (Table 37). When the measurements of drawings pre- and post-
intervention were compared, four out of six participants produced smaller drawings of 
bones in the post-intervention assessment.  
Table 37. Drawings of bones with and without osteoporosis; measurements through their 























1 12.5 6.0 12.6 7.1 
2 - 4.9 - 5.0 
3 - - - - 
4 2.4 1.3 2.3 1.7 
5 2.3 1.6 2.0 1.6 
6 3.6 3.7 2.9 3.1 
7 7.3 12.3 5.1 12.2 
8 8.7 6.9 9.5 7.4 
Shape 
The majority of participants created drawings of stereotypical type bones (see the 
example shown in Table 36). Two participants drew cross-sections of bones pre- and 
post-intervention, with one additional participant drawing a cross-section post-
intervention.  
Bone deformity 
Two participants did not draw holes/pores on their drawings of bones without 
osteoporosis in the pre-intervention assessment. Post-intervention, one of these 




participants drew holes/pores on the normal bone. Participants used holes or shading 
to signify bone damage. Although it appears that some patients used shading to signify 
bone damage, others used shading to indicate that the bones were stronger.  
Drawings of people with and without osteoporosis 
Length 
Table 38. Drawings of people with and without osteoporosis; measurements through 























1 8.4 3.1 11.1 5.0 
2 - 5.7 - 5.6 
3 - - - - 
4 5.1 4.2/5.0* 4.9 2.8/3.5* 
5 1.1 1.1 1.1 1.4 
6 7.4 9.3 9.1 9.2 
7 3.0 17.8 4.4 17.8 
8 5.6 5.0/3.5* 5.2 3.6 
*Two figures are provided when the participant produced two drawings. 
Fifty per cent of the participants created drawings of people with and without 
osteoporosis smaller in their post-intervention assessment than in their pre-
intervention assessment. One participant did drawings of people with osteoporosis 
pre- and post-intervention which were almost identical and were the same size. 
Two participants drew faces on their post-intervention drawings of people without 
osteoporosis, whereas in the pre-intervention assessment they did not. One of these 
participants drew no faces on her pair of pre-intervention drawings and faded faces on 




her post-intervention drawings of people with and without osteoporosis. One 
participant drew her post-intervention pictures as male where as her pre-intervention 
pictures were female. 
9.6.4 Were there common trends between participants? 
There were common trends for the following beliefs: treatment control and necessity 
for medication. The data showed that perceived coherence increased for all 
participants during the intervention period. This increase was maintained for all but 
one participant at the post-intervention assessment. As can be seen in the graphs 
above for each participant, the scores for the majority of psychological factors 
fluctuated over the intervention period. It was common for emotional responses, 
medication efficacy and concerns about medication scores to fluctuate. There was one 
exception to this; participant 8’s scores stayed fairly constant across all the scales 
measured, apart from her medication adherence scores which increased. 
Perceived coherence increased for all participants, with the exception of participant 3, 
who, during the intervention period, received some information from her osteoporosis 
consultant that the medication was potentially unsafe for her use. Her perceived 
coherence increased after the information booklet and decreased by the final 
assessment. One participant reported more barriers post-intervention than she did at 
her pre-intervention assessment (participant 2). 
It is noteworthy that three participants’ self-efficacy decreased in the assessment after 
they received their information booklet (participants 1, 4 and 8), but increased for 3 
participants after the MI and plan-setting session. Susceptibility to fracture decreased 
for three participants between baseline and the end of the intervention (participants 1, 
5 and 6). 
Of the seven participants who showed an increase in adherence throughout the course 
of the intervention, six created a drawing of their condition before and after the 
intervention. Five of these participants showed either an increase or a decrease in size 
of their drawings of bones post-intervention. The participant whose adherence did not 




change during the intervention (participant 5) produced drawings of a very similar size 
in her pre- and post-intervention assessments. 
9.7 Discussion 
Key findings 
This theory-based adherence intervention aimed to reduce intentional and 
unintentional non-adherence to osteoporosis medication. Self-reported adherence 
increased for seven of the eight study participants during the course of the 
intervention. Four of the participants were not taking their prescribed medication at 
the outset of the study and three of this group initiated their medication during the 
intervention period. The other four patients were taking their SR prior to the 
intervention but with some difficulty, all of them increased their adherence 
throughout the intervention.  
These results are in contrast to those of a previous intervention. Guilera (2006) carried 
out an intervention using education, motivational interviewing and telephone follow-
up. The study participants showed no increase in adherence to medication. There are 
three key differences which might be responsible for the differences in the results 
observed. In the present study theory was used to select the educational materials, the 
educational materials were tailored to individuals needs and implementation 
intentions (plan-setting) was added to the components mentioned above. Given the 
strong links between self-efficacy and adherence observed in study 3, it is possible that 
the implementation-intentions element was an effective ingredient of the ATOM 
intervention. 
An important question for discussion is whether the observed changes in adherence 
can be attributed to changes in beliefs or other psychological constructs? Studies of a 
larger sample size are required to provide an answer to this. There is some support for 
changes in psychological constructs resulting in changes in adherence, because there 
were three constructs (perceived coherence, treatment control and a belief in the 
necessity of the medication) for which increases were observed in the majority of the 
study participants. Further, the fluctuation observed in participants’ scores for many of 




the psychological constructs measured provides some support for the extended self-
regulation model (SRM), where participants are continuously evaluating their 
condition, assimilating new information and updating their cognitive and emotional 
representations of their condition. 
It is possible that the increase in perceived coherence is a factor which led to increased 
adherence. This finding supports Leventhal’s SRM, that patients are more likely to 
select a problem-focused coping mechanism if they have a coherent 
understanding/model of their condition (Leventhal et al, 1984). Another mechanism 
which may have increased adherence was the increase in perceived need for 
medication, which was previously documented to be related to osteoporosis 
medication persistence (Schousboe et al, 2010). Perceived necessity increased for six 
of the eight patients, though in the final assessment for one of the patients it dropped 
back to the same low level it was at baseline. 
Treatment control ratings increased for all the study participants. This is another 
possible mechanism through which the intervention might be effective. There was not 
such a clear increase in the belief in medication to reduce the chance of fracture (RPQ 
medication self-efficacy scale), with many participants’ scores fluctuating throughout 
the intervention. This indicates that perhaps while it is possible for patients to 
understand that the medication can control osteoporosis, they find it very difficult to 
comprehend that medication has the specific role to reduce fracture risk. 
This N-of-1 trial was beneficial in determining who the intervention was appropriate 
and beneficial for. Only one of the study participants did not benefit from the 
intervention in terms of adherence. Another two participants did not have large 
increases in adherence, because their MARS scores were on the border line for non-
adherence. Both participants scored low on DOTMQ at baseline 1, reporting very few 
barriers to adherence. In future studies, both the MARS score and the total barriers 
scores could be used to identify patients who require an intervention to improve 
adherence. However, while they did not benefit in terms of large increases in 
adherence, there were other changes which are likely to help them to manage their 




condition better. For example, perceived coherence and treatment control increased 
for each of these participants. 
In terms of negative effects, there were a few potentially problematic effects noted in 
the results section. Self-efficacy decreased for some patients after they received their 
information booklet, but increased after the MI and plan-setting session. Perhaps this 
explains why education is not always effective in increasing adherence as would be 
hypothesised. The information booklet may have been difficult for the patients to 
assimilate if they had not been followed-up and assisted to make a medication plan if 
needed, rather than just leaving them with difficult information. However, a larger 
powered study is needed to investigate this further. Perceived susceptibility to fracture 
also reduced for some participants after the intervention. While this could be a 
negative effect, it could also be positive. Perhaps some patients felt less susceptible to 
a fracture post-intervention, given that they are taking steps to prevent fractures 
through increased adherence.   
Asking patients to do simple sketches of their condition pre-and post-intervention has 
provided some insight into how they perceive their condition. It is interesting that four 
out of six participants’ drawings were smaller in their post-intervention assessment 
than in their pre-intervention assessment. This finding is in agreement with the 
findings of previous researchers, that patients’ drawings become smaller after an 
intervention to manage a health problem (Broadbent et al, 2006a). Perhaps this 
indicates that the intervention helped patients to feel that they could cope effectively 
with their condition. 
A major question for discussion is, were the changes in osteoporosis patients’ beliefs 
and adherence the result of the Hawthorne effect? There are other factors which may 
have led to increases in patients’ adherence such as: the attention they received, the 
social interaction, an educational class, or a medical consultation attended by a 
participant? To monitor this contextual data was collected. As shown in the case study 
narratives, there were no reports of any significant events which might alter beliefs or 
medication-taking, e.g. major changes in medical condition or a fracture. With this 




small sample size, it is not possible to attribute the changes observed in patients to the 
intervention, as it is not possible to determine whether the changes were due to 
chance, or a factor other than the intervention. However, the evaluation data suggest 
that participants believe their adherence improved as a result of the intervention and 
no other factors (see following chapter).  
Limitations 
The time available for follow-up for the assessment of adherence and psychological 
factors was limited, with the final follow-up at 1 month post-intervention. This poses 
an important limitation, where is it unknown whether and for how long the increases 
in adherence were sustained. This raises the question of how long an intervention of 
this nature would be anticipated to increase adherence for.  Without a control group, 
the results are only valid for the patients in the study. Considering this, there could 
have been extraneous variables other than the intervention that had an effect on 
adherence or psychological factors.  
This intervention focused upon self-management of osteoporosis, particularly using 
medication. While information about diet and falls prevention was also included in this 
intervention, due to time limitations it was not possible to include the management of 
other medical conditions. Participants in study 2 and the present study discussed that 
managing multiple comorbidities with multiple medications was a problem for them. 
Therefore future, larger scale studies could benefit from taking this into account. 
The varying time lag between baseline one and baseline two assessment is 
problematic when comparing data between baseline one and baseline two. Some 
patients had their first baseline assessment two years before their second assessment. 
This problem resulted from the difficulties of recruiting patients for study 3, which 
meant that study 5 started much later than originally planned.  
9.8 Conclusions 
Adherence increased for the majority of osteoporosis patients who took part in the 
ATOM intervention. For patients who did not show large increases in medication 




adherence, there were other benefits to taking part, particularly an increase in their 
understanding of the condition and the need for medication. The evaluation of the 
outcome data suggests that changes in behaviour may have been brought about by the 
changes in perceptions observed throughout the study for many participants: 
 Increases in perceived coherence or understanding of the condition 
 Increased belief in the ability of treatment to control osteoporosis 
 Increased belief in the necessity of medication for the treatment of 
osteoporosis 
 




10 Study 6: Process evaluation of a complex 
behaviour change intervention to increase 
adherence to osteoporosis medication 
Chapter overview 
The major benefit of delivering an intervention using a case-series approach is the 
opportunity to carry out detailed evaluation of the intervention process with all of the 
study participants. This provides an opportunity to gather detailed information about 
patients’ subjective experiences of the intervention. Following the MRC’s framework 
for the design and evaluation of complex interventions, the evaluation data can be 
applied to the intervention in order to improve and refine it for future use in a 
randomised controlled trial. The aim was to understand patients’ perceptions of the 
intervention and to determine the mechanism of change. This chapter presents the 
results of the process evaluation of the ATOM Study and provides a theory for the 
mechanism of change in adherence observed in the study participants.   
10.1 Introduction 
While there are a multitude of published interventions to promote adherence, few 
have been evaluated in sufficient detail (Gleeson et al, 2009). In order to design more 
effective interventions, the MRC recommends the inclusion of a detailed evaluation, 
built into the intervention design (MRC, 2008) to identify the active/effective 
ingredients. There are two main issues which can be addressed in a process evaluation; 
why was the intervention (un) successful and how can it be optimised? (MRC, 2008). It 
is also important to gain an understanding of individual variation in response to 
different intervention components. 
There are few guidelines for process evaluations of interventions delivered to patients 
(Grant et al, 2003). There is a growing literature on the evaluation of complex 
interventions, with many previously published interventions focussing on the 
behaviour change of healthcare professionals, to promote evidence-based healthcare 
practice. For example Normalisation Process Theory (NPT) (May & Finch, 2009) can be 




used to evaluate the effectiveness of interventions delivered by Healthcare 
Professionals (HCPs).  
NPT focuses on 4 components of an intervention: 
‘NPT is concerned with identifying and understanding the ways that people make sense 
of the work of implementing and integrating a complex intervention (coherence); how 
they engage with it (cognitive participation); enact it (collective action); and appraise 
its effects (reflexive monitoring).’ (May & Finch, 2010). 
Leaving aside the issue of implementation, NPT can be used to guide evaluation which 
focuses on how patients experienced the intervention, including whether it made 
sense to them. In addition, Grant et al (2013) suggested that the maintenance of the 
target behaviour should be evaluated after the intervention is completed. For the 
present pilot trial, it was essential to determine what worked well and what did not, so 
that it can be developed and made useful for larger groups of patients. This process 
evaluation used an adaptation of NPT (May & Finch, 2010) and process evaluations for 
cluster randomised controlled trials (Grant et al, 2013) in order to evaluate the 
process, effectiveness and acceptability of the ATOM intervention.  
Research questions 
 What were the mechanisms of the changes observed in adherence and/or 
psychological factors? 
 What was each participant’s subjective experience of taking part in the 
adherence intervention research? 
 Were participants’ satisfied with the different components of the intervention? 
10.2 Method 
10.2.1 Research design 
The participants were the eight osteoporosis patients who received the ATOM 
intervention presented in study 5. Mixed methods were used, utilizing both Likert 
scales and in-depth qualitative interviewing. This chapter is the result of the process 
evaluation, using data collected at two points during the intervention. 




The reasons patients decided to participate in the intervention were explored, using 
the NPT (May & Finch, 2009). In addition, the effectiveness and maintenance of the 
intervention were explored using the framework for the design and reporting of 
complex intervention evaluations (Grant et al, 2013). The duration of the interviews 
was between 35 minutes and 1 hour 15 minutes. 
10.2.2 Measure 
In the first phase of the process evaluation patients were asked ‘what did you think of 
the information booklet you received in the post?’ In the second phase, interviews 
were carried out to explore patients’ perceptions of the purpose of the intervention. 
Based upon two components of NPT, the reasons for participation were explored, as 
well as their understanding of the objective of the intervention (May & Finch, 2009). 
NPT was originally designed to evaluate the delivery of interventions by healthcare 
professionals. Therefore some of the elements of NPT were not relevant for a process 
evaluation of an intervention from the perspective of research participants. The 
elements not relevant to study participants were collective action and reflexive 
monitoring. In addition, effectiveness and maintenance of the intervention were 
explored using the framework for the design and reporting of complex intervention 













Table 62. Participant 8. People drawings 























APPENDIX 26. The interview questions were adapted slightly for each participant, so 
that they were asked about the individual components of the intervention they 
received. For example, patients who received the decisional balance element of the 
intervention were questioned about it, but for those that did not receive decisional 
balance, the question was not appropriate and so was excluded from their interview. 
10.2.3 Procedure 
The first phase of the evaluation assessed the information booklet with an open ended 
question to enable participants to provide feedback. This took place one week after 
participants received the information booklet. Following this, the process evaluation of 
the entire intervention was carried out by an independent assessor at the end of the 
study. An independent assessor was necessary in order to reduce bias in patients’ 
responses, which may have been introduced if the evaluation was carried out by the 
author, given that the author designed the intervention. A semi-structured interview 
using both open-ended questions and Likert scales was used to collect data. Each 
phase of the intervention was evaluated close to the time it occurred to minimise bias 
and memory confounders.  
10.3 Analysis 
A research assistant conducted framework analysis for this process evaluation. The 
rationale for this was to enable the intervention to be analysed by an individual who 
was not involved in the intervention design, to reduce the risk of bias. Two transcripts 
were analysed for themes by both the author and the independent assessor, who then 
met to discuss the coding framework. Both researchers recorded the themes they had 
identified on post-it notes, so that themes could be easily moved to another category 
if required. Any disagreements were discussed until consensus was reached. The 
independent assessor analysed the remaining transcripts, which were then interpreted 
by the author. 
10.4  Results  
The results section presents firstly the evaluation of the information booklet, before 
progressing to the evaluation of the entire ATOM intervention. All eight study 




participants provided useful evaluations of the intervention. The themes that emerged 
from patients interviews are presented below. Three overarching or ‘global themes’ 
were used to categorise the data: pre-intervention thoughts and behaviours, post-
intervention changes and the intervention. The following sections present a summary 
of the data which can be used to answer each research question. Before the results of 
the thematic analysis, the evaluation of the information booklet is presented. 
10.4.1 Evaluation of the information booklet 
The vast majority of patients reported that they liked the information booklet and that 
they were able to learn new facts about osteoporosis. Patients’ comments about the 
booklet were divided into positive and negative responses and are shown in Table 39. 
Two participants however, felt neutral about the booklet, they neither rated it 
positively or negatively. These are participants 2 and 3 who have missing data below. 
The comments were not transcribed verbatim and are summaries of each patient’s 
comments. 
Table 39. Evaluation of tailored information booklet 
Participant 
number 
Positive comments Negative comments 
1 Useful, did not know that 
osteoporosis was asymptomatic 
before receiving the booklet. 
The image of osteoporosis was 
frightening but it was good to 
know that there were steps 
which could be taken to prevent 
further deterioration. She highly 
rated the diet section and 
reported that the size of the 
booklet was useful 
 
2 - - 
3 - - 
4 The image was useful. She 
found it useful to learn that a 
high alcohol intake was related 
Did not feel personalised enough. She 
felt that on her image it was not clear 
that there were holes in the bones. 






Positive comments Negative comments 
to increased risk of fracture. She 
liked the dietary information 
She did not like the terminology used 
in the dietary information, which she 
said was too Americanised. 
5 The booklet was helpful - 
6 This patient reported that the 
leaflet was helpful and she 
wished she had been given it at 
the time of diagnosis. She said 
she felt that patients could 
manage their condition better 
with more information. She 
found the food list helpful 
- 
7 She said it was useful to know 
that a fracture is also known as 
a broken bone 
- 
8 The leaflet was helpful and the 
best part was the benefits and 
barriers to taking SR 
The leaflet was too repetitive. The 
font was too small 
  
10.4.2 What were the perceived mechanisms of the changes observed in 
adherence and/or psychological factors? 
Participants were interviewed about the changes they experienced in their thoughts 
and behaviour as a result of the intervention. Ten themes relevant to this question are 
presented in Table 40 below and explored in the subsequent sections.  
Table 40. Study 6 thematic analysis  
Global themes Themes 
Pre-intervention thoughts and 
behaviours 
Adherence 
Barriers to adherence 
Knowledge and understanding 
Medication side effects 




Global themes Themes 
Post-intervention changes Changes in adherence/attitude towards 
adherence 




Changes in medication knowledge 
Changes in diet and exercise 
Post research barriers to adherence 
Pre-intervention thoughts and behaviours 
Participants discussed their adherence to SR prior to taking part in the intervention. 
Some participants reported little concern about missed doses. Participants also 
described barriers to taking SR prior to participating in the intervention, particularly 
their concerns about the medication and the difficulties experienced with fasting for 
four hours in order to take the medication as recommended.  
Participants discussed their knowledge/understanding of osteoporosis and medication 
prior to the intervention. One participant suggested that she was in denial about 
having osteoporosis when first diagnosed with it, another participant suggested she 
had little knowledge of SR prior to the study. Some participants discussed their 
concerns about medication side effects they held prior to the intervention, as well as 
their concerns about SR and other medications they had previously been prescribed 
for osteoporosis. 
Table 41 Pre-intervention thoughts and behaviours 
Themes Quotes 
1. Adherence 
“Yes I was much more haphazard about it 
(SR) before… I was less committed to 
taking it really, I was forgetting more 





often.” (participant 3) 
“I took it because I’d been told to take it 
but if I missed one or two I didn’t really 
think about it too much.” (participant 6) 
2. Barriers to adherence 
“Before I had all these concerns and on 
top of that I, it was like this is what you’re 
supposed to do; take it, so I was resisting 
that, so I had a level of resistance… So 
before the research, I was really 
concerned about taking the medicine.” 
(participant 7) 
“I said that the problem from my point of 
view and apparently I’m not alone, is this 
4 hour fast. I don’t have problems taking 
medication in any other way I mean I’m 
not somebody who is avert to medication 
or finds I can’t swallow tablets or 
anything it’s just that the 2 hours and 
then the medication then another 2 hours 
with my particular life style is really really 
difficult.” (participant 8) 
3. Knowledge and understanding 
“I suppose with osteoporosis at the 
beginning you think osteoporosis; that’s 
an old woman’s disease, but it isn’t, that’s 
the other thing I’ve learnt it isn’t.” 
(participant 1) 
 “I knew a reasonable amount but I also 
didn’t know a lot about the medication I 
was given or why or how to interpret any 
of the bone scan results… Yea I didn’t feel 
that I knew really what this medicine was 
going to do for me, I didn’t know how 
valuable it was.” (participant 6) 
4. Medication side effects 
“I had first of all been given tablets to 
take one a week which made me feel 





really sick.” (participant 1) 
“It’s just that the medication that I’m on I 
had sort of doubts about whether they 
might cause other problems taking it, you 
end up with strong bones and everything 
else collapses around you!” (participant 2) 
 
Post-intervention changes 
Many participants reported increases in their adherence and they provided some 
insight into what they believed was responsible for this change. Table 42 shows how 
participants varied in their perceptions of the mechanism of the changes they 
experienced during the intervention. Participants discussed issues of confidence, 
competence and fear reduction that were addressed in the intervention. Many 
participants reported increases in knowledge/understanding or perceptions of 
osteoporosis as a result of the intervention. Some participants reported no changes in 
their perceptions of osteoporosis or the medication. Post-intervention, some 
participants reported increases in knowledge about SR, particularly about the role of 
medication in reducing fracture risk. 
Some participants reported changes in health behaviours other than adherence as a 
result of the intervention. When participants were asked whether they felt the 
intervention would continue to be beneficial to them after it was complete, some 
participants reported potential barriers to their future medication adherence. 
Participants also discussed their future intentions to change other health related 
behaviours post-intervention. This shows it is likely that the intervention gave 
participants a sense that they can take action to prevent fractures. The participant who 
refused to take her prescribed SR reported that she would not rule out other 
treatments developed for osteoporosis in the future, with less strict dosing 
instructions.  




Table 42. Post intervention changes 
Themes Quotes 
1. Changes in adherence/attitude 
towards adherence “It made me realise how important it 
was, even though it doesn’t sound very 
much to remember to take it every day, 
but I’m much more… what’s the word… I 
make sure I take it every day rather than 
thinking I’ll do it tomorrow.” (participant 
1) 
“I feel more confident taking it now 
anyway, I haven’t got the doubts in my 
mind that I might have had before.” 
(participant 2) 
“I think engagement and active 
engagement and understanding of the 
condition is an incentive for taking the 
medication now…I’ve realised now that it 
is very important, much more important 
than I had given it credit for. I’m much 
more compliant.” (participant 6) 
“It’s only changed because of the 
research because you’ve allayed my 
fears; we’ve discussed all these fears and 
concerns.” (participant 7) 
“Sarah was very nice but persistent about 
how could we actually get me to take this 
retched stuff and because I felt 
committed to trying to be helpful I 
actually did get a regime going which I 
hadn’t managed previously.” (participant 
8) 
2. Future intention to change 
“My intention is to do a bit more exercise 
apart from my swimming.” (participant 
1) 
“My next plan of action is to be much 
more diligent about my diet as well.” 






“Well no only that you know I do, I have 
got in mind osteoporosis you know, that 
if anything came out that I would look at 
it again.” (participant 5) 
3. Changes in 
knowledge/understanding/ 
perceptions of osteoporosis 
“The medication I’ve been given, there is 
only a 5 year window in which I can take 
it and I didn’t know that and there’s a lot 
of information I didn’t know that I 
wouldn’t have gleaned without the 
research.” (participant 1) 
“Yes, in that it’s forced me to address my 
situation in a more committed way… I 
have to really face up to the fact that it is 
a problem whereas for a while I was just 
ignoring it really.” (participant 3) 
“I haven’t really ever been too worried 
about it, I don’t see that my bones are 
very weak or anything I know that it is 
only when you fall over that’s when it 
happens, I have fallen over several times 
and I’ve had no problems so I have been 
lucky in that respect but I don’t think it 
sort of changed my mind about it any 
way. I don’t feel more worried or less 
worried about it.” (participant 2) 
4. Changes in medication knowledge 
“I thought that it probably does some 
good to the bones but as I mentioned 
before I wasn’t sure what else it might do 
to you so that has really been sorted out 
through this research.” (participant 2) 
“It’s given me, well it’s given me lots and 
I was motivated because I didn’t really 
understand the benefits of taking 
strontium ranelate I could only see the 





handicap.” (participant 7) 
5. Changes in diet and exercise 
“I’ve done a lot more walking let’s say.” 
(participant 1) 
“It is yes, so that is a definite change I’ve 
made so eating more oysters regularly 
and tahini instead of butter.” (participant 
7) 
6. Post research barriers to adherence 
“Yea the other one is going to the doctors 
to get a prescription renewal, I must 
make sure that I do that in time as well.” 
(participant 1) 
“My GP is very concerned and doesn’t 
want me to take it but then what am I 
left with you see, I’m left in mid-air with 
no help for osteoporosis as such and the 
support needs to continue, it would have 
been good if Sarah’s study had continued 
a bit longer as its been left in mid-air at 
quite a crucial time.” (participant 3) 
“I will probably never get to taking it 7 
days in a row and also because my GP 
was quite chilled about the necessity to 
take it full time but did pass me back to 
say as I’m under a specialist to follow 
what they say rather than what she is 
saying because she is not a specialist.” 
(participant 8) 
 
10.4.3 What was each participant’s subjective experience of taking part in 
the intervention? 
Overall, the majority of participants reported that the intervention was a valuable 
experience for them. One participant felt that it had not helped her very much, 
although she could report some benefits for her participation. 





Participants were asked to describe what they believed the purpose of the research 
was. There were a range of interpretations, with the majority believing it was enable 
osteoporosis patients to self-manage their condition through better knowledge of both 
osteoporosis and SR. One participant identified the goal of the study as an 
investigation of compliance, whereas another participant believed the purpose of the 
research was to enable HCPs to have better knowledge of patients with osteoporosis. 
On the other hand, one participant was unsure of the study aim.  
Given that participants invested a substantial amount of time and effort over the four 
month intervention period, participants were asked to describe their reasons for 
taking part. Motivation for participation can be divided into altruistic and personal 
reasons, with the majority indicating altruistic reasons. Some participants agreed to 
take part in the hope that the intervention would be of benefit to them, others said 
they wished to take part because they were supporters of the NHS. One participant 
discussed a mix of altruism and a will to start taking her medication. Some participants 
took part because they found the research topic interesting. 
Participants were asked to describe the benefits and barriers of the intervention. The 
majority of participants reported a highly positive experience of being involved in the 
intervention. A commonly discussed benefit was the increase in understanding of the 
benefits of SR. Some participants reported that the research increased their awareness 
of the condition. Many participants commented on the benefits of having the 
opportunity to ask questions about their condition and medication. Some participants 
reported that they enjoyed the time and attention they received as a result of taking 
part in the research. However, one participant reported that she thought she had not 
benefited from the intervention. 
Although not a direct consequence of taking part, participant 3 had a negative 
experience during the intervention period. Immediately after her MI session she 
reported feeling very motivated to take her medication and could list various reasons 
for wanting to reinitiate her medication. However, when she proceeded to ask her 




osteoporosis consultant for her prescription, she was asked to wait for 2 weeks before 
reinitiating SR, pending information from the MHRA regarding drug safety. 
Participants reported the intervention was carried out over an adequate time period, 
because this allowed them sufficient time to absorb the relevant information. 
Participants valued the information booklet, particularly the list of foods containing 
calcium and magnesium. Participants were also pleased with ‘the benefits and barriers 
to SR’ section of the information booklet. Participants also reported that they found 
the images of osteoporosis included in their information booklets informative.  
Participants pointed out a small number of negative aspects of taking part. The most 
common negative aspect discussed was the repetition of assessment questions, as well 
as some criticism of the assessment questions. One of the participants was confused 
that there were questions asking about symptoms when she did not experience any. 
Table 43. Subjective experience of the intervention 
Themes Quotes 
Research interpretations 
“I think, first of all it made me more aware 
of what it is, osteoporosis is, secondly and 
how it can be treated and the importance 
of taking medication.” (participant 1) 
“It’s about strontium ranelate and the 
benefits of taking it to manage 
osteoporosis.” (participant 7) 
“The purpose of the research was to look 
at compliance with medication and that’s 
how I understood it.” (participant 6) 
“Well I imagine two areas, one would be 
definitely from the point of view of 
osteoporosis and how one can partly 
prevent it, because Sarah was trying that 
as well, preventative, but also as well how 
one can heal it or improve it in a sense as 
well and how the medical profession and 





the health professionals can get more 
knowledge really of the patients and of 
this illness so to speak.” (participant 3) 
Motivation for participation 
“Well it was if it was going to help gage 
how the doctors and nurses and the 
consultants and so on should handle 
individuals with this condition… If I can 
help for that to be done in a good way for 
individuals who have got the condition.” 
(participant 4) 
 “I wanted to see if I actually could get my 
head around taking it and doing that, 
secondly because I will back the NHS in 
doing research because I think that it is a 
good thing to do and it wasn’t too 
onerous, answering a few questions, I 
didn’t have to take medication.” 
(participant 8) 
 “Well I was quite happy to help; I also 
found it beneficial really as I had certain 
doubts in my mind about the medication 
which has been sorted out now really 
because of that.” (participant 2) 
“I also didn’t know a lot about the 
medication I was given or why or how to 
interpret any of the bone scan results so 
when this project came along I had a lot of 
questions.” (participant 6) 
 “Well I find all research…. I shouldn’t say 
all… I choose to take part in research that 
I would find interesting... I’m someone 
that enjoys taking part in research let’s 
say.” (participant 3) 
Benefits of research participation 
“I suppose the biggest thing was talking to 
Sarah about what the medication actually 
does to your body and how effective it can 





or can’t be.” (participant 1) 
“I think that being on the research has 
forced me to take a little bit more 
responsibility in a way and to become 
more aware about my condition.” 
(participant 3) 
“I was forced to think about what I was 
doing much more and I was able to ask an 
awful lot of questions of Sarah and she 
was very very good and went off and 
found the answers which really helped me 
and so I think this has really helped me 
engage in a way with the condition and 
with treatment of the condition.” 
(participant 6) 
“In a sense having the support from the 
study… it’s been like a mini counselling in 
sorts” (participant 3) 
“There’s a time factor that you spend with 
the consultant which was very brief and it 
is incredibly busy but to some extent this is 
the missing piece of the jigsaw in the 
whole process and I think that that has 
universal application across the whole 
NHS and I think it could be extended 
further.” (participant 6) 
“it was quite useful to me so from a selfish 
point of view it was useful, the other thing 
is again being the centre of attention the 
me, me, me bit, is quite nice when you’ve 
got research going on that you haven’t 
just been abandoned to some old bit of 
medication that you’ve actually got 
someone taking notice and that’s quite 
encouraging if you’re taking something 
that you have slight concerns 
about.”(participant 8) 





Negative aspects of research participation 
“Not a lot… I found it very boring and a 
bit… repetitive and I went along with it in 
the hope that it was going to be helpful. 
It’s been of very little value to me 
personally but the more important thing is 
the greater good”(participant 4) 
“I’ve been left with a lot of questions and 
some confusion, particularly from the 
medical profession...it’s also brought up 
an area of confusion as to whether this 
particular drug is actually going to help or 
not help!” (participant 3) 
Positive aspects of intervention materials “The booklet that Sarah did was very very 
useful indeed and it was very nice that it 
was handbag size so that you could put it 
in your handbag because you could just 
pop it in your handbag and take it out if 
you wanted to get some shopping you 
think; oh well this would be good for… you 
know” (participant 1) 
“It was the ‘benefits and barriers of your 
strontium ranelate’, that’s what I found 
was the most useful, it was at the back; 
the benefits of taking didle didle didle 
didley and then a whole list of things and 
then problems with taking it for 
osteoporosis, no immediate response, it 
can be difficult to fit it with medication, 
forgetting to take medication etc., etc., so 
there were very practical points.” 
(participant 8) 
Negative aspects of intervention materials 
“It does have an impact because you think 
you are going to shrink and bend over 
and… not have a very straight back… that 
sort of image.” (participant 2) 
“Oh yes the image is of bones with the 
holes in, you know, how it thins and you 





know how it can go to powder really sort 
of thing with osteoporosis yea… That was, 
you know, I knew that your bones went 
but I didn’t realise they could go really 
holey... Yea because that was good yea 
because it told you without frightening 
you and shows you what happens.” 
(participant 5) 
“It does have an impact because you think 
you are going to shrink and bend over 
and… not have a very straight back… that 
sort of image.” (participant 2) 
Recommendations for future adherence 
interventions “Well I do think that going through the 
questions, the same questions on a 
regular basis that I found really quite 
extraordinary.” (participant 7)  
There were some things where it said 
agree, disagree, unsure and there wasn’t 
a space to say… inappropriate… not 
relevant.” (participant 4) 
“But bits of the booklet were very 
repetitive and there were some things 
about the food which were quite 
American.” (participant 8) 
“The other thing is talking about 
symptoms of osteoporosis which I didn’t 
have any… but I suppose that other people 
do, you probably have to put that in 
anyway because it’s not just for me that 
questionnaire but I didn’t have any 
symptoms at all so I was like; ‘oh my god! 
Should I have some?’… Maybe the 
questions should say; if you do have 
symptoms the...” (participant 1) 




Recommendations for future adherence interventions 
Some participants gave some ideas for other types of adherence interventions which 
they thought might be beneficial for patients in the future. The suggestions were: a 
Frequently Asked Questions (FAQs) information sheet and also a patient support 
group. 
 “I mean I almost think that you need to get a full diagnosis and probably a Q and A 
sheet maybe several sheets when you receive the diagnosis and the prescription if you 
like so that you have all these answers I mean it’s not rocket science, how long has it 
been licensed? How long can I take this for?”(Participant 6) 
“I’m not very good at these Facebook groups, but an opportunity for people to share 
their experiences.” (Participant 8) 
10.4.4 Were participants satisfied with the intervention? 
Overall, it is clear from the interview data that the majority of participants were 
satisfied with their experience of the intervention. Four of the eight participants 
spontaneously contacted the author after the study was completed to say that their 
participation in the intervention had been valuable for them. Table 44 shows the result 
of the questions assessed using Likert scales. Participant 4 was unsatisfied with the 
research, largely because of the repetitive nature of the questionnaire data collection. 
Participant 3 was only moderately satisfied, which she attributed to her experience of 
being asked to wait before reinitiating her medication.  
Table 44. Participant satisfaction with the intervention 
Participant 1 
 
2 3 4 5 6 7 8 






Yes Yes Yes No Yes Yes Yes Yes 
*The scale was 1-5 with 5 indicating high satisfaction 





10.5.1 Summary of key findings  
The detailed process evaluation of the overall intervention indicates that it was 
effective and well accepted by the majority of this group of patients. Participants were 
able to provide their accounts of the potential mechanisms that resulted in increased 
adherence. The results of the framework analysis showed that the reported 
mechanisms of change varied between participants. When participants were asked 
directly about the mechanisms of any changes, the following were the most salient:  
 Monitoring 
 Increased understanding of the condition 
 Increased understanding of the importance/necessity or benefits of SR 
Other mechanisms patients discussed included acceptance of having osteoporosis and 
having their concerns about osteoporosis medication addressed. 
The intervention appears to have increased adherence through different mechanisms 
for each participant. This provides support for selecting a multi-faceted intervention. 
However, it should be noted that these are patient’s opinions of change which may not 
reflect the underlying mechanisms of behaviour change. Their responses are possibly 
subject to response bias and it is possible that participants were unable to account for 
the exact mechanisms of change. However, responses were in agreement with the 
outcome evaluation data from study 5, which demonstrated an increase in perceived 
coherence for all participants, as well as an increase in the perceived need for and the 
efficacy of osteoporosis medication. 
Consistent with an observation in the previously presented qualitative project (study 
2), patients had a large number of questions about their osteoporosis and the 
medication. It is evident from the process evaluation that patients highly valued the 
opportunity to ask questions (which were referred to a medical specialist if required). 
This educational component of the intervention provided patients with space to think 




about the questions they had about their condition. It also provided the opportunity to 
open up a channel of communication between doctor and patient. Patients who asked 
more questions engaged better with the intervention. One patient asked a very long 
list of questions about the condition and relevant medication and at the end of the 
study reported high satisfaction with the intervention and that it was a luxury to have 
had all her questions addressed. The finding that patients valued the opportunity to 
ask questions has implications for clinical practice. It appears patients need more time 
with healthcare professionals in order to ask questions.   
Many participants commented on the size of the information booklet, which was A5. 
They reported that the size enabled them to carry the booklet in their handbag and 
refer to it when they needed. The finding that participants valued this detail of the 
intervention was interesting, considering that the booklet size was the suggestion of 
one of the expert patients involved in the study design. This provides support for the 
value of including expert patients at the study design stage, which in turn can help to 
make the intervention more convenient and acceptable for patients. 
At the end of the study, patients were asked if anything else had happened during the 
intervention period which may have altered their medication-taking. All patients who 
increased their medication-taking attributed this change to the intervention. An 
important issue is whether the assessment acts as a kind of monitoring intervention, 
where a patient changes their behaviour because they know they will be questioned 
about adherence. It would be worthwhile to replicate this study with fewer points of 
assessment to remove the possible effect of monitoring. Removing the monthly 
assessments would also make the intervention less time consuming. 
Another important question is; could this research be delivered over a shorter time 
span, perhaps over the telephone? The evaluation data strongly suggested that 
patients were pleased with the amount of time devoted to this intervention and 
valued the amount of space between each element. Further, they reported that they 
believed they benefited from the face-to-face session. Although it could be more 




time/cost effective, it appears it would be unadvisable to remove these elements of 
the intervention. 
An important strength of this process evaluation was the employment of an 
independent assessor, who neither designed nor delivered the intervention. The 
independent assessor interviewed participants and analysed the data to control for 
bias at all stages of the project. This is of great importance, because it removed the 
potential bias which would be highly likely if the evaluation was carried out by the 
author, who may have had an emotional attachment to the intervention. The result of 
this was a well-balanced evaluation of the intervention. A further strength was that an 
effort was made to ensure that patients received the intervention as intended, which 
has been recommended as good research practice (Bellg et al, 2004). This was 
achieved by a follow-up phone call to check whether patients had understood the 
educational material they were sent and whether there were any questions. 
10.5.2 Suggested improvements for future adherence intervention design 
 Include an information sheet with FAQs about osteoporosis and relevant 
medication  
 Make the information booklet more tailored 
 Select patients based upon their total barriers score from the DOTMQ as well 
as MARS (discussed in previous chapter) 
To reduce the time spent researching answers to patients’ questions about their illness 
and medication, a participant suggested it might be beneficial to provide osteoporosis 
patients with a FAQs information sheet. This information sheet could perhaps be 
designed based on questions and answers generated from this study. However, this 
removes an element of tailoring from the ATOM study which may have been an 
effective ingredient.  
One participant reported that tailoring was not important. Another participant 
commented that the tailored information booklet did not feel tailored enough. For 
example, in the section about personal control, it was recommended to all patients to 




avoid smoking. One participant suggested removing this, or for people who have quit 
smoking, to commend them for this effort. Perhaps the way in which the information 
was tailored should have been more highly emphasized. It should be noted that 
perhaps the effects of tailoring the informational booklet were not highly visible to the 
participants, because they were not aware of the detailed method used to select 
information for each of their booklets or how their own booklets differed from those 
of other patients. 
10.5.3 Limitations 
It is possible that the results were affected by social desirability bias, in that patients 
knew the objective of the study was to improve adherence, so they demonstrated that 
they improved when in fact they did not. A possible example of this was evident from 
one participant’s dialogue who suggested at the beginning of the intervention: ‘I will 
be one of your success stories.’ 
A factor which could be regarded as both an advantage and disadvantage was that 
many participants reported that the author (who delivered the intervention) and the 
independent assessor (who assessed the intervention) were reliable and pleasant to 
work with. While this can be seen as a study strength in terms of researcher 
professionalism and patient satisfaction, there is an issue as to whether the 
effectiveness of the intervention could be attributed to the nature of the researchers 
to some extent. To control for this in future, it is recommended that participants are 
asked to record the warmth of the researchers, so that it can be ascertained whether 
this factor predicts the outcome under investigation (Bellg et al, 2004). This is 
particularly the case for interventions which are delivered by more than one 
researcher or health care professional. 
A challenge for process evaluations is to differentiate between the effects of the 
intervention (e.g. education or motivational intervention) and the research 
(assessments using questionnaires). However, it is not possible to separate the 
research from the intervention using the case study approach and indeed some 
participants discussed the monthly assessments as an element which 




encouraged/reminded them to take their medication; indicating that monitoring may 
in fact have become an effective ingredient of the intervention. It would be 
informative to test this intervention in an RCT which would have a control group who 
receive the assessments but not the intervention.  
The process evaluation interview schedule did not include a question to assess any 
unwanted effects of the intervention. It was hoped that any unwanted effects could be 
assessed from the evaluation of the outcome data from the study 5 assessments. 
Negative responses to visual images of osteoporosis were thoroughly explored in study 
4.   
10.6 Conclusions 
Overall, there is evidence to suggest that different elements of the intervention were 
effective for each participant. Mechanisms that increased adherence were suggested 
by patients to be:  
*increased understanding of the importance and benefits of SR for osteoporosis 
*increased perceived understanding of the condition 
*monitoring 
*addressing concerns about the medication 
The data also indicates that increased attention and the opportunity to ask questions 
about the condition and medication may have been key elements resulting in the 
increased adherence observed in study 5. While patients found the regular 
assessments tedious, they reported a very positive subjective experience of taking part 
in ATOM intervention, with the majority reporting high satisfaction. However, future 
work is needed to test whether the ATOM intervention (tailored education, 
motivational interviewing, plan setting and telephone follow-up) was effective when 
independent from the research (monthly assessments of psychological factors and 
adherence). 




11 General Discussion 
Chapter overview 
The overall objective of the research presented in this thesis was to develop and test a 
psychological intervention to improve adherence to osteoporosis medication. This final 
chapter will describe some of the theoretical and methodological contributions to the 
knowledge of patients’ adherence to osteoporosis medication. The MRC’s framework 
for the design and evaluation of complex interventions was used to guide a series of 
intervention development studies, to provide a theoretical underpinning for the ATOM 
intervention. The critical review enabled the identification of a strong evidence base 
concerning the link between psychological factors and adherence to osteoporosis 
medication. The subsequent intervention development studies enabled further insight 
into how patients view their condition and the reasons for low adherence in this 
population. As each study chapter included a detailed discussion of the findings, this 
chapter will draw together these findings and give a summary of the unique 
contributions of the present research.  
11.1 Summary of studies 
To assist readers to follow this general discussion, a summary of each study along with 
the study number is provided. 
Table 45. Summary of the intervention development studies presented in this thesis 
Study number Title of study Research design 





medication; a critical 
review 
Literature  review 
Study 2 How do osteoporosis 








Study number Title of study Research design 
medication? 
Study 3 The psychological 






Study 4 Osteoporosis patients’ 
ratings of five visual 




Study 5 A multifaceted 
intervention to 





series of case 
studies 
Study 6 Process evaluation of a 
complex behaviour 
change intervention to 






11.2 Contributions to knowledge about the psychology of 
osteoporosis medication adherence 
The critical review (study 1) provided some useful insights into previous research 
which investigated the relationship between psychological factors and adherence to 
osteoporosis medication. Knowledge, medication side effects and medication beliefs 
were the common focus of much previous research about the determinants of 
adherence. The review enabled the identification of gaps in the literature, with very 
few studies investigating osteoporosis patients’ illness perceptions and risk 
perceptions and no studies investigating whether individuals’ emotional responses to 
having osteoporosis influenced their medication adherence. Perhaps the most 
important finding was that with the exception of the necessity-concerns framework, 
studies did not utilize health psychology theories to guide the investigation of the 




relationship between psychological factors and adherence. This review indicates that it 
is well established that psychological factors are related to osteoporosis medication 
adherence, particularly knowledge, medication side effects and concerns about 
medication. The following studies provided insight into other psychological factors 
which are implicated in osteoporosis medication adherence, with motivation and self-
efficacy as the strongest predictors of the factors investigated. 
Studies 2, 3 and 5 demonstrated that osteoporosis patients have a wide range of 
illness and medication beliefs associated with their condition. These individual 
differences suggest that tailored interventions would be beneficial. A common reason 
patients gave for not taking their prescribed osteoporosis medication was that they did 
not fully understand its benefits (studies 2 and 6). While this supports the findings of 
previous research (Ringe et al, 2003), it goes further to suggest that patients 
specifically do not understand that the goal of medication for osteoporosis is to reduce 
the associated risk of fragility fracture (study 2).  
The ATOM intervention consisted of several novel dimensions, including the use of 
psychological theory to inform the intervention design, the tailoring of educational 
materials for individual patients and the use of a detailed process evaluation (studies 5 
and 6). In addition, the study investigated patients’ drawings of their condition as well 
as interpretations of their drawings. There were overlaps in the findings of the 
outcome and process evaluation of the intervention (studies 5 and 6). They both 
indicated similar possible mechanisms underlying the increases in adherence 
demonstrated in the ATOM intervention. Table 46 shows the mechanisms of behaviour 
change as indicated by each study. 
 
   




Table 46. Successful mechanisms for increasing adherence 
Psychological construct Outcome evaluation 
(study 5) 
Process evaluation 













Increased beliefs in the 















A key finding of the intervention process evaluation (study 6) was that patients valued 
the opportunity to explore the benefits of and barriers associated with strontium 
ranelate. It seems that acknowledging the barriers to adherence was helpful for 
patients, perhaps because this provided them with a well-balanced argument enabling 
them to make an informed decision about their medication. A likely mechanism of 
change (the increases in adherence observed in the intervention study) was partly due 
to the patients being better informed about the specific role of their medication in the 
reduction of fracture risk. 
It is important to note that while the above mentioned mechanisms applied to the 
majority of the group, the study 6 data indicates that different components of the 
intervention were effective for each individual. In the intervention process evaluation, 
one participant described that allaying her concerns about the medication was the key 
ingredient which enabled her to take her medication, though other participants did not 
mention this. Concerns were addressed via the question and answer element of the 




psycho-educational component of the intervention, in which many participants 
inquired about the safety of the treatment for long-term use. Some participants 
described the effects of monitoring and social support, while others did not. The 
tailored elements of the intervention are likely to be responsible for the intervention 
effectiveness. Details of how the educational materials were tailored are included in 
the methodological contributions section. 
11.3 Theoretical contributions 
The use of psychological theory provided a systematic method for designing and 
testing a behaviour change intervention to promote adherence. This is the first study 
to use a combination of the extended Self-Regulation Model (SRM) and the Extended 
Parallel Process Model (EPPM) to inform an adherence intervention for osteoporosis 
patients. The research included in this thesis provides support for using the 
Information, Motivation and Behavioural (IMB) skills model (Fisher & Fisher, 1992) to 
guide the selection of behaviour change techniques. Study 3 found that motivation and 
self-efficacy were significant predictors of adherence to osteoporosis medication. 
These findings are congruent with the IMB model. The resultant intervention appears 
to have been successful, though future work with a larger sample is required to 
ascertain whether the results observed were due to chance, or factors outside the 
actual intervention components. 
All six studies presented in this thesis provide support for Leventhal’s SRM (Leventhal 
et al, 1984). While it might be expected that this model was most appropriate for 
symptomatic conditions, the work presented in this thesis demonstrates the utility of 
the model for osteoporosis which, until the later stages, is largely an asymptomatic 
condition. There is clear support for the SRM in the ATOM intervention outcome data 
(study 5), where there were many fluctuations in psychological factors, indicating that 
these factors are dynamic in nature. Although perceived coherence was not a 
significant predictor of adherence in the univariate analysis (study 3), the results of the 
outcome and process evaluations indicate that when patients have a coherent model 
of their illness, they are more likely to take their prescribed medication. Further, 




perceived coherence increased for all of the study 5 patients, as did adherence for all 
but one. The extended SRM variables explained a small but significant amount of the 
variance in adherence to osteoporosis medication. 
Further, this thesis supports Witte’s EPPM (Witte, 1992). Some participants in study 6 
commented that the image of osteoporosis presented with efficacy information for 
how to reduce the risk of osteoporotic fracture was beneficial, helping them 
understand the severity and how to manage it. The EPPM variables explained a 
significant amount of the variance in adherence to osteoporosis medication. There was 
no increase in patients’ emotional responses to the condition during the intervention, 
this could be attributed to the use of the EPPM to guide the intervention design, in so 
far as providing both threat and treatment efficacy information. There is further 
support for the both the SRM and the EPPM in study 4. Osteoporosis patients’ ratings 
of depression and worry were significantly related to their adherence, perhaps 
indicating that a high emotional response leads to emotion focused coping/fear 
control rather than problem focused coping/danger control. 
However, there were some discrepancies in relation to findings of whether emotional 
response was related to adherence. The discrepancy was between the findings of 
studies 3 and 4, where in study 3 emotional response was not related to adherence, 
but in study 4 depression and worry had a small but significant association with 
adherence. Perhaps this discrepancy can be explained by the different methods of 
measuring emotional response. More research is needed with a larger sample size and 
a longitudinal focus to determine the strength and direction of the relationship 
between adherence and emotional responses to osteoporosis.  
Factors from both of the theories investigated predicted adherence to osteoporosis 
medication (study 3). While these theories have proved useful in the design of an 
intervention to promote adherence to osteoporosis medication, it should be noted 
that they did not provide a complete explanation of adherence behaviour. When these 
models were combined, they explained 35% of the variance in adherence behaviour. 
This indicates that there are gaps we still need to understand and this informs us that 




there are factors not included in the theories which should be included in adherence 
interventions. Other possible factors which may account for further variance in 
adherence include: HCP-patient communication, past behaviour, unconscious thought 
processes, social/cultural factors, social support and mood. 
A further theoretical contribution was the adaptation of Normalisation Process Theory 
(NPT) (May & Finch, 2009) to evaluate individual behaviour change. This model was 
useful because it enabled an exploration of the mechanism of change. Importantly, 
study 6 showed that the mechanism of change varied widely between participants. 
11.4 Methodological contributions 
There were many methodological contributions in the present research. Although this 
was not the first study to use the MRC’s framework (Campbell et al, 2000) to design an 
adherence intervention, it was the first use of this framework to design an intervention 
for patients prescribed with oral medication for osteoporosis. The studies included in 
this thesis provide good evidence for using the MRC’s framework, given that it resulted 
in an intervention which increased adherence for seven out of eight osteoporosis 
patients. It proved to be important to assess the psychological factors related to non-
adherence to medication, because when these factors were targeted in an 
intervention, the intervention had a positive effect on adherence. Similar results were 
found in another adherence intervention, which used the MRC’s framework to create 
an effective intervention to increase stroke patients’ medication adherence (O’ Carroll 
et al, 2013). The present research and the research carried out by O’Carroll et al (2010; 
2013) indicates that a project following the MRC’s framework for the design and 
evaluation of complex interventions enables the psychological constructs relevant to 
adherence to be identified and addressed.  
As far as the author is aware, this was the first study to use an N-of-1 case-series 
design to investigate low medication adherence in osteoporosis patients. The use of 
this approach was beneficial because it allowed the measurement of many 
psychological factors with participants at multiple time points, as well as an in-depth 
evaluation of the intervention with the entire study sample. Useful results were 




revealed by using this case study approach. However, some things are still not clear. It 
is still unknown why the intervention did not work for one of the patients. Although 
there is some evidence to suggest the ATOM intervention could be beneficial for roll 
out in the NHS, a much larger sample and study time period is required to assess the 
long-term effects. There is a strong indication that the ATOM intervention was 
effective in increasing adherence for seven out of eight participants which provides an 
evidence base for testing this intervention with a larger sample. 
A novel contribution from the present research was the design of a systematic method 
of assessing patients’ health informational needs and tailoring educational material. To 
diagnose patients’ information needs, they were assessed using questionnaires and 
their scores indicated the medical information they required or did not require. They 
did not require medical information for questionnaire items when their scores 
indicated understanding of a particular element of osteoporosis or strontium ranelate. 
This was the first study to use this type of methodology for tailoring information using 
the extended SRM and the EPPM. This method enabled the diagnosis of patients’ 
informational needs to guide the selection of educational information to meet these 
needs. There is evidence to suggest that this method was successful when considering 
the increases in adherence and perceived coherence observed in study 5. However, it 
is necessary to compare tailored and non-tailored educational materials for 
osteoporosis patients in a randomised controlled trial before concluding that tailored 
educational materials are beneficial. 
Two questionnaires were developed as part of the present research, the Difficulties Of 
Taking Osteoporosis Medication Questionnaire (DOTMQ) and the Osteoporosis Images 
Questionnaire (OIQ). The DOTMQ has proved to be a useful measure of participants’ 
barriers to taking their treatment. Interestingly, it was found the DOTMQ score was 
more indicative of patients with low adherence than the MARS score in study 5. 
Perhaps the barriers score provides a proxy measure of adherence. Another possibility 
is that the DOTMQ provides a better indicator of adherence because it is a more covert 
measurement. The OIQ enabled the capture of data regarding patients’ ratings of 




visual images of osteoporosis. This is a novel method of assessing patients’ responses 
to the condition. 
11.5 The contribution of drawings and images of osteoporosis 
Patients’ drawings of osteoporosis were used as a tool for gaining insight into patients’ 
perceptions of osteoporosis, as well as their response to the ATOM intervention. To 
the author’s knowledge, for the first time it was demonstrated that osteoporosis 
patient’s drawings of their condition can provide insight into how they view their 
condition (Besser et al, 2012). Patients’ narratives about their drawings appeared to 
reveal emotional responses to the condition which were masked during the interview 
conversation, though more research with a larger sample would be ideal to explore 
this further. However, these results suggest that the use of drawings provided access 
to some unconscious thoughts/emotional responses to the condition.  
Given that drawings seemed to access masked emotions, osteoporosis patient’s 
responses to images/pictures of osteoporosis were explored in further detail in study 
4. This was carried out to explore the potential of images of osteoporosis as adherence 
intervention materials, or whether they produced negative effects on patients. While 
there were mixed results, the majority of participants welcomed the opportunity to be 
presented with an image of their condition, which was expected in a condition which is 
asymptomatic and therefore invisible to the patient. The qualitative analysis of 
patients’ responses to images (study 4) suggested that many patients found the images 
informative and motivational, therefore it was decided it would be beneficial to 
include them in an adherence intervention. One of participants declined to complete 
the OIQ in study 4, reporting that she would find the images too pessimistic. Therefore 
this patient was not provided with an image in her tailored information booklet in 
study 5. This, together with the range of participants’ responses to each different 
image of osteoporosis provided evidence for selecting different images for each 
patient in the intervention study. The results of the intervention process evaluation 
(study 6) imply that images of osteoporosis may be effective in helping patients to 
understand the risks in osteoporosis and the overall study indicates that tailoring the 




choice of these images is important, though more work with a larger sample is 
required. 
As far as the author is aware, this was the first study to assess osteoporosis patients’ 
visual representations before and after an adherence intervention. In both studies 
which included drawing as a research method (studies 2 and 5), there were differences 
in the sizes of drawings made by participants in different groups or stages of the 
intervention. These size differences are interesting, particularly given that the size of 
drawings could be related to the salience of the problem to the patient (Broadbent et 
al, 2006a). Of particular interest was the finding of pre-and post-intervention size 
differences for participants whose adherence increased, but no size difference for the 
participant who showed no change in adherence behaviour. It seems that using 
drawing to explore patients’ response to osteoporosis accesses a different medium of 
expression.       
11.6 Patient and public involvement 
Following good research practice, patients and the public were involved in several 
stages of the research process, including the design of the research. Before beginning 
this project, a member of staff at the National Osteoporosis Society was contacted to 
find out whether the topic of adherence to osteoporosis medication was a priority for 
them. Two patients with osteoporosis were involved in the design of the overall PhD 
project idea, to check that this is something important and relevant to patients. The 
use of Patient and Public Involvement (PPI) in the present research is a strength that 
was confirmed in the evaluation of the intervention, where patients valued the 
elements suggested by the expert patients. The following table shows the activities 
expert patients and service users participated in for each study. 
Table 47. Patient and Public Involvement in research 
Study number PPI members Activities involved in 
2 Expert patients *Study design 
*Interview schedule 








*Pilot of drawing exercise 
*Pilot interview 
Service Users *Interview schedule 
design 
3 Expert patients *PIS 
4 Expert patients *Image Questionnaire 
design 
5 Expert patients *Study design 
*Information booklet 
design 
6 Service users *Information booklet 
design 
 
As well as involving patients and members of the public in the study design, the author 
presented this research at various conferences. A further method of public 
engagement was when the author presented the problem of adherence to medication 
at Speakers Corner in Hyde Park, London, as part of a public speaking course. This 
enabled the author to gain some insight into the views of the general public about the 
problem of low adherence to medication in chronic conditions. Some reflections of this 
are provided in the overall conclusions section. 
11.7 Limitations 
The limitations specific to each study were presented in the discussion section of each 
chapter. This section will provide some general limitations which are applicable to the 
majority of work presented in this thesis. The issue of using self-report measures of 




adherence should be addressed, because of the bias involved, particularly when 
collecting this data retrospectively. Self-report is likely to provide an overestimation of 
adherence. Both reports from doctors in clinical practice and comparisons of self-
reported data with Mean Possession Ratio (MPR) data confirm this (Ziller et al, 2011). 
The defence for using self-report measures is that there is no accurate or gold standard 
measure of adherence, however, self-report is the most practical. In an attempt to 
overcome presentational bias, three measures of self-report were used so that the 
data could be compared.  
Considering that men are known to seek-help less frequently than women in relation 
to health related issues (Weissman & Klerman, 1977), it is important that future 
research investigates adherence in males. The reason for excluding males from this 
study was the low number of male patients diagnosed with osteoporosis, which would 
have made recruitment to the study difficult. In view of the high number of factors 
being explored in this research, excluding men enabled a reduction in the number of 
study variables. It is possible that men and women have different common sense 
models of their illness, with different psychological factors explaining adherence. 
Other studies have investigated the way in which men with osteoporosis understand 
and make sense of their illness. Solimeo et al (2011) found that for men a particular 
barrier to adherence was concerns with the safety and efficacy of osteoporosis 
medication for men, because of their awareness that many clinical trials of 
osteoporosis medication were carried out with female osteoporosis patients, due to 
the low ratio of male to female osteoporosis sufferers.  
Another methodological problem is related to the drawing part of the intervention 
assessment. The participants who received the ATOM intervention (study 5) had 
already seen some images of osteoporosis for study 4 and their depictions of 
osteoporosis were likely to be influenced by these. A final important limitation was the 
use of a cross-sectional design in study 3, given that this design does not allow 
identification of the direction of causality. However, the cross-sectional design was 
suitable for the purpose it served in the intervention development.   




11.8  Overall conclusions 
The research presented in this thesis suggests that future interventions to improve 
osteoporosis medication adherence could benefit from using a refined version of the 
ATOM intervention. This method of designing an intervention appears to have been 
effective in changing psychological factors and increasing adherence, though more 
research is needed. Given that the intervention was effective and satisfactory to 
patients, the next step is to carry out a further trial of this intervention, to assess 
whether the changes observed were statistically significant and to investigate its utility 
in various settings. However, a much longer intervention follow-up period is required 
in order to determine whether the increase in adherence has an impact on fracture 
risk, as well as whether the changes in medication-taking behaviour are sustainable in 
the long-term.  
It was apparent that many patients required additional information and support in 
order to be able to self-manage their osteoporosis effectively. Overall, the research 
presented in this thesis provides an argument for the use of health psychology 
expertise in the design of behaviour change interventions in order to support patients 
with self-management of chronic medical conditions. The argument is justified by the 
many misconceptions patients had about their illness and medication (in studies 2 & 3, 
5 and 6), as well as the various questions they asked about their condition and 
medication (studies 2 and 5). More psychological and informational support is 
paramount to empower osteoporosis patients to effectively self-manage their 
condition. There is also a role for health psychologists in the provision of training for 
doctors, nurses, pharmacists and other key health professionals in relation to how to 
deliver adherence interventions. 
Much of the work presented in this thesis shows that managing a complex chronic 
condition such as osteoporosis can be very challenging.  On reflection, overall the 
interviews in study 2 indicate that osteoporosis is a condition of many confusing 
inconsistencies about self-management for its sufferers: on one hand, osteoporosis 
patients are asked to have a high calcium intake, on the other they are reminded to 
keep their cholesterol levels low by eliminating cheese and milk from their diet; they 




are required to obtain vitamin D from exposure to sunlight, but to avoid developing 
skin cancer; they are encouraged to engage in weight bearing exercise to strengthen 
their bones, yet prevent themselves from falls to avoid fractures. Hence, osteoporosis 
sufferers need to continuously weigh up the risks associated with osteoporosis against 
those of other medical conditions. These mismatches in health advice may play a part 
in explaining non-adherence in patients with osteoporosis. It seems that this is an 
important part of the story of why some osteoporosis patients may be non-adherent 
to medication or other lifestyle recommendations.  The qualitative studies (studies 2 
and 6) indicate that patients need much more information about their condition, 
particularly the risks involved. There is evidence that patients have feelings of denial 
about the condition and avoiding anything to do with osteoporosis, which was derived 
from both qualitative studies.  
It is important to note some problems which are related to the complexity of the 
adherence problem. Adherence to medication does not always lead to the desired 
improved health outcome. Some patients may do not respond to their medication 
even if they are adherent and some classes of medication can result in additional 
medical problems (e.g. the use of steroids for various medical conditions can lead to 
osteoporosis). Promoting adherence is only acceptable and of benefit when the 
prescription is correct. A significant event that occurred during the course of this 
doctoral research was that during the delivery of the ATOM intervention (study 5) it 
was announced that strontium ranelate was not a safe treatment choice for 
osteoporosis patients with coronary disease because it might increase the risk of 
myocardial infarction (MHRA, 2013). A participant involved in study 5 suffered with 
high blood pressure. She initiated strontium ranelate during the intervention, 
however, she and her health care professionals were unaware of the potential danger 
it was causing, because of her pre-existing cardiovascular condition. This shows how 
medication can be harmful to patients even though the harmful effect is not known at 
the time of prescription. There can be adverse effects on patients which are not yet 
realised.  




Although there is strong evidence to suggest that adherence to prescribed medication 
in general results in better health outcomes, a group of HCPs was found to have sub-
optimal medication adherence (Ley, 1988). This perhaps shows that knowledge of 
medication is not the only contributing factor to low adherence. Another 
interpretation of this low HCP adherence is a possible general level of scepticism about 
the effectiveness/safety of medication, which is apparent in previous and the present 
research (e.g. Horne 1997). There was evidence of distrust of pharmaceutical 
companies in the present research. One of the participants who took part in the 
adherence intervention described how she thought she had a healthy scepticism about 
medication and some participants from study 2 made similar comments. Further, there 
are recent examples of pharmaceutical companies making unjustified profits from the 
sale of medication (Bryant et al, 2013). When pharmaceutical companies are 
concerned with money and profit, it is not surprising that individuals will question 
whether these companies have their best interests at heart. Every effort should be 
made to ensure that patients are well informed about their healthcare choices and the 
research/evidence that lies behind these treatments.  
When the present research was presented at Speakers Corner, some members of the 
public argued that interventions to improve adherence could be seen as health 
fascism. It should be noted that the aim of adherence interventions is to give patients 
the chance for informed adherence (Horne et al, 2005). This is the opportunity to have 
a clear understanding so that the patient can make an informed decision in relation to 
how to manage their health. This is where motivational interviewing has its strength in 
adherence interventions, because it is focused on helping a patient to explore their 
own motivation for taking medication.  
The change in the terminology used to describe medication-taking is interesting. The 
term has shifted from “compliance” to “adherence”. Could changing the terminology 
used to describe medication-taking behaviour have an effect on adherence to 
treatment? The idea of a shared agreement between a doctor and their patient or 
shared decision making could leave the patient more open to deciding not to take their 
treatment, rather than if they were told that they need to take it. It could cause 




confusion for patients who are not aware of this shift in healthcare control. Further it 
is likely that the term “compliance” was never about doctors telling patients what to 
do against their will. The usefulness of this change in terminology might be questioned, 
particularly when the term “adherence” has not been adopted in clinical practice and 
adherence rates have not improved. In an attempt to address concerns around the 
terminology used to describe medication-taking, the term “concordance” was 
suggested to signify agreement between a HCP and a patient about therapeutic goals. 
This term has not been universally adopted and is often used in error as synonymous 
for adherence (Horne et al, 2005). A further reflection is that the term adherence is too 
strong, because although it was suggested as a replacement of the term compliance, it 
still implies that the healthcare professional is in control when in fact the patient is in 
control in terms of self-management. I would recommend that health care 
professionals and researchers replace the term again from adherence to medication-
taking, which implies no blame on either the patient or the healthcare professional. 
A final reflection is that although there is a multitude of research projects investigating 
the factors related to non-adherence in many medical conditions, there is relatively 
little happening at the front line of healthcare to promote adherence. The results of 
the intervention process evaluation (study 6) indicate that there is a need for better 
information for patients about their illness and medication. As well as information 
there is a need for better communication and delivery of information about health. 
This is a practical role that health psychologists could undertake with osteoporosis 
patients, as well as in a wide variety of other healthcare specialities. 
11.9 Future work 
Although there was an increase in adherence in the ATOM intervention study, the 
positive result should be taken with caution and there is a need for future work to 
determine whether the intervention is as successful with a larger sample. Before 
progressing to an RCT, the next step could be to conduct a study comparing the 
intervention group to a control group who receive usual care. Future developments of 
the intervention could test which behaviour change techniques are the most suitable 




to modify each psychological determinant of adherence (Michie et al, 2008), e.g. is 
psycho-education the best intervention to increase patients perceived need for 
medication? It would be beneficial to develop the intervention, including some of the 
suggestions of the participants in study 6. 
Although the present study indicates that tailored educational materials were a 
successful element of the ATOM intervention, more knowledge of the effectiveness of 
tailored materials is needed. To progress knowledge in this area, it would be beneficial 
to conduct an RCT to compare adherence in three groups: a group who receive 
tailored educational materials, a group who receive educational material which is not 
tailored and a control group who have assessments of adherence only. 
Further work is needed to ascertain whether the results of the drawing exercise, 
particularly the smaller size of bone drawings post-intervention in comparison to pre-
intervention, were statistically significant. To develop research of depictions of 
osteoporosis, it would be interesting to approach the drawing exercise differently. 
Rather than asking patients to draw how they visualise bones and people with and 
without osteoporosis, it would be interesting to ask them to simply draw how they 
visualise osteoporosis, in order to investigate what aspect of it they would draw. 
The present research provided patients with information about diet and exercise 
which was well accepted. The ATOM intervention could be adapted to promote 
adherence to diet and exercise recommendations. Before designing other types of 
non-pharmacological interventions, more knowledge is needed regarding non-
pharmacological treatments for osteoporosis, e.g. diet and exercise interventions and 
their effects on bone health. While there has been much research about the role of 
calcium in bone health, more research is needed to determine the effects of other 
minerals such as magnesium and potassium, as well as vitamins B, C and K (NOS, 
2013), which are expected to be important in maintenance of the skeletal system. 
Although it is known that magnesium is important for a multitude of health benefits, 
including strong bones, there is currently a lack of research as to whether it is as 
important to bone health as calcium and vitamin D supplementation. A recent study 




indicated that magnesium may be as important as calcium, if not more so for 
increasing bone mineral density in children (Abrams et al, 2013). 
Overall studies 5 and 6 indicate that the ATOM intervention is likely to be successful in 
increasing adherence. Prior to the implementation of this intervention on a large 
scale, the intervention will need to be tested against a control group. Importantly, the 
intervention should be fully powered and based at various sites. An important factor in 
the implementation of ATOM is to determine the optimal healthcare setting for the 
intervention delivery. To gain insight into which setting this intervention would be 
best placed within the NHS, it would be beneficial to test the feasibility of the 
intervention in a variety of healthcare settings, including primary care and pharmacy. 
The pharmacy may be a particularly important point of care, considering that this is 
the place where the patient receives their medication and may be thinking about how 
they will use it.  Further, it may be beneficial to develop the intervention for use with 
patients with other chronic conditions. 
To translate the intervention into practice, health psychologists could be involved in 
both the delivery of the intervention and in the training of other healthcare 
professionals (e.g. doctors, nurses and pharmacists) in how to deliver adherence 
interventions. In the future, in the author’s opinion, it would be beneficial if all 
healthcare settings were able to draw on health psychology expertise. Knowledge 
from health psychology could be used to promote self-management of chronic 
conditions and to improve service delivery. This would improve the quality of the 
healthcare service, based upon some of the comments from patients in study 6. As 
well as increasing patients’ satisfaction with the service, better self-management may 
also improve patients’ health outcomes. 
The logic of using the MRC’s framework for the design and evaluation of complex 
interventions is to build on each stage of intervention development, as the evidence of 
the interventions effectiveness increases. Therefore a recommendation for the next 
stage of the ATOM intervention development is a small trial with an intervention group 
and a control group, before progressing to an RCT. Based upon the present research, 




the recommendations for the future development of the ATOM intervention are 
provided below. 
Study features recommended for the next stage of intervention 
development 
 A control group consisting of patients who have usual care with assessments of 
adherence only 
 A comparison of tailored and non-tailored educational materials based upon 
the extended self-regulation model and the extended parallel process model 
 Assessment of emotional responses to osteoporosis and their relationship with 
adherence 
 Use the DOTMQ questionnaire to ascertain the number of barriers to 
adherence each patient experiences. Deliver the intervention to those who 
report a high number of barriers > 2 and a MARS score < 23  
 Rather than collecting and addressing patients questions about their condition 
or medication, a FAQ information sheet about osteoporosis and medication 
could be used to address patients concerns 
 Long-term follow-up to assess outcome variables: 3 months, 6 months and 1 
year post-intervention 
 Include both male and female osteoporosis patients 
 Test an adaptation of the ATOM intervention for improving adherence in other 
chronic and asymptomatic medical conditions 
 Test an adaptation of the ATOM intervention for promoting diet, exercise and 
falls prevention for osteoporosis patients 
 Test the ATOM intervention in a variety of healthcare settings, e.g. pharmacy 
and primary care 




11.10 Concluding remarks 
Osteoporosis is a prevalent and serious condition, with considerable risks if left 
untreated, particularly if patients fail to make the best use of their prescribed 
medication. The work presented in this thesis attempted to gain a better 
understanding of why many patients with osteoporosis do not adhere. It has also 
attempted to use this understanding as a basis for a novel intervention, to help 
patients make an informed decision about their medication, as well as to provide 
guidance for how to prevent unintentional non-adherence such as forgetting. It is 
hoped that this intervention development study can be progressed to the next stage of 
development in future research. 
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APPENDIX 1. Search Strategy (study 1) 
Osteoporosis (osteop*) 
and 
adherence (adheren* or non?adheren* or persist* or non?persist* or complia* or 
non?complian* or 'patient?compliance’ or 'non?fulfilment' or 'medication adherence’ 
or 'medication?use' or 'drug?use' or 'medication?taking' or ‘mean possession ratio’ or 
‘medication possession ratio’) 
and 
predictor (predictor* or factor* or determinant* or 'Illness?perception*' or 
‘illness?belief*’ or ‘illness?representation*’ or ‘illness?schemata’ or belief* or 
‘treatment?belief*’ or knowledge or medication?belief* or thought* or cognit* or 
understanding or ‘risk?perception*’ or motivation or ‘perceived?need’ or 
‘perceived?necessity’ or concern* or ‘self?efficacy’ or ‘health?belief*’ or ’causal 
attributions’ or attribution* or attitude* or expectation* or perception* or 
'psycho?social' or psychological or depression or personality or mood or anxiety) 
and 
medication (medic* or treatment or bisphosphonate or strontium?ranelate or 
alendronic acid, or bisphosphonic acid derivative or raloxifene or risedronic acid) 




APPENDIX 2. Checklist for study inclusion (study 1)15 
Question  Yes (2) No (1) Unsure (0) 
1 Study design 
evident and 
appropriate? 
    
2 Question / 
objective sufficiently 
described? 
    
3 Method of 
subject/comparison 





    
4 Subject (and 





    
5 Outcome and (if 
applicable) exposure 
measure(s) well 
defined and robust 
to measurement / 
misclassification 
bias? Means of 
assessment 
reported? 
    
6 Sample size 
appropriate? 
    
7 Analytic methods 
described/justified 
    
                                                     
15
 Kmet, L., Lee, R., & Cook, L. Standard Quality Assessment Criteria for Evaluating Primary 
Research Papers from a Variety of Fields. 2004. Alberta: Canada: Alberta Heritage Foundation 
for Medical Research. 




Question  Yes (2) No (1) Unsure (0) 
and appropriate? 
8 Some estimate of 
variance is reported 
for the main results? 
    
9 Results reported in 
sufficient detail? 
    
10 Conclusions 
supported by the 
results? 
    
 




APPENDIX 3. First page of favourable opinion letter from research ethics committee 
for Study 2 
 




APPENDIX 4. Paper published in peer reviewed medical journal (study 2) 
 
 




APPENDIX 5. Topic guide (study 2) 
Introduction 
This is a psychology student project.  This interview is in 2 parts. The first is about your 
thoughts and beliefs about your illness, the second is about medication. 
Doctors are becoming increasingly aware of the need to understand patients’ views 
and experiences of their illnesses and conditions.  Therefore this study aims to find out 
about your views and experiences of your osteoporosis and about how you see your 
bone problem. To do this, I would like to have a conversation with you, in which I will 
ask you some questions about your illness experience.  It is not a test! There are no 
right or wrong answers to the questions I will ask you, this study is being done in order 
to learn about your experience of your condition. It may sound like some the questions 
are repetitive. Everything you tell me will be completely confidential. Try and forget 
that the tape recorder is there is you can. 
Carry out demographic questionnaire 
Beliefs about illness Questions (Identity and Cause) 
In your own words, can you tell me about your bone problem? 
Prompts 
What is osteoporosis? 
What are the symptoms? 
Can you describe what you think is happening to your bones? – How does this affect 
you?  
What do you think causes osteoporosis in general?   Why do you think it happened to 
you? 
Have you ever suffered a fracture? 
What do you think caused your fracture? 
Is there anything else you can you tell me about your bone problem? 
Drawing Exercise 
Now that you have told me a bit about osteoporosis, I would like to move on to the 
drawing exercise. 
Could you draw a picture of 2 bones, 1 with osteoporosis 1 without? 




Could you draw (using stick people drawings for ease) a person with and person 
without osteoporosis? 
Risk Perceptions  
Do you think osteoporosis is a serious condition in general? 
Prompts  
How serious is your own osteoporosis? 
Do you think it is serious in comparison to other illnesses, such as cancer, or heart 
disease? 
In your opinion, what is the worst that could happen as a result of osteoporosis? 
Consequences (Perceived Severity) 
What are the consequences of the illness for you? 
Prompts 
How does your bone problem affect your daily life? 
What do you think will happen to you if your bone problem gets worse? 
What has your condition stopped your from doing? 
Risk Perceptions and Perceived Susceptibility 
What is your chance of having a fracture in the next year, compared to other 
men/women of your age? 
Prompt 
Is your chance greater or less compared to other men/women of your age? 
What are the chances of you having another fracture in your lifetime? 
What can you do to reduce your risk of future fracture? 
Do you think you will break a bone again? Why? Why not? 
Timeline and Cure 
How long do you expect to have this condition for? 
Prompt 
Will you have it for the rest of your life? 




Is there any cure for your condition? 
Controllability (Perceived preventability) 
Do you think you can stop your bone problem from getting worse? How? 
Prompts 
How much do you think your treatment can make a difference to your bone problem.   
Is there anything else you can do to prevent your condition from getting worse? 
Emotions and Coping 
Does your bone problem have an effect on your feelings/emotions? 
If the patient describes feelings ask, what do you do to cope with that? 
Can you tell me about when you were diagnosed with your bone problem? (Reserve 
Question) 
Health Behaviour Questions 
Now we are going to move on to talk about actions you take to take control of your 
bone problem (Reserve question). 
On a day to day basis, what do you do to manage your bone problem?  
Prompts 
Have you changed your diet? 
Have you altered your exercise uptake? 
Medication 
Do you do anything to prevent yourself from falling? 
Which of these measures do you take? Which do you not take? Why? 
Prompt 
What stops you from taking protective measures against your bone problem? 
Medication Questions (treatment) 
Now we are going to move on to talk about your treatment for your bone problem.  
While we have discussed it before, I am now particularly interested in finding out 
about problems patients have with sticking to medication regimens.  




What do you think about medication in general? Is it positive or negative? Do you 
have any concerns about taking medication in general. 
 What is the treatment for your bone problem?  Can you talk me through you 
medication regime (including how you remember to take it)? 
Prompts 
What were you told to do with the medication? Were you given any special 
instructions?  
Do you understand why you need to take this medication? 
What do you think the medication does? 
What are the difficulties with taking your specific osteoporosis medication? What are 
your concerns about taking it? 
Is the medication anything to do with fractures? 
Can the medication reduce your risk of fractures? 
Prompts 
Did you understand how to take your medication? E.g. on an empty stomach? 
Do you always take the medication as prescribed? 
Have you ever missed a dose of your medication? Why?  
Have you ever deliberately missed a dose? 
When you were given the prescription, did you feel able to follow it? 
What stops you from taking the medication as prescribed? 
Efficacy 
How much do you feel that the medication has helped your illness? 
Prompts 
Do you think that the medication will make your bone condition better? Why or why 
not? 
Do you think that medication can help to make your bones strong? 
Do you think you need to be on the medication that you were prescribed? 




Do you think that if you take your medication you will have less chance of breaking a 
bone? 
Are there any side effects from your medication? Do these affect whether you decide 
to take it. 
Motivation 
Is it important to you to take your medication as prescribed? Why? Why not? 
Other information 
We know that many patients have difficulties with taking their osteoporosis 
medication.  What do you think could be done by doctors to help other patients to 
take their medication? 
Is there anything else you would like to tell me about your experience of this bone 
problem before we finish the interview? Anything about the way you think or feel 
about this illness?  




APPENDIX 6. Reliability of the coding framework 
This document outlines the thematic framework used to describe the data from the 
study ‘How do osteoporosis patients perceive their illness and treatment? Implications 
for treatment adherence.’ The framework is divided into themes at 3 levels, global 
themes, themes and sub-themes. 
To check that my coding framework is accurate, please use this document to code the 
data from the transcript you have been given into the 11 global themes.  Please make 
note of any other themes that arise. 
Description of global themes 
1. Identity 
Any mention of symptoms, knowledge of condition, including osteoporosis is a disease 
in which bones become thin, weak, easy to break, decreased bone mineral density etc.    
e.g. “I know they say osteoporosis is painless, I can’t really believe that.” (participant 
14) 
2. Cause  
Ideas of what caused osteoporosis.  Also code if unsure about cause. 
Suggestions of the causes of fractures.  Also code if unsure about the cause of fracture. 
e.g. “I think anyone who would have fallen like that would have fractured. It was a hard 
fall. I am not able to see all that well so I think this is why I fell over.” (Participant 2) 
3. Timeline 
Discussion of how long the participant expects to have the illness for. Also include any 
mention of the timeline of the medication 
e.g. “You don’t get rid of it, do you?” (Participant 12) 
4. Controllability/Cure 
Any mention whether the illness is controllable/ uncontrollable, or they are unsure of 
whether it can be controlled.  Methods of control include: medication, diet, exercise, 
vitamin supplementation, falls/fracture prevention (e.g. being careful not to fall over). 
Also include any discussion about whether there is a cure for osteoporosis. 
e.g. “I’m always conscious that I must be careful, that’s the thing I live with.” 
(Participant 9) 




Then you, you never can stop falling over, accidents are going to happen aren’t they 
you know. (Participant 9) 
5 Consequences 
Physical consequences, impact of activity, or medication as the only consequence.  
Also include where participants have stated that it does not impact their daily lives. 
“It doesn’t really, apart from it does mean that I have to take pain medication every 
day. I can’t go through a day without pain medication, you know I’ve been on the 
whole range.” (Participant 3) 
6 Emotions 
Any mention words describing emotions or lack of emotions. 
e.g. “So if I fractured my spine, I could end up in a wheelchair couldn’t I? Which is my 
biggest fear” (Participant  4) 
7 Risk Perceptions 
Include mentions of severity of the condition 
Participants’ responses to the questions (1) What are your chances of having a fracture 
in the next year, compared to other men and women of your age. (2) What are your 
chances of having a fracture in your lifetime compared to other men and women of 
your age? 
e.g. “It’s the same, well I mean you never know who is going to be hit by a bus, this 
would cause anyone to fracture, so I’m not at more risk.” (Participant 1) 
8 Medication beliefs 
Discussion of whether medication in general is positive or negative. Discussion of 
concerns about medication in general and concerns about osteoporosis medication. 
“Doctors are enthusiastic to give medicines because that’s what they do.  I am keen to 
kind of make sure that it’s what I really need, so I’m kind of negative really” 
(Participant 13) 
9 Adherence 
Self-reported adherence to treatment.  Includes both intentional and unintentional 
reasons for non-adherence.  Any mention of alterations patients make to their 
medication prescription. 
“Let’s say I took it for 6 years, I might have missed it 3 times” (Participant 8) 
 





Doctor-patient relationship, social support and feedback 
11 Recommendations for future interventions 
Any ideas participants have given about what could improve adherence for patients 
who have difficulties with it. 
“I also think that showing patients pictures of bones could be useful in helping them to 
understand what is going on” (Participant 1) 
















































































































































































































APPENDIX 8. Participant drawings of people with and without osteoporosis 
Participant 
Number 




















































































APPENDIX 9. First page of favourable opinion letter from research ethics committee 








APPENDIX 10. Contextual data collection questionnaire (study 3) 
1.How many osteoporosis clinics do you run each week? 
2. How many patients are seen at each clinic (approximately)? 
  
3. How often are patients usually followed up? e.g. yearly 
  
4. How many times do you usually see patients before discharge? 
  
5. What is the allotted duration for each patient’s consultation? 
  
6. Do you currently offer any adherence to medication interventions to patients? e.g. written 
materials, education etc. 
  
7. Is there anything else you would like to note about your clinic which may be relevant to 
research investigating adherence to medication? 




APPENDIX 11. Demographic data collection sheet (study 3) 
Name  
Age  
Ethnicity e.g. British, Irish, Asian etc.  
Occupation or previous occupation  
Does anyone in your family have 
osteoporosis? 
 
Total Number of Fractures  
Number of years with Osteoporosis  
How many people do you live with?  
Are you are smoker?  
Are you on medication for 
osteoporosis?  
 
Name of osteoporosis medication  
 
 
Have you ever had a bone scan?  
Telephone Number  
 
Please read below and tick as appropriate: 
 I consent to the processing of my personal information for the purposes of 
this research study.  I understand that such information will be treated as 
strictly confidential and handled in accordance with the provisions of the data 
protection act 1998. 
 I agree to be invited for a future study (there is no obligation to take part 
in future studies) 
 I would like to receive a report of the findings from this study (and for my 
contact details to be stored for this 
 










Please list all other medical 
conditions you have (if any) 










































APPENDIX 12. Illness Perceptions Questionnaire Revised (IPQ-R) adapted for 
osteoporosis (study 3):   
Your osteoporosis 
We are interested in your views about your osteoporosis 
These are statements other people have made about their 
osteoporosis 
Please show how much you agree or disagree with each of the 
following statements by ticking one of the boxes 
 




Disagree Unsure Agree Strongly 
agree 
1) Having this osteoporosis 
makes me feel anxious 
 
     
2) I expect to have this 
osteoporosis for the rest of my 
life 
     
3) I get depressed when I think 
about my osteoporosis   
 
     
4) I go through cycles in which 
my osteoporosis gets better 
and worse 
     
5) My osteoporosis causes 
difficulties to those who are 
close to me 
     
6) My osteoporosis  has serious 
financial consequences for me 
 
     
7) I have the power to 
influence my osteoporosis 
 
     
8) My osteoporosis is a serious 
condition 
 
     
9) The course of my 
osteoporosis depends on me 
 
 
    








Disagree Unsure Agree Strongly 
agree 
10) My osteoporosis is likely to 
be permanent rather than 
temporary 
     
11) My osteoporosis is very 
unpredictable 
 
     
12) My osteoporosis makes me 
feel afraid 
 
     
13) My osteoporosis makes me 
feel angry 
 
     
14) My osteoporosis strongly 
affects the way others see me 
 
     
15) My osteoporosis will 
improve in time 
 
     
16) My osteoporosis has major 
consequences on my life 
 
     
17) What I do can determine 
whether my osteoporosis gets 
better or worse 
     
18) My osteoporosis will last 
for a long time 
 
     
19) My treatment can control 
my osteoporosis 
 
     
20) My treatment will be 
effective in curing my 
osteoporosis 
     
21) When I think about my 






    








Disagree Unsure Agree Strongly 
agree 
22) I have a clear picture or 
understanding of my 
osteoporosis 
     
23) The negative effects of my 
osteoporosis can be prevented 
(avoided) by my treatment 
 
 
    
24) My osteoporosis does not 
worry me 
 
     
25) The symptoms of my 
osteoporosis change a great 
deal from day to day 
     
26) My osteoporosis doesn’t 
make any sense to me 
 
     
27) I don’t understand my 
osteoporosis 
 
     
28) My osteoporosis is a 
mystery to me 
 
     
29) The symptoms of 
osteoporosis are puzzling to 
me 
     
30) There is nothing which can 
help my osteoporosis 
     
31)  There is very little that can 
be done to cure my 
osteoporosis 
     
32) Nothing I do will affect my 
osteoporosis 
 
     
33) My actions will have no 
effect on the outcome of my 
osteoporosis 
     
34) My osteoporosis does not 
have much effect on my life 
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Your views about symptoms you have experienced 
We would like to ask you about any symptoms you may have experienced since finding out about your osteoporosis. 
Some people do experience symptoms related to osteoporosis whilst others don’t 
Similarly, some people experience symptoms that are related to their medication and others don’t 
 
In the table below is a list of common symptoms 
Please show whether you have experienced each of the following symptoms recently by circling Yes or No 
For each symptom that you have experienced recently, please then show whether you believe it is related to your 
OSTEOPOROSIS or to the MEDICINE you take for you osteoporosis 
If you don’t know whether the symptom is related to your osteoporosis, or the medication you take for your 
osteoporosis, please circle don’t know. 
 




If answer is yes 
 
This symptom is related 
to my osteoporosis 
This symptom is related 
to the medicine I take 
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Symptom I have 
experienced this 
symptom recently 
If answer is yes 
 
This symptom is related to 
my osteoporosis 
This symptom is 
related to the 




























Yes No  
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If answer is yes 
 
This symptom is related to 
my osteoporosis 
This symptom is 
related to the 


























































































































































































Please turn to next Page






Your views about symptoms you may have experienced 
(continued) 
 
If you have experienced any other symptoms recently (not mentioned in 
the table above) that you believe may have been related to your 
osteoporosis, please write them in the table below 
 
Please show whether you believe they are related to your osteoporosis or 
to the medicine you take for your osteoporosis by circling yes, no or don’t 
know. 
 




This symptom is 
related to my 
osteoporosis 
This symptom is 
related to the 
















































































If you have experienced symptoms that you think are related to your 
osteoporosis, please answer the following questions.  If not, please go on 
to the next page 
We are interested in your views about your symptoms related to your 
osteoporosis 
These are statements other people have made about their symptoms 









Disagree Don’t know Agree Strongly 
agree 
55) There is a lot I 
can do to control my 
symptoms 
     
56) My symptoms 
come and go in 
cycles 
     
57) The symptoms of 
my osteoporosis 
change a great deal 
from day to day 




















Your views about causes of osteoporosis 
 
We are interested in your own views about what caused your 
osteoporosis 
 
Below is a list of possible causes 
Please show how much you agree and disagree that they were 
causes FOR YOU by ticking one of the boxes for each possible 
cause 
As people are very different, there are no correct answers for 
these questions 
 
Your views on 











58) Stress or 
Worry 
     
59) Heredity – it 
runs in my family 
     
60) A germ or virus 
 
     
61) Diet or eating 
habits 
     
62) Chance or bad 
luck 
 
     
63) Poor medical 
care in my past 
     





     






Your views on 




Disagree Unsure Agree Strongly 
agree 
65) My own 
behaviour 
     
66) My mental 
attitude e.g. 
thinking about life 
negatively 








     
69) My emotional 
state e.g. feeling 
down, lonely, 
anxious, empty 












     
73) Accident or 
injury 
 
     
74) My personality 
 
 
     
75) Poor immune  
System 
     






In the table below, please list the three most important factors that you 
believe caused YOUR osteoporosis 
 
You may use any of the items from the box above, or you may have 
additional ideas of your own. 
If you can’t think of three things that caused your osteoporosis, just write 
one or two. 
 The most important causes of my osteoporosis 
Cause 1  
Cause 2  
Cause 3  
 
 
End of questionnaire 
 






APPENDIX 13. The beliefs about medication questionnaire, adapted for osteoporosis 
(study 3) 
YOUR VIEWS ABOUT 
YOUR OSTEOPOROSIS MEDICINE 
 
 
We would like to ask you about your personal views about medicines 
prescribed for you 
These are statements other people have made about their medicines 
Please show how much you agree or disagree with them by ticking the 
appropriate box. 
End of questionnaire 
 
Views about your osteoporosis medicine Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
BS1 
My health at present depends on my osteoporosis 
medicine 
 
     
BS2 
Having to take my osteoporosis medicine worries 
me 
 
     
BS3 
My life would be impossible without my 
osteoporosis medicine 
     
BS5 
I sometimes worry about long-term effects of my 
osteoporosis medicine 
     
BS4 
Without my osteoporosis medicine I would be very 
ill 
 
     
BS6 
My osteoporosis medicine is a mystery to me 
 
     
BS7 
My health in the future will depend on my 
osteoporosis medicine 
     
BS8 
My osteoporosis medicine disrupts my life 
 
     
BS9 
I sometimes worry about becoming too dependent 
on my osteoporosis medicine 
     
BS10 
My osteoporosis medicine protects me from 
becoming worse 
 
     






APPENDIX 14. The Medication Adherence Report Scale (MARS) (studies 3 and 5) 
QUESTIONS ABOUT USING YOUR OSTEOPOROSIS MEDICINES 
 
 
Many people find a way of using their medicines which suits them. 
This may differ from the instructions on the label or from what their 
doctor has said. 
We would like to ask you 6 questions about how you use your medicines 
 
Here are some ways in which people have said that they use their 
medicines 
 





 Always  Often  Sometimes  Rarely  Never  
MARS1 
I forget to take my medicines      
MARS2
1 I alter the dose of my medicines      
MARS3 
I stop taking my medicines for a while      
MARS4 
I decide to miss out a dose      
MARS5 





During the last month, how many doses of 
your osteoporosis medication have you 
missed? 
 






APPENDIX 15. The Risk Perceptions Questionnaire (RPQ) (studies 3 and 5) 
 
The Risk Perceptions Questionnaire 
 
This questionnaire will ask you about how serious a condition you think osteoporosis is.  There 
are no right or wrong answers, we are interested in your opinion. 
 
Please circle either strongly disagree, disagree, neutral, agree or strongly agree for each 

















































2 3 4 5 
 































































































2 3 4 5 
 
 









2 3 4 5 
 
 
















End of Questionnaire 






APPENDIX 16. Difficulties Of Taking Osteoporosis Medication Questionnaire 
(DOTMQ) (studies 3 and 5) 
Difficulties with taking osteoporosis medication questionnaire 
 



















 YES NO  YES NO 
 
Interferes with daily 
activities 
  Don’t like taking 
medication every week 
  
Hard to swallow 
pills/liquid 
  Don’t understand how to 
take them 
  
Do not like the taste 
 
  Don’t want to take them   
Forget 
 
  Was not at home   
Not feeling well 
 
  Don’t like the side 
effects 
  
Not necessary  
 
 Ran out of medication   
Decided not to 
 
  Can’t afford   






APPENDIX 17. Scoring the Illness Perceptions Questionnaire Revised – for 
osteoporosis (3) 
Identity – total the number of yes for each participant 
Timeline (acute/chronic) -Items: 2,10,15,18 
Consequences – Items:  5, 6, 8, 14,16,34 
Personal Control – Items: 7,9, 17,32,33,55 
Treatment control –Items: 19,20,23, 30, 31 
Illness coherence – items: 22,26,27,28,29  
Timeline (Cyclical) – items: 25,(57), 4, 11,56 
Emotional representations  - items: 1, 3, 12,13, 21, 24,   
Reverse score:  IPQ15, IPQ24, IPQ26, IPQ27, IPQ28, IPQ29, IPQ30, IPQ31, IPQ32, IPQ33 
and IPQ34. 
Scoring the beliefs about medication questionnaire 
Necessity – items: 1,3,5,7,10 
Concerns – items: 2,4,6,8,9 
Reverse score: All 
Scoring the risk perceptions questionnaire 
Severity – items: 1,2 
Susceptibility – items: 3,4 
Response-efficacy – items: 5,6 
Self-efficacy – items: 7,8 
Emotions – items: 9,10,11 
Motivation – item 12 
Reverse Score: None 






APPENDIX 18. Distribution of extended SRM scores (study 3) 
 
Figure 41. Distribution of IPQ timeline scores 




















Figure 43. Distribution of IPQ personal control scores 








Figure 44. Distribution of IPQ treatment control scores 
 







Figure 45. Distribution of IPQ cyclical timeline scores 
 
 







Figure 46. Distribution of IPQ emotions scores 
 
 



















Figure 48. Distribution of BMQ necessity scores 
 







Figure 49. Distribution of BMQ concerns scores 






APPENDIX 19. Distribution of RPQ scores (study 3) 
 
Figure 50. Distribution of RPQ susceptibility scores 
 
 







Figure 51. Distribution of RPQ medication efficacy scores 
 


















Figure 53. Distribution of RPQ emotion scores 





APPENDIX 20. All study scale correlations (study 3) 
Scales 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
2 .414**
3 .684** .215
4 .386** .319** .247*
5 .152 .118 .015 .443**
6 .289** .340** .179 .660** .370**
7 -.036 .024 -.105 -.049 -.088 -.108
8 .408** .447** .116 .394** .156 .443** .129
9 -.109 -.161 .034 -.217* .133 -.353** -.198* -.187*
10 -.131 -.164 -.025 -.184 -.066 -.230* -.485** -.296** .565**
11 -.204 -.254** -.150 -.176 .081 -.270** .188 -.172 .376** .312**
12 .317** .373** .037 .313** .037 .501** -.038 .508** -.106 -.021 -.277**
13 .350** .459** .233* .474** .264** .359** .084 .755** -.106 -.234* -.187 .413**
14 .223* .292** .288* .418** .370** .322** .033 .363** -.128 -.121 -.226* .258** .562**
15 .074 .041 -.039 .096 .127 .029 .049 .317** .116 .104 .160 .111 .282** .118
16 .215* .102 -.065 .019 .182 -.013 .240* .375** -.034 -.085 .166 .079 .339** .014 .367**
17 -.010 -.138 .133 -.089 -.098 -.107 -.230* -.088 .339** .532** .162 .035 -.110 -.131 .211** -.185
18 -.090 -.084 -.281* -.119 -.208 -.114 .173 .036 -.077 -.156 -.020 -.087 -.064 -.386** -.018 -.045 -.144
19 .252* .320** .097 .407** .254** .284** .161 .547** -.148 -.196* -.157 .282** .787** .496** .302** .445** -.027 -.093
20 -.146 -.233* -.132 -.185 -.003 -.188 .189 -.178 -.040 .127 .222* -.161 -.194* -.314** .172 .298** .056 .228* -.005   
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APPENDIX 21. Osteoporosis Images Questionnaire (OIQ) (study 4) 
After looking at each picture, please tick in the table below how the 
picture makes you feel, e.g. tick strongly agree if it makes you feel fear and 
tick strongly disagree if it does not make you feel fear.  There are 5 
pictures to rate.  There are 9 questions which are the same for each image 









When I look at this picture I feel.... 
 
 





Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 
               
 
 
Confident that medication will improve osteoporosis 
 
 
Strongly Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 
               
 
 
If you have any other comments about how image 1 makes you feel please write in 
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Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
               
 




Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 
               
 
 




Disagree Neutral Agree Strongly agree 
               
 
 
If you have any other comments about how image 2 makes you feel please write in 
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Your bone can look more like normal bone if you take your medication for 
osteoporosis 
 
When I look at this picture I feel.... 
 
 





Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
               
 
 




Disagree Neutral Agree Strongly agree 
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If you have any other comments about how image 3 makes you feel please write in 













If you take your medication you can stop your osteoporosis from getting worse 
 
 
When I look at this picture I feel.... 
 
 





Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 
               
 
 
If you have any other comments about how image 4 makes you feel please write in 












Your bone can look more like normal bone if you take your medication for 
osteoporosis 
 
When I look at this picture I feel.... 
 
Frightened about osteoporosis 
 
 
Normal Bone Osteoporotic Bone 
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Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 








Disagree Neutral Agree Strongly agree 









Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
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Disagree Neutral Agree Strongly agree 
               
 
 





Disagree Neutral Agree Strongly agree 
               
 
 




Disagree Neutral Agree Strongly agree 
               
 
 
If you have any other comments about how image 5 makes you feel please write in 








End of Questionnaire 
This is the final questionnaire, thank you very much for taking the time to take part 
in this study 
 
Please now return the questionnaires in the stamped addressed envelope provided 
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APPENDIX 22. Scoring the image questionnaire (study 4) 
For each image 
Positive influence: 2,4,6,8 
Negative influence: 1,3,5,7,9 
Reverse Score: None 
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APPENDIX 23. Distributions of image rating scales (study 4)16 
 
Figure 54. Distribution of frightened rating scores 
                                                     
16
 A high score indicates a high level of response. For example a score of five signifies strong agreement 
that the image was frightening. 
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Figure 55. Distribution of informed image rating scores 
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Figure 56. Distribution of angry rating scores 
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Figure 57. Distribution of motivated rating scores 
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Figure 58. Distribution of depressed rating scores 
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Figure 59. Distribution of confidence rating scores 
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Figure 60. Distribution of worried rating scores 
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Figure 61. Distribution of confidence that medication can help rating scores 
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Figure 62. Distribution of helpless rating scores 
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APPENDIX 24. First page of favourable opinion letter from research ethics committee 
for Study 5 
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APPENDIX 25. Participant drawings of bone pre- and post- intervention (Study 5) 
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 Pre-intervention  Post-intervention 
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17
 Participant 2 reported that she did not know what to draw at baseline. 
 Pre-intervention  Post-intervention 
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18
 Participant 2 reported that she did not know what to draw at baseline. 
 Pre-intervention  Post-intervention 
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Table 53. Participant 4. Bone drawings 
Table 54. Participant 4. People drawings 










 Pre-intervention  Post-intervention 







a) Front view 
 
b) Side view 
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Table 55. Participant 5. Bone drawings 




a) Front view 
 
b) Side view 
 
 
 Pre-intervention  Post-intervention 
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Table 56. Participant 5. People drawings 
 
Table 57. Participant 6. Bone drawings 
 Pre-intervention  Post-intervention 










 Pre-intervention  Post-intervention 
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 Pre-intervention  Post-intervention 
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 Pre-intervention  Post-intervention 
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 Pre-intervention  Post-intervention 
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Table 62. Participant 8. People drawings 
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APPENDIX 26. Evaluation topic guide (Study 6) 
Opening: 
My aim here is to get a sense of your experience of being involved in the research for 
the last 4 months. The reason for doing this is that if the project was beneficial, it could 
be used with more people. If it was not beneficial, we would like to improve it. 
Please note that this call is audio recorded and everything you say here is confidential. 
There are no right or wrong answers here, I am interested in your experience. If you 
would you would like me to rephrase any of the questions please ask. 
This is about the work you did with Sarah, which we will call the research. 
1. Evaluation of process 
What did you think of THE RESEARCH? (Acceptability) 
What was your interpretation of the purpose of THE RESEARCH? (Coherence) 
Why did you agree to take part? (Cognitive participation) 
Was it clear what you were required to do throughout THE RESEARCH? (Coherence) 
2. Evaluation of thoughts and behaviour 
Do you think you have changed as a result of THE RESEARCH? (Effectiveness) 
Did THE RESEARCH change how you think about your osteoporosis? (Effectiveness) 
Did THE RESEARCH change how you take your osteoporosis medication in any way? 
(Effectiveness) 
Did THE RESEARCH change your decision about how or whether you take medication in 
any way? (Effectiveness) 
Did THE RESEARCH change how you think about osteoporosis medication? 
(Effectiveness) 
Which element of THE RESEARCH do you think helped you to change? (Mechanism of 
effectiveness) only for patients who report that they have changed. 
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Apart from your medication-taking, did anything else change in your opinion? 
(Effectiveness) 
How important is to you to take your osteoporosis medication on a scale of 0-10? 
With 0 being the least important and 10 being the most important. 
(Effectiveness) 
3. Evaluation of specific intervention components 
You were posted an educational booklet. What did you think of the personalised 
information booklet you were sent? (individual components) 
You received a telephone call from Sarah to check if you had any questions about the 
information in the educational booklet. She said she could refer any questions she 
could not answer to Dr FitzClarence. How did you find that? 
What did you think of the hospital session you had with Sarah at UCH? (Individual 
components) 
During the hospital appointment, you completed a worksheet with Sarah about the 
pros and cons of taking Strontium Ranelate. What did you think of that worksheet? 
(Individual components) only for some patients 
During your hospital appointment with Sarah, there was some discussion of your 
telephone questionnaire responses. What did you think of that discussion? (individual 
components) 
During the hospital appointment, you and Sarah together made a plan for helping you 
to take your medication. How did you find the plan for helping you to take your 
medication?  (Individual components) 
Other than this research, has anything else happened to you over the last 4 months 
which might have changed your medication-taking? (other factors) only for some 
patients. 
4. Evaluation of Acceptability 
What did you like about THE RESEARCH? (Acceptability) 
(prompts: education leaflet, hospital session, plan-setting, telephone follow-up) 
What did you dislike about THE RESEARCH? (Acceptability) 
(prompts: education leaflet, hospital session, plan-setting, telephone follow-up) 
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Please rate on a scale of 1-5 how satisfied you were with THE RESEARCH (1 being the 
least satisfied and 5 being the most satisfied. Could you tell me why you gave it that 
score? 
What could be done to improve THE RESEARCH for future use, to inform patients 
about their condition and help them with medication-taking? 
Do you think the THE RESEARCH will continue to be of benefit to you now that it is 
complete? (Maintenance)  
Would you recommend THE RESEARCH to a friend? Yes/No. Why? 
Is there anything else you would like to say about the project? 
Closing: 
Thank you very much for this interview and for taking part in the study. Sarah will be 
sending you an M & S voucher to thank you for your involvement. A copy of the study 
results will also be sent to you when it is complete. 
Please thank the patients for the large amount of time they have devoted to the study.
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APPENDIX 27. Example of framework analysis of interview data for the theme ‘pre-intervention adherence and beliefs’ (study 6) 
 Sub-Themes 
Participant Pre-intervention Adherence Pre-intervention barriers to Adherence Pre-intervention Knowledge & Understanding Pre-intervention perception Pre-intervention side-effects  Pre-intervention experience of health care 
service. 
1  what was really difficult is that sometimes I’m 
going to bed and I’m watching television late 
at night then I think; oh I’ll have a tangerine 
or something then I think Oh shit! It means 
I’ve got to get up at three o’clock in the 
morning and take the medication so you 




I suppose with osteoporosis at the beginning 
you think osteoporosis; that’s an old women’s 
disease, but it isn’t, that’s the other thing I’ve 
learnt it isn’t… 
PW: So it affects people of all ages really… (3, 
140 – 145) 
 
I think I was probably in a bit of a denial state 
at the beginning and it just made me open my 
eyes a bit really and I didn’t even know, it just 
informed me a lot really. (1, 29 – 31) 
 
that’s what made me go into a complete… No 
I’m not old, I haven’t got this, this is 
ridiculous, I’m not taking the medicine… 
which made me not take it at the beginning, 
it’s the way that its general perceived, I am of 
average intelligence so t hats how I perceived 
it before I went into the research or even 
thinking that I might have it all… (5, 239 – 
242) 
I had first of all been given tablets to take one 
a week which made me feel really sick…(2, 95 
– 96) 
 
2  there was a time that I was on tetracycline 
and I discovered that I shouldn’t be on both 
of them and in that case there was a couple 
of months a couple of years ago or last year 
that that I didn’t take it but I think I might 
have mentioned that to Sarah as well, it was 
really because they asked me to be on 
tetracycline for a few months. 
(2, 86 – 89) 
it’s just that the medication that I’m on I had 
sort of doubts about whether they might 
cause other problems taking it, you end up 
with strong bones and everything else 
collapses around you! (laughs) (1, 18 – 20) 
   
3 Yes I was much more haphazard about it 
before (3, 120) 
 
I’m likely to have been a bit more easy going 
if I wasn’t the study, the previous time I was 
on the strontium I was less committed to 
taking it really, I was forgetting more often… 
 I’ve been given to understand that strontium 
re-builds bones. I researched that and found 
out that that was the case. (1, 12 – 13) 
   




Participant Pre-intervention Adherence Pre-intervention barriers to Adherence Pre-intervention Knowledge & Understanding Pre-intervention perception Pre-intervention side-effects  Pre-intervention experience of health care 
service. 
(3, 134 – 135) 
4    it’s quite interesting because lots of people 
get strange conditions for instance somebody 
told me what it was like age 31 getting 
diabetes and suddenly finding that your body 
is letting you down, eating itself and not 
doing what it is supposed to do… I suppose 
that is what’s happening with the aging 
process as well anyway… but psychologically 
it’s a blow when what you thought was 
reliable is no longer reliable (4, 154 – 158) 
  
5 I’d stopped taking it and I wouldn’t take it 
again even with all that I’ve been reading, I 
would you know, I’m sure other things would 
come out eventually, but I wouldn’t take it 
again. (2, 72 – 74) 
 I do see when I go up the clinics some people 
who are very bent over which is very sad you 
know, but I did know that you should have a 
lot of calcium (3, 142 – 144) 
 
I do do exercise and when I first started doing 
exercise, I don’t know when that as… in the 
1990’s, you know when I first done my first 
study that’s when I started to do exercise and 
that helps apparently. (3, 144 – 146) 
 
Yea I did know a lot about osteoporosis 
because doing the study before more or less 
on the border line you know because that 
was a big study then but it wasn’t with 
strontium ranelate because that wasn’t out, it 
was that one that you take once a week 
which was fine and you can’t lay down with it, 
I think you can now (5, 230 – 233) 
 
 
I suppose I didn’t really have Osteoporosis 
then but I had broken an arm but I was very 
near to getting it but I did get it in the end! 
(laughs). (2, 58 – 59) 
  




Participant Pre-intervention Adherence Pre-intervention barriers to Adherence Pre-intervention Knowledge & Understanding Pre-intervention perception Pre-intervention side-effects  Pre-intervention experience of health care 
service. 
6 I took it because I’d been told to take it but if I 
missed one or two I didn’t really think about it 
too much (2, 53 – 54) 
 I should have done a lot more online research 
about my condition which I didn’t, I was given 
a lot of information a lot of information was 
said a lot of information by a friend who had 
done a lot of research and so I was quite 
ignorant about the illness (1, 44 – 47) 
 
I knew a reasonable amount but I also didn’t 
know a lot about the medication I was given 
or why or how to interpret any of the bone 
scan results (1, 47 – 48) 
 
Yea I didn’t feel that I knew really what this 
medicine was going to do for me I didn’t 
know how valuable it was (2, 52 – 53) 
  it’s quite a complicated area to talk about but 
basically you are given your medication in a 
very rushed environment and given your 
diagnosis in a very rushed environment and 
when I asked some questions of my 
consultant I don’t feel as though I was treated 
very receptively, I don’t want to criticise the 
consultant but that was my perception of it 
she was obviously in a rush, I felt a bit like I 
was being treated a bit like a bit of an idiot 
child really and it did make me a quite cross 
because you know I’ve got a degree I’ve had a 
whole career I’m at the end of my career I’m 
a reasonably intelligent person (1, 36 – 42) 
 
I mean I was given Calcium and Adcal I think 
for the first part of my diagnosis you know 
years ago and then when I was given a sheet 
to say sort of we are not giving out Calcium 
tablets anymore and this is the research 
paper to say why and I looked at the bottom 
and it was 2 years old, you know it was not 
very good. (7, 322 – 325) 
7  before I had all these concerns and on top of 
that I, it was like this is what you’re supposed 
to do; take it, so I was resisting that, so I had a 
level of resistance (1, 45 – 47) 
 
So before the research, I was really concerned 
about taking the medicine. (2, 59) 
 
I was depressed, it was making me depressed, 
I was allowing myself to be depressed 
because of this, it seemed like this was just 
another thing I had to do just because I had to 
    




Participant Pre-intervention Adherence Pre-intervention barriers to Adherence Pre-intervention Knowledge & Understanding Pre-intervention perception Pre-intervention side-effects  Pre-intervention experience of health care 
service. 
do it and it occurred to me that it wasn’t 
doing me any good! (2, 63 – 65) 
8  I said that the problem from my point of view 
and apparently I’m not alone, is this 4 hour 
fast, I don’t have problems taking medication 
in any other way I mean I’m not somebody 
who is avert to medication or finds I can’t 
swallow tablets or anything it’s just that the 2 
hours and then the medication then another 
2 hours with my particular life style is really 
really difficult. (1, 23 – 26) 
 
if you sort of go out and about and go to the 
theatre or you eat afterwards or you just have 
late suppers which is what we tend to do if 
one is working late or whatever, then it 
means it is just quite hard and therefore I 
wasn’t in anyway able to get that organised in 
the evening (1, 29 – 32) 
    
 
